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Abstract 
Myocardial recovery in patients with non-ischaemic end-stage dilated 
cardiomyopathy can occur following left ventricular assist device (LVAD) and 
drug combination therapy. The effects of LVAD and drug combination therapy on 
the cardiac nervous system have not been adequately studied. It is well recognised 
that contractile reserve is decreased in heart failure patients who have an increased 
level of circulating norepinephrine secondary to failure of the myocardial 
norepinephrine transporter system. The aims of this study are to examine 
prospectively the outcome of using continuous-flow Heart Mate (HM) II LVAD 
and drug combination therapy on the frequency and durability of recovery, the 
clinical effects of left ventricular unloading on cardiac sympathetic nervous 
system, and the impact on norepinephrine transporter activity and neurohormonal 
levels. 
23 non-ischaemic end-stage heart failure patients, confirmed histologically, were 
implanted with a HM II LVAD between February 2006 and March 2009. The 
combination therapy with anti-failure reverse remodelling medication was 
commenced once patients were off inotropes. The first objective was to determine 
a cut-off point where the contribution of the continuous-flow HM II LVAD was 
minimal thus allowing safe and reliable assessment of the underlying left 
ventricular function without causing left ventricular reloading. The impacts of 
LVAD and drug combination therapy on myocardial function and cardiac nervous 
system were assessed by studying: 1) contractile reserve using a 6–minute walk 
exercise test; 2) norepinephrine transporter using serial nuclear 
123
I-
mtaiodobenzylguanidine (
123
I-MIBG) imaging; 3) the changes in catecholamine 
levels using liquid chromatography mass spectrometry. Immunohistochemistry 
was utilised to assess norepinephrine transporter fibre concentration from the left 
ventricular apex biopsies taken at implantation in an attempt to correlate with 
myocardial recovery.  
Experimental and clinical studies identified 6000 rpm as an efficient and a safe 
―low‖ speed to study the underlying myocardial function. Out of the 23 patients, 
15 had recovered and had significant improvement in contractile reserve (the 
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ejection fraction has increased in the recovered patients by 7.73 ± 4.37% as 
compared to 1.13 ± 4.20% in non-recovered patients (p=0.012)). Recovered 
patients have also exhibited significant improvement in 
123
I-MIBG uptake 
parameters which were correlated significantly with changes in catecholamine 
levels. Further, recovered patients had higher percentage of norepinephrine 
transporter immunoreactive nerve fibers per total area in the left ventricular apex 
as compared to non-recovered patients and the concentration correlated positively 
with recovery. 
In conclusion, LVAD and drug combination therapy has a positive impact on 
myocardial function and the cardiac nervous system which were more enhanced in 
the recovered subpopulation. 
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1.1  Heart Failure 
 
 
 “…his heart is flooded…body parts are all together weak…obstruction in his abdomen… 
not in a condition to leap the Nile…stomach is swollen…chest is asthmatic…”  
 
Scripts from the Edwin Smith and the Ebers Egyptian papyri, 
written 2500 – 3000 BC and discovered in Thebes in 1862 referring to a  
clinical picture of a failing heart and signs of congestion in an Egyptian priest 
 
 
 
“…pulse had all kinds of irregularities...he was so weak that every breath involved great 
effort… unable to lie on either side… for never for one moment could he breathe 
freely…was forced to sit upright in order to breathe at all; if by chance he did lie on his 
back or side, the suffocation was awful…danger of asphyxia…at all times, asleep or 
awake, he was menaced by suffocation…incision at the elbow proved fruitless…stomach 
was visibly enlarged to a great size…feet swelled up …the circulation of blood in the 
arteries had finally stopped…” 
 
A biography of the Byzantine emperor  
Alexius I Comnenus (reigned from 1081 to 1118) written  
by his daughter Anna before his fatal illness of heart failure at age 62  
 
 
 
 
Although descriptions of heart failure (HF) exist from ancient Egyptians, Greece, 
India, and the Romans (Jon F.Lutz, 1988;Saba MM et al., 2006), it remains a 
clinical syndrome that largely defies definition. Many definitions have been 
proposed based on either physiologic or clinical attributes (Tan LB et al., 
1996;Ventura HO et al., 1992;Wagner S & Cohen K, 1977). In 1985, Poole 
Wilson was the first to suggest that HF is ―a clinical syndrome caused by an 
abnormality of the heart that is recognised by a characteristic pattern of 
haemodynamic, renal, neural and hormonal responses.‖  
Years later, the Heart Failure Task Force (Hunt SA et al., 2005) adapted this 
concept and defined heart failure as a complex clinical syndrome that can result 
from any structural or functional cardiac disorder that impairs the ability of 
the ventricle to fill with or eject blood. 
  
27 
 
1.2  Epidemiology and Aetiology of Heart 
Failure 
The incidence and prevalence of HF increase steeply with age reaching over 1% 
per annum in those aged 85 years and over. The average age at first diagnosis is 
76 years. There are more than 6 million people diagnosed with this disease in the 
USA and 6.5 million cases in Europe. In the UK the incidence is 140 per 100,000 
men and 120 per 100,000 women with approximately 120,000 new cases each 
year. Although the incidence is higher in men, evidences suggest higher mortality 
in women with the condition. 
HF has a poor prognosis, with about 40% of patients dying within the first year of 
diagnosis. Coronary artery disease acts as the commonest primary aetiology in 36 
– 57% of cases in HF (Cowie MR et al., 1999;Ho KK et al., 1993;McKee PA et 
al., 1971;Remes J et al., 2009;Adams KF et al., 2005;Lloyd-Jones DM et al., 
2006).  Other aetiological factors include cardiomyopathies characterised by 
progressive ventricular dilatation (i.e. dilated cardiomyopathy (DCM)) and 
restrictive cardiomyopathy, hypertension, valvular and congenital heart diseases, 
arrhythmias, alcohol and drugs, high output failure such as anaemia and 
thyrotoxicosis, pericardial heart disease, primary right heart failure, bacterial and 
viral myocarditis, collagen diseases such as rheumatoid arthritis and progressive 
systemic sclerosis, neuromuscular diseases such as muscular dystrophy, 
amyloidosis, sarcoidosis and peri-partum cardiomyopathy. 
As of 2004, the total annual cost was £716 million to the NHS; 60% for hospital 
inpatient care; 17% for primary care; 23% for outpatient care including outpatient 
investigations and drugs. The annual cost in the USA exceeds $60 billion 
accounting for approximately just over 5% of the total healthcare budget. In 
addition to the economic burden the management of this disease places on health 
care systems of the developed countries, HF has an immense negative impact on 
the psychological and sociological status of patients and their relatives and quality 
of life of the patients. HF has also placed patients at increased risk of re-
hospitalisation, social isolation, depression and anxiety. 
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Symptoms of HF range from mild breathlessness and reduced exercise tolerance 
to signs of reduced cardiac output and impaired myocardial contractility. 
Symptoms have been classified by the New York Heart Association (NYHA) as 
demonstrated in table 1.1. 
Table 1.1: NYHA classification of HF 
Class Description 
I No limitation is experienced by any activities  
II 
Slight, mild limitation of activity; the patient comfortable at rest 
or with mild exertion 
III 
Marked limitation of any activity; patient comfortable only at 
rest 
IV Any physical activity brings on discomfort and symptoms at rest 
Table 1.1: NYHA Classification focuses on functional limitations 
Cardinal manifestations of HF include dyspnoea, orthopnoea, paroxysmal 
nocturnal dyspnoea, fatigue, limitation to exercise tolerance, anorexia, and fluid 
retention, which may lead to pulmonary congestion and peripheral oedema. 
Fatigue and exercise intolerance are partly related to abnormalities in skeletal 
muscle with premature muscle lactate release, impaired muscle blood flow, 
deficient endothelial function, and abnormalities in skeletal muscle structure and 
function (Piña IL et al., 2003). Reduced cerebral blood flow, when accompanied 
by abnormal sleep pattern, may occasionally lead to somnolence and confusion in 
chronic HF (Watson RDS et al., 2000) contributing to the fatigue symptoms. 
Paroxysmal nocturnal dyspnoea results from increased left ventricular filling 
pressures and is considered an important predictive factor of HF (Watson RDS et 
al., 2000). Oedema is a sign of a right heart failure which is normally assoicated 
with right hypochnodrial pain secondary to liver distension, ascites, and rarely, 
bowel oedema (Watson RDS et al., 2000). 
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In 2001, the American College of Cardiology (ACC) introduced a new 
classification for HF that emphasizes the evolution and the progression of the 
disease through four different stages (table 1.2) (Hunt SA et al., 2005). 
Table 1.2: ACC staging classification of HF 
Stage Description 
A 
Patients at high risk for developing heart failure but no functional 
or structural heart disorders 
B A structural heart disorder but no symptoms at any stage 
C 
Previous or current symptoms of heart failure in the context of an 
underlying structural heart problem, but managed with medical 
treatment 
D 
Advanced disease refractory to standard treatment, requiring 
hospital-based support, a heart transplant or palliative care 
Table 1.2: ACC staging system of HF focusing on its evolution and progression. 
This staged classification is considered to be a departure from the traditional 
NYHA classification as it underpins the fact that established risk factors and 
structural abnormalities are necessary for the development and the progression of 
HF. Studies have shown that advanced HF accounts for approximately 5% of 
symptomatic HF with a 1-year mortality ranging from 33% - 50% (Brophy JM et 
al., 1994;The CONSENSUS Trial Study Group, 1987b;The SOLVD Investigators, 
1991;Adams KF & Zannad F, 1998;Shah M et al., 2001). 
The ACC classification can be linked to the clinical features in the NYHA 
classification as follows: Stage A encompasses ―pre-heart failure‖ and it does not 
have a corresponding NYHA class. It is recognised that intervention with 
treatment at Stage A could presumably prevent progression to overt symptoms. 
Stage B would correspond to NYHA Class I, Stage C to NYHA Class II and III, 
and Stage D overlaps with NYHA Class IV. 
30 
 
HF may progress from Stage A to Stage D in a given patient but does not usually 
follow the path in reverse. In contrast, a patient with NYHA class IV symptoms 
might have quick improvement to class III with diuretic therapy alone or even to 
class I with the use of a combination of mechanical circulatory support and 
pharmacological therapy ―the ethos of the present study‖. This staged HF 
classification promotes a way of thinking about the disease that is similar to 
thinking about cancer — that is, HF is a progressive disease with a scope of 
identifying and screening of patients who are at risk. 
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1.3  Pathogenesis and Pathophysiology of HF 
HF is commonly a disorder of left ventricular (LV) remodeling, which results 
from an index event (i.e. initial insult). This may be clinically silent, such as the 
expression of a genetic mutation, or obvious, such as the loss of a large mass of 
contractile tissue from acute myocardial infarction. 
Myocardial Remodeling 
Remodeling is a central feature in the progression of HF (Wilson S.Colucci, 
1997). It is associated with an increase in the LV muscle mass, an increase in 
ventricular volume, and a change in shape of the ventricle (Jay N.Cohn, 
2005;Bernard Swynghedauw, 1999;Bozkurt B, 1999). If the process is initiated by 
an acute myocardial infarction, remodeling is asymmetric because of the localised 
necrosis. However, if the results from a more generalized disease, such as 
cardiomyopathy, the ventricle remains symmetric but with different shape and 
volume (see later for the LV geometrical changes in HF). 
At the cellular level, the histologic changes that occur in the remodeled ventricle 
include myocyte hypertrophy (Cleutjens JP et al., 1995;Katz AM, 1994;Gaballa 
MA & Goldman S, 2002;Yacoub MH, 2001), myocyte slippage (Olivetti G et al., 
1990), interstitial growth (Hirohata S et al., 1997), myocyte lengthening, 
(Terracciano CMN et al., 2004) and myocyte apoptosis (Narula J et al., 1996) 
Mechanisms inducing remodeling are not fully established, but thought to be 
secondary to mechanical stretch (Chien KR, 1999;Hunter JJ & Chien KR, 1999). 
Furthermore, the cellular and molecular actors initiating the remodeling process 
remain incompletely understood.  
Until the early eighties, the stimulus for myocyte growth has been viewed as a 
haemodynamic response to the index event. However, this view has now been 
largely abandoned and its application is limited to the management of 
decompensated ―end-stage‖ HF patients where positive inotropic drugs and 
vasodilators remain widely used. 
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The more recent neurohormonal (NH) model describes the neuroendocrine 
activation process as the hallmark in the progression of HF and that inhibition of 
neurohormones is likely to have long-term benefits with regard to morbidity and 
mortality. This transitional change in the understanding of the pathophysiology of 
HF has resulted in improved medical and non-medical management of the disease. 
The second axis that has been shown to contribute to remodeling is inflammation 
with the activation of several inflammatory markers associated with certain 
changes that occur within the extracellular matrix (ECM) (Birks EJ & Yacoub 
MH, 1997). Figure 1.1 is a schematic representation of the mechanisms involved 
in myocardial remodeling.  
Figure 1.1: Mechanisms of remodeling 
 
Fig 1.1: A general overview of the mechanisms involved in myocardial 
remodeling. Adapted from (Francis GS & Wilson Tang WH, 2003;Wilson 
S.Colucci, 1997). 
 
Both NH model and inflammatory second axes with the involvement of the ECM 
will be discussed next. 
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1.3.1  The Neurohormonal Model 
Neurohormonal controls play an essential role in the haemostatic regulation of salt 
and water metabolism, circulatory function and blood pressure, through the 
activity of the sympathetic nervous system (SNS), renin angiotensin aldosterone 
system, natriuretic peptides, and endothelin. 
1.3.1.1  Cardiac Neuronal Anatomy and Role of Norepinephrine 
Sympathetic fibers leave the spinal cord at segments T1 to L2-3. Preganglionic 
sympathetic fibers consist of small myelinated fibers that come off the spinal roots 
as white rami communicantes and synapse in the paravertebral ganglia. 
Adrenergic fibers that innervate the heart originate in the left and right stellate 
ganglia. The left stellate innervates the right ventricle, whereas the right stellate 
innervates the anterior and lateral portions of the heart. Parasympathetic 
innervation originates from the medulla and follows through the right and left 
vagus nerves which then divide into superior and inferior cardiac nerves (figure 
1.2). 
Figure 1.2: The anatomy of cardiac neuronal system 
 
Figure 1.2: A schematic diagram of the anatomy of the sympathetic and the 
parasympathetic cardiac neuronal system. From (Olshansky B et al., 2008). 
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In 1984, Cohn et al were the first to demonstrate a link between sympathetic 
activation and mortality in HF (Cohen JN et al., 1984). Plasma norepinephrine 
(NE) has since been shown to be associated with progressive ventricular dilatation 
and the severity of cardiac dysfunction (Cohen JN, 1995;Cohen JN, 2002;Francis 
GS et al., 1990) . 
In HF patients there is a specific increased activity in cardiac sympathetic 
efferent neuronal activity rather than an increase in the generalised 
sympathetic activity which initially supports but then ultimately harms the 
failing heart (Davis D et al., 1988;Esler M et al., 1997;Kaye D & Esler M, 
2005). This contention is based on several observations. First, the heart exhibits 
substantial (Swedberg K et al., 1984) and selective adrenergic activation (Hasking 
G et al., 1986) compared with most other organs. Second, adrenergic activation is 
regionally regulated within the failing human heart (Bristow MR et al., 1992). 
Third, cardiac adrenergic activation is a better predictor of outcome than systemic 
sympathetic markers (Eisenhofer G et al., 1996;Hasking G et al., 1986;Rundqvist 
B et al., 1997;Kaye DM et al., 1994). Finally, recent data indicated that cardiac 
adrenergic activation is the first neurohormonal abnormality that can be detected 
in the progression of heart failure from asymptomatic LV dysfunction to the 
clinical syndrome (Eisenhofer G et al., 1996;Hasking G et al., 1986;Rundqvist B 
et al., 1997;Kaye DM et al., 1994). 
The release of NE from sympathetic nerves is controlled by the pre-synaptic 2A- 
and 2C- adrenergic receptors (AR) (Philipp M et al., 2002;Hein L et al., 1999) 
with 2C AR having the most affinity for NE (Bünemann M et al., 2001). 
Following the  interaction with - and β- receptors, NE is taken up by the 
catecholamine transporter of which there are two types; neuronal (uptake-1) and 
non-neuronal (uptake-2) transporters (Eisenhofer G, 2001). Uptake-1 transporters 
are located at the cardiac sympathetic nerve endings at the pre-synaptic level and 
include the norepinephrine transporter (NET) whilst the uptake-2 system is 
located on the myocyte and its activity is very low in the human heart (Figure 
1.3).  
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Figure 1.3: Schematic diagram illustrating the biosynthetic pathway of NE 
and the location of NET 
 
Fig 1.3: Catecholamine synthesis requires tyrosine hydroxylase (TH) and 
dopamine β-hydroxylase (DBH), as well as cytochrome b-561 as an electron 
shuttle. From (Fung MM et al., 2008). 
Once synthesised, NE transport and vesicle formation is aided by vesicular 
monoamine transporters (VMAT), NET, chromogranins A and B (CHGA, 
CHGB), and the vacuolar-ATPase (V-ATPase). NE is then released in a 
nonexocytotic mechanism by tyramine.  
The released NE acts on - and β- AR at the postsynaptic level. In normal 
individuals 92% of synaptic NE is removed from the synapse via NET (figure 
1.4). This is reduced to 85% in HF patients (Eisenhofer G, 2001).  
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Figure 1.4: Quantitative illustration of neuronal uptake 
 
Fig 1.4: Quantitative illustration of the processes of neuronal and extraneuronal 
uptake, synthesis, vesicular-axoplasmic exchange, metabolism, release, spillover, 
and turnover of NE in sympathetic nerves of the normal (left) and failing (right) 
human heart. From (Eisenhofer G, 2001). 
Initially, it was uncertain whether the rise in NE in HF is secondary to enhanced 
release of NE from the pre-synaptic membrane (Mancia G, 1990) or a defect in 
the NET system at the presynaptic level (Hasking G et al., 1986). Studies have 
later confirmed that although NE release is increased, it was the failure of the 
uptake system that was responsible for the abundance of the NE molecule at the 
synaptic level (Allman KC & Lahiri A, 2002;Lotze U et al., 1999;Eldadah BA et 
al., 2004;Böhm M et al., 1995). The role of NET is described in details in chapter 
5 entitled ―Mechanical left ventricular unloading results in normalisation of the 
cardiac norepinephrine transporter uptake mechanism‖. 
Abundance of NE in the synapse leads to increased sympathetic drive which 
initially acts as a method of compensatory inotropic mechanism (Eisenhofer G, 
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2001) such that it helps to restore cardiovascular haemostasis. This has been 
referred to as ―asymptomatic left ventricular dysfunction‖ phase (McDonagh TA 
et al., 1997;Thomas KG & Redfield MM, 1997a) which is associated with an 
initial increase in mean arterial blood pressure and tachycardia(Thomas KG & 
Redfield MM, 1997b), both are usually concealed from the patient and the 
physician. Shortly afterwards, the asymptomatic left ventricular dysfunction 
develops into an overt or symptomatic heart failure which is characterised by 
progressive neurohumoral activation and LV remodeling (Fu YC et al., 2004;Shah 
M et al., 2001). The net result is the development of arrhythmias, myocardial 
apoptosis and necrosis, tissue hypoxia, increased cardiac oxygen consumption 
and myocardial oxygen wastage, reduced coronary blood flow, and loss of 
contractile reserve (Fukuoka S et al., 1997;Gudjonsson T & Rahko PS, 
2002b;Liang C, 2003;Opie LH, 2002).  
Animal studies have shown that acute intravenous infusions of isoproterenol or 
NE result in acute contraction band lesions attributed to relative hypoxia, 
increased sarcolemmal permeability, calcium overload, elevation of cyclic AMP 
(cAMP), activation of - and β- ARs, and formation of oxidative catecholamine 
metabolites (Todd GL et al., 1985;Mann DL et al., 1992). Chronic catecholamine 
administration in rats causes interstitial fibrosis, reduces β-adrenergic receptor 
mediated inotropic responses, promotes myocyte apoptosis, and induces pump 
dysfunction primarily through LV dilatation, all features of remodeling (Osadchii 
OE et al., 2007;Brouri N et al., 2004).  
Excessive NE exerts its toxic effects directly through five different mechanisms: 
cardiac ARs (Gerald W Dron II, 2002;Lefkowitz RJ et al., 2000), renin-
angiotensin-aldosterone system (Packer M, 1992), calcium handling (Arai M et 
al., 1993), natriuretic peptides (Rodeheffer RJ, 2004), and endothelin (Henrion D 
& Laher I, 1993). The following five subsections discuss the involvement of each 
of these mechanisms in the pathophysiological process of HF.  
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1.3.1.2  Adrenergic Receptors (ARs) 
Total adrenergic signalling in the heart is the sum of systemic epinephrine release 
from the medulla of the adrenal glands and local myocardial NE release from 
cardiac sympathetic nerves. The adrenergic hypothesis of HF is represented in 
figure 1.5. 
 
Figure 1.5: The adrenergic hypothesis of heart failure 
 
Fig 1.5: The adrenergic hypothesis of HF. Increased cardiac adrenergic drive 
contributes to 2 hallmarks of the natural history of HF: impaired exercise response 
and progressive myocardial dysfunction. Adapted from (Bristow MR, 1993). 
Both NE and epinephrine exert their biological actions via the activation of 9 
different AR subtypes, 3 alpha1-receptros ( 1A, 1B, and 1D), 3 alpha2-receptors 
( 2A, 2B, and 2c), and 3 beta-receptors (β1, β2, and β3). All have 7 
transmembrane domains and signal via the interaction of the heterotrimeric G-
proteins. 
Of the β-AR subtypes, β1-AR is the most abundant in the cardiac tissue with a 
ratio to β2-AR of 70:30 (Bristow MR et al., 1986). It exerts its potent positive 
inotropic, chronotropic, and lusitropic effects by stimulating the adenylyl cyclase 
(AC) / protein kinase A (PKA) signaling pathway through the overexpression of 
the stimulatory -subunit of G-protein (G s). 
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The targets of PKA are illustrated in figure 1.6 and include:  
1) the L-type calcium channels (LTCC) and ryanodine receptors (RyR): 
activation of each results in intracellular leak in calcium ions (Ca
2+
) and an 
increase in Ca
2+
 entry into the sarcoplasmic reticulum (SR) (Lehnart SE et 
al., 2005;Zhao XL et al., 1994);  
2) the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, 
which initiate and modulate the rhythmic activity in cardiac pacemaker cells 
(Ludwig A et al., 1998);  
3) phospholamban (PLB), which accelerates Ca2+ reuptake by 
sercaendoplasmic reticulum (SERCA) hence accelerating cardiac relaxation 
(Sulakhe PV & Vo XT, 1995);  
4) troponin I and myosin binding protein-C, which reduce myofilament 
sensitivity to Ca
2+ 
and hence the relaxation of myofilaments is accelerated 
(Sulakhe PV & Vo XT, 1995); 
5) phospholemman (PLM), relieving its inhibitory influence and resulting in 
the stimulation of the sodium pump (Despa S et al., 2005). 
Figure 1.6: β-AR signalling 
 
Fig 1.6: The major intracellular effects of the sympathetic transmitters NE and 
epinephrine is mediated by formation of cAMP, which increases the activity of 
the cAMP-dependent PKA. ATP, adenosine triphosphate; CNBD, cyclic 
nucleotide-binding domain; G i and G s, G protein alpha-subunit subtypes. From 
(Triposkiadis F et al., 2009). 
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Associated with β-AR activation is the autoregulation process of receptor 
desensitisation. This process operates as a safety device to prevent 
overstimulation of receptors in the face of excessive β-AR agonist (Malcolm 
Johnson, 2006). Therefore, abundance of NE in the synaptic cleft results into four 
different alterations in the β-AR: i) downregulation of the receptor secondary to 
either reduced mRNA levels or enhanced receptor degradation (Hadcock JR & 
Malbon CC, 1991;Hausdorff WP et al., 1990;Ali Ahmed, 2003); ii) impairment 
of the remaining β-AR i.e. receptor uncoupling from adenylate cyclase (Bristow 
MR et al., 1982;Brodde OE, 1991); iii) internalisation of the uncoupled receptors 
(Malcolm Johnson, 2006); and iv) phosphorylation of the internalised receptors 
(Malcolm Johnson, 2006).  
Another mechanism of action of NE on β-AR is the self-phosphorylation by the 
specific β-adrenergic receptor kinase (βARK1). Once phosphorylated, the 
inhibitor protein β-arrestin binds to it and inhibits its function by up to 70% 
(Benovic JL et al., 1987;Lohse MJ et al., 1990a;Lohse MJ et al., 1990b;Ungerer 
M et al., 1993). Gene-targeted animal studies have shown that in HF βARK1 
activity is increased and that partial inhibition of βARK1 enhances β-AR 
signaling (Rockman HA et al., 1998;Koch WJ et al., 1995;Akhter SA et al., 1997). 
Furthermore, overexpression of G s following NE binding results in the 
development of progressive myocardial fibrosis, apoptosis (modulated by Ca
2+
-
activated calmodulin kinase II pathway and inhibited by reactive oxygen species 
products such as superoxide dismutase/catalase-mimetics and catalase), and 
cardiomyocyte hypertrophy with functional deterioration – cardinal changes in 
DCM (Engelhardt S et al., 1999;Iwase M et al., 1996;Iwase M et al., 1997;Colucci 
WS, 1998;Colucci WS et al., 2000b;Communal C & Colucci WS, 2005). 
At the post synaptic membrane, the concentrations of 1A- and 1B -ARs is 
equivalent to 20% of the total β-AR (Woodcock EA et al., 2008). Both 1A- and 
1B -ARs subtypes couple to the Gq family of heterotrimeric G-proteins, which, in 
turn, activate phospholipase Cb (PLCb). The latter hydrolyzes phosphatidylinositol 
bisphosphate (PIP2) to generate the second messengers inositol trisphosphate (IP3) 
and 2-diacylglycerol (DAG). IP3 contributes to the regulation of intracellular Ca
2+
 
responses and interacts with perinuclear inositol triphsophate receptors (IP3R) 
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distinguishing growth related gene transcription. DAG activates protein kinase C 
(PKC) as well as some of the transient receptor potential (Trp) channels. Trp 
activation results in an increase in the permeability to Ca
2+
 which enters the cell 
and activates calcineurin to initiate downstream growth signaling pathways. The 
1-AR also transactivates epithelial growth factor receptors, resulting in formation 
of phosphoinositide 3-kinase (PI3K) and phosphatidylinositol trisphosphate (PIP3), 
activation of the Akt pathway, and initiation of cell-survival signaling pathways. 
(figure 1.7). 
Figure 1.7: -AR signalling 
 
 
Fig 1.7: Agonist-induced stimulation of 1-ARs activates Gq family and PLCb, 
resulting in hydrolysis of PIP2, to generate IP3 and DAG which in turn activates 
PKC to initiate a series of phosphorylations that alter channel activity and induce 
transcriptional changes. From (Triposkiadis F et al., 2009). 
Studies have shown that over stimulation of -AR for example due to the 
abundance of NE results in eccentric cardiac hypertrophy, increased cardiac 
myocyte cross-sectional area, intrinsic myocyte contractile dysfunction, striking 
changes in cardiac gene expression recapitulating those seen in the 
haemodynamically overloaded heart, and a unique predisposition to 
cardiomyocyte apoptosis, which is the mechanism for progression to dilated 
cardiomyopathy (Bishopric NH et al., 1987;Long CS et al., 1989;Milano CA et 
al., 1994;Adams JW et al., 1998;D'Angelo DD et al., 1997;Satoh N et al., 2000).  
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1.3.1.3  Renin-Angiotensin-Aldosterone System 
In 1989, Anand et al have demonstrated that HF is associated with marked 
elevations of each of the components of the Renin-Angiotensin-Aldosterone 
System (RAAS) (Anand IS et al., 1989). Normally, renin is released from the 
juxtaglomerular apparatus in response to sympathetic stimulation and reduced 
renal blood flow (Hall JE et al., 1990). In HF, the RAAS is overstimulated 
causing an in increase in renin production. The resulting angiotensin II (AngII) 
has direct myocardial toxic effects by stimulating cytokines, growth factors and 
fibroblast activity (Boateng SY et al., 2009;Francis GS et al., 1993;Sadoshima J et 
al., 1993;Tan LB et al., 1991) and acts directly as a vasoconstrictor (Sadoshima J 
& Izumo S, 1993). Plasma aldosterone levels may be elevated as high as 20-fold 
in patients with HF, primarily due to increased production by the adrenal glands 
following stimulation by the high plasma AngII concentrations. In addition to its 
electrolyte and metabolic effects, aldosterone promotes collagen accumulation and 
cardiac fibrosis altering the filling characteristics of the LV and impairing 
contractile function (Izawa H et al., 2005;Swedberg K et al., 1990;Weber KT et 
al., 1993;Weber KT & Brilla CG, 1991), exerts a negative effect on endothelial 
function via prostacycline (Johnson FK et al., 2005), and increases plasminogen 
activator inhibitor-1 levels (Chun TY & Pratt JH, 2005).  
A possible common pathogenic mechanism that would cause the effects seen by 
the increased levels of AngII and aldosterone in heart failure is the enhanced 
release and the reduced uptake of NE at nerve endings (Sunners C & Raizada 
MK, 1986;Weber MA & Rurdy RE, 1982). Type-1 AngII (AT1) receptor is 
responsible for most of the effects of AngII. It has a pathogenic role through 
promotion of myocyte growth and fibrosis in cardiac hypertrophy and HF (Varo et 
al., 2000). Stimulation also results in vasoconstriction through IP3 and Ca
2+
 
release, myocardial cell growth through PKC release, positive inotropy, 
catecholamine release and increased aldosterone secretion with fibrosis. Nuclear 
factor kappa B (NF- B), a ubiquitous nuclear transcription factor which promotes 
the expression of many inflammatory genes, may also be activated (Ruiz-Ortega 
et al., 2000). Type-2 AngII (AT2) receptors mediate antigrowth effects which 
might be useful during AT1 blockade (Ohkubo et al., 1997).  
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1.3.1.4  Calcium Handling in Heart Failure 
In the heart, excitation-contraction (EC) coupling is the central mechanism by 
which electrical activation is translated into cardiac contraction and its initiation 
in ventricular myocytes is highly localized to the T-tubule network. T-tubules is  a 
complex system of interconnected membrane structures continuous with the 
extracellular space which is integrally involved in multiple cellular processes 
including membrane transport, excitability, and cellular signalling (Kenneth B 
Margulies, 2002). T-tubules are also the site of most junctional complexes formed 
between sarcolemma containing LTCC and junctional SR. 
SR controls Ca
2+
 uptake, storage and release. At rest calsequestrin, a Ca
2+
 binding 
protein holds Ca
2+
 in the SR. Following excitation, Ca
2+
 induced Ca
2+
 release 
(CICR) occurs through the RyR channel of which only the RyR2 isoform is 
expressed in cardiac tissue (Fleischer & Inui, 1989;Otsu et al., 1990;Arai et al., 
1992). Myocyte relaxation is initiated by SERCA (Nagai et al., 1989;Lytton et al., 
1989;Lompre et al., 1994;Colyer, 1993;Arai et al., 1992) and its function is 
attenuated by the regulatory protein PLB (Tada & Katz, 1982) as depicted in 
figure 1.6.  
In HF, several proteins are changed with respect to their expression, 
phosphorylation status, and function leading to remodelling of EC coupling. 
Dysfunctional Ca
2+
 handling in HF leads to impaired cardiac contraction and 
relaxation (Arai et al., 1993;Richard et al., 1998;Wickenden et al., 1998;Morgan 
et al., 1990). Investigators have demonstrated that Ca
2+
 transport proteins are 
either affected or decreased in hypertrophy and severe HF (Arai et al., 1993;Kiss 
et al., 1995;Lehnart et al., 2005). In the failing ventricular myocytes T-tubules are 
depleted and dilated and associated with changes in the density of a variety of 
proteins in both surface and T-tubular sarcolemma but with preservation of the 
protein composition of junctional complexes (Kostin S et al., 1998;Balijepallia 
RC et al., 2003). This subcellular remodelling contributes to abnormal EC 
coupling in HF. In addition, the action potential is initially prolonged in HF 
mainly due to Ca
2+
 flux (which acts as a compensatory mechanism) but later 
becomes maladaptive due to decreased Ca
2+
 response (Wickenden AD et al., 
1998). 
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Animal studies have shown that over-expression of other Ca
2+
 handling proteins 
such as calmodulin (CaM) or calsequestrin may induce hypertrophy and 
hyperplasia (Gruver et al., 1993;Jones et al., 1998;Sato et al., 1998). In contrast, 
PLB-knockouts cannot inhibit SERCA2a (the SERCA cardiac isoform) and 
therefore show positive inotropism and lusitropism, but are not hypertrophied 
(Luo et al., 1994). Over-expression of SERCA2a causes similar results also 
without hypertrophy (He et al., 1997).  
As mentioned above and depicted in figure 1.6, heart failure is associated with 
over activation of the AC/PKA signaling pathway which in turn results in 
excessive Ca
2+
 leakage, and enhanced Ca
2+
 uptake by the SR therefore 
accelerating cardiac relaxation. The physiological outcome is prolonged Ca
2+
 
transients during both release and re-uptake and reduced the capacity to restore 
lower resting Ca
2+
 during diastole (Arai et al., 1993;Gwathmey et al., 
1987;Morgan et al., 1990).  
1.3.1.5  Natriuretic Peptides 
The initial discovery of Atrial Natriuretic Peptide (ANP) in the early 1980s led to 
the discovery of Brain Natriuretic Peptide (BNP), the most important natriuretic 
peptide to be released by cardiac myocytes in response to bio-mechanical stretch. 
BNP is released as a prohormone which is then cleaved into a biologically 
inactive N-terminal fragment and a bioactive C-terminal fragment. BNP causes 
vasodilatation and suppression of RAAS (Sudoh et al., 1988;Davis et al., 
1992;Struthers, 1994), natriuresis (Torda et al., 1989;Fregoneze et al., 1989), and 
attenuation of hypertrophic signaling pathways in cardiac myocytes (Struthers, 
1994;Fleischer et al., 1997). As such, BNP can be considered as an endogenous 
anti-remodeling hormone. In HF, BNP levels are elevated secondary to the 
mechanical stretch induced by remodeling. Therefore, it has been a useful marker 
for the diagnosis and the potential treatment of HF and has been recently shown to 
be a strong prognostic indicator for both asymptomatic and symptomatic patients 
with HF (Maisel A & Mehra MR, 2005;Pfister R et al., 2004;Rodeheffer RJ, 
2004). 
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1.3.1.6  Endothelins 
Produced in many tissues, endothelins modulate vasomotor tone, cell proliferation 
and hormone production and are important in vascular physiology and disease. 
Discovered in late 1980‘s, there are three endothelin peptides; endothelin-1 (ET-
1) has hormone or growth factor like properties in many mammalian cells, 
inducing expression of proto-oncogenes, myosin heavy chains, -actin and 
troponin in cardiac myocytes; endothelin-2 (ET-2) is produced mainly in the gut 
but has no unique physiological functions; endothelin-3 (ET-3) is of unknown 
origin but is thought to act mainly act on neurological tissue.  
ET-1 is the only endothelin to be produced in endothelial cells and the most potent 
endogenous vasoconstrictor identified (100 times greater than NE). ET-1 has a 
positive inotropic effect, induces myocyte hypertrophy, and stimulates fibroblastic 
proliferation. It is elevated in HF and promotes sympatho-adrenergic 
overstimulation by potentiating NE-induced effects on vascular smooth muscle 
cells (Henrion D & Laher L, 1993). Upregulation of ET-1 is important in the 
development of cardiac hypertrophy and the amount locally produced might relate 
to the degree of hypertrophy and HF (Lerman et al., 1991). Shubeita et al showed 
that ET-1 can induce molecular and cellular changes generating cardiac 
hypertrophy that include initiation of the growth program through activation of 
early genes, reactivation of embryonic genes and stimulation of myosin light 
chain production (Shubeita et al., 1990). It is also possible that ET-1 may lead to 
the stimulation of adrenal aldosterone production thereby worsening the effects of 
HF (Rosolowsky & Campbell, 1990). 
In 2005, Backs et al have identified the relationship between ET-1 and NET 
(Backs J et al., 2005). In addition to promoting NE-induced effects at the post-
synaptic level in HF, the group demonstrated that ET-1 inhibits NET uptake 
mechanism at the pre-synaptic membrane through the endothelin A receptor and 
hence enhances sympathetic overstimulation. 
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1.3.2  Inflammatory Axis 
The interest in understanding the role of inflammatory mediators
 
in HF arises 
from the observation that many aspects
 
of the syndrome of HF can be explained 
by the known
 
biological effects of proinflammatory cytokines.  When expressed at 
sufficiently high concentrations, tissue necrosis factor  (TNF ), interleukin 1 
(IL-1) and interleukin 6 (IL-6) are sufficient
 
to mimic some aspects of the so-
called HF phenotype: LV remodeling and dysfunction, pulmonary oedema, 
cardiomyopathy, reduced skeletal muscle blood flow, endothelial dysfunction, 
anorexia and cachexia, activation of foetal gene program, and cardiac myocyte 
apoptosis (Bozkurt B et al., 1998;Thaik CM et al., 1995). 
Thus, the "cytokine
 
hypothesis" (Seta Y et al., 1996) for HF states that heart 
failure progresses,
 
at least in part, as a result of the toxic effects exerted by
 
endogenous cytokine cascades on the heart and the peripheral
 
circulation. It is 
important to note that the ―cytokine hypothesis‖ does not imply that cytokines 
cause HF, per se, but
 
rather that the overexpression of cytokine cascades 
contributes
 
to the disease progression. 
Experimental studies showed that direct injection of TNF  would induce 
hypotension, metabolic acidosis, haemoconcentration, and death within minutes 
(Pagani FD et al., 1992) and that the negative inotropic effects induced by the 
circulating TNF  is completely reversible once the TNF -infusion is stopped 
(Bozkurt B et al., 1998). 
Plasma TNF  concentrations are elevated in patients with HF (Novo G et al., 
2009) in correlation with NYHA functional class (Torre-Amione G et al., 
1996;Kapadia SR et al., 2000) and prognosis (Rauchhaus M et al., 2000). From 
the Vesnarinone Trial (VEST) study, Deswal et al studied 1200 patients with 
advanced HF with a mean follow-up of 55 weeks to demonstrate that high TNF  
levels at baseline were associated with increased mortality (Deswal A et al., 
2001). Investigators have speculated five possible sources for the elevated levels 
of TNF  in HF (Torre-Amione G et al., 1999): 
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i) activation of the immune system, 
ii) the failing heart may be a source itself such that TNF  mRNA and protein 
were present in the failing heart but not detectable in the non-failing heart, 
iii) decreased cardiac output leads to elaboration of TNF  by underperfused 
metabolic tissues, 
iv) increased bowel permeability as a result of mesentric congestion in end-
stage HF leads to bacterial translocation and endotoxin release (a potent 
stimulus for TNF  production), and 
v) polymorphism in the TNF  gene locus might be responsible for the 
increased TNF  expression. 
Recently, Selmeczy et al have shown that abundance of NE secondary to NET 
deficiency in NET knockout mice resulted in elevated TNF  (Selmeczy Z et al., 
2003). Administration of desipramine caused a reduction in TNF  and induced 
interleukin-10 (IL-10) production.  
TNF  modulates myocardial function through two different pathways: i) an 
immediate pathway that is manifested within minutes and mediated by the 
activation of the neutral sphingomyelinase pathway (Oral H et al., 1997) ; and ii) a 
delayed pathway that requires hours to days to develop and is mediated by nitric 
oxide (NO) (Gulick TS et al., 1989;Ballingand JL et al., 1993). The effects of 
TNF  in HF are represented in table 1.3.  
Table 1.3: The effects of TNF  in heart failure 
Effects of TNF  in HF Modulators of the effects of TNF  in HF 
Apoptosis ↑Fas, ↓BcL2 
Cardiotoxicity ↑iNOS 
Oxidative stress ↑O2
-, ↑iNOS 
Vascular dysfunction ↑Bax, ↓BcL2, ↑iNOS 
Proteolysis ↑Ubiquitin proteosome activity 
 
Table 1.3: Increased expression of TNF  stimulates apoptosis, cardiotoxicity, 
vascular dysfunction, oxidative stress, and proteolysis. Adapted from (Berry C & 
Clark AL, 2000). 
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Progressive LV dysfunction in human and animal cardiomyopathy is asoscaited 
with loss of nearly one-third of cardiomyocytes as a result of apoptosis (Narula J 
et al., 2006;Narula J et al., 1996). Apoptosis is initiated by two pathways, the 
adrenergic and the reactive oxygen species–tumor necrosis factor–caspase 
signaling pathways (Communal C et al., 1998;Fu YC et al., 2004). The activation 
of Fas, a transmembrane cell surface protein, has also been highlighted as an 
important mechanism in the devleopment of apoptosis in HF (Sheppard R et al., 
2005). 
High TNF  and IL-1 concentrations are accompanied by NO generation (Gross & 
Levi, 1992). NO is a free radical gas that functions as a biological messenger in 
physiological solutions and can diffuse easily across membranes to interact with 
other enzymes leading to the production of messengers such as cyclic guanosine 
monophosphate (cGMP). It is synthesised by NO synthase of which there are 3 
types – endothelial, neuronal and inducible (Loscalzo & Welch, 1995). Current 
evidence suggests that endothelial NO synthase (eNOS) predominates in the 
normal heart in contrast to the failing heart in which inducible NOS (iNOS) 
predominates (Drexler et al., 1998).  
iNOS is Ca
2+
 independent, present in cardiac myocytes, vascular smooth muscle 
cells and infiltrating inflammatory cells and regulated at transcriptional level, thus 
taking hours to produce (Loscalzo & Welch, 1995). Increased expression in HF 
has been shown to parallel the induction of myocardial ANP (Habib et al., 
1996;Haywood et al., 1996). Once induced by IL-1 and TNF , iNOS is activated 
by NF B (Barnes PJ & Karin M, 1997). Transcription is also increased by AngII 
but inhibited by transforming growth factor β (TGF-β) (Ikeda et al., 1995;Ikeda et 
al., 1996). The activated iNOS produces large amounts of NO for prolonged 
periods (Moilanen & Vapaatalo, 1995).  
Once produced, NO exerts negative inotropic effects over a time course (Schulz 
et al., 1995), increases ventricular relaxation affecting diastolic function (Paulus et 
al., 1994), modulates NET activity in a cGMP independent manner (Kaye DM et 
al., 1997;Kaye DM et al., 2000a), induces apoptosis in myocytes and fibroblasts 
(Narula J et al., 1996), and generates reactive oxygen species which in turn result 
in oxidative stress on the myocardium and apoptosis (Colucci WS, 1997). In 2 
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communications, Dhalla et al have shown that oxidative stress is increased in the 
myocardium during the transition from compensated hypertrophy to failure 
(Dhalla AK et al., 1996;Dhalla AK & Singal PK, 1994). 
IL-1, released from activated T lymphocytes is activated in HF. It stimulates 
cardiomyocyte hypertrophy by inhibiting transcription of the alpha-actin gene 
promoter in vitro (Patten M et al., 1996) and activating foetal gene program 
(Colucci WS, 1997). The latter is characterised by increased expression of ANP 
and downregulation of adult, muscle-specific genes such as SR Ca2+ adenosine 
triphosphatase (Thaik CM et al., 1995). Similar to TNF , its negative inotropic 
effects are mediated through the production of NO (Panas D et al., 1998). 
IL-6 is proinflammatory, proteolytic (Goodman MN, 1994), increases endothelial 
vasoactive peptides (Xin X et al., 1995), and enhances the catabolic actions of 
TNF  (Tsujinaka T et al., 1996). Its production is also increased in HF (Torre-
Amione G et al., 1996;Testa M et al., 1996). Similar to TNF , high levels of 
circulating IL-6 was associated with increased mortality (Deswal A et al., 2001). 
Triggers for IL-6 production from cells within the vascular wall and in leucocytes 
are hypoxia, SNS activation, endothelin and TNF  (Berry C & Clark AL, 2000). 
The proteolytic effect of TNF  is thought to be mediated through IL-6.  
Circulating interleukin-2 (IL-2) and IL-10 levels can also be elevated in patients 
with DCM (Marriott JB et al., 1998) such that IL-2 may be elevated as a result of 
abnormal lymphocyte function, and the anti-inflammatory cytokine IL-10 may be 
increased as a counter-regulatory response. 
Li et al demonstrated a direct relation between cardiotrophin-1 (CT-1), an 
inflammatory cytokine induced following myocardial infarction, and NE release 
and uptake (Li W et al., 2003). The group studied the effects of CT-1 on cultured 
sympathetic neurons and showed that CT-1 suppresses NE uptake by decreasing 
tyrosine hydroxylase and NET mRNA. 
To date, anti-TNF  therapy has shown to be ineffective in HF patients. Two large 
trials of anti-cytokine medication, Etanercept, in HF were recently stopped (Anker 
& Coats, 2002). The Randomised Etanercept North American Strategy to Study 
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Antagonism of Cytokines (RENAISSANCE) and Research into Etanercept: 
Cytokine Antagonism in Ventricular Dysfunction (RECOVER) trials and their 
combined analysis – Randomised Etanercept Worldwide Evaluation 
(RENEWAL) examined the effects of Etanercept, a fusion protein directed against 
TNF  (Coletta A et al., 2002). A total of 1123 patients were recruited into the 
RECOVER study
 
and 925 into RENNAISSANCE, of these 25% were NYHA 
class II,
 
70% class III and 4% were in class IV; 62% of patients had ischaemic
 
heart disease. The mean treatment period was 12.7 months in
 
the RENAISSANCE 
study and 5.7 months in the RECOVER study.
 
There was no significant difference 
between placebo and etanercept
 
in terms of the primary endpoint in either study. 
Analysis of
 
hazard ratios for death/worsening heart failure showed that
 
in the 
RECOVER study patients on the higher dose appeared to
 
show slightly better 
results than those on the lower dose (0.87
 
versus 1.01). In the RENAISSANCE 
study the hazard ratio
 
was increased in the etanercept treatment group. There
 
was 
also a trend towards an increased risk of death in the etanercept
 
group for both 
studies combined (hazard ratio of 1.10) and an
 
indication of worse outcome in 
patients with non-ischaemic heart
 
disease and in those aged less than 65 years. A 
smaller study, the anti-TNF alpha therapy against chronic heart failure 
(ATTACH), that examined the effect of Infliximab (antibody against TNF) was 
also stopped early due to increased adverse events in the treatment group (Coletta 
A et al., 2002).  
Questions, however, persist about the administered doses and HF classes of the 
patients involved. Thus, although high dose anti-TNF  therapy may not be useful 
in HF, the effect of lower doses on the cytokine hypothesis of HF has not yet been 
adequately established (Anker & Coats, 2002). 
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1.3.3  Involvement of the Extracellular Matrix in 
Remodeling 
The ECM plays a key role in both systolic and diastolic myocardial performance 
and cell signaling since it is an important determinant of the structural 
characteristics of the myocardium and consists of different components such as 
collagens, proteoglycans, glycoproteins (e.g. fibronectin), peptide growth factors, 
and proteases. The ECM is in dynamic equilibrium, regulated by a family of 
metabolic zinc dependent proteases termed matrix metalloproteinases (MMPs) 
and their tissue inhibitors (TIMPS) (Dollery et al., 1995;Li et al., 1998). There is 
an increasing appreciation that through changes in the nature and quantity of the 
ECM, non-myocyte could play an essential role in determining the response of the 
myocardium to pathologic stimuli (Weber KT & Brilla CG, 1991). ECM is 
important in myocardial remodeling as it alters architectural structure and 
mechanical properties exerting profound functional effects (Rossi et al., 
1998;Weber et al., 1988;Gunja-Smith et al., 1996;Spinale et al., 1991).  
Different mechanisms have been shown to activate MMPs. However, the most 
relevant in the pathogenesis of HF is TNF-induced activation of MMPs associated 
with the loss of fibrillar collagen. The outcome is LV dilatation (Sivasubramanian 
N et al., 2001;Li YY et al., 2000). The dissolution
 
of the fibrillar collagen weave 
that surrounds the individual
 
cardiac myocytes and links the myocytes together 
would be expected
 
to allow for rearrangement (slippage) of myofibrillar bundles
 
within the ventricular wall (Weber KT, 1989). However, long-term stimulation 
(i.e., 8 to 12 weeks) with TNF in TNF-transgenic mice resulted
 
in an increase in 
fibrillar collagen content that was accompanied
 
by decreased MMP activity and 
increased expression
 
of TIMPs. Taken together,
 
these observations suggest that 
sustained myocardial inflammation
 
provokes time-dependent changes in the 
balance between MMP activity
 
and TIMP activity. That is, during the early stages 
of inflammation,
 
there is an increase in the ratio of MMP activity to TIMP levels
 
that fosters LV dilation. However, with chronic inflammatory
 
signaling, there is a 
time-dependent increase in TIMP levels,
 
with a resultant decrease in the ratio of 
MMP activity to TIMP
 
activity and a subsequent increase in myocardial fibrillar 
collagen deposition. 
52 
 
Pathologic myocardial hypertrophy also involves interstitial fibrosis, which may 
both alter the mechanical properties of the myocardium (e.g. impair relaxation) 
and restrict the delivery of nutrients to myocytes (Conrad CH et al., 1995). 
Conversely, a reduction or alteration in the quantity or quality of certain structural 
proteins could compromise the integrity of the extracellular skeleton and lead to 
chamber dilatation. Many factors present in the failing myocardium can influence 
the composition of the ECM for example, NE, acting on β-AR, can stimulate 
fibroblast DNA and protein synthesis (Calderone A et al., 1995), and endothelin 
can affect the synthesis and degradation of collagen in the myocardium (Guarda E 
et al., 1993). 
In addition to these structural defects, studies have shown the involvement of the 
both intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1) in the pathogenesis of HF (Terracio L et al., 1991). 
Immunohistochemical studies have shown that both ICAM-1 and VCAM-1 to be 
persistent in HF and myocarditis suggesting myocardial cell damage is partly 
induced through different immunological pathways (Ino T et al., 1997).  
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1.3.4  Alteration in LV Chamber Geometry 
The net outcome of the involvement of the inflammatory cytokines and the ECM 
is alteration in the ventricular chamber geometry. There are four patterns of LV 
geometry based on the relative wall thickness and the LV mass index (figure 1.8). 
Figure 1.8: Patterns of LV geometry 
 
Figure 1.8: Four different patterns of LV geometry based on relative wall 
thickness and LV mass index. Adapted from (Lang RM et al., 2005;Opie LH et 
al., 2006) 
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Normal Geometry 
Buckberg described the normal myocardium to consist of a single, continuous 
tissue that wraps around itself, spiraling up from the apex of the heart in a 
clockwise and anticlockwise fashion, to form a helix with elliptically shaped 
ventricles (Gerald D.Buckberg, 2002) (figure 1.9). 
Figure 1.9: The helical structure of the heart 
 
Figure 1.9: The helical heart is seen in (a). The apical view in (b) defines the 
clockwise and counterclockwise spirals. From (Gerald D.Buckberg, 2002). 
These spiral rotations produce an oblique muscle fiber orientation. Interestingly, 
the predominant motion of the heart
 
is not constricting and dilating, but rather 
shortening and
 
narrowing and hence when fibers shorten 15%, the net production 
is a 60% ejection fraction (EF) as depicted in figure 1.10. Because of its elliptical 
shape and defined apex, the ventricle is subjected to a relatively low level of 
lateral stress.  
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Figure 1.10: Relationship between fiber shortening and EF 
 
 
Figure 1.10: The relationship between fiber angle and ejection fraction is 
compared for contractile shortening of 15%. The transverse, or circular, 
arrangement allows a 30% EF, which becomes 60% with a spiral orientation. 
From (Gerald D.Buckberg, 2002;Buckberg GD et al., 2001a). 
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LV chamber geometry in HF 
In HF the geometry is altered depending on the initial insult. In HF secondary to 
anterior MI, the heart dilates because the apex is lost. Apical dilatation can also 
occur from valvular
 
insufficiency with ventricular stretching caused by volume 
overload.
 
In the non-ischemic failing heart, the muscle itself becomes
 
damaged 
and the spherical shape replaces the apical contour. From (Buckberg GD et al., 
2001b).
 
With HF, the helical
 
apex is lost and becomes replaced by a sphere. The structural
 
consequence is that the oblique apical loop fibers become more
 
transverse, so that 
the fiber orientation of the apical loop
 
begins to resemble the basal loop. 
Subsequently, the EF decreases and a 15% shortening produce only a 30% EF 
(Gerald D.Buckberg, 2002). 
1.3.5  Role of neurohormonal activity and inflammation in 
acute decompensated heart failure 
Chronic HF patients usually decompensate and present as de novo cardiac 
decompensation (Summers RL & Amsterdam E, 2009). The precipitating factors 
include non-compliance with diet and medication, uncontrolled hypertension, 
cardiac ischaemia, arrhythmias, pulmonary embolism, and other systemic illness. 
Studies have shown that patients with decompensated chronic HF have increased 
NH activity as reflected by elevated levels of NE, renin activity, endothelin, and  
aldosterone (Aronson D & Burger AJ, 2003b;Aronson D & Burger AJ, 2003a). 
These mediators are associated with vasoconstriction, fluid retention, and cardiac 
arrhythmias. In addition, increased levels of cytokines have been documented in 
those patients and have been significantly correlated with prognosis (Chin, 
2003;Mueller C et al., 2006). 
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In summary, HF is a complex syndrome that is associated with 
neurohormonal activation. The pathophysiology of HF is initiated by over-
stimulation of the cardiac SNS. The synaptic NE abundance in HF is 
secondary to excessive release from the afferent neurons and the failure of 
the NET uptake mechanism at the presynaptic membrane. Activation of the 
inflammatory axis and different pathways of the ECM will result into the 
pathological and remodeling features seen in HF. At the clinical level, cardiac 
sympathetic dysfunction has been correlated to impaired myocardial 
contractile reserve, impaired contractility, and reduced exercise tolerance 
(Ohshima S et al., 2005;L'abbate A & Sambuceti G, 2001).  
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1.4  Management 
Historically, prolonged bed rest was used to reduce heart rate, blood pressure, 
cardiac output and cardiac size, thus promoting recovery of the myocardial 
function (Burch GE & DePasquale NP, 1966).  
Over the past four decades management of HF has become more advanced and 
highly dependent on disease stage (Young JB, 2004). Mild to moderate disease is 
managed symptomatically using medications that include diuretics, β-blockers, 
angiotensin converting enzyme inhibitors (ACE-I), angiotensin II antagonist, and 
aldosterone antagonist (spironolactone). However, for advanced HF, cardiac 
transplantation has been the only effective treatment and remains the gold 
standard treatment (Korewicki J, 2009). 
 
1.4.1  Medical Management 
 
Modern therapeutic strategies usually involve reduction of myocardial work with 
stabilisation and improvement of myocyte function using a combination of 
pharmacological, non-pharmacological and surgical management. Advances in 
medical therapy to alleviate symptoms and favor prognosis have occurred in 
recent years with increased use of β-blockers, ACE-I, angiotensin II antagonist, 
and aldosterone antagonist. 
 
1.4.1.1  β-blockers 
Formerly, adrenergic blockade using β-blockers was contraindicated in HF due to 
the short-term adverse effects on the myocardial function (Epstein SE & 
Braunwald E, 1966;Gaffney TE & Braunwald E, 1963). Over the past two 
decades major randomised trials have confirmed that early initiation of β-blockade 
therapy is safe and improves the outcome of HF patients (Table 1.4). 
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Table 1.4: Summary of large randomised trials with β-blockers and the ACC/AHA guidelines recommended doses.  
β-blocker Trial 
Patients 
(n) 
Benefit 
Initial Dose 
(mg) 
Maximum 
Dose (mg) 
Metoprolol MDC 383 
All-cause mortality or morbidity was 34% lower in the metoprolol as compared to the 
placebo group. The change in EF from baseline to 12 months was significantly greater 
with metoprolol than with placebo (p < 0.0001). 
5–10 bd 100 bd 
Metoprolol 
CR/XL 
MERIT-HF 3,991 
All-cause mortality was 34% lower in the metoprolol CR/XL group than in the placebo 
group (7.2% versus 11.0%, p = 0.00009). 
12.5–25 od 200 od 
Carvedilol 
USCP 1,094 
All-cause mortality was 65% lower in the carvedilol than in the placebo group (3.2 versus 
7.8%, p < 0.001). 
3.125 bd 25 bd 
CAPRICORN 1,959 
All-cause mortality was lower in the carvedilol than in the placebo group (12% versus 
15%; p = 0.03). 
COPERNICUS 2,289 
Carvedilol reduced the combined risk of death or hospitalization for a cardiovascular 
reason by 27% (p = 0.00002) and the combined risk of death or HF hospitalisation by 
31% (p = 0.000004). 
COMET 3,029 
All-cause mortality was lower in the carvedilol than in the metoprolol group (34% versus 
40%, p = 0.0017). 
Bisoprolol 
CIBIS 641 Bisoprolol reduced HF hospitalisation (p < 0.01) and improved the functional status. 
1.25 od 10 od 
CIBIS II 2,647 
All-cause mortality was 34% lower with bisoprolol than in the placebo group (11.8% 
versus 17.3%, p < 0.0001). 
CIBIS III 1,010 
This study demonstrated that it may be as safe and efficacious to initiate treatment for 
CHF with bisoprolol as with enalapril. 
Table 1.4: Large randomised trials with β-blockers. MDC, Metoprolol in Dilated Cardiomyopahty Study; MERIT-HF, Metoprolol CR/XL 
Randomised Intervention Trial in Congestive Heart Failure; USCP, US Carvedilol Program; CAPRICORN, Carvedilol Post-Infarct Survival 
Control in Left Ventricular Dysfunction; COPERNICUS, Carvedilol Prospective
 
Randomized Cumulative Survival; COMET, Carvedilol or 
Metoprolol European Trial; CIBIS, Cardiac Insufficiency Bisoprolol Study. Adapted from (Mann DL & Bristow MR, 2005).  
60 
 
At the cellular and molecular levels, β-blockers have been shown to prevent the toxic 
effects of NE, improve myocardial oxygen supply to demand ratio by lengthening 
diastolic coronary flow, reduce contractile responses to increased sympathetic 
activity, increase the use of more energy efficient substrates, reduce LV volumes and 
hence improve systolic function, increase functional capacity and exercise tolerance, 
reduce re-infarction rate post-MI and overall mortality, improve tachycardia, reduce 
the progression to symptomatic HF, reduce the production of aldosterone, and induce 
molecular remodeling through induction of the foetal gene program (Wild DM & 
Kukin M, 2007;Bristow MR, 1997;Hall SA et al., 1995;Lowes BD et al., 202;Lowes 
BD et al., 1999;Bristow MR et al., 1998;Doughty RN et al., 1997;Eichhorm EJ, 
1992;Eichhorm EJ et al., 2009;Lechat P et al., 1998;Metra M et al., 1994;The 
Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group, 1998;Colucci 
WS, 1997;Lechat P et al., 2001).  
These beneficial effects on LV remodeling might be responsible for the improvement 
in symptoms and reduction in mortality seen with the use of β-blockade therapy 
(Cleland JGF et al., 1999). 
Differences exist in adrenergic receptor selectivity. Both metoprolol and bisoprolol 
(second generation) are β1 specific blockers that increase the density of β-receptors 
and cardiac NE concentrations (Bristow MR, 1997;Heilbrunn SM et al., 1989). In the 
MDC trial, the need for cardiac transplantation but not death was reduced in those 
treated with metoprolol (Waagstein F et al., 1993). In the CIBIS trial, there was a 
20% reduction in mortality and 30% fewer admissions for HF (CIBIS Investigators 
and Committees, 1994). The follow-on CIBIS-II trial showed a 32% reduction in 
hospitalisation (similar to the 34% from metoprolol in the MERIT-HF  study and 
35% from carvedilol in the COPERNICUS trial) (Leizorovicz A et al., 2002;Sallach 
JA & Goldstein S, 2003;Domanski MJ et al., 2003;MERIT-HF Trial, 1999;Packer M 
et al., 2001a).. 
Carvedilol, a third generation β-blocker and a slightly β1 selective antagonist but 
non-selective at higher doses (Bristow MR, 2000), reduces cardiac NE concentration 
(Ruffolo RR Jr & Feuerstein GZ, 1997), decreases cardiac adrenergic drive (Ruffolo 
RR Jr & Feuerstein GZ, 1997), has anti-oxidant properties which will reduce the 
oxidative stress observed in remodeling and apoptosis (Feuerstein GZ et al., 
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1997;Feuerstein GZ et al., 1993;Yue TL et al., 1992;Nakamura K et al., 2002). 
Carvedilol does not up-regulate cardiac β-receptors (Gilbert EM et al., 1993) and 
when administered in conjunction with digoxin, diuretics and ACE inhibitor, there 
was a significant reduction in mortality rate to 3.2% as compared to 7.8% in the 
placebo treated group and in the rate of hospitalisation by 26% - 38% (Colucci WS et 
al., 1996;Packer M et al., 1996b;Packer M et al., 1996a). 
According to Bristow, carvedilol is tolerated by around 92% of those with mild-
moderate HF (Bristow MR et al., 1998). In meta-analyses, carvedilol has been 
associated with greater increase in EF than metoprolol (Gilbert EM et al., 
1996;Metra A et al., 2000;Packer M et al., 2001a;Packer et al., 2001;Metra et al., 
2000;Francis & Cohn, 1990;Doughty et al., 1997;Lowes et al., 1999;Gilbert et al., 
1996). In addition, carvedilol was shown to reduce LV mass and mitral regurgitation 
whilst improving cardiac geometry (Bristow MR, 1997;Bristow MR et al., 1998;Hall 
SA et al., 1995;Lowes BD et al., 1999). 
Recently, two trials have provided further insight into the benefits of carvedilol in 
HF. The COMET trial addressed the heterogeneity of β-blockers with respect to the 
outcome and showed over 5-years period, carvedilol reduced mortality by 17% in HF 
patients as compared to metoprolol (Poole-Wilson PA et al., 2003). The second 
study, the Carvedilol Hibernation Reversible Ischaemia Trial: marker of success trial 
(CHRISTMAS), investigated possible mechanisms of β-blocker induced 
improvement of myocardial function (Cleland JGF et al., 2003). Investigators 
hypothesised that carvedilol induced improvement in EF is associated with the extent 
of hibernating or reversibly ischaemic myocardium such that the majority (66%) of 
those who benefited had evidence of hibernating myocardium or reversible 
ischaemia in two or more segments of myocardium. Carvedilol was shown to 
improve function in hibernating segments through reduction in heart rate, conserving 
energy and improving myocyte efficiency, increasing duration of diastolic blood 
flow, switching energy substrate from free fatty acids to the more efficient glucose 
and enhancing the protective effects of its antioxidant actions (Feuerstein GZ & 
Ruffolo RR Jr, 1995). 
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1.4.1.2  Renin Angiotensin Aldosterone System blockers 
Development of ACE-I was the first major pharmacological step in achieving RAAS 
blockade (Ondetti MA et al., 1977). Initially they were used in hypertension but it 
emerged that their mechanism was greater than simply reducing systemic vascular 
resistance. They reduce production of AngII and bradykinin breakdown with 
beneficial effects on vascular tone, atherosclerosis and thrombosis (Chobanian AV et 
al., 1990;Ridker PM et al., 1993). 
It has become clear that ACE inhibition leads to arterial and venous vasodilatation 
and unloads the LV thereby improving cardiac pump function, leading to 
improvement in clinical condition, exercise tolerance and prognosis (The 
CONSENSUS Trial Study Group, 1987a). Addition of an ACE-I inhibitor to a 
regime of rest, salt restriction and a diuretic has therefore become an established 
approach to clinical management of post-MI patients with LV dysfunction and 
symptoms of HF (ACE Inhibitor Myocardial Infarction Collaborative Group, 
1998;Garg R & Yusuf S, 1995).  
Although there were differences in the characteristics of the studied population, both 
Studies of Left Ventricular Dysfunction (SOLVD) and Survival and Ventricular 
Enlargement (SAVE) trials have suggested that ACE-I treatment reduced the risk of 
cardiovascular events and hospitalisation (Yusuf S et al., 1992). The SOLVD trial 
studied the effects of enalapril in patients with low EF with or without symptoms of 
HF. Those treated with enalapril had reduced remodeling with a significant reduction 
in the risk of developing HF (Greenberg BH et al., 1995;Konstam MA et al., 1992). 
In the SAVE trial, the effects of captopril was studied in MI survivors with LV 
dysfunction with no symptoms of HF. It showed that  long-term captopril treatment 
is associated with improved survival and reduced morbidity and mortality, reduced 
post MI LV remodeling and reduced risk of death from cardiovascular causes by 
21%, risk of heart failure by 37%, and recurrent MI by 25% (Pfeffer MA et al., 
1992;St John SM et al., 1994). In contrast results from the Cooperative New 
Scandinavian Enalapril Survival Study (CONSENSUS II), also designed to evaluate 
enalapril post-MI, failed to show improved survival during the six months follow-up 
peiod (CONSENSUS Trial Study Group, 1987). 
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The results of both SOLVD and SAVE trials led to the Heart Outcomes Prevention 
Evaluation (HOPE) study in which ramipril was administered to those at high risk of 
cardiovascular disease but without LV dysfunction or symptoms of HF. The 
outcomes were that ramipril prevented events related to ischaemia and 
atherosclerosis in addition to those already identified relating to HF and LV 
dysfunction. Further, risk of death, MI, cerebrovascular accidents (CVA), coronary 
revascularisation, HF, new cases of diabetes mellitus and its complications were 
substantially reduced (McQueen MJ et al., 2005). 
These findings suggested that reducing tissue activity of the RAAS allowed the 
cardiovascular and renal systems to avoid the deleterious effects of AngII and 
aldosterone activities which were discussed in section 1.3.1.3 and included growth, 
hypertrophy, proliferation, collagen deposition and tissue remodeling. In particular, 
there was enough evidence that ACE inhibition prevented the adverse long-term 
consequences of cardiac remodeling, with beneficial reductions in HF and mortality 
(Lonn EM et al., 1994;Pfeffer MA et al., 1988;Cohn JN et al., 2000;Sutton MG & 
Sharpe N, 2000).  
The vascular protective effects include direct anti-atherogenesis through increased 
production of prostacyclin, anti-proliferative and anti-migratory effects on smooth 
muscle cells, neutrophils and mononuclear cells, improvement of endothelial 
function, protection from plaque rupture, anti-platelet effects, enhancing endogenous 
fibrinolysis, anti-hypertensive effects and improved arterial compliance and tone 
(Lonn EM et al., 1994). Rutherford et al have also shown that the need for 
revascularisation is reduced in patients receiving long-term captopril therapy for 
ischaemic heart disease (IHD) induced HF (Rutherford JD et al., 1994). The 
cardioprotective effects included restoration of balanced oxygen supply and demand 
through haemodynamic alterations, reduction of LV mass and sympathetic 
stimulation, and beneficial effects on reperfusion injury (Lonn EM et al., 
1994;Pfeffer MA et al., 1988). Coronary vasoconstriction may also benefit through 
reduced production of AngII, inhibition of bradykinin breakdown and increased 
production of NO (Perondi R et al., 1992). ACE inhibition was also shown to stop 
the reduction in SERCA2a seen in cardiac hypertrophy, normalise SERCA2a protein 
levels and Ca
2+
 uptake, normalise myocyte relaxation and decline in intracellular 
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Ca
2+ 
concentration, and improve both SR dependent and independent Ca
2+
 cycling 
(Boateng et al., 1998;Boateng et al., 2001;Zierhut et al., 1996;Bruckschlegel et al., 
1995;Anger et al., 1995) although the precise signalling mechanisms remain unclear 
(Boateng et al., 1998).  
In addition to the effects on Ca
2+
 handling proteins, ACE-I were found to reverse 
cardiac sympathetic nerve terminal abnormalities seen in HF. Finally, Kawai et al 
have demonstrated a significant improvement in cardiac NE uptake and the reversal 
of cardiac sympathetic nerve terminal abnormalities seen in HF with ACE inhibition 
(Kawai H et al., 1999;Kawai H et al., 2000). 
1.4.1.3  Angiotensin II Antagonists 
It is well recognised that ACE inhibition does not fully block AngII production since 
other pathways allow continued residual AngII activity (Urata H et al., 1990). 
Therefore, blocking AT receptors is considered to be a more beneficial target to 
inhibit the effects of AngII. 
Recent evidence suggests that AT1 blockers have similar effects as ACE inhibitors 
on cardiac remodeling and HF. However, pharmacological differences exist in that 
they can inhibit the action of AngII generated through not only by ACE but also from 
other pathways (Urata H et al., 1990;Liu YH et al., 1997;Pitt B et al., 2000;Liu et al., 
1997;Pitt et al., 2000;Urata et al., 1990). Many AT1 receptor blockers are available 
that might shift activity toward stimulation of the beneficial (AT2) receptors. 
Interestingly, activation of AT2 receptors mediate antigrowth effects (Ohkubo N et 
al., 1997). Therefore blocking the deleterious actions of AngII at the AT1 receptor 
may make the favourable actions of AngII on the AT2 receptor unopposed. Although 
evidence is conflicting, this may counter-regulate the detrimental effects of the AT1 
receptor during cardiac hypertrophy and HF (Horiuchi M et al., 1999). No 
therapeutic agents are currently available for specific action on the AT2 receptors. 
Experimental studies have revealed that combination therapy of ACE-I and AT1 
receptor blockers have benefits in excess of single agent therapy both in HF and 
remodeling post-MI (Nakamura Y et al., 2009;Kim S et al., 2001). In clinical 
practice, Hamroff et al demonstrated that HF patients treated with losartan in 
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addition to ACE-I had improved exercise tolerance (Hamroff G et al., 1999). Another 
study, the Randomised Evaluation of Strategies for Left Ventricular Dysfunction trial 
(RESOLVD) studied the combined effects of candesartan and enalapril in 
symptomatic HF (The CONSENSUS Trial Study Group, 1987a). RESOLVD 
investigators demonstrated that the combined therapy was well tolerated by most, 
prevented increases in LV systolic and diastolic volumes seen when single agent 
therapy is used, resulted in the most significant reduction of aldosterone and BNP 
levels, and prevented cardiac remodeling. The Valsartan Heart Failure Trial (Val-
HeFT) examined the effects of adding valsartan to standard HF therapy and similarly 
demonstrated a significant reduction in mortality and morbidity (Cohn JN & Tognoni 
G, 2001). 
1.4.1.4  Aldosterone Antagonist 
As discussed above, ACE inhibition will inhibit aldosterone production, a transient 
effect of ACE-I.  
The Randomised Aldactone Evaluation Study (RALES) showed beneficial effects 
from spironolactone administration in HF resulting in 30% increased survival due to 
reverse remodeling by reversal of matrix fibrosis (Zannad F et al., 2000). It also 
showed that low doses could oppose the effect of aldosterone in promoting cardiac 
fibrosis. Only those patients with a reduction in serum profibrotic markers following 
administration had improved survival benefit and the largest benefit was found in 
those groups with the highest baseline serum collagen markers. Two further trials 
have shown significant benefit with aldosterone antagonism in heart failure patients 
and concluded that the benefits may be partially related to enhanced NE uptake and 
decreased NE release from nerve terminals (Pitt B et al., 1999;Pitt B et al., 2003). 
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1.4.1.5  Digitalis 
The use of digitalis has been plagued by controversy since its
 
initial use by Withering 
in 1775 (Harding JP & Jessup M, 2005). In addition to its well-known positive 
inotropic effect, digoxin has been shown to lessen autonomic dysfunction.  
The Digitalis Investigation Group (DIG) has illustrated that the incidence
 
of both 
death and hospitalization has reduced when digoxin was added to diuretics and ACE-
I (The Digitalis Investigation Group, 1997). The effectiveness of digoxin therapy in
 
men with heart failure and a LV EF
 
of 45% may be optimal when the serum 
digoxin concentration is
 
in the range of 0.5 to 0.8 ng/ml (Rathore SS et al., 2003) 
suggesting that lower doses
 
of digoxin may be safer. Digoxin may also be less safe in 
women (Rathore SS et al., 2002). The most recent DIG trial examined the effects of 
digoxin on all cause mortality and hospitalisation in HF patients with EF <45% 
(Collins JF et al., 2003). The outcome was improved symptoms, but no significant 
effect on mortality. 
1.4.1.6  Inotropes 
Although their use is controversial, inotropes have been extensively kept as the last 
non-surgical therapeutic option in the treatment of patients with acute HF. The most 
commonly used intravenous inotropes include adrenergic agonists, endogenous 
catecholamines, and phosphodiesterase inhibitors. Intravenous inotropic therapy for 
acute HF has various regimens: short-term, long-term, or intermittent infusion, as 
described below (Brater DC, 1998): 
 Short-term inpatient therapy consists of infusion lasting several hours to a 
few days in combination with diuretics until patients are clinically 
stabilized. 
 Prolonged continuous infusion via an indwelling intravenous catheter 
may become necessary in patients with advanced HF who cannot be 
weaned from intravenous to oral therapy (1) to enable them to be 
discharged from the hospital, (2) to serve as a bridge to a more definitive 
intervention (eg, revascularization, assist device placement, or cardiac 
transplantation), or (3) to serve as a palliative care. 
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 Periodic intermittent infusion has been proposed in an attempt to improve 
clinical outcomes, for example, as a pulse infusion (4–6 hours) for several 
days per week or as a single longer infusion (24–72 hours) once 
weekly(Brater DC, 1998;Hunt SA et al., 2005). This strategy has been 
controversial. The American College of Cardiology/American Heart 
Association (ACC/AHA) 2005 guideline on chronic HF(Hunt SA et al., 
2005) recommends against intermittent intravenous positive inotropic 
therapy for HF, even in its advanced stages. 
Inotrope usage is associated with extensive injury to the myocardium. In one study, 
approximately 14% of patients were treated with inotropes where only 15% had 
preserved LV systolic function following treatment (Adams KF et al., 2003). A 
retrospective observational analysis has shown that short-term inotrope therapy 
(dobutamine or milrinone) was associated with significantly higher in hospital 
mortality compared with short-term vasodilator therapy (nitroglycerin or nesiritide) 
(Abraham WT et al., 2005). These findings have also been confirmed by other 
investigators (Boehar N et al., 2008;Shin DD et al., 2007) and raise concerns that 
inotrope therapy for acute HF may be harmful, especially when used in patients who 
do not have low blood pressure or low cardiac output.  
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1.4.2  ICD implantation and resynchronisation therapy 
Approximately 25% of patients with HF have abnormal electrical activation of the 
LV leading to dyssynchronous contraction between the walls of the LV (Kass DA, 
2003). The result is less efficient ventricular emptying and in many cases mitral 
regurgitation. Dyssynchrony also increases net end-systolic volume and wall stress 
and induces regional redistribution of stress. Chronically, this leads to hypertrophy of 
the stressed region with increased metabolic demand coupled with higher glucose 
metabolism and blood flow requirements (Kass DA, 2003). In addition, 50% of 
patients with severely reduced LV EF (<30%) die suddenly, mostly as a result of 
ventricular arrhythmias (Ehlert FA et al., 2010). 
The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) showed that an 
implantable cardioverter defibrillator (ICD) reduced the risk of death by 23% in 
patients with mild to severe symptomatic HF and reduced EF who were receiving 
optimum antiarrhythmic therapy (Bardy GH et al., 2005a). These findings are 
supported by similar large reductions in death with a cardiac resynchronisation-
defibrillator device (CRT-D) in patients with severe symptomatic HF and a low LV 
EF in the COMPANION study (Comparison of Medical Therapy, Pacing and 
Defibrillation in Heart Failure) (Bristow MR et al., 2004a) and with an ICD in 
survivors of myocardial function with a reduced LV EF in the MADIT-2 trial 
(Multicenter Automatic Defibrillator Implantation Trial with Cardiac 
Resynchronization Therapy) (Moss et al., 2002). A major limitation of ICD is its cost 
as it has been estimated that the number of ICD‘s needed to be implanted to save 1 
life is 18 (Sanders GD et al., 2005). 
Cardiac-resynchronization therapy (CRT) received Food and Drug
 
Administration 
(FDA) approval for use in selected patients with severe systolic dysfunction in 2001. 
A number of pivotal prospective trials have consistently shown that
 
CRT improves 
EF, quality of life (QOL), and functional status
 
in symptomatic patients with an EF 
of less than 35% and a
 
prolonged QRS duration (mean range, 155 to 209 msec) (Bax 
JJ et al., 2005). In addition,
 
a systematic review in 2007 demonstrated that CRT 
decreased the rate
 
of hospitalization by 37% and lowered the rate of death from
 
any 
cause by 23% in HF patients (McAlister FA et al., 2007).  
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In 2009, Bax and Gorcsan reported that 30% of patients who received CRT do not 
benefit (Bax JJ & Gorcsan J, 2009) as they demonstrated a positive clinical response 
as shown by an increase in exercise capacity and improvement in QOL measures. 
These improvements, however, were not accompanied by improvements in LV 
systolic function. This observation has led to two related areas of investigation: i) 
alternative measures to detect mechanical dyssynchrony (i.e. disparity
 
in the timing 
of regional ventricular contraction) apart from
 
the electrical delay that is manifested 
by a wide QRS duration, and ii) selection of patients who are likely to have more 
consistent
 
benefit from CRT. Evidence of mechanical dyssynchrony has been
 
shown 
to be an independent predictor of clinical events and
 
worsened survival in patients 
with HF and has correlated
 
better than the QRS duration with the long-term benefit 
of CRT (Bax JJ & Gorcsan J, 2009). 
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1.4.3  Surgical Management 
Despite the advances in medical management of HF, there remain circumstances in 
which surgical procedures are the only or best treatment option. 
1.4.3.1  Cardiac Transplantation 
The first successful human-to-human heart transplant was performed in 1967 
(Barnard CN, 1967). Early results were not very promising due to allograft rejection 
and the procedure was dedicated to highly specialised centres. It wasn‘t until the 
introduction of cyclosporine A in the early eighties that cardiac transplantation has 
become the therapeutic procedure of choice for patients with end-stage HF (Hunt SA, 
1998). Unfortunately, transplantation is limited by the small number of donor hearts 
available such that transplant numbers have decreased worldwide and meet less than 
10% of the need for cardiac replacement therapy. Figure 1.11 represents the trend in 
cardiac transplantation since the registry has started in 1982. 
Figure 1.11: The ISHLT Registry of adult heart transplants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.11: The ISHLT registry of all adult heart transplants since 1982 until 31 
December 2007. From (ISHLT Registry, 2009). 
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It is also worth noting that transplantation is inapplicable in older patients or those 
with co-morbid medical conditions that could preclude them from consideration for 
transplantation. Other problems associated with transplantation include rejection and 
coronary graft atherosclerosis. Even following successful transplantation, 1-year 
survival is only around 79% with a subsequent attrition rate of 4% per annum and 
10-year survival <50% (Hosenpud et al., 1998). Although these results are better than 
medical therapy, they remain far from ideal. 
To address this problem alternative supportive surgical strategies have evolved 
including coronary artery revascularisation, mitral valve surgery, left ventricular 
reduction, cardiomyoplasty, and mechanical circulatory support (Bolling SF et al., 
2001;Garrido MJ & Oz MC, 2002;Gregoric I et al., 2002;Slaughter MS & Ward HB, 
2000;Zeltsman D & Acker MA, 2002). 
1.4.3.2  Revascularisation 
From 25 multi-center trials (where approximately 44,000 HF patients were studied) 
coronary artery disease was reported to be the cause of HF in nearly 65% of the 
patients (Cohn JN et al., 1986;CONSENSUS Trial Study Group, 1987;DiBianco R et 
al., 1987;Studies of Left Ventricular Dysfunction Investigators (SOLVD), 
1991;Cohn JN et al., 1991;Packer M et al., 1991;Studies of Left Ventricular 
Dysfunction Investigators, 1992;Packer M et al., 1993;Feldman AM et al., 
1993;Singh SN et al., 1995;Packer M et al., 1996a;Packer M et al., 1996c;Digitalis 
Investigation Group, 1997;Cohn JN et al., 1998;Pitt B et al., 1999;Torp-Pedersen C 
et al., 1999;Colucci WS et al., 2000a;Packer M et al., 2001b;Beta-Blocker Evaluation 
of Survival Trial Investigators, 2001;Cohn JN & Tognoni G, 2001;Abraham WT et 
al., 2002;Bristow MR et al., 2004b;Bardy GH et al., 2005b;Cleland JGF et al., 
2005;Taylor AL et al., 2004;Jones RH et al., 2009a). 
It is well established that coronary artery bypass grafting (CABG) increases survival, 
improves angina, and improves QOL in patients with HF secondary to IHD 
(Alderman EL et al., 1983;Edmond M et al., 1994;CASS Investigators, 1984). The 
use of arterial revascularisation and off-pump techniques has produced additional 
benefits (Bittner HB & Savitt MA, 2002) and studies have shown that viable 
myocardium, as assessed using stress echocardiography or positron emission 
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tomography (PET), is a prerequisite for successful coronary revascularisation (Pitt M 
et al., 2001;Kalra DK & Zoghbi WA, 2002;Allman KC et al., 2002). 
1.4.3.3  Mitral Valve Surgery 
Functional mitral regurgitation is a significant complication of end-stage HF, and 
may affect all patients as a pre-terminal or terminal event. Mitral regurgitation 
develops secondary to an alteration in the annular-ventricular apparatus (Chen FY et 
al., 1998) and altered ventricular geometry (Boltwood CM et al., 1983), resulting in 
incomplete leaflet coaptation 
*
.  
In ischaemic HF this can be attributed to papillary or lateral wall muscle dysfunction, 
whereas in non-ischaemic HF patients, mitral regurgitation can be ascribed to 
annular dilatation and chordal tethering, all as a result of remodeling. Left ventricular 
adaptations to mitral regurgitation include increase in pre-load, wall tension, diastolic 
volume, and stroke volume (SV). 
Historically, the surgical approach to treat functional mitral regurgitation in HF was 
mitral valve replacement. However, studies have shown that interruption of the 
annulus-papillary muscle continuity is associated with very high mortality 
(Stevenson LW et al., 1987;Blondheim DS et al., 1991;Pitarys CJ II et al., 
1990;Pinson CW et al., 1984). In 1983, Tyrone David reported the importance of 
preserving the annulus-papillary muscle continuity (David TE et al., 1983) such that 
preserving the mitral valve apparatus enhances and maintains LV function and 
geometry with an associated decrease in wall stress (Goldman ME et al., 
1987;Tischler MD et al., 1994). There is now compelling evidence that mitral valve 
annuloplasty using an undersized remodeling ring with or without mitral valve repair 
is more superior to mitral valve replacement (Smolens IA et al., 2000;Badhwar V & 
Bolling SF, 2002;Bolling SF, 2002;Carpentier A et al., 1980;Enriquez-Sarano M et 
al., 1995). The aim of the annuloplasty is to reduce the mitral annulus to correct for 
the zone of coaptation. Either procedures has been shown to re-establish the ellipsoid 
shape and somewhat the normal geometry to the base of the LV (Bolling SF et al., 
1995;Bach DS & Bolling SF, 1996;Bach DS & Bolling SF, 1995;Romano MA & 
                                                 
*
 Coaptation generally requires a large leaflet area greater than 2.5 times than the area of the mitral 
valve orifice (Bolling SF et al., 2001). 
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Bolling SF, 2004), to improve coronary flow reserve and velocity especially in those 
with restricted coronary flow reserve (Akasaka T et al., 1998), and to reduce the 
activated cytokines and pro-inflammatory markers seen in HF (Smolens IA et al., 
2000). Furthermore, operative mortality is reduced to less than 5% and one year 
survival exceeds 80% (Smolens IA et al., 2000;Bishay ES et al., 2000;Bitran D et al., 
2001). In patients with mild to moderate mitral regurgitation secondary to ischaemic 
HF, Tolie et al have suggested that revascularisation alone is sufficient to enhance 
improvement in mitral regurgitation with perioperative mortality of 2% and 50% 5-
year survival (Tolis GA Jr et al., 2002). It is worth noting that mitral insufficiency 
may still occur with adequate coaptation suggesting that there is a subvalvular 
malfunction and hence the optimal surgical intervention in these situations is mitral 
valve replacement (Calafiore AM et al., 2001). 
1.4.3.4  LV Volume Reduction 
In 1996, Batista was the first to state that all mammalian hearts share the same ratio 
of mass to diameter, regardless of the size of the heart (m = 4r
3
, where m and r 
represent the mass of the heart and the radius of the LV chamber, respectively) 
(Batista RJ et al., 1996). The group proposed that for those hearts that do not comply 
with this relationship, an operative procedure, LV myoreduction surgery, should be 
performed to restore the ratio to normal. With this procedure, Batista has 
demonstrated a reduction in the LV volume from 200 mls to approximately 90-100 
mls, intra-operative mortality of 5%, a 30-day mortality of 22%, and a 2-year 
survival of 55%. The Cleveland group reported perioperative mortality of 3.2% and a 
2-year survival rate of 68% (McCarthy PM, 1999). This procedure, however, has not 
been met with great success in the United States or worldwide due to the high 
incidence of procedure failure (McCarthy JF et al., 1998;Konertz W et al., 1999). 
From the Surgical Treatment for Ischemic Heart Failure (STICH) trial, Jones et al 
concluded that adding surgical ventricular reconstruction surgery to CABG has 
resulted in a significant reduction in the LV volumes as compared with CABG alone, 
however, there was no greater improvement in symptoms, exercise tolerance, 
reduction in death rate or hospitalisation for cardiac causes (Jones RH et al., 2009b).  
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In 1985 Professor Dor and his group introduced an endoventricular circular patch in 
an attempt to restore the natural geometry and the dynamics of the LV (Dor V et al., 
2001) in ischaeic HF with anterior infarct that involves the apex. The idea is based 
on the fact that ventricular contraction starts at the apex and moves to the left-
ventricular outflow tract. By excluding the infarcted apical septum and replacing it 
with a patch, a more ellipsoid ventricle is created (De Bonis M & Alfieri O, 2006). 
The left ventricle is opened through the infracted apex and the transitional zone 
between scar tissue and viable myocardium is identified. A circular purse-string 
suture is applied. Finally, the apex is closed either directly or using a patch. Care 
must be taken not to undersize the ventricular cavity. This approach has been limited 
to ischaemic dilated cardiomyopathy and its use was contraindicated in patients with: 
i) systolic pulmonary artery pressure more than 60 mm Hg (when
 
not associated with 
severe mitral regurgitation); ii) severe right
 
ventricular dysfunction as assessed by 
tricuspid
 
anulus
 
plane systolic excursion technique; and iii) regional asynergy 
without dilation of the ventricle (Menicanti L & Di Donato M, 2002). Other relative 
contraindicating factors include NYHA class IV, EF less than
 
20%, age more than 70 
years, the need for urgent intervention, and the need for an additional mitral 
procedure
 
(especially mitral valve replacement).
 
 
1.4.3.5  External Compression 
In 1984, Professor Carpentier was the first to introduce external compression as 
dynamic cardiomyoplasty technique. Recently, studies have shown that positioning a 
mesh graft around the heart had: 
i. stopped further dilatation in the LV (Oz MC, 2001),  
ii. induced a significant reduction in wall stress and myocyte stretch (Oz MC, 
2001;Konertz WF et al., 2001),  
iii. resulted in improved functional mitral regurgitation (Chaudhry PA et al., 
2001),  
iv. enhanced ejection fraction (Konertz W et al., 2001),  
v. caused an improvement in end-systolic and end-diastolic volumes by an 
average of 15.6 mls and 18.8 mls, respectively (Starling RC et al., 2007), 
vi. resulted in a significant improvement in NYHA classification from 2.7 ± 0.1 
to 1.8 ± 0.2, p<0.001 (Bredin E et al., 2009), 
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vii. caused an increase in exercise tolerance as assessed by the 6-minute walk 
test (Bredin E et al., 2009), and 
viii. caused a significant reduction in BNP levels from 0.14 ± 0.04 ng/ml to 0.06 
± 0.03 ng/ml, p<0.05 (Bredin E et al., 2009).  
Examples of external compression devices are the Acorn device which comes in six 
different sizes to avoid overcompression. Another device is the Myosplint which 
consists of an implantable transventricular 1.4 mm polyethylene braided splint coated 
with expanded polytetrafluoroethylene and two polyestercoated epicardial pads. The 
splint is positioned to bisect the dilated LV, effectively creating two smaller LV 
chambers. The epicardial pads are adjusted to reduce the LV diameter. Based on 
Laplace‘ Law the wall tension is thereby decreased. Although early clinical results 
are promising, the need for a non-randomised clinical trial remains to be awaited 
(Fukamachi K & McCarthy PM, 2005).  
1.4.3.6  Mechanical Circulatory Assistance 
Mechanical circulatory assistance is an important adjunct to the management of 
patients with severe end-stage heart failure. This is a life saving approach in patients 
who fail to improve or stabilise with intravenous inotropes or vasodilators, intra-
aortic balloon pump (IABP) support and mechanical ventilation (Delgado DH et al., 
2002). 
Patients requiring mechanical circulatory assistance generally fall into four 
categories, those with: 
i) cardiogenic shock resulting from acute MI, 
ii) post-surgical myocardial dysfunction, 
iii) acute cardiac failure from myocarditis, 
iv) decompensating chronic HF. 
Although this approach falls under the surgical management category, it will be 
discussed separately in section 1.5. 
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1.5  Mechanical Circulatory Support 
Ventricular assist device (VAD)s are mechanical circulatory support (MCS) devices 
that assist the circulation. They are rapidly evolving and are being inserted into an 
increasing number of patients with advanced heart failure. VADs are not only life 
saving in decompensating chronic HF patients that would otherwise die before a 
donor heart became available, but also improve secondary organ function for 
transplantation, reduce pulmonary hypertension and allow for improvement of 
nutritional status.  
The future use of these devices, particularly as survival continues to increase, is 
likely to extend to their wider use as destination therapy i.e. when the device is 
inserted lifelong as an alternative to transplantation. 
There is also now compelling evidence that with LV unloading uing left ventricular 
assist devices (LVAD)s recovery of patients‘ myocardial function can also occur, 
allowing device removal and avoiding the need for transplantation, 
immunosuppression and its associated complications and leaving the patient with an 
excellent QOL. This also means that the precious resource of a donor organ can be 
used for another needy individual. This indication, known as ―bridge to recovery‖ 
(BTR), is a newer and expanding indication and will be the focus of this thesis. 
1.5.1  Overview of LVADs  
In 1953, Gibbon was the first to perform an open-heart surgery using 
cardiopulmonary bypass (CPB) circuit (Gibbon, 1954;Frazier, 2000). By the mid 
1960s, a shift had occurred from CPB circuits towards more dedicated cardiac assist 
devices.  
In 1971, De Bakey reported the first successful clinical application of a 
pneumatically driven VAD in a 37-year-old woman who could not be weaned from 
CPB following valve replacements (DeBakey M, 1971). She was supported for 10 
days with the paracorporeal circuit from left atrium to right axillary artery and was 
then weaned successfully and subsequently discharged from hospital. Seven years 
later, Norman et al reported a case of bridging to transplantation using an 
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intracorporeal pneumatic abdominal LVAD for 5 days when the patient survived the 
support but died after transplantation (Norman JC et al., 1978).  
The total artificial heart (TAH), developed by Liotta and DeBakey Baylor-Rice 
research team (DeBakey M, 2000), was first used as a temporary support device by 
Cooley et al in 1969 in a 47-year-old man who could not be weaned from CPB 
following repair of a LV aneurysm (Cooley D et al., 1969). The world‘s first 
permanent TAH implant occurred in 1982 with the Jarvik-7 in a 61-year-old man 
with advanced DCM who survived 112 days on support (Kirklin JK & Frazier OH, 
2006). 
Indication for TAH include: biventricular failure, LV failure with intractable 
arrhythmia, LV failure with prior mechanical heart valve replacement and LV failure 
with severe anatomical damage such as ventricular septal defect, or ventricular 
rupture. The CardioWest TAH is approved for use in the USA. It is pneumatically 
driven and is implanted in the orthotopic position. Its use has been assessed in five 
centres and the outcome was a significant improvement in the rate of survival to 
cardiac transplantation and survival after transplantation (Copeland JG et al., 2004). 
The AbioCor, anotherTAH has obtained conditional FDA approval as a destination 
device (Rohinton J Morris, 2008). 
VADs can be classified according to their principle of operation. First generation 
devices are pulsatile devices that generate pulsatile flow. They consist of multiple 
moving components and are subdivided into extracorporeal pneumatic (e.g. Abiomed 
AB5000 and Thoratec), intracorporeal pneumatic (e.g. Thoratec HeartMate I IP) or 
electromechanical (e.g. Novacor and Thoratec HeartMate I VE). Second generation 
devices are rotary pumps with one moving part that generate axial continuous flow. 
Examples include HeartMate II, MicroMed-Debakey, and Jarvik2000. Implantation 
of second generation devices is easier with greater reliability and reduced 
complications as compared to the first generation devices (Song et al., 2003). Third 
generation devices are based on magnetic levitation technology with no bearing parts 
such as the HeartWare VAD. 
All these devices are operated using an external power source with a driveline that 
usually exits the right upper abdominal quadrant and connects to the external 
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controller and batteries. The exit site of the drive line is an important source of 
infection. The future direction is to operate LVADs through a transcutaneous energy 
transfer system to avoid the need for an external driveline.  
MCS devices provide a spectrum of short or long-term circulatory support. LV 
support can be partial or complete and additional RV (RVAD) or even biventricular 
support (BiVAD) can be tailored to haemodynamic needs. The technology is being 
refined for application to broader patient groups with increased safety and lower cost 
(Frazier, 2003). 
Key features of long-term mechanical circulatory support are reliability, durability, 
biocompatibility, functionality and affordability. Blood-biomaterial interaction, the 
coagulation system and the immune response are all challenging biological barriers 
to the development of long term MCS (Dee K et al., 2002;Didisheim P, 1994;Koster 
A et al., 2000;Loebe M et al., 2001;Menconi MJ et al., 1995;Schuster M et al., 
2001;Spanier T et al., 1996). These have been partially defeated by developing and 
using specific materials and specific blood-contacting corrosion resistance surfaces 
which have certain structural strength and almost no toxicity levels (Burgreen GW et 
al., 2004). Other key features include reduced risk of infection and low incidence of 
device malfunction requiring part or all of the device to be replaced. 
Tables 1.5, 1.6, and 1.7 represent the characteristics of different types of VADs. 
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Table 1.5: Different Pulsatile VADs 
Pump Type Device Description Clinical Experience 
 
Thoratec Paracorporeal 
(PVAD) 
 
 
 
    
     
 
     
 
A positive displacement pump that generates a 65 ml 
of SV. 
 
It has volume capacity of 318 mls, weighs 417 grams 
and has a thick percutaneous lead (20 mm). 
 
The blood pumping chamber has two mechanical 
valves to ensure unidirectional flow and can produce a 
beat rate of 40-110 with a flow rate of 1.3-7.2 l/min 
using alternating positive and negative air pressures. 
 
Approved in USA, Europe, Japan, Canada and Australia for 
Bridge-to-Transplant (BTT) and postcardiotomy recovery. Can 
be used as an LVAD, RVAD, or BiVAD. 
 
INR needs to be maintained between 2.5 and 3.5. 
 
Until March 2005, 2900 patients were implanted with the 
PVAD. Worldwide, survival from implant to either 
transplantation or recovery was 64.8% when used as an LVAD, 
56.6% when used as a BiVAD, and 31.2% when used as an 
RVAD (www.thoratec.com).  
 
Been used for BTR in 3.8% with LVAD, 5.6% with BiVAD, 
and 8.3% with RVAD. The 5-year transplant-free survival was 
77% for this subgroup (www.thoratec.com).  
 
 
Thoratec Intracorpreal (IVAD) 
 
        
 
Implantable version of PVAD with slightly reduced 
weight (399 grams) and volume (252 mls). 
Percutaneous lead is also thinner (9 mm). 
 
Has a smooth polished titanium housing for 
implantability, and optical sensor that determines 
whether the pump is full or empty. 
 
Approved by the FDA in August 2004. 
 
Similar to PVAD, INR needs to be maintained between 2.5 and 
3.5. 
 
Until March 2005, 86 patients had IVAD of which 63 were for 
BTT (www.thoratec.com).  
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HeartMate I (HM I) 
 
2 models 
1) Implantable Pneumatic (IP) 
2) Vented Electric (VE) which 
has been modified to the 
XVE model 
  
(The modified version has: 1) the 
percutaneous lead strengthened 
to reduce kinking and occlusion; 
2) became more fatigue resistant; 
3)  provided more comfort; 4) the 
diaphragm repositioned to 
prevent diaphragm buckling; 5) 
the valve has been modified to 
prevent commisural dehiscence 
and incompetence; 6) the 
pressure chamber has been 
reduced to reduce stress on 
valves, motor, bearings and 
diaphragm). 
 
Made of titanium with polyurethane diaphragm.  
 
Has a low-speed torque motor that operates a pusher 
plate mechanism. Can be powered pneumatically and 
electrically (through two external batteries) and operates 
on two modes: auto and fixed 
 
Porcine valves (25 mm) are suspended in the inflow 
cannula and the outflow Dacron graft (diameter 20 mm) 
to ensure unidirectional blood flow. 
 
The device pumps between 4 and 10 l/min with a 
maximum SV of 83 mls. 
 
It has a unique blood pumping surface which consists of 
titanium microspheres and a fibrillar textured surface 
that promotes ―pseudointima‖ that resists 
thrombogenesis, although it has also been shown to be 
immunologically active (Ankersmit HJ et al., 
1999;Spanier TB et al., 1999). 
 
Ejection occurs when the pump chamber is filled. 
However, timing is not linked to the native cardiac cycle 
so changes in left ventricular-LVAD phase relations can 
occur, with LVAD ejection occurring either 
‗synchronously‘ with LV systole or ‗asynchronously‘. 
Dependent upon whether the LV generates sufficient 
pressure to open the aortic valve, blood flow may either 
be in series (LV - LVAD – aorta), or in parallel (LV & 
LVAD – aorta, through the aortic valve and device 
outflow conduit respectively). 
 
The IP model was first implanted in 1986 and since then 5000 
devices have been used where 65% experienced a successful 
outcome as BTT. 
 
The electric version was first introduced in 1991. 
 
Anticoagulation is limited to aspirin. 
 
REMATCH trial started in 1998 as a multicentre study and 
compared the outcome of using the HM I LVAD with optimal 
medical management. The outcome was improved 1-year 
survival (52% versus 25%, p=0.002) and an improved QOL 
(Long JW, 2001;Long JW et al., 2005). 
 
Also been used as BTR (Harefield Bridge to Recovery 
Protocol) in combination with pharmacological therapy. 
Explantation rate was 73% and 4-year survival exceeded 90% 
(Birks EJ et al., 2006). See text for study details and the BTR 
protocol.  
 
Since FDA approval in 2002 for destination therapy (DT), 246 
patients were implanted of which 67% were discharged home 
with longest duration of support of 86 days to date. 
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Novacor LVAS 
 
   
 
Uses an implanted pump drive unit (PDU) which is 
implanted in a pocket in the left upper abdominal 
quadrant. 
 
It produces a SV of 70 mls and has a symmetrical dual 
pusher plate and two porcine valves to control a 
unidirectional flow of blood.  
 
The sac-type blood pump has a smooth blood-containing 
surface coupled to a pulsed-solenoid energy converter 
that drives the blood pump to match the physiological 
requirements. 
 
 
INR needs to be maintained between 2.0 and 3.0. 
 
Since 1984 to date, more than 1700 have been implanted with 
the majority for BTT. Maximum duration of support was 6.1 
years (Wheeldon DR et al., 2002). 
 
BTR and DT represent a much smaller experience. 
 
Abiomed 5000 
 
         
 
Houses an Angioflex® membrane and two proprietary 
tri-leaflet valves. The pump fills with blood by 
gravitational force and by vacuum assistance from the 
drive console.  
 
The cannulae and drive console are the same as those 
used for the ABIOMED BVS 5000 (see below).  
 
Can provide flow rates of up to 6 l/min. 
 
 
Can be used as an LVAD, RVAD or BiVAD 
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BVS 5000 
 
   
 
Houses two polyurethane chambers: an atrial chamber 
that fills with blood through gravitational force and a 
ventricular chamber that pumps blood by air-driven 
power. Produces up to 5 l/min. 
 
Atrial chamber is vented outside the patient. Ventricular 
chamber is connected to the power console by a 0.25-
inch pneumatic line. Two trileaflet valves separate the 
atrial and ventricular chambers. 
  
 
It was the first external/outside the body (extracorporeal) VAD 
on the market and has been used in more than 700 institutions 
throughout the world. 
It was also the first FDA approved device for the support of all 
patients with reversible heart failure. 
 
 
Table 1.5: Discriptive summaries of the properties of some pulsatile first generation LVADs. These devices have one way valves to ensure 
unidriectional flow of blood. Due to the numerous components in each device, for example the HeartMate I XVE has 38 moving components, 
pulsatile LVADs are prone to mechanical wear and tear. 
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Table 1.6: Different Continuous Flow VADs  
Pump Type Device Description Clinical Experience 
 
Jarvik 2000 
 
    
 
 
 
 
This device is placed in the LV with no inlet cannula. 
 
No valves, internal compliance chamber, or an 
externalised vent. Operates in a range of 8000-12000 
rotations per minute (rpm) generating flow of up to 8 
l/min. Uses a brushless direct-current motor which is 
contained within the titanium housing and creates 
electromagnetic force necessary to rotate the impeller. 
 
 
 
Power consumption is only 3-7 watts and supplied by a 
12 volts battery. Power cable can come out abdominally 
or post auricular through a skull-mounted pedestal and 
hence reduce risk of infection. 
 
 
INR to be kept between 2.5 and 3.5. 
 
To date implanted in over 100 patients; 80% received the 
device as BTT and 20% as DT.  
 
Has also been used as BTR in a small number of patients using 
the Harefield BTR protocol (George RS et al, in press). 
 
Associated with low rates of infection and device failure. 
Following completion of a pilot US study, approval was 
granted in July 2005 for it to undergo clinical trials in the USA 
as a BTT and for use as DT. In Europe it is already in use in 
both settings. 
 
Haemolysis has been reported with this device. 
 
 
Micromed-Debakey 
 
     
 
 
1/10
th
 the size of pulsatile device and weighs 93 grams. 
 
Has ceramic bearings. 
 
Can provide up to 10 l/min of blood flow. 
 
INR to be maintained between 2.5 and 3.5. 
 
326 implanted worldwide for BTT purposes 
(www.micromedtech.com).  
 
Current trials remain ongoing in both BTT and DT settings. 
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INCOR
®
 (Berlin Heart) 
 
 
 
 
 
 
 
Wighs 200 grams and its volume is 82 mls. 
Diameter 30 mm and length 12 cms.  
 
Rotational speed 5000-10000 rpm. Typical power 
consumption of 4W. 
 
 
Axially active and radially passive without 
producing any actual physical contact. There is no 
direct mechanical contact between it – as the only 
movable part in the INCOR
®
 pump - and its static 
components. This prevents any mechanical friction 
and, as a result, no frictional heat. This means no 
wear and tear at all to the parts and, consequently, a 
potentially infinite product life span for the INCOR
®
 
heart support system. 
 
Has sensors linked to the magnetic bearing to 
prevent any suction through the pump in the left 
ventricle. Sensors detect the residual pulsality linked 
with the devicxe and the pump then automatically 
reduces its rotation speed and allows a renewed 
filling of the ventricle. The originally selected pump 
performance is then restored slowly and in a 
controlled way. 
 
 
INR to be kept between 2.8 and 3.2 
 
Its use was first reported in 2005 in 15 patients in NYHA 
class IV (Schmid C et al., 2005). No earlt bleeding 
complications were reported. None of the patients had 
developed drive line infections. 
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HeartMate II (HM II) 
 
  
 
     
 
 
 
    
 
Small, lightweight device (350 grams) designed to 
accommodate a broad patient population - body 
surface area (BSA) as low as 1.2 m
2
. 
 
It represents 1/7
th
 the size and ¼ the weight of the 
first generation HM I VAD. 
 
Flexible inflow and outflow conduits to 
accommodate anatomical changes. Consists of an 
internal blood pump (a 12 mm diameter straight tube 
made of titanium alloy).  
 
It is implanted in the pre-peritoneal position. In 
automatic mode of 9000-11000 revolutions/min, it 
can produce a flow of 4-7 l/min. The maximum flow 
that can be produced is 10 l/min. 
 
The tube incorporates the hydraulic components of 
the pump: the inlet stator, a pump rotor (incorporates 
a pump magnet), and an outlet stator. Helical blades 
curve around a central shaft. The blades introduce a 
radial / tangential velocity. The outlet stator vanes 
convert the radial velocity of the blood flow to an 
axial flow. 
 
Shares the same hardware platform and system 
components as the HM XVE LVAD. 
 
 
INR to be kept between 2.0 and 3.0 
 
Following the successful completion of its phase I pilot 
study in 2004, Thoratec was granted approval to begin a 
phase II pivotal trial in February 2005. The HM II Pivotal 
Trial is a multi-centre evaluation of the HM II LVAD for 
advanced-stage HF patients (Butler KC & Farrar DJ, 
2005;Frazier OH et al., 2004a;Pagani FD et al., 2005). 
 
To date, more than 1000 patients have been implanted with 
the device. 
 
Been successfully used for DT (Slaughter MS et al., 
2009b). 
 
Using Harefield Bridge to Recovery Protocol the device 
was used as BTR (results to be published) 
 
Table 1.6. Descriptive summaries of the properties of some of the non-pulsatile devices along with their clinical use. The second generation 
axial flow pump devices are being increasingly used now. These are continuous flow rotary pumps with only one moving part, the rotor, which 
is considered virtually silent compared to first generation devices and is associated with reduced risk of device failure. 
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Table 1.7: Third generation device 
Pump Type Device Description Clinical Experience 
 
HeartWare 
 
 
    
 
 
 
 
One moving part, the impeller, with no mechanical 
bearing. The impeller spins at rates between 2,000 
and 4,000 rpm to generate up to 10 l/min of blood 
flow.   
The total size is equivalent to 50 cubic centimeters 
making it implantable in the pericardial space. The 
inflow cannula is integrated with the device itself, 
ensuring proximity between the heart and the 
pumping mechanism 
The impeller is suspended within the pump housing 
through a combination of passive magnets and a 
hydrodynamic thrust bearing.  This hydrodynamic 
suspension is achieved by a gentle incline on the 
upper surfaces of the wide impeller blades (wide 
blades minimise risk of pump induced haemolysis 
and thrombus). When the impeller spins, blood flows 
across these inclined surfaces, creating a "cushion" 
between the impeller and the pump housing.  At no 
point there is contact between the impeller and the 
housing chamber. 
Reliability is enhanced through the use of dual motor 
stators allowing a seamless transition between dual 
and single stator mode if required. 
 
INR to be kept between 2.0 and 3.0. 
 
Use as BTR was first reported in 2008 (Wood C et al., 2008) 
 
HeartWare remains under investigation and although it has 
been awarded the CE trademark, its use in USA has not been 
approved by the FDA as yet. 
 
 
Table 1.7: HeartWare VAD, a third generation device with magnetic levitation technology. 
87 
 
1.5.2  Clinical Application of VADs  
1.5.2.1  Bridging to transplantation 
Even with medical treatment, those with advanced HF have a very poor prognosis 
often worse than malignancy with 40-60% annual mortality (Gheorghiade et al., 
2000;Swedberg et al., 1999) unless patients are transplanted. But due to limited 
donor organ supply-demand mismatch (as discussed above), MCS devices provide 
the only practical alternative to heart transplantation (Deng & Naka, 2002). It is 
estimated that as many as 60,000 patients with HF could be helped in the USA 
alone (Kenneth L Franco, 2001;W Piccione, 2001). 
According to the United Network for Organ Sharing (UNOS) in USA the death 
rates for advanced HF patients on the waiting list have decreased from 43% in 
1990 to 17% in 1999 (Deng MC, 2002). This significant reduction may be 
contributed by the increasing use of MCS devices in urgently listed patients. 
In the UK, indications for VAD implantation for the purpose of BTT is limited to 
patients who: 
i) are appropriate candidates for cardiac transplantation (transpulmonary 
pressure gradient <14 mm Hg, mVO2<14 ml/kg/min, CI<2.1 l/min/m
2
, 
no active infection or malignancy, no recurrent pulmonary embolism), 
or 
ii) would become appropriate after a period of VAD support 
iii) had rapidly deteriorating heart function and clearly would not survive 
to transplant despite the provision of an ―urgent‖ category nationally. 
The presence of a MCS device per se does not increase the risk of subsequent 
transplantation (Frazier et al., 2001;Jaski et al., 2001;Massad et al., 1996;Taylor et 
al., 2003;Birks et al., 2002). Transplantation results may even be improved if this 
kind of pre-operative support is used (Goldstein et al., 1998;Aaronson et al., 
2002;Bank et al., 2000). However, the use of LVAD as a BTT is associated with 
drive line infections and increased HLA antibodies. The latter would reduce the 
chance of transplantation. Further, LVAD patients would have had at least one 
sternotomy which adds to the surgical complications at the time of transplantation.  
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Support on the device allows renal function, nutritional status and pulmonary 
vascular resistance to improve before transplantation, which usually takes several 
weeks or months. Transplantation should only be considered once these 
improvements have occurred. 
In
 
a prospective, multicenter clinical trial conducted at 24 centres
 
in the United 
States, 280 transplant candidates (232 men, 48
 
women; median age, 55 years; 
range, 11-72 years) unresponsive
 
to inotropic drugs, IABP, or
 
both, were treated 
with the HM I pulsatile LVAD (Frazier OH et al., 2001). Average support was 
112 days (range, < 1-691 days), with 54 patients (approximately 20%) supported
 
for more than 6 months. 71% of patients (198/280) survived with 67% (188/280) 
receiving heart transplant, and 4%
 
(10/280) had the device removed electively. 
There was also a significant improvement in metabolic parameters (bilirubin 
decreased from 1.2 mg/dL to 0.7 mg/dL (p = 0.0001) and creatinine decreased
 
from 1.5 mg/dL to 1.1 mg/dL (p = 0.0001)). Adverse events associated with 
LVAD support were low.  
In 2007, Sharples et al reported a 44% survival rate to transplantation in the UK 
having studied the population between 2002 and 2004 (Sharples LD et al., 2007). 
In contrast, Park et al had a survival rate to transplantation of 85.7% (Park SJ et 
al., 2000).On average the reported survival rates to transplantation ranged between 
60% to 75% (Navia JL et al., 2002;El-Banayosy A et al., 2000;Sun BC et al., 
1999;DeRose JJ Jr et al., 1997). These data are all from the first-generation 
pumps. 
Data from the second-generation pumps, which would be expected to have a 
better outcome owing to their smaller size, easier surgical implantation etc, are 
now becoming available. Miller et al published a prospective multicentre study of 
133 NYHA class IV patients on a transplant waiting list who underwent HM II 
LVAD implantation as BTT (Miller LW et al., 2007). All patients were receiving 
inotropic support (except for 11% intolerant because of arrhythmia) and 41% 
were also IABP dependent. After 180 days, 100 (75%) patients had reached the 
principal outcome of transplantation, recovery or survival on ongoing support 
with eligibility for transplantation. Patients on HM II support had improved 
NYHA class, 6MW functional status and QOL. The overall survival was 81% at 6 
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months and at 1 year the overall survival of patients who underwent 
transplantation or continued to receive MCS while remaining a candidate for 
transplantation was estimated to be 70%. These 133 patients, enrolled from March 
2005 to May 2006, represented the primary cohort. Enrolment continued 
following this and Pagani et al published the results of 281 of 469 patients 
enrolled by April 2008 that had completed study end points or had at least 18 
months of follow-up with ongoing device support (Pagain FD et al., 2009). Of 
these, 79% had either received a transplant, been explanted due to myocardial 
recovery, or remained alive on a VAD at 18 months. Of the 55.8% (n = 157) that 
received a transplant, post-transplant survival was 96% at 30 days and 86% at 1 
year. During the study period 78% of patients were discharged from the hospital 
with a VAD, after a median post surgery stay of 25 days. 
Data has also started to emerge from third-generation devices. VentrAssist have 
published data describing a success rate of 82% in 33 patients at a follow-up point 
of 154 days with these results maintained at 365 days with 60.6% receiving 
transplantation and 21.2% remained eligible for transplantation (Esmore D et al., 
2008). Patients who have received the Duraheart VAD as BTT had a 78% 2-years 
survival rate to transplantation (Nojiri C et al., 2008). Fifty patients have received 
the HeartWare device with an 85% 1-year actuarial survival to transplantation 
(Wieselthaler GM et al., 2008). 
In addition to the improved survival rate to transplantation the clinical outcome 
following transplantation had also improved. In 2006, Drakos et al reported the 
outcome of 278 patients who underwent cardiac transplantation from 1993 to 
2002 (Drakos SG et al., 2006). Pre-transplant MCS was required in 72 patients 
and was not required in the remaining 206 patients. One-month and 1-year 
survival after transplantation was similar between the two groups (MCS, 92% and 
85%, respectively versus no MCS, 97% and 92%, respectively). At 1 year of 
follow-up 56% of MSC patients were free from rejection as compared to 52% of 
patients who did not require MCS (p=0.60). Post transplant events such as 
hospital stay, intensive care unit stay, extubation time, acute allograft dysfunction, 
reoperation rates, acute renal and hepatic dysfunction, infections, arrhythmias, 
thromboembolic and neurologic complications, and the development of cardiac 
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allograft vasculopathy were similar between the two groups. The incidence of 
chronic renal insufficiency was lower in the MCS group (15.3% versus 37.9%, 
p<0.001). Similarly, those who were bridged to transplantation had significantly 
lower incidence of acute renal failure as compared to those who did not receive a 
MCS prior to transplantation (5.6% versus 16.7%, p<0.05) (Bank AJ et al., 2000). 
Right sided HF was also lower (31.6% versus 52.6%, p<0.05). The same group 
reported a lower incidence of re-operation, rejection, disability post 
transplantation, and infection (Bank AJ et al., 2000). 
In 2008, using SF36 QOL questionnaire, we reported that BTT patients had a 
significantly higher mental health dimension as compared to those who were 
transplanted without pre-transplant MCS (71.4 ± 21.1 versus 39.4 ± 44, p=0.01) 
(George RS et al., 2008b). These findings raise an important question of the 
significance of LVAD in affecting patients QOL outcome post transplantation. 
Patients supported with LVAD for BTT experienced multiple complications 
(Dembitsky WP et al., 2004). In 2003, John et al reported that the incidence of 
post-transplantation rejection was greater in LVAD recipients who were 
sensitized by LVAD use prior to transplantation, but lower in unsensitised 
recipients not supported in this way (John et al., 2003). In contrast, Birks et al 
reported a lower rate of rejection in LVAD supported patients bridged to 
transplantation (Birks et al., 2002). Device failure is another problem that can be 
life threatening and a limiting factor of long periods of use of an LVAD. Navia et 
al reported device failure in 7.6% of patients implanted with HM I VE LVAD 
(Navia JL et al., 2002). In our centre, Birks et al reported cumulative probability 
of device failure in 6% of patients at 6 months, 12% at 1 year, 27% at 18 months, 
and 64% at 2 years (Birks EJ et al., 2004b). This is far less of a problem, however, 
with the newer generation devices. 
Another major limitation of using VAD as BTT is the cost associated with the 
procedure. As expected the total cost for LVADs exceeded that of orthotopic heart 
transplant (DiGiorgi PL et al., 2005;Sharples LD et al., 2006). Interestingly, Bank 
et al reported that the average daily cost was similar between those who were 
bridged to transplantation and those who did not receive a MCS device (Bank AJ 
et al., 2000). 
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1.5.2.2  Destination therapy 
Technological improvements now allow consideration of long-term LVAD 
implantation as an alternative to cardiac transplantation in those who do not show 
signs of recovery or for whom transplantation is contraindicated (Birks et al., 
2004;Rose et al., 2001). 
DT refers to the use of MCS devices as the final means by which a patient will be 
treated (Clark & Zafirelis, 2000). The results of the Randomised Evaluation of 
Mechanical Assistance for the Treatment of Congestive Heart Failure trial 
(REMATCH) had effectively demonstrated the efficiency of permanent device 
therapy. This study compared the use of the pulsatile HM I VE LVAD with 
optimal medical management in those with end-stage heart failure and ineligible 
to receive cardiac transplantation (Rose et al., 1999;Rose et al., 2001). The trial 
began randomisation in 1998 and was the first to demonstrate the positive impact 
of MCS on QOL and survival in end stage HF (Rose et al., 2001). In total, 129 
patients were enrolled from 20 centres, and received either optimal medical 
therapy or permanent therapy with HM I VE LVAD (Rose et al., 2001). All 
patients were in NYHA class IV for at least 60 of 90 days despite maximal 
medical treatment and they were ineligible for cardiac transplantation for any of 
the following single or combined reasons: age > 65 years, insulin-dependent 
diabetes with end-organ damage, chronic renal failure or significant irreversible 
comorbidity. Median age was 69 years. Those who received the MCS benefited 
from 48% reduced all cause mortality. At 1 year, survival was 52% (74% if < 
60yrs) as compared to 25% in the medically managed group. The 2-years survival 
was 23% as compared to 8%. Overall the median survival was 408 days for MCS 
patients as compared to 150 days in the medical treatment group. Terminal HF 
caused most deaths in the medical therapy group, in contrast to sepsis (41% 
deaths) and device failure (17% deaths) in the MCS group. QOL and NYHA class 
improved at follow up with MCS, but adverse events were twice those of the 
medical group, mainly comprising infection, bleeding and device malfunction 
(Rose et al., 2001). There was a significant improvement in survival for LVAD 
patients enrolled during the second half of the trial (January 2000 to July 2001) 
compared with the first half (May 1998 to December 1999) (Park SJ et al., 2005) 
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reflecting improvements in patient management and device modifications even 
throughout the period of the trial. The 1-year survival in the second half of the 
trial was 59% versus 44% in the first half (p = 0.029) and the 2-year survival was 
38% versus 21%. Both the Minnesota Living with Heart Failure QOL scores 
(Stevenson LW et al., 2004) and NYHA functional class (Richenbacher WE et al., 
2003) have improved significantly over the course of the trial. Although survival 
was better in the LVAD group, the risk of CVA was higher in the LVAD group as 
compared to the medically treated group (0.19 versus 0.052) (Lazar RM et al., 
2004) and device related sepsis such as drive line infections caused substantial 
morbidity and mortality (Holman WL et al., 2004). The REMATCH investigators 
concluded MCS as an acceptable alternative treatment if a patient is ineligible for 
transplantation and that 270 deaths/yr/1000 patients could be prevented (Rose EA 
et al., 2001). 
In 2005, Long et al reported their experience with the modified HM I XVE LVAD 
(see table 1.5 for the new features of the modified version) in four high volume 
centers (Long JW et al., 2005). The group reported an improved 90% and 61% 
30-day and 1-year survival, respectively. The death rates due to sepsis and device 
failure were 8.3 times and 2.2 times lower than the REMATCH trial, respectively. 
Overall, patients were 2.1 times less likely to experience an adverse event and 
there was a reduction of 66%, 63%, 89% and 92% in neurological dysfunction, 
sepsis, site infection, and for combined and suspected device failure respectively. 
In a non-randomised trial, Rogers et al showed that patients treated with the 
Novocor first generation LVAD had better survival rates as compared to 
medically treated patients, 46% versus 22% at 6 months and 27% versus 11% at 
12 months (Rogers JG et al., 2007). In this trial, 85% of patients receiving LVAD 
had either no symptoms or minimal HF symptoms at the last assessment. None of 
the medically treated group reported any improvement in NYHA functional class. 
QOL measures had also improved in the LVAD group.  
Introduction of axial flow and centrifugal devices have improved LVAD survival, 
haemodynamics, end-organ function, quality of life and functional capacity 
(Miller LW et al., 2007) and reduced VAD-related complications. In Dec 2009, 
Slaughter et al randomised patients with advanced heart failure who were 
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ineligible for transplantation to receive either the continuous-flow HM II LVAD 
or the pulsatile-flow HM I LVAD (Slaughter MS et al., 2009b). The trial was 
conducted in 38 centers with a randomisation ratio of 2:1. The investigators 
reported that both devices improved the QOL and functional capacity. Those who 
received the HM II LVAD had a significantly higher probability of survival from 
stroke and device failure at 2 years as compared to those who received the HM I 
LVAD (46% versus 11%, p<0.001).  
To determine which end-stage heart failure patient who is ineligible for 
transplantation would have a better outcome, Lietz et al devised a scoring system 
that used  9 pre-implant parameters to identify 90-day in-hospital mortality after 
LVAD implantation as DT, survival to hospital discharge, and 1-year survival 
(Lietz K et al., 2007). The group determined that a score of 0-8 represent a low 
operative risk, a score of 9-19 represent a medium risk, and a score of 20-31 
represent a high risk.  
Cost analysis of the REMATCH trial showed that sepsis, pump infection and 
perioperative bleeding were the main sources of increased implantation costs (Oz 
et al., 2003). The greatest expense was in non-survivors. The cost of implantation 
and readmission in those who survived more than 1 year was comparable to other 
life saving organ replacement procedures (Oz et al., 2003;Showstack et al., 1999). 
  
94 
 
1.5.2.3  Bridging to recovery 
Levin et al termed the process of reversal of the adverse changes in HF as ―reverse 
remodeling‖ (Levin HR et al., 1995). Over the years there has been ample 
evidence supporting the notion of reverse remodeling following LVAD 
implantation at the molecular, cellular and clinical levels. 
1.5.2.3.i LVAD and reverse remodelling – molecular and cellular levels 
The exact mechanisms of myocardial recovery remain unclear (Caforio et al., 
1990). Whether reverse remodelling is due to a ―U-turn‖ of the pathological 
mechanisms that occur in remodelling or the generation of new pathways remains 
unclear. However, the following changes have been reported during unloading 
with an LVAD (Hetzer et al., 2000;Hummel et al., 1994;Altemose et al., 
1997;Wallukat & Wollenberger, 1987;Wallukat et al., 1995;Loebe et al., 
1997b;Muller et al., 1997): 
i) normalisation of deranged Ca2+ transport,  
ii) reduction in cytokines and neurohumeral activity,  
iii) improved glucose utilisation,  
iv) improvements in HF related gene expression,  
v) up-regulation of ß-adrenergic receptors, improved myocyte 
contractility, and 
vi) reduction in ß1-adrenoceptor auto-antibodies. 
The effects of unloading on myocyte size and structural proteins 
Hematoxylin and eosion (H&E) staining of longitudinal and cross-sectional 
myocardial samples taken from patients with end-stage HF demonstrated an 
increase in the size of cardiomyocytes with loading followed by reduction in 
myocyte size after long-term LVAD support (figure 1.12) (Dipla K et al., 
1998a;Khan N et al., 2003a;Xydas S et al., 2006;Zafeiridis A et al., 1998a).  
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Figure 1.12: Effects of LVAD support on myocyte size 
 
Figure 1.12: Myocardial longitudinal and cross-sectional samples taken from a 
patient pre- and post-LVAD support. The paired samples demonstrate reduction in 
myocyte size after long-term LVAD support. From (Khan N et al., 2003a). 
 
Interestingly, Bruckner et al showed a significant correlation between the length 
of LVAD support and the percentage change in myocyte size (figure 1.13) 
(Bruckner BA et al., 2001). 
 
Figure 1.13: Correlation between length of LVAD support and myocyte size 
 
 
Figure 1.13: There is significant correlation between duration of LVAD support 
and the percentage reduction in myocyte size. From (Bruckner BA et al., 2001).  
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Enlargement of isolated myocytes in HF might be more pronounced in the long 
axis dimension as compared to the width or depth (Yacoub MH, 2001). Figure 
1.14 depicts isolated ventricular myocytes from patients at the time of insertion of 
an LVAD (middle horizontal panel) showing severe hypertrophy as compared to 
normal controls (top horizontal panel). Bottom panel shows ‗normalization‘ of the 
size of the myocytes post left ventricular assist device (Yacoub MH, 2001). 
Figure 1.14: Cardiac myocyte size in normal, HF and post LVAD support 
 
Figure 1.14: LVAD normalises the size o the myocytes. 
 
In addition to the changes seen in myocyte size, LVAD support has resulted in 
decreased apoptosis through complex mechanisms. Some of these mechanisms 
include an increase in mRNA levels for apoptosis-inhibiting proteins FasEx06del 
and Bcl-XL (Cascino I et al., 1996;Schumann H et al., 1997), reduced apoptotic 
DNA fragmentation (Bartling B et al., 1999;Milting H et al., 1999), and 
upregulation of genes associated with cell growth, DNA repair and apoptosis 
(Chen Y et al., 2003). 
As previously described, remodeling is associated with induction of specific gene 
programmes involving several groups of gene and enhanced secretory activity of 
the fibroblasts which leads to both reparative and reactive fibrosis which is related 
to changes in total collagen content, an increase in collagen I and III concentration 
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and a change in collagen cross-linking in the cardiac ECM. The responses of 
collagen concentration and cross-linking to LVAD support remains controversial. 
Klotz et al demonstrated an increase in collagen cross-linking
 
and the ratio of 
collagen type I to III after 145±33 days of LVAD support and hence an increase in 
myocardial stiffness (Klotz S et al., 2005b). Xydas et al, on the other hand showed 
a decrease in collagen deposition from time of LVAD implantation to time of 
transplantation in 17 patients who were bridged to transplantation (Xydas S et al., 
2006). Similarly, Bruckner et al demonstrated that long-term mechanical 
circulatory support significantly reduced collagen content and fibrosis (Bruckner 
BA et al., 2001). Bruggink et al, suggested a biphasic pattern for the collagen 
turnover and the volume of ECM with LVAD support (Bruggink AH et al., 2006). 
They showed that the initial response of the cardiac ECM response to LVAD 
(within 200 days of support) was an increase in Types I and III collagen turnover 
and after 400 days of support there was a reduction in both the collagen and the 
volume of the ECM. Therefore, it could be assumed that the pattern of ECM and 
collagen response to LVAD is correlated to the length of support. 
Using real time polymerase chain reaction, Felkin et al. demonstrated that patients 
in deteriorating HF requiring LVAD support have elevated MMP1and MMP8 
mRNA levels compared to patients with stable heart failure undergoing elective 
heart transplantation (Felkin LE et al., 2006). In addition TIMP 1-4 mRNA levels 
were also higher in the deteriorating patients requiring LVAD support with only 
TIMP4 reaching statistical significance (Felkin LE et al., 2006). Li et al looked at 
the protein expression of MMPs and TIMPs after LVAD support and showed that 
MMP-1 and -9 were decreased, TIMP-1
 
and -3 were increased, and there was no 
change in MMP-2 and
 
-3 and TIMP-2 and -4 after LVAD support (Li YY et al., 
2001). 
Using real time polymerase chain reaction paired myocardial samples collected at 
implantation and explantation following myocardial recovery were analysed. We 
described that LVAD support was associated with a specific pattern of changes in 
the mRNA content of some sarcomeric, non-sarcomeric, and membrane-
associated genes (Birks EJ et al., 2005).  This was also confirmed at the protein 
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level (Latif N et al., 2007) and paralleled improvements in haemodynamic 
function in LVAD patients showing clinical myocardial recovery. 
Dystrophin is another structural protein that provides support for the myocyte and 
the cardiomyocyte membrane by linking N-terminus with the dystrophin-
associated protein complex and sarcolemmal at the C-terminus. Studies have 
shown that mutations in the N-terminus of dystrophin are responsible for x-linked 
dilated cardiomyopathy (Ortiz-Lopez R et al., 1997;Towbin JA et al., 1993). Vatta 
et al demonstrated that with prolonged unloading with an LVAD most patients 
with reduced N-terminus expression before implantation exhibited an increase in 
expression (Vatta M et al., 2002). 
Reverse remodelling and adrenergic receptors 
LV unloading has been associated with restoration of cardiac β-AR signalling 
(Pandalai PK et al., 2006), reversal of the downregulation of β-AR (Ogletree-
Hughes ML et al., 2001), an increase in β-AR responsiveness (Dipla K et al., 
1998a) especially to inotropic stimulation by the SNS (Ogletree-Hughes ML et 
al., 2001), and an increase in β-AR density in both left and right ventricles (Klotz 
S et al., 2005a). The primary mechanisms behind these improvements is 
diminished myocardial G-protein coupled receptor kinase-2 activity and reduction 
in PKA hyperphophorylation of the RyR2/Ca
2+
 release channels (Pandalai PK et 
al., 2006;Klotz S et al., 2005a). LVAD support has also been associated with an 
increase in 1-AR density and alteration in distribution (Grigore A et al., 2005). 
Reverse remodelling and calcium regulation 
Terracciano et al, studied the effects of LVAD and myocardial recovery on SR 
Ca
2+
 content and EC coupling by studying isolated cardiomyocytes from the 
LVAD core at the time of LVAD implantation and from myocardial biopsy 
samples at the time of explantation in patients who recovered and at the time of 
transplantation in those who did not recover and were transplanted (Terracciano 
CMN et al., 2003;Terracciano CMN et al., 2004). They showed that recovered 
patients had an increase in their SR Ca
2+
 content and an increased gain in EC 
coupling resulting in larger Ca
2+
 transient and stronger cell contraction (figure 
1.15).  
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Figure 1.15: Effects of LVAD Support on Current Density and SR Ca
2+
 
 
Figure 1.15: SR Ca
2+
 content from myocytes isolated from LVAD cores and 
tissue from explanted (recovery) and transplanted hearts (without recovery). Cells 
were voltage-clamped at their resting membrane potentials. The SR Ca
2+
 content 
was significantly higher in the recovered patients and was associated with an 
improved current density. 
The group speculated that the increased levels of SR Ca
2+
 could be due to one of 
the following: 1) increased SR Ca
2+
 uptake, 2) reduced SR Ca
2+
 leak as a 
consequence of a more stable ryanodine receptor complex, 3) or possibly, altered 
function of the sodium-calcium (Na
+
/Ca
2+
) exchanger. 
Interestingly this study showed that reduction in cell capacitance and cell size 
were not necessarily associated with clinical recovery (Terracciano CMN et al., 
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2004).
 
Further studies of the effects of LVAD on the Na
+
/Ca
2+
 exchanger 
suggested that unloading increases the function of the exchanger (Terracciano CM 
et al., 2007), an important player which is over expressed in heart failure (Stagg 
MA et al., 2004). 
Reverse remodelling and neurohormonal levels 
Studies have shown that LVAD support lessened neurohormonal activation. 
Quantitative real time polymerase chain reaction revealed that LVAD support 
resulted in normalisation of ANP and BNP mRNA levels in a significant 
correlation fashion with reversal of cardiomyocyte hypertrophy (Kuhn M et al., 
2004). Others have shown that LVAD support has induced significant reduction in 
NE, plasma renin activity, AngII levels, epinephrine, and vasopressin (Estrada-
Quintero T et al., 1995;James KB et al., 1995). 
 
1.5.2.3.ii LVAD and reverse remodelling – clinical application 
In 1996, Dr Frazier was the first to report that the LV structure and function 
change with LVAD support (Frazier OH et al., 1996). His observation was 
confirmed when several groups studied the LV‘s response to LVAD support and 
identified sufficient degree of myocardial recovery for device explantation 
(Frazier OH et al., 1996;Levin HR et al., 1996;Loebe M et al., 1997;Müller J et 
al., 1997;Mancini DM et al., 1998;Frazier OH & Myers TJ, 1999;Farrar DJ et al., 
2002;Dandel M et al., 2005). In addition, examination of patients who had been 
transplanted showed that some reversibility of HF had been achieved at structural, 
cellular, molecular and functional levels although the mechanisms remained 
unknown (Altemose et al., 1997;Bartling et al., 1999;Bruckner et al., 2001;Heerdt 
et al., 2000;Hetzer et al., 2000;Li et al., 2001;Takeishi et al., 2000;Zafeiridis et al., 
1998). Also patients who had had their device removed early due to infection or 
malfunction were observed to have good myocardial function that was maintained 
(Frazier & Myers, 1999;Hetzer et al., 1999). 
Studies that have demonstrated myocardial recovery have all shown significant 
improvement in the ventricular dimensions with LVAD support. At 30 days of 
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support, end-diastolic diameter decreased from 71±12 mm (pre-implantation) to 
49±10 mm (p<0.001) (Xydas S et al., 2006). Similarly, Dr. Maybaum and his 
group demonstrated that end-diastolic diameter has also decreased from 71±12 
mm at pre-implant to 51±11 mm (p<0.001) (Maybaum S et al., 2007). 
Until recently, the explantation rate, however, remained small and ranged from 5-
24% (Dandel M et al., 2005;Frazier OH & Myers TJ, 1999;Frazier OH et al., 
2004b;Hetzer R et al., 2000;Hetzer R et al., 2001;Mancini DM et al., 1998;Mann 
DL & Willerson JT, 1998). In addition, HF has shown to recur again in some 
patients within the first two years of explantation (Hetzer R et al., 2000;Mancini 
DM et al., 1998) mainly in those who had spent more time on MCS support 
(Hetzer et al., 1999;Loebe et al., 1997b). One interpretation for this phenomenon 
was that excessive LV unloading might have resulted in cardiac atrophy (Loebe et 
al., 1997a;Madigan et al., 2001). 
To enhance the degree of myocardial recovery some investigators have used 
additional pharmacological therapy including ACE inhibition to ameliorate 
neurohormonal activation and β-blockade to improve cardiac function and 
influence any underlying β-receptor autoimmune disease (Hetzer et al., 
2000;Wallukat et al., 1996;Muller et al., 2000).  
Harefield Bridge-to-Recovery Protocol and Rationale  
The Harefield strategy was developed in an attempt to induce greater and more 
predictable recovery and allow elective explantation with reduced risk of re-
dilatation and HF (Hon & Yacoub, 2003;Yacoub, 2001;Yacoub et al., 
2001b;Yacoub et al., 2001a). The Harefield strategy combined mechanical 
unloading with pharmacological agents to assist unloading and induce maximal 
regression of pathological hypertrophy through reverse remodeling of the 
myocytes and cytoskeleton and normalisation of cellular metabolic function in 
non-ischaemic DCM patients. 
The pharmacological regimen consists of two phases. In phase I five 
pharmacological agents are given based on the evidence described above of their 
clinical benefits in HF and induction of reverse remodeling. Oral medications are 
commenced after stopping all inotropic therapy following implantation of the 
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LVAD. Digoxin is the first to be introduced and is administered as positive 
inotrope. Both lisinopril and carvedilol are started at low doses and uptitrated 
according to patient‘s tolerance. Spironolactone is then started. Low doses of 
spironolactone exert no diuretic effect and are insignificant haemodynamically. 
They are also effective in the treatment of HF as shown by the RALES trial. On 
this basis low dose administration was incorporated into the treatment regimen to 
inhibit the actions of aldosterone at the cellular level. Losartan is then added as 
the last anti-failure medication in those who tolerated the up-titration of both 
carvedilol and lisinopril. Table 1.8 represents that pharmacological regimen and 
the maximum dosage. 
Table 1.8: Phase I pharmacological therapy 
Pharmacological Agent Initial Dose Maximum Dose 
Digoxin  62.5-125 mcg 125 mcg 
Spironolactone 25 mg 25 mg 
Lisinopril 2.5 mg od 20 mg bd 
Carvedilol 3.125 mg od 25 mg bd 
Losartan 12.5 mg od 100 mg od 
 
Table 1.8: The five pharmacological agents administered as a phase I therapy of 
the Harefield BTR protocol to induce reverse remodeling. Adapted from (Birks EJ 
et al., 2006). 
The second stage of the pharmacologic therapy is instituted after maximal 
regression in the LVEDD has been achieved whilst the LVAD was in situ (but 
reduced to a degree to unmask the underlying LV function). When constant 
LVEDD (<60 mm) and EF (>50%) are maintained for at least 2 weeks, according 
to echocardiographic assessment, carvedilol is replaced by the selective β1-
blocker, bisoprolol. Following maximal bisoprolol up-titration, as per patient 
tolerance, an attempt to induce physiological hypertrophy of both cardiac and 
skeletal muscle is made using the β2 agonist, clenbuterol (Hon J et al., 2001;Hon 
J & Yacoub M, 2003;Petrou M et al., 1995;Petrou M et al., 1999;Soppa G et al., 
2004;Tansley P et al., 2004;Wong K et al., 1998;Yacoub M et al., 2001). 
Clenbuterol is started at 40 μg twice daily and is up-titrated to a maximum dose of 
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700 μg three times daily. The dose is adjusted to maintain a resting heart rate 
below 100 bpm. 
In 2006, Birks et al prospectively studied 15 non-ischaemic DCM patients 
receiving LVAD and drug combination therapy, the Harefield Bridge-to-Recovery 
Protocol (Birks EJ et al., 2006). This strategy resulted in sufficient myocardial 
recovery that allowed LVAD to be explanted in 73% of the studied patients. 1- 
and 4-years actuarial survival of 90.9% and 81.8%, respectively, and freedom 
from recurrent HF in the surviving patients of 100% and 88.9% at 1- and 4-years, 
respectively. 
Using the above protocol these patients demonstrated an improvement in PCWP 
from 24.9±7 mmHg on inotropic therapy before implantation to 9.0±4.1 mmHg, 
p=0.004, a significant 55% increase in the CI (Birks EJ et al., 2006). To illustrate 
the sustainability of myocardial recovery we have showed that at three months 
following device explantation the right atrial pressure (RAP) was 6.2±2.1 mmHg, 
PCWP was 12.8±6.9 mmHg, left ventricular end-diastolic pressure LVEDP) was 
12.9±5.9 mmHg, cardiac output (CO) was 4.9±2.1 l/min, CI of 2.4±1.0 l/min/m
2
, 
and pulmonary-artery oxygen saturation (sVO2) was 69.8± 29.9%. Repeat 
catheterisation at one year after explantation, revealed an RAP of 5.1±3.3 mmHg, 
PCWP of 9.5±6.2 mmHg, LVEDP of 9.3±5.5 mmHg, CO of 4.9±2.1 l/min, CI of 
2.4±1.2 l/min/m
2
, and sVO2 of 73.5±32%. 
Similarly, exercise capacity further improved following explantation as reflected 
by an increase in the oxygen consumption to a mean of 26.6 mls/min/kg at 2 years 
following explantation. This was better than that observed after cardiac 
transplantation and could be due to the fact that the recovery patients retained 
innervation or possibly be due to the effect of temporary treatment with 
clenbuterol. 
Before discussing the benefits of using clenbuterol, it is essential to note that the 
hallmark feature of myocardial recovery is the “search” for recovery. This is 
achieved by the continuous and vigorous assessment of the underlying / native LV 
function to determine which patients would recover and when. 
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Monitoring recovery 
Critical to myocardial recovery is the accurate assessment of mycaordial function 
in these patients. Previously described weaning protocols have not assessed the 
true myocardial response to device cessation as the device‘s contribution into the 
circulation remained significant (Dandel M et al., 2005;Maybaum S et al., 
2003;Slaughter M et al., 2001). Those groups have generally relied on assessing 
patients whilst the device is on, or after only reducing the speed of the device and 
hence reducing its power, or after only momentarily discontinuing the device 
(Dandel M et al., 2005;Hetzer R et al., 2001;Maybaum S et al., 2003;Slaughter M 
et al., 2001). This has only provided a rough estimate of the underlying 
myocardial function. Full device cessation on the other hand allows clinicians to 
assess the true capacity of the unaided myocardium to support the circulation and 
importantly the response to increased demand through loading and exercise. In 
our previous recovery series, the pulsatile HM I LVAD was switched off for 15 
minutes or more and patients were exercised using a 6MW test with continuous 
monitoring of several clinical, haemodynamic and echocardiographic parameters 
(Birks EJ et al., 2006). This approach provided a more robust method to assess the 
true underlying function and inotropic reserve (George RS et al., 2006;George RS 
et al., 2007b;George RS et al., 2007a).  
Clenbuterol in the Harefield BTR protocol 
Concerns about cardiac muscle ‗atrophy‘ following chronic LVAD myocardial 
unloading formed the basis for some explanations of low incidence of myocardial 
recovery (Soloff LA, 2009). In late 1990‘s, Professor Yacoub hypothesised that in 
order to achieve consistent successful device explantation, regression of 
myocardial pathological hypertrophy should be followed by the induction of 
physiological hypertrophy (Yacoub MH, 2001;Yacoub MH et al., 2001b).  
Until mid 90‘s, the pathophysiology of cardiac hypertrophy was little known 
(Petrou et al., 1995). Two types exist depending on the stimulus and the 
mechanisms (Scheuer & Buttrick, 1987;Morgan & Baker, 1991). Isoproterenol (a 
β1 & β2 agonist) and norepinephrine lead to ‗pathological‘ hypertrophy, whereas 
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thyroxine and exercise training produce the ‗physiological‘ type (Bersohn & 
Scheuer, 1977). 
‗Pathological‘ myocardial hypertrophy seen in overload, hypothyroidism and after 
catecholamine administration involves re-expression of proteins as foetal 
isoforms. RNA molecular markers of gene expression are often used to 
differentiate the ‗pathological‘ from ‗physiological‘ condition (Lipkin et al., 
1988). In rat heart models they comprise sarcomeric -actins, cardiac myosin 
heavy chains (MHC)s and ANF (Petrou et al., 1995). Cardiac -actin is the usual 
predominant type of sarcomeric -actin, but in pathological hypertrophy, skeletal 
-actin is induced instead (Izumo et al., 1988;Carrier et al., 1992). Similarly, 
MHC isoform expression also changes (Waspe et al., 1990;Schwartz et al., 1992). 
Down regulation of SERCA2 and PLB also occurs along with increased 
interstitial collagen that may result in impaired cardiac function (Kiss et al., 
1995;Wong et al., 1997;Stein et al., 1996;Brilla et al., 1991;Doering et al., 1988). 
‗Physiological‘ myocardial hypertrophy is defined as increased LV mass with 
normal systolic and diastolic LV function, normal relaxation times (consistent 
with normal expression of SERCA2 and PLB), normal morphology, normal 
extracellular structure (LV collagen concentration) and gene expression (SERCA2 
and PLB mRNA), and LV re-expression of ANF mRNA (non-specific molecular 
marker of LV hypertrophy) but without contractile protein isoform switching 
from cardiac to skeletal -actin to β-MHC (Petrou et al., 1995;Wong et al., 
1998;Scheuer et al., 1982;Scheuer & Buttrick, 1987;Buttrick et al., 1994;Lompre 
et al., 1984;Doering et al., 1988).  
Clenbuterol induces this type of ‗physiological‘ myocardial hypertrophy which 
can be summarized as follows: 
 ‗morphologically‘ - the induction of hypertrophy associated with improved 
function;  
 ‗functionally‘ - enhanced systolic and diastolic function; 
 ‗histochemically‘ by prevention of increased fibrosis; and  
 ‗molecularly‘ by ‗physiological‘ gene expression (Petrou et al., 
1995;Wong et al., 1998;Hon et al., 2001). 
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Clenbuterol, a potent synthetic pharmacological analogue to epinephrine, is used 
clinically in asthma and obstructive airways disease and formerly in the meat 
industry to increase muscle bulk. It was abused by athletes at the 1992 Barcelona 
Olympic Games for its ‗anabolic‘ properties, despite not being a steroid and there 
was considerable subsequent dispute about its mechanism of action (Beckett AH, 
1992;Petrou M et al., 1995). 
Research groups have reported consistent beneficial functional effects of β2 
adrenergic overexpression in mouse hearts (Liggett et al., 2000;Milano et al., 
1994;Turki et al., 1996). One of these showed that the beneficial effect of β2 
cardiac receptors is prolonged (Liggett et al., 2000). In addition, β receptor 
mediated apoptosis has been shown to be selectively associated with β1 rather than 
β2 receptors (Zaugg et al., 2000). One study showed that overexpression of β2 
receptors potentiated the functional recovery of unloaded failing hearts, consistent 
with our use of the drug (Tevaearai et al., 2002). As most negative effects of β 
stimulation seem to be β1 receptor mediated, administration of β1 antagonists in 
conjunction with β2 agonists such as clenbuterol appears appropriate. Others 
demonstrated that clenbuterol induced nerve regeneration (Frerichs O et al., 2001) 
and increased nerve growth factor mRNA (an important regulator of NET – see 
chapter 5) (Hayes VY et al., 1995). 
In 2004, Terracciano et al showed that the use of clenbuterol in combination 
therapy, has induced an increase in cardiac SR Ca
2+
 content and prolonged the 
action potential (Terracciano et al., 2004). This group from our centre has also 
identified that chronic administration of clenbuterol induced changes in Ca
2+
 
regulation, energy metabolism and organ and cellular hypertrophy in rat hearts. 
Investigating the mechanisms involved at molecular and cellular level have 
identified clenbuterol to induce development of cellular and organ hypertrophy 
(cardiac hypertrophy identified by echocardiography), increase Ca
2+
 transients and 
SR Ca
2+
 content without changes in the rate of Ca
2+
 decline in isolated ventricular 
myocytes, increase expression of SERCA2a, PLB and Na+/Ca
2+
 exchanger and 
increase oxidative carbohydrate utilisation in the heart (Soppa et al., 2004). Rise 
in Ca
2+
 transients generate larger contractions and can be explained by the 
increased Ca
2+
 content. In HF the Ca
2+
 transients are reduced in size and have a 
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slower decline, acting as a possible basis for systolic and diastolic dysfunction 
(Beuckelmann et al., 1992). Restoring Ca
2+
 content has been shown to reverse 
Ca
2+
 dysregulation (Hobai & O'Rourke, 2001). 
The mechanism of myocardial growth after stimulation by clenbuterol remains 
unclear. It has been speculated that physiological myocardial hypertrophy might 
be an indirect myocardial response from increased demand from clenbuterol-
induced hypertrophy of skeletal muscle. This is supported by the absence of 
necrosis or fibrosis in clenbuterol treated hearts in contrast to the effects of the β-
agonist isoproterenol (Ferrans et al., 1964). In addition, in vitro clenbuterol 
stimulated cardiac myocyte culture has no effect on cell morphology, in contrast 
to that of isoproterenol which did cause change and induced skeletal -actin in 
myocytes, a recognised feature of ‗pathological‘ hypertrophy (Petrou et al., 
1995;Bishopric & Kedes, 1991). Other mechanisms may also be involved as there 
is some evidence that myocardial β2 receptors operate through a different pathway 
to β1 receptors (Petrou et al., 1995;Kuznetsov et al., 1995). 
In animal models, it induces skeletal muscle hypertrophy (Petrou M et al., 1995). 
Investigators showed chronic β2 agonist administration induces slow-to-fast fibre 
type transition resulting in an increase in greater, faster contractions with 
increased stroke power and reduced contraction and relaxation times (Petrou M et 
al., 1999;Zeman RJ et al., 2004). It induces IGF1 through which skeletal muscle 
hypertrophy is mediated (Awede et al., 2002). A trend is observed to increased 
fast isoforms of myosin heavy chain and SERCA (Petrou M et al., 1999). It also 
inhibits and reverses skeletal muscle atrophy caused by denervation, disuse, 
endotoxaemia and cachexia (Maltin et al., 1986;Maltin et al., 1992;Maltin et al., 
1993;Delday & Maltin, 1997;Choo et al., 1989;Chance et al., 1991). Atrophic 
skeletal muscles are more sensitive to clenbuterol and can respond to doses 
sufficiently low to avoid general skeletal or cardiac hypertrophy (Maltin et al., 
1992). Induction of skeletal muscle hypertrophy may have been beneficial as 
many patients with severe HF have structural and functional cachexia of their 
skeletal muscles (Lipkin et al., 1988;Mancini et al., 1992). In skeletal muscle, 
clenbuterol induces variable degrees of hypertrophy in the same organism which 
may relate to heterogenous β2 receptor density in different muscles (Maltin et al., 
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1993;Williams et al., 1984). The antagonist propranolol has shown varying 
degrees of blockade, suggesting that other mechanisms may also be involved 
(MacLennan & Edwards, 1989;Maltin et al., 1987). 
In summary, LVAD can be utilised as BTT, DT or BTR. At the non-clinical 
level LV unloading using LVAD has resulted in significant changes in 
adrenergic receptors, Ca2
+
 handling proteins, ECM and fibrosis, apoptosis, 
and myocyte characteristics. The use of the Harefield BTR protocol which 
uses reverse remodeling drugs followed by clenbuterol in the second stage of 
the pharmacological regimen has enhanced myocardial recovery and made 
recovery more sustainable.  Clinically these changes were translated into 
significant improvements in haemodynamic and echocardiographic 
parameters, exercise tolerance, and QOL. The effects of LVAD and LV 
unloading, however, on different clinical components of the SNS such as 
contractile reserve and metaiodobenzylguanidine uptake remain to be 
investigated.  
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1.6  Aims of the study 
As described above, LV unloading has a significant impact on haemodynamic and 
echocardiographic parameters as established in HF patients. The effects of 
unloading on the adrenergic receptors, calcium handling proteins, ECM and 
fibrosis, anti-apoptotic genes and proteins have been previously studied at the 
molecular and cellular level. The effects of LVAD, however, on the SNS at the 
clinical setting and the effect on NET (the failure of which is the reason why NE 
is abundant in heart failure which in turn stimulates the neurohormonal pathway) 
remain to be investigated. 
Therefore, the main aims of this thesis are: 
1) to examine prospectively the outcome of using continuous flow HM II 
LVAD and drug combination therapy on the frequency and durability of 
recovery, 
2) to determine the clinical effects of LV unloading on cardiac sympathetic 
nervous system, 
3) to examine the impact of LVAD and drug combination therapy on the 
activity of NET and neurohormonal levels. 
Objectives: 
Assessment of the native LV function depends on regular monitoring of 
myocardial recovery whilst the support of LVAD is ceased. The first objective is 
to determine a cut-off point where the contribution of the HM II LVAD could be 
interrupted to allow assessment of the native LV function without causing 
reloading of the LV. Secondly, the effects of LVAD and drug combination 
therapy on the sympathetic nervous system will be studied at a clinical setting by 
assessing the contractile reserve of the myocardium following exercise. 
123
I-
metaiodobenzylguanidine nuclear imaging will be used to assess the effects of 
LVAD and drug combination therapy on NET response. The fourth objective is to 
attempt to correlate the concentration of NET-fibers in end-stage heart failure 
using immunohistochemistry techniques with myocardial recovery and to 
investigate the effects of unloading on the neurohormonal levels. 
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CHAPTER 2 - Study Population 
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2.1  Study Design 
2.1.1  Population characteristics 
From the 1
st
 of February 2006 until the 31
st
 of March 2009, 36 patients were 
implanted with continuous flow HM II LVADs. All patients were in NYHA class 
IV with severe low cardiac output state, on intravenous diuretic, and inotrope 
dependent. According to the Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS), their pre-implant profile ranged from 1 – 2. 
In general all implanted patients satisfied most of the domains that make up the 
definition of advanced heart failure described by the European Society of 
Cardiology (Metra A et al., 2007) – Refer to Box 1 and Box 2 in Appendix A for 
the descripions of INTERMACS classification and advanced HF, respectively. 
Figure 2.1 is a consort diagram representing the flow of the patients; 23 fulfilled 
the inclusion criteria for this study and 13 did not (table 2.1 and sections 2.1.2 and 
2.1.4). 
 
Figure 2.1: Consort diagram of all patients receiving HM II LVAD 
               
 
Fig 2.1: Consort diagram illustrating the flow of the 36 patients implanted with 
HM II LVAD during the study period. 
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Table 2.1 Inclusion / exclusion criteria 
Table 2.1: Inclusion and exclusion criteria to enter the recovery study 
2.1.2   Demographics and clinical characteristics of included 
patients  
Demographics and clinical parameters of individual patients are included in 
tables 2.2 and 2.3. 21 patients had idiopathic DCM and 2 had familia DCM (refer 
to section 2.1.3 for the histological analysis of the underlying pathology). Table 
2.4 is a summary of pre-implant demographics and clinical parameters with data 
being presented as means ± S.D. (minimum – maximum). Prior to implantation 
four patients required short term mechanical support for 40.75 ± 30.52 days. 
Patient 2 was intubated and the use of short-term support allowed us to assess his 
neurological status prior to switching to long-term support. The remaining three 
(patients 6, 13, and 18) were not responsive to inotropic therapy and the decision 
to support with short-term device was based on the fact that they had severely 
deranged renal function and a period of stabilisation was required prior to 
commitment with longer-term support devices. 
Inclusion Criteria 
1. Patient has refractory symptomatic heart failure (NYHA Class IV or Stage D) 
due to dilated, non-ischemic cardiomyopathy 
2. Severe clinical heart failure with associated haemodynamic compromise 
resistant to intensive medical therapy and requiring LVAD implantation 
3. LVEF ≤ 30% and cardiomegaly at the time of LVAD implantation as 
documented by radionuclide or contrast ventriculography or by 
echocardiography 
4. ≥ 18 years of age 
5. Body surface area ≥ 1.5 m2 
Exclusion Criteria 
1. Not a heart transplant candidate  
2. Evidence of active acute myocarditis 
3. Hypertrophic obstructive cardiomyopathy 
4. Restrictive cardiomyopathy 
5. Irreversible multiorgan failure 
6. Underlying bleeding disorder 
7. Pregnant or lactating woman 
8. Unable to follow the recovery protocol i.e. perform ―off-pump‖ testing to 
assess the native LV function 
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Table 2.2: Pre-implantation demographics and clinical parameters of each individual patient. 
Patient 
Number 
Diagnosis Gender 
Disease 
Duration 
(mths) 
Symptoms 
Duration 
(mths) 
Implant 
Age (yrs) 
BMI 
(kg/m
2
) 
BSA 
(m
2
) 
PMH 
Number of 
Inotropes 
1 *
, ††
 DCM M 2 2 16.88 20.68 1.83 Nil 4 
2 *
, †, §
 DCM M 2 2 18.89 25.62 2.04 Nil 4 
3 DCM M 48 6 41.41 23.77 1.96 ICD 1 
4 DCM F 4 4 58.26 19.01 1.38 Nil 2 
5 
†, ††
 DCM M 132 2 42.86 22.86 1.84 Nil 2 
6 
††, §
 DCM M 50 9 27.14 25.57 1.95 ICD 4 
7 DCM M 2 2 29.71 22.52 2.10 Nil 1 
8 
††
 Familial DCM M 48 4 21.04 19.14 1.76 Nil 2 
9 DCM M 108 12 55.89 28.85 1.74 ICD, Type II DM, AF 1 
10 DCM M 48 4 39.67 25.94 1.85 Asthma 2 
11 DCM M 1.5 1.5 35.23 26.85 2.09 Multiple PE‘s 2 
12 DCM M 1.5 1.5 21.55 21.30 1.73 Mild asthma 2 
13 
§
 DCM M 84 6 48.10 24.98 1.77 DVT 2 
14 DCM M 12 12 23.90 26.84 2.07 Nil 2 
15 DCM F 9 9 33.92 19.83 1.57 Nil 1 
16 DCM M 78 12 51.66 24.09 1.78 ICD, Hypercholesterolaemia 2 
17 DCM M 30 1 24.18 20.63 1.79 ICD 2 
18 
§
 DCM M 1.5 1.5 16.58 26.73 1.96 Nil 2 
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19 
††
 DCM M 5 5 42.37 21.50 1.74 Nil 2 
20 DCM M 14 14 53.23 23.05 1.81 CRT-D, restless leg syndrome, Type II DM 2 
21 DCM M 36 3 58.82 24.21 1.91 ICD, Aortic regurgitation 2 
22 DCM M 1.5 1.5 32.39 29.32 2.18 Mild asthma 2 
23 DCM M 1.5 1.5 16.72 21.05 1.74 Nil 2 
Table 2.2: Pre-implant demographics. Table A.1 in Appendix A includes details of the implantation date and duration of study on individual 
patients 
 
* Patient 1 and 2 were intubated prior to device implantation 
† Patients 2 and 5 were haemofiltered prior to device implantation 
†† Patients 1,5,6,8 and 19 had IABP prior to device implantation 
§ Patients 2,6,13, and 18 had pre-implant short term support (patients 2,6, and 13 had BiVAD Levitornics
®
 and patient 18 had ECMO) 
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Table 2.3: Pre-implantation haemodynamics and echocardiographic data 
Patient 
Number 
Pre-Implant Haemodynamcis Pre-Implant Echocardiography 
Sys PA 
(mmHg) 
Dia PA 
(mmHg) 
Mean PA 
(mmHg) 
PCWP 
(mmHg) 
CO (l/min) 
CI 
(l/min/m
2
) 
PA sats 
(%) 
LVEDD 
(mm) 
LVESD 
(mm) 
FS (%) EF (%) 
1 - - - 31 5.4 2.9 43 73 70 4.11 11.83 
2 - - - - - - - 63 59 6.35 17.86 
3 31 20 27 22 1.7 0.9 38.4 70 65 7.14 19.93 
4 43 17 32 23 2.1 1.53 61.6 67 63 5.97 16.86 
5 42 32 38 - - - - - - - 20.00 
6 - - - - - - - - - - - 
7 - - - - - - - 69 67 2.90 8.45 
8 37 35 33 28 2.9 1.65 - 66 61 7.58 21.05 
9 72 37 52 48 2.9 1.7 58 78 72 7.69 21.35 
10 58 25 42 26 2.21 1.2 35 85 78 8.23 22.73 
11 38 23 28 27 4.23 2.03 36 63 61 3.18 9.23 
12 43 31 36 29 2.7 1.56 - 63 59 6.35 17.86 
13 46 19 32 34 1.55 0.88 25 74 67 9.46 25.78 
14 40 27 33 33 2.1 1.1 36 78 73 6.41 18.02 
15 - - - 32 2.1 1.33 - 69 65 5.80 16.40 
16 62 31 44 33 - - - 79 71 10.13 27.41 
17 53 32 39 29 2.9 1.6 51 91 82 9.89 26.83 
18 - - - - - - - 62 58 6.45 18.13 
19 57 19 33 22 3.4 1.9 - 76 61 19.74 48.29 
20 39 26 31 23 2 1.6 - 67 62 7.46 20.76 
21 53 31 38 32 3.12 1.63 53 81 79 2.47 7.23 
22 - - - - - - - 62 54 12.90 33.93 
23 - - - - - - - 83 75 9.64 26.22 
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Table 2.3 (cont.): 
 
Patient 
Number 
Pre-Implant Serum Biochemistry 
Urea 
(2.3-6.7 mmol/L) 
Creatinine 
(60-130 μmol/L) 
Bilirubin 
(0-20 μmol/L) 
ALP (30-130 U/L) ALT(5-65 U/L) BNP 
1 17.7 159 58 83 1026 - 
2 17.9 318 18 36 970 - 
3 10.6 122 66 62 30 71 
4 5 71 34 41 28 99 
5 18.3 341 47 75 38 592 
6 21.8 315 55 101 13 16 
7 4.6 100 21 80 294 - 
8 6.4 100 14 82 42 248 
9 11.7 170 30 133 47 271 
10 9.9 132 78 102 629 220 
11 10.4 96 38 70 33 146 
12 11.8 127 76 86 2180 - 
13 5.3 173 22 57 36 50 
14 10.2 131 65 44 62 95 
15 13.7 104 99 265 531 373 
16 30.3 277 54 80 220 360 
17 8.6 105 29 57 140 >1352 
18 13 248 60 57 1484 >919 
19 7.3 53 85 83 1258 214 
20 13.5 139 8 64 29 31 
21 13.6 138 39 84 32 >919 
22 9.2 145 60 87 101 - 
23 5.5 84 18 91 17 112 
 
Table 2.3: Pre-implant haemodynamics, echocardiographic and biochemical profile of individual patients.
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Table 2.4: Summary of pre-implantation demographics of the studied 
population (n=23) 
Variable Value 
Gender (male : female) 21 : 2 
Diagnosis 
21non-ischaemic idiopathic 
DCM, 2 familial 
Age at implantation (years) 35.24 ± 14.27 (16.58 – 58.82) 
Duration of Heart Failure (months) 
31.29 ± 38.03 (1.5 – 132; 
median 12 months) 
Symptoms duration (months) 5.07 ± 4.17 (1 – 14) 
INTERMACS Classification 
Weight (kg) 
1.65 ± 0.49 (1 – 2) 
71.48 ± 11.41 (44.5 – 95) 
Height (cms) 173.54 ± 8.51 (153 – 192) 
Body mass index (kg/m
2
) 23.67 ± 3.00 (19.00 – 29.32) 
Body surface area (m
2
) 1.85 ± 0.19 (1.38 – 2.18) 
Number of inotropes 
Haemodynamic Parameters 
Systolic PA pressure (mmHg) 
Diastole PA pressure(mmHg) 
Mean PA pressure (mmHg) 
PC Wedge Pressure (mmHg) 
Cardiac Output (l/min) 
Cardiac Index (l/min/m
2
) 
PA saturation (%) 
Echocardiographic Parameters 
End-diastolic diameter (mm) 
End-systolic diameter (mm) 
Fractional shortening (%) 
Ejection Fraction (%) 
2.09 ± 0.85 (1 – 4) 
 
47.61 ± 11.17 (31 – 72) 
27.00 ± 6.32 (17 – 37) 
35.87 ± 6.56 (27 – 52) 
29.88 ± 6.42 (22 – 48) 
2.69 ± 1.01 (1.55 – 5.4) 
1.46 ± 0.57 (0.40 – 2.9) 
43.00 ± 11.36 (25 – 61.6) 
 
72.33 ± 8.43 (62 – 91) 
66.76 ± 7.66 (54 – 82) 
7.61 ± 3.79 (2.47 – 19.74) 
20.73 ± 8.96 (7.23 – 48.29) 
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Table 2.4 (cont.) 
 
 Variable  Value 
Biochemical Parameters 
Haemoglobin (g/dl) 
White cell count 
Urea (mmol/L) 
Creatinine (μmol/L) 
Bilirubin (μmol/L) 
Alkaline Phosphotase (U/L) 
Alanine Transaminase (U/L) 
Albumin (g/dL) 
BNP (pmol/L) 
 
12.77 ± 2.22 (8.1 – 16) 
9.97 ± 3.58 (5.1 – 19.2) 
12.01 ± 6.12 (4.6 – 30.3) 
158.61 ± 82.93 (53 – 341) 
46.70 ± 24.98 (8 – 99) 
83.48 ± 45.21 (36 – 265) 
401.74 ± 590.71 (13 – 2180) 
31.48 ± 5.66 (23 – 45) 
338.22 ± 373.20 (16 – 1352) 
Number requiring pre-implant support 4 patients 
Duration of pre-implant support (days) 40.75 ± 30.52 (6 – 74) 
Type of support 3 BiVAD Levitronix
®
, 1 
ECMO 
Number requiring pre-implant ventilation 2 patients 
Number requiring pre-implant haemofilter 2 patients 
Number requiring pre-implant IABP 5 patients 
 
Table 2.4: Summary of pre-implantation demographics. Data are presented as 
means ± S.D. Minimum-maximum, where relevant, is presented in brackets. 
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2.1.3  Histological analysis of included patients 
Histological evaluation of the LV cores obtained from the 23 studied patients at 
time of implantation showed interstitial and replacement fibrosis with myocyte 
hypertrophy, nuclear enlargement and occasional vacuolated myocytes, 
compatible with dilated cardiomyopathy. By conventional light microscopy there 
was no lymphocytic myocarditis, but occasional foci of mixed chronic 
inflammation surrounding damaged myocytes were noted, suggesting inotrope-
related myocardial damage. 
 
2.1.4  Demographics and clinical characteristics of excluded 
patients 
 
As depicted in figure 2.1, 13 patients were excluded as they did not fulfil the 
inclusion criteria (table 2.1). Pre-implantation demographics, clinical parameters 
and reasons for exclusion for each individual patient are included in table 2.5. 
 
 
 
 
120 
 
Table 2.5: Excluded patients (n=13) 
Patient 
Number 
Diagnosis Gender 
Implant 
Date 
Implant 
Age (yrs) 
Global 
EF (%) 
Reason for exclusion 
E1 IHD M 20/07/2006 60.48 42 Ischaemic Origin 
E2 HOCM M 28/08/2006 41.07 12 HOCM 
E3 PPM DCM F 16/10/2006 35.09 28 
Developed chest pain every time the speed of the HM II 
was reduced to assess the underlying myocardial function 
E4 IHD F 12/02/2007 45.43 30 Ischaemic Origin 
E5 DCM M 26/02/2007 57.46 10 Apical VSDs 
E6 DCM M 03/03/2007 27.51 10 Died 23 days after device implantation 
E7 DCM M 26/06/2007 47.20 - Died 9 days after device implantation 
E8 Becker’s MD M 10/07/2007 18.67 - Becker’s muscular dystrophy 
E9 DCM M 11/07/2007 21.87 24 Severe MR 
E10 IHD M 13/10/2007 56.04 25 Ischaemic Origin 
E11 DCM F 29/12/2007 28.85 15 
Severe MR and prolonged ITU stay prevented from 
recovery assessment 
E12 PPM DCM F 30/09/2008 41.94 20 Poor clinic attendance and compliance with medication 
E13 IHD F 09/02/2009 32.08 - Ischaemic Origin 
Table 2.5: Basic demographics of the 13 excluded patients and the reasons for their exclusion from the study. 
 
121 
 
2.1.5  Pharmacological regimen 
Following LVAD implantation, patients were started on Phase I medication of the 
Harefield Bridge-to-Recovery Protocol to induce reverse remodelling (Birks EJ et 
al., 2006;Yacoub MH et al., 2001a) immediately after weaning the patients from 
inotropic therapy with adequate end-organ recovery. As described in chapter 1, 
the regimen consisted of: 
i) Cardiac digitalis (digoxin) – titrated up to 125 μg od; 
ii) Non-selective β-blocker (carvedilol) – titrated up to 25 mg bd; 
iii) Angiotensin converting enzyme inhibitor (lisinopril) – titrated up 
to 40 mg od; and 
iv) Aldosterone antagonist (spironolactone) – titrated up to 25 mg od. 
The second stage of pharmacologic therapy was commenced after maximal 
regression in the left ventricular end-diastolic diameter had been achieved while 
the left ventricular assist device was in place. When constant left ventricular end 
diastolic diameter (<60 mm) and ejection fraction (>50%) had been maintained 
for at least 2 weeks, according to echocardiographic assessment, carvedilol was 
replaced by the selective β1 blocker, bisoprolol. Following maximal bisoprolol up-
titration, as per patient tolerance, clenbuterol (β2 agonist) was started at 40 μg bd 
and was up-titrated to a maximum dose of 700 μg tds to induce physiological 
hypertrophy (Birks EJ et al., 2006;Hon J et al., 2001;Hon J & Yacoub M, 
2003;Petrou M et al., 1995;Petrou M et al., 1999;Soppa G et al., 2004;Tansley P 
et al., 2004;Wong K et al., 1998;Yacoub M et al., 2001). Clenbuterol dose was 
adjusted to maintain a resting heart rate below 100 bpm. 
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2.2  Post-implantation Clinical Outcome 
2.2.1  Post implant RVAD support  
Following the implantation of HM II LVAD, five patients had acute right 
ventricular failure requiring immediate support using RVAD for 25 ± 9.6 days 
(range 16-36 days). One patient (patient 13) who required 58 days of preoperative 
support with a BIVAD Levitronix
®
 due to end-organ failure prior to his HM II 
implantation developed a dense left hemiparesis following his HM II upgrade and 
BIVAD removal. He recovered well from this event and managed recovery 
assessments with no further complications. 
 
2.2.2  Recovered and non-recovered patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
By the 31
st
 of October 2009 (the follow-up cut-off date – total study duration 
was three years and ten months), 15 patients had recovered and fulfilled the 
Harefield Bridge-to-Recovery explantation criteria whilst the remaining eight did 
not show any signs of myocardial recovery and were either transplanted or 
transplant listed (sections 2.3.2.1 and 2.3.2.2 include details of the recovered and 
the non-recovered patients). Table 2.6 represents a comparison of the pre-
implantation clinical parameters between the recovered and the non-recovered 
patients. The total duration of HF was significantly higher in the non-recovered 
patients as compared to the recovered patients. In addition, ventricular dimensions 
were significantly larger in the non-recovered as compared to the recovered 
patients. Haemodynamic parameters were similar between the two groups.  
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Table 2.6: Comparison of the pre-implantation clinical parameters between 
the recovered (n=15) and the non-recovered (n=8) patients. 
Variable 
Recovered 
Patients (n=15) 
Non-Recovered 
Patients (n=8) 
p-value 
HF Duration (months) 15.03 ± 24.81 61.75 ± 41.08 0.002 
Implant Age (yers) 32.30 ± 13.85 40.73 ± 14.26 0.149 
BMI (kg/m
2
) 23.17 ± 3.20 24.61 ± 2.50 0.357 
BSA (m
2
) 1.84 ± 0.21 1.88 ± 0.11 0.548 
Systolic PA pressure (mmHg) 45.13 ± 8.20 50.43 ± 13.96 0.536 
Diastole PA pressure(mmHg) 24.38 ± 6.25 30.00 ± 5.29 0.072 
Mean PA pressure (mmHg) 33.38 ± 4.14 38.71 ± 7.91 0.121 
PCWP (mmHg) 27.50 ± 4.09 33.29 ± 7.87 0.070 
Cardiac Output (l/min) 2.76 ± 1.17 2.54 ± 0.61 1.000 
Cardiac Index (l/min/m
2
) 1.54 ± 0.64 1.30 ± 0.39 0.525 
PA saturation (%) 39.43 ± 12.29 47.28 ± 9.59 0.247 
End-diastolic diameter (mm) 69.47 ± 7.38 79.50 ± 6.77 0.011 
End-systolic diameter (mm) 64.00 ± 6.49 73.67 ± 6.06 0.006 
Fractional shortening (%) 7.74 ± 4.20 7.29 ± 2.79 0.677 
Ejection Fraction (%) 21.03 ± 10.04 20.11 ± 6.71 0.680 
Urea (mmol/L) 10.08 ± 4.45 16.09 ± 7.06 0.065 
Creatinine (μmol/L) 136.60 ± 69.07 201.78 ± 89.38 0.101 
Bilirubin (μmol/L) 45.93 ± 29.56 45.56 ± 15.57 0.728 
Alkaline Phosphotase (U/L) 85.60 ± 53.01 76.33 ± 27.75 0.925 
Alanine Transaminase (U/L) 577.20 ± 671.55 90.78 ± 85.62 0.149 
Albumin(g/dL) 31.67 ± 5.65 30.56 ± 5.90 0.925 
BNP (pmol/L) 241.10 ± 259.31 459.50 ± 470.74 0.460 
Table 2.6: Direct comparison of pre-implant demographics, clinical parameters 
and biochemical profile between the recovered and the non-recovered patients. 
Analysis performed using unpaired t-test and Mann-Whitney U test for normally 
distributed and non-parametric variables, respectively. Means ± SD. 
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Linear regression analysis revealed no correlation between pre-implant heart 
failure duration and myocardial recovery (r=0.03; p=0.765) and pre-implant LV 
dimension and myocardial recovery (LVEDD and LVESD). The total support 
duration in the recovered patients was 270.3 ± 98.8 days (range 138 – 474 days, 
median 227 days). 
2.2.2.1  Recovered patients 
These were the recovered patients: 1, 2, 4, 7, 8, 10, 11, 12, 13, 15, 18, 19, 20, 22, 
23. All recovered patients were started on clenbuterol as the second phase 
therapy after achieving sustained regression in LVEDD (< 60 mm)  for at 
least two weeks (the remaining criterion for commencing clenbuterol was 
discussed on page 118).  Table 2.7 represents the explantation criteria. 
Table 2.7: Explantation Criteria 
Parameter with the speed of HM II 
reduced to 6000 rpm for 15 minutes *  
Value 
LV end-diastolic diameter (mm)  < 60 
LV end-systolic diameter (mm) < 50 
Ejection Fraction (%) > 45 
Maximal VO2 (mls/min/kg) > 16 
LV end-diastolic pressure (mmHg) 
Cardiac Index (l/min/m
2
) 
< 12 
> 2.8 
Table 2.7: Explantation criteria as been previously described (Birks EJ et al., 
2006).  
* Clinical and bench-side experiments revealed that by reducing the speed of the 
HM II LVAD to 6000 rpm the underlying LV is unmasked sufficiently, enough to 
allow the assessment of the native LV function (see chapter 3). 
 
A comparison of the pre-implantation and pre-explantation haemodynamic and 
echocardiographic parameters in the recovered group are presented in table 2.8.  
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Table 2.8: Comparison between pre-implantation and explantation 
parameters in the recovered group (n=15). 
Variable 
Pre-
implantation 
Pre- 
explantation* 
p-value 
Systolic PA pressure (mmHg) 45.13 ± 8.20 20.00 ± 4.66 0.020 
Diastole PA pressure(mmHg) 24.38 ± 6.26 6.14 ± 2.80 0.040 
Mean PA pressure (mmHg) 33.38 ± 4.14 11.36 ± 3.27 0.020 
PC Wedge Pressure (mmHg) 27.50 ± 4.09 5.71 ± 4.29 0.008 
LV End Diastolic Pressure 
(mmHg) 
- 6.90 ± 6.39 N/A 
Cardiac Output (l/min) 2.76 ± 1.17 6.33 ± 1.30 0.008 
Cardiac Index (l/min/m
2
) 1.54 ± 0.64 3.58 ± 0.65 0.008 
PA saturation (%) 39.43 ± 12.29 68.66 ± 9.08 0.08 
End-diastolic diameter (mm) 69.47 ± 7.38 50.07 ± 6.26 <0.001 
End-systolic diameter (mm) 64.00 ± 6.49 33.53 ± 5.82 <0.001 
Fractional shortening (%) 7.74 ± 4.20 33.28 ± 5.18 <0.001 
Ejection Fraction (%) 21.03 ± 10.04 69.81 ± 6.64 <0.001 
Maximal VO2 (mls/kg/min) - 22.56 ± 4.80 N/A 
Urea (mmol/L) 10.08 ± 4.45 7.22 ± 2.82 0.311 
Creatinine (μmol/L) 136.58 ± 69.07 92.00 ± 13.22 0.03 
Bilirubin (μmol/L) 45.93 ± 29.56 11.85 ± 3.73 0.001 
Alkaline Phosphotase (U/L) 85.60 ± 29.56 73.46 ± 20.26 0.151 
Alanine Transaminase (U/L) 577.20 ± 671.55 32.15 ± 23.96 0.010 
Albumin(g/dL) 31.67 ± 5.65 43.38 ± 16.40 0.006 
BNP (pmol/L) 241.20 ± 259.22 8.52 ± 5.13 <0.001 
Table 2.8: Direct comparison between pre-implant and pre-explant parameters. 
Analysis performed using paired t-test for normally distributed variables and 
Wilcoxon signed-rank test for non-parametric variables.  Data are presented as 
means ± SD. * Pre-explantation assessments were performed whilst on low-
speed of 6000 rpm for 15 minutes.  
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2.2.2.1.i Device explantation 
As of the 31
st
 of October 2009, out of the 15 recovered patients, 14 were 
explanted and one patient (patient 20) was confirmed recovered as demonstrated 
by the echocardiographic and maximal VO2 criteria and was waiting to be 
discussed in the MDT for device explantation.  
8 of the 14 (57.1%) explanted patients (patients 1, 10, 11,12, 18, 19, 22, and 23) 
were explanted using the mini-invasive approach, previously described by 
Professor Yacoub (Tansley P & Yacoub M, 2002). Three patients had planned full 
redo-sternotomy (patients 2, 8, and 15) for the following reasons: 
i) patient 2 had pre-implant BiVAD Levitronix® and thought he may 
need an RVAD following explantation,  
ii) the presence of thrombus in the ascending aorta of patient 8, 
iii) patient 15 had parts of the upper lobe of the right lung in front of the 
outflow cannula as assessed by pre-implantation reconstructive CT 
scan. 
One patient (patient 4) started with the limited surgical approach but developed 
RV failure once the LVAD was discontinued and hence the procedure was 
converted into median sternotomy to implant post explant RVAD. 
The remaining two patients had limited median and lower sternotomies as pre-
cautionary measure. Patient 13 required a BiVAD Levitronix
®
 pre-upgrade to HM 
II LVAD and patient 7 had recurrent drive line infections which were resistant to 
antibiotics despite normalisation in his LV function. 
2.2.2.1.ii Predicors of myocardial recovery 
Receiver operating characteristics analysis was used to determine possible pre-
implant predictors of subsequent recovery (table 2.9). Duration of HF, end 
diastolic and end-systolic diameters were all identified. HF duration of 12 months 
or less had 100% sensitivity and 73.3% specificity. Both pre-implant end-diastolic 
and end-systolic diameters of 77 mm or less and 70 mm or less, respectively, had 
sensitivities of 83.3% and specificites of 86.7%. Table 2.10 is a logistic regression 
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analysis representing the degree of the correlation between all pre-implant 
parameters and myocardial recovery. 
Table 2.9: Predictors of myocardial recovery 
 
Pre-implant Variable 
Area Under 
Curve (AUC) 
Sensitivity
(%) 
Specificity 
(%) 
p-value 
HF duration 
Pre-implant age 
BMI (kg/m
2
) 
BSA (m
2
) 
Systolic PA pressure (mmHg) 
0.833 
0.692 
0.625 
0.579 
0.607 
100 
- 
- 
- 
- 
73.3 
- 
- 
- 
- 
0.003 
0.138 
0.333 
0.540 
0.487 
Diastole PA pressure(mmHg) 0.786 - - 0.104 
Mean PA pressure (mmHg) 0.750 - - 0.105 
PC Wedge Pressure (mmHg) 0.764 - - 0.098 
Cardiac Output (l/min) 0.509 - - 0.955 
Cardiac Index (l/min/m
2
) 0.402 - - 0.514 
PA saturation (%) 0.733 - - 0.201 
End-diastolic diameter (mm) 0.856 83.3 86.7 0.013 
End-systolic diameter (mm) 0.872 83.3 86.7 0.009 
Fractional shortening (%) 0.567 - - 0.640 
Ejection Fraction (%) 0.562 - - 0.647 
Urea (mmol/L) 0.742 - - 0.208 
Creatinine (μmol/L) 0.717 - - 0.093 
Bilirubin (μmol/L) 0.550 - - 0.699 
Alkaline Phosphotase (U/L) 0.480 - - 0.923 
Alanine Transaminase (U/L) 0.308 - - 0.138 
Albumin(g/dL) 0.513 - - 0.923 
BNP (pmol/L) 0.606 - - 0.450 
Table 2.9: ROC analysis of pre-implant variables 
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Table 2.10: Logistic regression analysis to correlated pre-implant parameters 
with myocardial recovery  
 
Pre-implant Variable R-value p-value 
HF duration ≤ 12 months 
Pre-implant age 
BMI (kg/m
2
) 
BSA (m
2
) 
Systolic PA pressure (mmHg) 
0.699 
0.288 
0.232 
0.114 
0.244 
<0.001 
0.183 
0.285 
0.598 
0.378 
Diastole PA pressure(mmHg) 0.459 0.085 
Mean PA pressure (mmHg) 0.342 0.119 
PC Wedge Pressure (mmHg) 0.457 0.065 
Cardiac Output (l/min) 0.105 0.703 
Cardiac Index (l/min/m
2
) 0.214 0.408 
PA saturation (%) 0.367 0.276 
End-diastolic diameter ≤ 77 mm 0.603 0.004 
End-systolic diameter ≤ 70 mm 0.671 0.001 
Fractional shortening (%) 0.055 0.812 
Ejection Fraction (%) 0.045 0.830 
Urea (mmol/L) 0.443 0.084 
Creatinine (μmol/L) 0.371 0.081 
Bilirubin (μmol/L) 0.045 0.846 
Alkaline Phosphotase (U/L) 0.063 0.766 
Alanine Transaminase (U/L) 0.416 0.082 
Albumin(g/dL) 0.045 0.833 
BNP (pmol/L) 0.300 0.228 
 
Table 2.10: Logistic regression anaylsis of the ideintifed paramteres in table 2.9 
showed that HF duration ≤ 12 months, EDD ≤ 77 mm, and ESD ≤ 70 mm to 
correlate with recovery 
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2.2.2.1.iii Final outcome of the explanted patients 
Of the 14 explanted patients, two died at 14 and 26 days post-explantation from 
intra-cerebral haemorrhage and cerebral infarcts, respectively. Patient 8 was 21yrs 
with familial DCM and had signs of good recovery (pre-explant after 15 minutes 
of 6000 rpm (see chapter 3 for low speed testing protocol) his EF was 61%, 
LVEDD was 41 mm, LVESD was 30 mm, mVO2 was 27.4 mls/min/kg, CO was 
6.4 L/min, CI was 4 L/min/m
2
, PCWP was 6 mmHg, and the PA saturations was 
74.5%. He was explanted after 260 days of support. At explantation, 
transoesophageal echocardiogram revealed a new thrombus in the ascending aorta 
around the coronary sinuses. Subsequently the aortic root was explored with the 
HM II LVAD turned up to 10,000 rpm in the interim period in an attempt to stop 
the valve opening. However, by the time the root was explored there was no 
thrombus remaining. It took several attempts to wean him from cardiopulmonary 
bypass and a Levitronix
®
 short-term LVAD had to be inserted. He then had a 
period of profound vasoplegia requiring norepinephrine, vasopressin and 
haemofiltration. By the sixth post operative day he was weaned from all inotropes, 
extubated and off haemofiltration. However, he then became septic which started 
resolving when he had a massive intra-cerebral haemorrhage and died on post 
operative day 14. 
The second patient, patient 7, had had reasonable recovery (pre-explant at 6000 
rpm, his mVO2 was 21.5 mls/min/kg, CO was 7.06 L/min, CI was 3.4 L/min/m
2
, 
PCWP was 2.0 mmHg, PA saturation was 70%, EF was 59%, LVEDD was 58 
mm, and LVESD was 43 mm) but had recurrent drive line infection (Enterobacter 
cloacae and Acinotabacter baumanii). He was explanted after 474 days of support 
once the driveline infections were considered under control. Following 
explantation, he was extubated in the operating room and initially did extremely 
well. However on day 3 he was sitting out of bed when he became very sweaty, 
tachycardic and had a VF arrest. He required CPR, re-intubation and ECMO 
insertion (post arrest EF was 5%). Unfortunately he made a poor neurological 
recovery, decerebrated and CT suggested ischaemic change. ECMO was 
withdrawn and he died on day 26 post-explantation. 
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A further patient (patient 4) required 7 days of short-term RVAD support 
following explantation due to intra-operative air passing down the right coronary 
artery, but recovered well. She remains extremely well and active 690 days 
following explantation with LVEDD of 48 mm, LVESD of 29 mm, EF of 64.6%, 
and mVO2 of 21.2 mls/min/kg. 
The remaining 11 explanted  patients remain in NYHA class I 371.75 ± 342.85 
days post device explantation (range 24 – 1123 days, median 256 days) with 
LVEDD 61.18 ± 8.66 mm, LVESD 45.50 ± 11.84 mm, FS 25.03 ± 7.97%, EF 
56.52 ± 15.14%, and mVO2 22.97 ± 5.20 mls/min/kg. 
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2.2.2.2  Non-recovered patients 
Pre-implantation parameters of the eight non-recovered patients were included in 
table 2.6. They were transplant listed following 395.50 ± 139.33 days of LVAD 
support (range 215 – 607 days, median 354 days) as they had not met the 
explantation criteria highlighted in table 2.7.  
Main reasons for not recovering were chronic drive line infection in two patients 
(patients 5 and 9) and resistance to recovery with no signs of myocardial recovery 
on echocardiography despite maximal phase I medication in five patients (3, 6, 
16, 17 and 21). Patient 14 showed some signs of myocardial recovery after 8 
months of support; however, he developed chronic drive line infection which has 
resulted in a significant reduction in his LV function / performance. None of the 
non-recovered patients received phase two therapy - clenbuterol. Table 2.11 
represents a direct comparison between pre-implantation and pre-transplant listing 
echocardiographic parameters. 
Table 2.11: Comparison between pre-implantation and transplant listing 
echocardiographic parameters in the non-recovered group (n=8). 
Variable 
Pre-
implantation 
Pre- 
transplant listing * 
p-value 
End-diastolic diameter (mm) 79.50 ± 6.77 71.88 ± 10.45 0.147 
End-systolic diameter (mm) 73.67 ± 6.06 64.38 ± 12.61 0.124 
Fractional shortening (%) 7.29 ± 2.79 10.80 ± 6.94 0.268 
Ejection Fraction (%) 20.11 ± 6.71 27.91 ± 16.35 0.261 
Table 2.11: Echocardiographic comparison between pre-implant and pre-
transplant. Analysis performed using paired t-test.  Data are presented as means ± 
SD. Two of the eight patients were transplanted. Patient 5 was transplanted 131 
days after listing with total LVAD support duration of 607 days. Patient 9 was 
transplanted 65 days post listing with total LVAD support duration of 298 days. 
Both patients died of primary graft failure 38 days and 82 days post 
transplantation, respectively. The other six patients remain on the transplant 
waiting list as of the 31
st
 of October 2009. * Pre-transplant listing assessment 
was performed whilst on low-speed of 6000 rpm for 15 minutes. 
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2.3  Discussion 
DCM is one of the commonest cardiomyopathies. There is a 3:1 male to female 
ratio and most presentations occur between 3
rd
 - 5
th
 decades with high associated 
mortality (Dec & Fuster, 1994). In the 23 studied patients the average age of 
presentation was 35 years (range 16.5 - 59) with male to female ratio of 10.5:1. 
Aetiological heterogeneity is likely to include direct myocardial toxicity from 
factors such as alcohol, drugs or heavy metals, viral infection, altered immunity, 
familial factors, and peri-partum states (Davies et al., 1995;Why et al., 
1994;Schonian et al., 1993;Kandolf & Hofschneider, 1989;Caforio et al., 1994). 
In our studied patients, DCM had non-ischaemic origin, no evidence of 
myocarditis and none of the patients had post-partum DCM.  
The most possible cause of idiopathic DCM in our patients was viral infection. 
Viral infection in animal models can cause acute myocarditis with a high 
mortality. After a long latent period in survivors, HF may occur in which 
myocardial changes consistent with DCM develop (Schnitt et al., 1993). This has 
been found with Coxsackie infection in mice and Papovavirus in dogs. Similarly 
in humans, some studies have shown that long-term LV dysfunction can follow 
viral myocarditis and that some develop DCM (Levi et al., 1988;Matoba et al., 
1990;Tazelaar & Billingham, 1987). However, most have no known previous 
acute myocarditis. This may be true in our patients such that histological 
evaluation of LV core showed evidence of inflammation with no lymphocytic 
infiltration which is hallmark in the diagnosis of myocarditis.  
The mechanisms by which viral infection may induce LV dysfunction remain 
unclear. Genetic studies have shown that less than 50% of DCM patients are 
positive for enteroviruses with viral RNA present in 25% (Kandolf et al., 1987). 
Proposed mechanisms for the role of viral infection in DCM pathogenesis include 
direct viral cytotoxicity, immunological involvement and viral RNA persistence 
(Martino et al., 1994). Enteroviral protease 2A has been shown to cleave 
dystrophin thus impairing structure and function of the myocardial cytoskeleton, 
acting as possible mechanism of direct coxsackie myocardial cytotoxicity 
(Badorff et al., 1999). 
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Two of the studied patients (patients 8 and 12) had familial DCM and both had 
their HM II LVAD explanted for myocardial recovery. Familial inheritance has 
been identified in 20-30%, with a prevalent autosomal dominant trait and variable 
penetrance (Mestroni & Giacca, 1997). Underlying genetic defects require further 
investigation along with the molecular basis of the myocardial dysfunction. Genes 
possibly involved might affect immune regulation or be responsible for normal 
heart function. X-linked DCM and rare recessive forms also exist.  
Pre-implant support with Levitronix
®
 short-term device 
The use of Levtironix
®
 VAD, a short-term low cost device, has been described as 
a bridge-to-decision in extremely sick patients who have contraindications to the 
implantation of a long-term VAD or requiring urgent transplantation (Bhama JK 
et al., 2009;DeRobertis F et al., 2008). The use of this short-term device has 
proven to be very effective in stabilising the haemodynamic status and improve 
the end-organ function prior to deciding if a more expensive device or transplant 
should be used. Four of our patients required pre-implantation short-term support 
for 40.75 ± 30.52 days. One of the patients (patient 2) was intubated and the use 
of short-term support allowed us to assess his neurological status prior to 
switching to long-term support. The remaining three (patients 6, 13, and 18) were 
not responsive to inotropic therapy and the decision to support with short-term 
device was based on the fact that they had severely deranged renal function and a 
period of stabilisation was required prior to commitment with longer-term support 
devices. 
DCM and histological features 
In the studied group, histological evaluation of the LV cores acquired at 
implantation showed interstitial fibrosis, with myocyte hypertrophy and nuclear 
enlargement. DCM is characterised by abnormal morphological features such as 
increased heart mass, weight and LV cavity diameter, with normal or reduced LV 
wall thickness. There is impaired systolic contraction, reduced EF and increased 
end-systolic and end-diastolic volumes (Richardson et al., 1996). Histological 
diagnosis of DCM can be difficult due to variable myocyte changes and interstitial 
fibrosis. The histological pattern of DCM may be described as a complex of non-
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specific features, common to many end-stage cardiac conditions. All myocardial 
components are involved comprising interstitium, small vessels and endocardium 
but myocytes are the most profoundly affected (Mosseri et al., 1986;Tanganelli et 
al., 1990). Hypertrophic myocytes often contain irregularly shaped enlarged 
nuclei. Attenuated myocytes are also present and myofibrillar loss is typical. 
Myocytes often appear abnormally vacuolated and variable myocyte death may be 
present. Coexistence of large hypertrophied and small, attenuated cells, therefore 
produces a characteristically variable picture. Increased intramyocardial fibrillar 
collagen, especially type I:III ratio is typical (Marijianowski et al., 1995). 
Increased fine and coarse interstitial fibrosis is common, but focal replacement 
sclerosis and apical endocardial fibrosis may also be present. About one-third 
exhibit an increase in inflammatory cells (Davies et al., 1995) which infiltrate the 
myocardium typically adjacent to areas of replacement fibrosis. Much controversy 
has arisen regarding their quantification and utility to distinguish DCM from 
myocarditis (Aretz et al., 1987).  
RVAD support following implantation 
Following implantation 5 patients (21.7%; patients 3, 10, 15, 17, and 21) needed a 
short term RVAD Levitronix
®
 due to acute right ventricular failure. Interestingly, 
Maeder et al reported that RV dysfunction is an acute feature and does not worsen 
during the intermediate term (Maeder MT et al., 2009). The number of RVADs 
needed post LVAD implantation was consistent with previous studies where 11-
30% develop right-sided HF post-LVAD implantation (Goldstein DJ et al., 
1998;Frazier OH et al., 1992;Farrar DJ et al., 1985;Pavie A & Leger P, 1996;Van 
Meter CH, 2001;Fukamachi K et al., 1999). The causes for right-side circulatory 
failure are multifactorial and are considered to be related to anatomic, intra-
operative and perioperative factors. In many instances, right-sided HF becomes 
clinically evident only after LVAD support has been initiated. It is difficult to 
predict which patients will develop RV failure after LVAD implantation, and 
those who do have a poor prognosis (Morgan JA et al., 2004;Deng MC et al., 
2005;Kavarana MN et al., 2002;Dang NC et al., 2006). In this studied series none 
of those requiring an RVAD post HM II LVAD implantation had pre-operative 
features of right-side HF.  
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Despite the frequency and significance of RV failure in LVAD recipients, 
relatively few studies have identified predictors of post-LVAD RV failure. More 
concerning is the lack of consensus among these. For example, Dang et al 
reported that elevated central venous pressure (CVP) predicts post-LVAD RV 
failure, but no study has corroborated this finding (Dang NC et al., 2006). 
Similarly, Kormos et al identified pulmonary edema, fever without infection and 
pre-operative mental impairment as predictors of RVAD use, but no subsequent 
study has provided confirmation (Kormos RL et al., 1996). More recently, 
Fitzpatrick III et al have devised a score that predicts which LVAD patient will 
require an RVAD support (Fitzpatrick III JR et al., 2008). Based on analysing data 
from 266 LVAD recipients, the investigators identified the following six criteria 
as risk factors: CI  2.2 l/min/m
2
, creatinine  1.9 mg/dl, right ventricular stroke 
work index  0.25 mmHg.litre/m
2
, severe pre-VAD RV dysfunction, previous 
cardiac surgery, systolic blood pressure  96 mmHg. For a high risk criterion the 
group assigned a score of 1 and for low risk criterion they assigned a score of 0 
(e.g. for creatinine  1.9 mg/dl a score of 1 was assigned and for creatinine < 1.9 
mg/dl a score of 0 was assigned). The scores were then entered into the final risk 
score equation: 
18(CI) + 18(right ventricle stroke work index) + 17(creatinine) + 16(previous 
cardiac surgery) + 16(pre-implant RV dysfunction) + 13(systolic blood 
pressure) 
Maximum possible score is 98 and a score of  50 predicted the need of an RVAD 
with sensitivity and specificity of 83% and 80%, respectively. This score could 
have not been applied in our group since all 23 patients were on at least two 
inotropes and those with measurable central haemodynamics had a CI of less than 
2.2 (apart from patient 1 who was on IABP and 4 inotropes, had a CI of 2.9). 
Fitzpatrick III et al did not take inotropic support into consideration (Fitzpatrick 
III JR et al., 2008). Therefore, the systolic blood pressure would have been an 
inaccurate representation. In matter of fact the three patients who required pre-
HM II BiVAD Levitronix
®
 did not need an RVAD post upgrade with HM II 
LVAD. To conclude, right-sided HF stems from changes in right ventricular 
geometry and flow/pressure dynamics as a direct result of LV unloading (Dang 
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NC et al., 2006). Regardless of the cause, unless properly corrected, right-side HF 
results in considerable disturbances in volume and pressure distribution across 
both systemic and pulmonary circulation. These effects have untoward 
consequences on other organ systems and confer significant morbidity and 
mortality. 
Use of ICD post implantation 
Andersen et al demonstrated that 12 out of 23 patients implanted with HM II 
LVAD developed sustained VT or VF with 8 requiring ICD or external 
defibrillator shock (Andersen M et al., 2009). In our studied patients none had 
developed VT or VF. The main reason is that we ensured that LV was not sucked 
down by adjusting the speed using echocardiography to ensure no septal shift. 
Also digoxin was started as early as possible once inotropes have been stopped. 
Pharmacological therapy 
Phase I pharmacological therapy was commenced as soon as inotropic support 
was stopped post device implantation. The benefits of using β-blockers, ACE-I, 
AngII antagonists, aldosterone antagonist and digitalis have been discussed in 
chapter 1. In most cases lisinopril was commenced as the first oral medication 
based on the facts that ACE-I was the first agent to demonstrate a mortality 
benefit in HF patients. Further, ACE-I tend to induce vasodilatation which 
improves the neurohormonal profile and hence allows a certain degree of 
stabilisation prior to commencing β-blocker therapy (Hall SA et al., 1995).  
Switching between different β-blocker therapies has previously shown to be safe 
and tolerable providing the switch is managed carefully (Abraham WT, 2003). In 
our studied patients, carvedilol was switched to bisoprolol to spare β2 receptors 
for clenbuterol over an average of two weeks. The initial dose of bisoprolol is 
1.25 mg once daily which is increased to 10 mg once daily. The use of clenbuterol 
as a pharmacological agent to induce LV ―physiological‖ hypertrophy was 
described in chapter 1. 
 
137 
 
Clinical outcome 
As discussed earlier, the hallmark of recovery is to assess the native LV function 
by minimising the input from the device. Previously described weaning protocols 
have not assessed the true myocardial response to device cessation as the device‘s 
contribution into the circulation remained significant (Dandel M et al., 
2005;Maybaum S et al., 2003;Slaughter M et al., 2001). In our previous recovery 
series, the pulsatile HM I LVAD was switched off for 15 minutes or more and 
patients were exercised using a 6MW test with continuous monitoring of several 
clinical, haemodynamic and echocardiographic parameters (Birks EJ et al., 2006). 
This approach provided a more robust method to assess the true underlying 
function and inotropic reserve (George RS et al., 2006;George RS et al., 
2007b;George RS et al., 2007a).  
In this series the speed of the HM II LVAD was reduced to 6000 rpm. The choice 
of this speed was based on laboratory and clinical experiments (see chapter 3). 
The recovery rate with the continuous flow HM II LVAD and drug combination 
therapy was 65.2% (15 out of 23). This was close to our previous series where the 
rate of recovery was 73.3% (11 out 15) in patients treated with the pulsatile HM I 
LVAD and the same pharmacological regimen (Birks EJ et al., 2006). Following 
explantation 12 patients remain alive with excellent myocardial function and 
exercise tolerance. 
Receiver operating characteristics analysis revealed that short HF duration, small 
end-diastolic and end-systolic diameters are favourables of subsequent recovery. 
Plotting those variables identified HF duration of 12 months or less, end-diastolic 
diameter of 77 mm or less, and end-systolic diameter of 70 mm or less, as 
possible predictors of recovery. Combining these results with logisitc regression 
analysis determined a correlation between those cut-off points and recovery. To 
our knowledge this the first report that had identified potential predictors of 
recovery at the time of implantation. However, these data need to be interpreted 
cautiously as 4 out of the 15 recovered patients (26.7%) had HF duration longer 
than 12 months. 
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Device explantation 
Explantation using the mini-invasive approach was previously described by 
Professor Yacoub in explanting the pulsatile HM I LVAD (Tansley P & Yacoub 
M, 2002). This approach involves exposing the apex of the heart through an 
anterolateral mini-thoracotomy. Two other separate small incisions are made; an 
epigastric incision to expose the device and a limited anterior thoracotomy 
through the second intercostal space to expose the aortic anastomosis of the 
outflow cannula (figure 2.2). 
 
Figure 2.2: Mini-invasive explantation technique 
 
Fig 2.2: Sites of the mini-invasive incisions with arteriovenous groin cannulation. 
From (Tansley P & Yacoub M, 2002). Incision (i) an anterolateral mini 
thoracotomy to expose the apex of the heart and disconnect the inflow cannula, 
incision (ii) is performed to expose the device and the power cable, and incision 
(iii), a limited anterior thoracotomy incision through the second intercostal space 
to disconnect the outflow graft from the ascending aorta. 
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To verify the exact position of the inflow and the outflow cannulae, a planned 
reconstructive CT scan was performed prior to device explantation which was 
discussed in the transplant / VAD MDT (figure 2.3). 
 
Figure 2.3: A pre-explant reconstructive CT scan 
 
Fig 2.3: A pre-explant reconstructive CT scan showing the inflow cannula in the 
LV apex and the outflow graft anastemosed to the ascending aorta behind the 
sternum. In this patient median sternotomy was challenging due to the position of 
the outflow graft.  
 In 2008, we have described a similar approach in explanting the HM II LVAD 
(Haj-Yahia S et al., 2008). This surgical approach limited post-operative 
complications and the necessity of use of blood products. In a retrospective 
review of 23 patients explanted using limited surgical approach, we have 
demonstrated that the median post-operative duration of ventilation, intensive care 
unit length of stay and hospital stay were 1.5, 4, and 23 days, respectively and the 
median postoperative blood loss was 263ml. The median numbers of blood 
products given within the first 24 hours postoperatively were 2, 3, 1 and 0 units 
for cross matched blood, fresh frozen plasma, platelets and cryoprecipitate, 
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respectively. Two (8.7%) patients had wound infection with a cumulative 
postoperative survival rate of 87% (Haj-Yahia S et al., 2009). 
Finally, none of our studied patient had had device related malfunction / failure 
despite maximal support duration of 989 days in a non-recovered group patient. 
This is considered superior to the first generation devices which have been 
associated with life-threatening device failure incidences (Birks EJ et al., 2004a). 
The most common types of pulsatile device related malfunction are: inflow valve 
regurgitation, kinking in the outflow graft, embolisation from the LVAD pumping 
chamber, acute motor cessation requiring support with pneumatic driver, ruptured 
pump diaphragm, fractured power cable, and pneumoperitoneum resulting from a 
leak at the junction of the pneumatic driveline (Birks EJ et al., 2004a;Horton SC 
et al., 2004;Martin J et al., 2006). Apart from possible power cable fracture, none 
of the other complications is likely to have occurred in the HM II LVAD as the 
device consists of one moving component only (figure 2.4) and hence the risk of 
malfunction is dramatically improved.  
Figure 2.4: The interior structure of the HM II LVAD 
 
Fig 2.4: A schematic diagram of the interior structure of the HM II LVAD 
showing one moving component only. 
The use of the third generation devices will minimise the risk of device 
malfunction even further as they will work on bearing-less principle. Further, 
when the technology of Transcutaneous Energy Transfer System is introduced, 
drive line related infections will be eradicated. 
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2.4   Study Plan 
Due to different clinical reasons not every patient was able to contribute in every 
component of the thesis. Reasons for exclusion from each study are included in 
the beginning of the methods section in each chapter. Figure 2.5 is a consort 
diagram representing a general overview of the flow of the 23 patients throughout 
the thesis and table 2.12 is a detailed representation of their flow. 
Figure 2.5: Consort diagram representing the number of patients included in 
each component of the thesis 
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Table 2.12: Flow of individual patients throughout the thesis 
 
Table 2.12: The flow of individual patients throughout the different components of the thesis. Tick () implies patients involvement in different 
studies. Cross () indicates that the patient did not contribute in different components of the thesis (reasons for exclusion are included in each 
chapter).
Patient 
Number 
Recovery 
Status 
Chapter 3 (Low 
Speed Assessment) 
Chapter 4 (Echocardiograms, 
Contractile Reserve & 6-
Minute Walk Test) 
Chapter 5 
(MIBG) 
Chapter 6 
(Immunohistochemistry) 
Chapter 7 
(Catecholamine 
Levels) 
1 Recovered      
2 Recovered      
3 Non-recovered      
4 Recovered      
5 Non-recovered      
6 Non-recovered      
7 Recovered      
8 Recovered      
9 Non-recovered      
10 Recovered      
11 Recovered      
12 Recovered      
13 Recovered      
14 Non-recovered      
15 Recovered      
16 Non-recovered      
17 Non-recovered      
18 Recovered      
19 Recovered      
20 Recovered      
21 Non-recovered      
22 Recovered      
23 Recovered      
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CHAPTER 3 - Low Speed “Off-
Pump” Testing 
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3.1  Background 
Recovery of myocardial function can occur following LVAD support (Farrar DJ 
et al., 1990;Frazier OH & Myers TJ, 1999;Hetzer R et al., 2001;Entwistle JW 3rd, 
2003;Birks EJ et al., 2006). This myocardial recovery can be sufficient to allow 
device removal. However, monitoring recovery prior to device explantation 
remains an issue such that assessment of the degree of myocardial recovery 
depends critically on a safe, accurate and reproducible method of monitoring the 
native LV function during the period of LVAD support. 
Some investigators have relied on examining patients while the device is on, after 
reducing the speed of the device and hence reducing its power, or after 
momentary discontinuation of the device (Hetzer R et al., 2001;Maybaum S et al., 
2003;Slaughter M et al., 2001;Myers T et al., 2006). Each of these techniques, 
however, provided an indication of the native myocardial function rather than 
a true assessment of the underlying function. 
We have previously described our experience with recovery assessment in 
patients with pulsatile HM I XVE LVAD (Thoratec Corp., Pleasanton, California, 
USA) where acute device cessation ―off-pump‖ after heparinisation was safe and 
efficient to assess the underlying function and the inotropic / contractile reserve of 
the native myocardium (George RS et al., 2007b;George RS et al., 2006;George 
RS et al., 2007a). In these studies, HM I XVE LVAD was switched off 
completely in 22 patients for 15 minutes with intermittent hand-pumping to avoid 
blood stagnation within the device, followed by a 6MW exercise with continuous 
monitoring of several clinical, peripheral haemodynamic and echocardiographic 
parameters. This approach provided a robust method to assess the true underlying 
function and the inotropic reserve and was implemented in the explantation 
guidelines for myocardial recovery (Birks EJ et al., 2006).  
Unlike the pulsatile flow LVADs, continuous-flow LVADs do not have a one-
way valve and therefore switching-off of the continuous flow devices would result 
in blood regurgitating in the backward direction ―reverse flow‖ into the left 
ventricle causing full loading of the LV. As could be expected backward flow will 
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happen in diastole, analogous to aortic regurgitation, and its volume will be 
maximal when the device is switched off. Having blood regurgitating in the 
backward direction will result in an inaccurate assessment. Therefore, it is 
important to examine the native myocardium at a speed where there is no 
backward flow through the device into the LV and where the forward flow 
contribution from the device into the circulation is kept to minimal. This approach 
would provide an ―off-pump‖ testing equivalent to that used in patients with HM I 
XVE LVAD (George RS et al., 2007a). 
In early local pilot examinations, we have used 6000 rpm as the lowest speed to 
assess the native myocardial function in patients with HM II LVAD. This speed 
was determined by the Thoratec engineers based on estimation that at 6000 rpm 
the forward flow generated by the HM II LVAD would counteract the reverse 
flow occurring in diastole. However, we did not have concrete clinical or 
experimental data to illustrate whether the speed of 6000 rpm would be sufficient 
to assess the native myocardial function and the effects of speed reduction on 
forward and retrograde flows. 
The aims of the present study were therefore to: 1) identify the optimal speed at 
which the native myocardium could be assessed; 2) determine whether 6000 rpm 
is sufficiently low to assess the native myocardial function; and 3) establish 
whether it is possible for blood to regurgitate in the backward direction into the 
LV whilst the rotor is running. 
This component of the thesis consists of three parts; part one is a preliminary 
multi-level statistical modelling illustrating the lack of validity of examining the 
native LV function whilst the device is on full support and the importance of 
reducing the speed of the HM II LVAD to assess the underlying LV function. Part 
two is a bench work experimental study that tests the effects of different speeds on 
flow in a mock circuit. Part three is a clinical study investigating the effects of 
different speeds of the HM II LVAD on LV dimensions and function in a subset 
of the population.  
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3.2  Part One – Multi-Level Modelling 
3.2.1  METHODS 
3.2.1.1  Echocardiographic Assessments of the LV Size and Function 
All 23 HM II LVAD patients were included in this analysis. Pre-implantation 
demographics are included in chapter 2. 
Echocardiographic parameters were measured sequentially in each patient every 4 
to 6 weeks at four different conditions:  
i. Condition A - device running at baseline speed;  
ii. Condition B - at 5 minutes of 6000 rpm (5Mins);  
iii. Condition C - at 15 minutes of 6000 rpm (15Mins); and  
iv. Condition D - after a 6-MW test whilst on 6000 rpm. 
All measurements were performed in the M-Mode. Left ventricular end diastolic 
diameter (LVEDD) and Left ventricular end systolic diameter (LVESD) were 
obtained from the parasternal long axis of the LV at the level of chordal-mitral 
valve junction. Fractional shortening (FS) was calculated as the percentage 
change in the LV cavity dimension with systole whilst ejection fraction (EF) was 
calculated using the cubed function formula of the ventricular dimensions. Further 
details of the assessments are included in chapter 4. 
3.2.1.2  Statistical analysis 
To illustrate the necessity of speed reduction in the assessment of the underlying 
LV function a multilevel modelling over a 1-year of LVAD support was 
performed using MLwiN version 2.14 for windows (Centre for Multilevel 
Modelling, university of Bristol, United Kingdom). This model looks at the 
changes in the trends of the examined parameters over a one year period by 
averaging the response of each parameter at each condition for all the patients. It 
is assumed that for each patient there is a linear relationship between the mean of 
each of the M-Mode measured parameters taken at each of the four different 
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conditions and the duration of support (a 1-year period). The mean intercept of 
this relationship represents the value of the measured parameter at time 0 whilst 
the mean slope refers to the change in the measured parameter over a period of 
time such that a positive slope indicates an increase in the value and a negative 
slope indicates a reduction in the value. For model details, refer to Model 1 in 
Appendix B. 
3.2.2  RESULTS 
Throughout the LVAD support period, the echocardiographic assessment was 
performed on 170 occasions (mean of 7.4 tests per patient, range 4-14 tests). The 
model extrapolated its values from these measurements where the effects of two 
different speeds (baseline speed and 6000 rpm) on the echocardiographic 
parameters were tested. Figure 3.1 illustrates the estimates of change in each of 
the four echocardiographic measured parameters over the 1 year period. 
Figure 3.1: Multi-level time model analysis 
 
Fig 3.1: Multi-level time model analysis of echocardiographic parameters measured at 
baseline speed, after speed reduction for 5 and 15 minutes, and after 6MW exercise test. 
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Multi-level time modelling revealed that all four parameters (LVEDD, LVESD, 
FS and EF) measured whilst the HM II LVAD running at full speed (range 8600 – 
9800 rpm) would not change during the support period (black line on the four 
graphs). In table 3.1, the model revealed that over a 1-year period the slope of 
LVEDD increased by 1.638 mm (p=0.634), the slope of LVESD decreased by 
0.178 mm (p=0.960), the slope of FS increased by 0.026% (p=0.990) and the 
slope of EF decreased by 0.565% (p=0.843). These changes were minute, non-
significant, and unpredictable despite longer support duration and the changes in 
medication as per the Harefield Bridge to Recovery Protocol. The lack of 
alteration in these measurments whilst the device is running on full speed suggests 
that contribution from the HM II LVAD persists throughout the support period 
masking the native LV function and preventing real assessment of the underlying 
LV function. 
By applying the model after reducing the speed of the HM II LVAD to 6000 rpm, 
all four parameters changed over the 1-year modelling period. Such that the slopes 
of both FS and EF measured after 5 and 15 minutes of low speed and after the 
6MW test have increased significantly. The slope of LVESD also decreased 
significantly at 5 and 15 minutes of low speed and after the 6MW exercise test. 
The slope of the LVEDD followed the same trend as that of the LVESD but the 
reduction was not as significant (table 3.1). 
Table 3.1: Multilevel analysis and slope values 
 
Parameters 
Baseline 5-minutes 15-minutes Post 6MW 
Slope p-value Slope p-value Slope p-value Slope p-value 
LVEDD 1.638 0.634 -1.25 0.540 -2.7 0.160 -1.922 0.230 
LVESD -0.178 0.960 -6.557 0.008 -7.298 0.017 -4.577 0.050 
FS 0.026 0.990 11.186 <0.001 9.572 0.001 6.553 0.040 
EF -0.565 0.843 17.513 <0.001 14.617 0.003 6.93 0.050 
 
Table 3.1: Values of slopes of LVEDD, LVESD, FS and EF modelled over one-
year. 
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These modelling results illustrate the necessity to reduce the speed of the HM II 
LVAD to unmask the native LV function. In addition, the speed should be low 
enough to ensure that the contribution from the device into the cardiac output is 
kept to minimum and that LV loading, which occurs after speed reduction as 
evidenced by the increase in the intercept values in both LVESD and LVEDD 
(figure 3.1), is a physiological response rather than secondary to retrograde filling. 
Part two of this study looks at the effects of incremental speed reduction in a 
mock circuit. 
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3.3  Part Two – Mock Circulation 
3.3.1  METHODS 
3.3.1.1  Equipments, System Setup and Data Acquisition 
The aim is to set up a model of the LVAD circulatory system.
†
 The first stage 
includes modelling of a patient heart. The Abiomed BVS5000 Extracorporeal 
Pump (Massachusetts, USA) was chosen as a heart model since it is easy to 
modify and allows for the addition of a HM II VAD.  
Figure 3.2 is a picture of the mock circuit and figure 3.3 is a schematic diagram of 
the different components of the mock circuit.  
 
Figure 3.2: The mock circuit 
 
 
Fig 3.2: A photograph of the mock circuit with a HM II VAD attached to the side 
in parallel to the Abiomed BVS5000 device. The text below and the schematic 
diagram in figure 3.3 represent detailed description of the different circuit‘s 
components. 
 
  
                                                 
†
 The circuit was set up in Professor Kim Parker‘s laboratory, Department of Biomedical 
Engineering at Imperial College, London. 
151 
 
Figure 3.3: The Abiomed BVS5000 extracorporeal system and the HM II 
VAD 
 
 
 
 
 
Fig 3.3: A schematic diagram of the experimental setup of the circuit excluding 
the extracorporeal pump drive system and the HM II control system. A, head tank 
reservoir; B, Abiomed BVS5000 extracorporeal pump; C, extra cylindrical 
chamber after the ventricle and before the aorta; D, HM II VAD attached to the 
extra cylindrical cahmber (C); E, ruler marked Windkessel system; F, gate clamp 
providing adjustable resistance to fluid flow; G, ventricular pressure transducer; 
H, aortic pressure transducer; I, flow probe; J, inlet opening for the pneumatic 
system to drive the Abiomed device; K, blunt syringe placed in the outflow graft; 
L, blunt needle placed in the inflow graft; M, direction of fluid flowing from the 
head tank into the Abiomed BVS5000 system. 
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Circuit components: The circuit consists of three main components, the head 
reservoir, the Abiomed pump and a Windkessel system. The head reservoir tank 
(A) represents the pre-load volume and is connected to the Abiomed pump which 
itself is divided into two chambers by one way valves just as the heart. The first 
chamber of the device (B) has a valve acting as the mitral valve, whereas the 
second chamber has an aortic valve between the ventricular chamber and the 
output to the rest of the system. The ventricular chamber has been extended by 
adding a cylindrical chamber (C) after the ventricle and before the aortic valve. 
Chamber (C) has an opening which allowed the installation of the inflow cannula 
of a HM II VAD (D). The outflow cannula of the HM II VAD is connected to the 
system using a Y junction located before the Windkessel system (E).  
The third component of this circuit is a ruler marked Windkessel system (E). This 
is a cylinder holding fluid to levels which determine the base value of the aortic 
pressure (afterload). Using an air valve on the top of the cylinder the fluid level 
can be adjusted. The idea of the system is to provide a steady flow to the systemic 
part of the circulation, downstream from the pump. When fluid is pumped into the 
cylinder during systole the fluid level rises and pressurises the trapped air, during 
diastole the trapped air pressure forces fluid at a constant rate to the systemic 
system. After the Windkessel system there is a gate clamp (F) which provides a 
fully adjustable resistance to fluid flow, just as the body systemic arterioles would 
provide to blood. Increasing the resistance by closing the gate clamp creates a 
higher aortic ―after-load‖ pressure. Standard one inch diameter PVC tubing is 
used throughout the setup. 
Pressure measurements: There are two pressure transducers (Gaeltec Transducer 
Interface S13, Isle of Skye, Scotland) that measure the ventricular and aortic 
pressures. The first pressure transducer, ventricular pressure transducer (G), is 
placed in the extended ventricle chamber (C) of the Abiomed pump and provides 
a continuous trace of the left ventricular pressure. The second pressure transducer, 
the aortic pressure transducer (H), is placed before the Windkessel system and 
after the Y junction and provides a continuous trace of the aortic pressure. Prior to 
data acquisition the two probes were calibrated using a standard manometer. 
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Flow measurements: An ultrasonic flow probe (I) is located around the aorta 
before the Windkessel system and after the Y junction to measure the flow rate. 
The rate of the fluid flowing after the Y junction (litres/minute) is the sum of the 
fluid driven by the Abiomed system and the HM II VAD. The probe was 
immersed in a tank of water after ensuring no air bubbles were trapped in the 
probe‘s two side arms. 
Control of the Abiomed System: The extracorporeal Abiomed pump is driven 
by the Thoratec HeartMate Implantable Pneumatic Left Ventricle Assist System 
Drive Console (TCI, Thermo Cardio System Inc., USA). The system driver uses a 
pneumatic system to drive the Abiomed pump and is connected to the Abiomed 
system in the ventricular chamber at opening J in figure 3.3. By changing the 
amount of air that is being forced by the driver into the system it would be 
possible to alter the pumping strength of the ventricle. A 50 mls syringe was used 
on the PVC tube feeding the extracorporeal pump to control pumping strength by 
either driving air into- or withdrawing air from- the extracorporeal circuit. 
Solution preparation: To account for the viscosity of blood, the circulating 
solution was made up with glycerol. Depending on the temperature, the kinematic 
viscosity of blood is 3.6 – 4.0 centistokes. Using a cannon-fenske routine 
viscometer (Poulten Selfe & Lee, Ltd), 99% glycerol (Sigma, UK) was diluted to 
40% at 23
o
C (room temperature) to obtain a viscosity of 3.8 centistokes. Since the 
system‘s capacity is 6 litres, the system required 2.4 litres of 99% glycerol 
(Sigma, UK) and 3.6 litres of water. The viscosity of the circulating solution was 
repeated at the end of the day to ensure no alteration in the viscosity had occurred 
throughout the experiment. Refer to Appendix C for the viscosity calculations. 
Dye simulation: 18G blunt needles (K and L) were inserted into the outflow and 
the inflow grafts of the HM II VAD before the HM II VAD itself and before the Y 
junction, respectively. Each needle was connected to a 50 mls syringe filled with 
10 mls of blue ink and 40 mls of the diluted glycerol solution (20% blue ink 
concentration) to simulate the dye injected during cardiac catheterisation. The 
syringe was driven at a constant pressure using an IVAC P7000 syringe pump 
(Cardinal Health, Switzerland). This technique allowed visualisation and 
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qualitative analysis of the flow pattern within the inflow and outflow grafts of the 
HM II VAD. 
The HM II VAD was controlled by a modified speed controller especially 
manufactured by Thoratec Corporation Inc (software version 3.11) which can 
control the speed of the device between 4000 rpm and 14000 rpm compared to the 
standard controller which drops the speed of the device to a minimum of 6000 
rpm. The speed was adjusted using a standard HM II monitor (figure 3.4). 
 
Figure 3.4: HM II monitor with low speed controller 
 
 
 
Fig 3.4: A touch digital monitor connected to the low speed controller to control 
the speed of the HM II VAD. 
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3.3.1.2  Experimental Protocols 
In most clinical applications the baseline speed was set to ensure no septal shift 
and that the aortic valve remains closed i.e. blood will flow into the HM II‘s 
inflow cannula and then into the ascending aorta bypassing the aortic valve. This 
ensures maximal unloading of the LV. In the studied population the speed of the 
HM II LVAD ranged from 8600 rpm to 9800 rpm.  
In the mock circuit the effects of 7 different speeds (range 4000 – 10,000 rpm) 
were tested in four different experimental ventricular conditions. In the beginning 
of each experiment the systolic ventricular pressure of the Abiomed device was 
set to simulate four different ventricular conditions:  
i) Abiomed system off (0 mmHg – experiment 1) to understand the 
independent effects of the HM II VAD on the circulation;  
ii) mild ventricle (40 mmHg – experiment 2);  
iii) moderate ventricle (80mmHg – experiment 3);  
iv) strong ventricle (120 mmHg – experiment 4).  
Experiments 2, 3 and 4 were performed whilst the Abiomed system running at 60 
bpm.
‡
 Table 3.2 shows the matrix of the runs performed at various conditions of 
the ventricle and the different speeds of the HM II VAD.  
Table 3.2: Experimental Matrix 
Peak Ventricular 
Condition 
Speed of HM II VAD (rpm) 
0 mmHg 10000 9000 8000 7000 6000 5000 4000 
40 mmHg 10000 9000 8000 7000 6000 5000 4000 
80 mmHg 10000 9000 8000 7000 6000 5000 4000 
120 mmHg 10000 9000 8000 7000 6000 5000 4000 
Table 3.2: The experimental matrix of the 28 different runs performed at 4 
different ventricular strengths and 7 different HM II VAD speeds at a constant 
Abiomed rate of 60 bpm. 
                                                 
‡
 60 bpm was chosen instead of 80 bpm to allow for slower flow and hence better visualisation and 
recording of the flow pattern. 
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As stated above the ventricular pressure was controlled by the pneumatic system 
that drives the Abiomed system (label J in figure 3.3). The ventricular strength of 
the Abiomed system was set by altering the amount of air driven into it whilst the 
HM II VAD is switched off and the inflow cannula is clamped. This ensures 
accurate setting of the ventricular pressure without being affected by the 
suctioning effects of the rotor of the HM II VAD. After setting up the LV pressure 
at the desired value, the clamp was released and the HM II VAD was started at 
10000 rpm. The first recording was taken at 10000 rpm and then at the 6 other 
lower speeds after allowing the system to settle for 5 minutes after each 
incremental reduction. During each run, the quoted ventricular and aortic 
pressures are the peak pressures.  
To visualise and record the flow pattern and the direction of flow, 2 mls of 20% 
blue ink were purged into the outflow and inflow grafts through the blunt needles 
(structures K and L in figure 3.3) in each of the 28 runs using the syringe driver. 
The pattern and direction of flow were recorded visually using a 30 frame per 
second Sony HD movie camera (model DSC-T500, 5x optical zoom) in the macro 
mode. The camera lens was placed 5 centimetres away from the outflow graft 
focusing on the blunt needle‘s point of insertion in the centre of the frame. Each 
recording started 2 seconds prior to purging, continued throughout the ink 
injection, and for 5 seconds after purging. Recording was repeated by 
repositioning the camera at the inflow cannula to determine if any of the ink ―dye‖ 
would regurgitate back into the LV. 
3.3.1.2  Data Acquisition and Analysis 
The two pressure probes and the flow probe were connected to a transducer 
amplifier (PM – 1000, CWE, Inc., USA, figure 3.5). Pressure and flow signals 
were recorded at 2000 Hz (i.e. 2000 data points per second) and entered to a 
Notocord Systems Software (France). Data was imported onto Matlab Statistics 
Software version 7.5 (MathWorks, UK) where Savitzky-Golay filter 
§
 was applied 
                                                 
§
 The Savitzky-Golay electronic filter performs a local polynomial regression on a trace to 
determine the smoothed value for each point. It eliminates noise and preserves features of the 
distribution such as relative maxima, minima and width. 
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(figure 3.6). See Appendix D for the computer script written to plot 2000 filtered 
data points per second in single graphs. 
Figure 3.5: Pressure and flow signal amplifier 
 
Fig 3.5: Four channel signal amplifier that amplifies ventricular pressure, aortic 
pressure and flow signals. This amplifier is connected to the Notocord Systems 
Software. 
 
Figure 3.6: An example of Savitzky-Golay electronic filter being applied to a 
ventricular pressure trace 
 
Fig 3.6: Savitzky-Golay electronic filter being applied to an example of 
ventricular trace. The filter smoothes the curves by eliminating the noise and 
preserves the main features of the distribution i.e. relative maxima, minima and 
width. 
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3.3.2  RESULTS 
The first step was to test the setup of the mock circuit without the HM II VAD 
being connected to compare the pressure traces produced by the model with 
normal heart traces. Figure 3.7A shows a screen capture of Notocord and the 
traces obtained from the test-run. There is marked similarity with figure 3.7B, 
normal heart traces. The ventricular pressure and the aortic pressure traces were 
reproducible with every beat at heart rate of 60 bpm. 
 
Figure 3.7: Comparison between acquired pressure and flow traces from 
Notocord System and the traces from a normal heart 
 
             
Fig 3.7: A) a screen capture of Notocord System illustrating the pressure and the 
flow traces. B) LV and Aortic pressure traces in normal LV. It is worth noting the 
noise in the traces acquired from the Notocord screen. The noise was eliminated 
using the Savitzky-Golay filter as described above. 
The next step was to test the effectiveness of the air syringe system to adjust the 
ventricular pressure of the Abiomed system. As mentioned above, peak 
ventricular pressure values of 120 mmHg, 80 mmHg and 40 mmHg were obtained 
by either removing air from- or driving air into- the drive tube that is connected to 
the Abiomed Extracorporeal pump whilst the HM II VAD was switched off and 
the inflow cannula was clamped. The aortic pressure trace was initially altered by 
A) B) 
A
o
rt
ic
 
P
re
ss
u
re
 
V
en
tr
ic
u
la
r
 
P
re
ss
u
re
 
F
lo
w
 
159 
 
adjusting the Windkessel fluid level and changing the systemic circulatory 
resistance using the gate clamp then it left to self adjust once the HM II VAD was 
switched on and the clamp was removed. 
 
Experiment 1: Abiomed System Switched off – 0 mmHg 
Figure 3.8 represents the traces obtained whilst the Abiomed system was switched 
off and the HM II VAD running at seven different speeds. In this experiment, air 
was fully drawn from the Abiomed system leaving the ventricle with no pumping 
strength and the aortic valve closed i.e. simulating a dead ventricle such that blood 
was flowing from the head reservoir through the HM II VAD into the Windkessel 
system bypassing the closed aortic valve. At 10000 rpm the ventricular pressure 
was a flat line and subzero due to the negative pressure being generated as a result 
of the suctioning effect of the HMII VAD. The aortic pressure was 50mmHg. This 
was generated by the forward flow driven from the HM II VAD. The flow 
measured using the flow transducer was approximately 6 l/min. As the speed of 
the HM II VAD decreased by increments of 1000 rpm, both flow and aortic 
pressure decreased steadily reflecting reduced contribution from the HM II VAD. 
Inversely, the ventricular pressure increased steadily to reach almost 0 mmHg. 
The inverse relationship between the ventricular pressure and the speed of the HM 
II VAD is due to the decreasing negative pressure generated from the suctioning 
power of the HM II VAD. 
Video captures (figure 3.9) of ink flowing within the outflow graft at 10,000 rpm 
revealed a turbulent, complex and a non-pulsatile flow pattern that is being driven 
only in the forward direction i.e. towards the Windkessel system. As the speed 
decreased the ink pattern became less turbulent but remained complex with no 
evidence of pulsatility and continued to be driven in the forward direction. In 
addition, the ink flow became stagnant within the outflow cannula and took longer 
time to clear. At no point the ink has reached the ventricle in the retrograde 
direction. 
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Figure 3.8: Pressure and flow traces with a switched off Abiomed system 
 
 
 
Fig 3.8: The pressure and flow traces recorded with the HM II VAD running at 7 different speeds whilst the Abiomed is effectively ―switched 
off‖. Red trace represents aortic pressure; blue trace represents ventricular pressure; and black trace represents flow in l/min. The ventricular 
pressure is subzero at 10,000 rpm due to the suctioning effect of the HM II VAD whilst the Abiomed is ―switched off‖. The aortic pressure was 
50 mmHg at 10,000 rpm and represents the pressure generated from the HM II VAD. As the speed decreased, the ventricular pressure increased 
as a consequence of the reduction in the suctioning power of the HM II VAD, and the aortic pressure decreased as a consequence of reduction in 
flow being generated by the HM II VAD. It is important to note that the aortic valve remained closed throughout the 7 runs due to the absence of 
ventricular contractility. 
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Figure 3.9: Ink flow pattern within the outflow graft in experiment 1 with the Abiomed system switched off 
 
  
Fig 3.9: The ink flow pattern was turbulent, complex, and non-pulsatile 
at higher speeds (10,000-7000 rpm). As the speed of the HM II VAD 
decreased bleow 7000 rpm, the pattern became less turbulent and more 
central but remained complex with no evidence of pulsatility. In 
addition, the force driving the ink towards the Windkessel System was 
lower such that it had the tendency to stagnate within the outflow graft. 
Arrow represents flow direction. 
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Experiment 2: Poor ventricle 
In this experiment the initial ventricular systolic pressure was set at 40 mmHg. 
Figure 3.10 represents the pressure and flow traces obtained with the HM II VAD 
running at 7 different speeds. At 10,000 rpm the aortic valve remained closed, the 
ventricular diastolic pressure was below zero, and the aortic diastolic pressure was 
approximately 50 mmHg. The systolic aortic pressure was consistent with 
ventricular pulsatility such that the rise in the aortic pressure was due to the 
pulsatility being generated from the Abiomed‘s ventricular system. At 7000 rpm 
as the ventricular pressure exceeded the aortic pressure the aortic valve started 
opening and continued to open in systole at 6000 rpm, 5000 rpm and 4000 rpm. 
The flow pattern of the injected ink at 10,000 rpm continued to be complex and 
turbulent (figure 3.11). As the speed of the HM II decreased there was evidence of 
pulsatility in the flow pattern of the injected ink into the outflow graft consistent 
with systole and diastole. At 6000 rpm, the ink injected in the outflow graft 
formed a compact pattern ―cloud-like‖ that moved forward in systole with a 
minute non-significant backward movement in early diastole. However, at a 
certain point the pressure generated by the turbine nature of the rotor of the HM II 
VAD was high enough to stop the ink flowing further backward even at aortic 
pressure higher than the ventricular pressure and pushed the ink back into the 
forward direction. This imaginary point was referred to as a point of stagnation 
(figure 3.12). The amount of backward movement did not change with further 
speed reduction and again at no point the flow bypassed the rotor of the HM II in 
the reverse direction to reach the ventricle. 
Visualisation of flow in the inflow cannula identified flow moving forward 
towards the tip of the inflow cannula in systole. In early diastole there was a 
minute non-significant backward displacement of ink in the inflow cannula that 
did not change in quantity as the speed decreased to 4000 rpm. At 10,000 rpm the 
systolic flow was 6.5 l/min and the diastolic flow was 5 l/min giving a difference 
in flow rate between systole and diastole (ΔQ) of 1.5 l/min. However, as the speed 
of the HM II VAD decreased, ΔQ increased to 3l/min at 4000 rpm suggesting 
increased contribution from the Abiomed system and reduced contribution from 
the HM II VAD. 
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Figure 3.10: Pressure and flow traces with the ventricular pressure set at 40mmHg 
 
 
 
 
Fig 3.10: The pressure and flow traces recorded with the HM II VAD running at 7 different speeds with the initial ventricular pressure set at 
40mmHg. Red trace represents aortic pressure; blue trace represents ventricular pressure; and black trace represents flow in l/min. Similar to the 
―switched off‖ setting (figure 3.8), at 10,000 rpm the aortic pressure was approximately 50mmHg and was exceeding the ventricular pressure. 
The aortic valve started opening at 7000 rpm when the peak ventricular pressure exceeded the aortic pressure. As the speed decreased the 
ventricular pressure continued to rise and the aortic pressure continued to decrease due to the reduced flow being generated by the HM II VAD. 
Also the flow generated from the pulsatility of the Abiomed system and the HM II decreased as the speed of HM II decreased. 
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Figure 3.11: Ink flow pattern within the outflow graft in experiment 2 
Fig 3.11: The ink flow pattern in experiment 2 became more turbulent 
and complex. Evidence of pulsatility started appearing as the speed of 
the HM II VAD was reduced to be consistent with systole and diastole. 
At 6000 rpm there was a ―cloud-like‖ pattern. Ink never flowed back 
into the LV. Arrow represents flow direction. 
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Figure 3.12: A schematic diagram illustrating the flow of the ink in the 
outflow graft 
 
 
 
 
 
Fig 3.12: As the speed of the device is reduced the flow becomes steadier and 
less turbulent forming a compact pattern ―cloud-like‖. There is displacement of 
ink in the backward direction towards the tip of the outflow cannula in early 
diastole. However, at point X (point of stagnation), the ink stops travelling 
backwards and starts moving along the peripheries. 
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Experiments 3 and 4: Moderate and strong ventricle 
In these two experiments (figures 3.13 and 3.14), the initial ventricular systolic 
pressure was set at 80 mmHg and 120 mmHg, respectively.  In both experiments 
the aortic valve was opening at 10000 rpm. As the speed of the HM II VAD 
decreased, the ventricular diastolic pressure increased and the aortic pressure 
decreased steadily. Furthermore, throughout the two experiments the aortic 
systolic pressure was related to the ventricular systolic pressure.  
Similar to experiment 2, the flow pattern at 10,000 rpm continued to be complex 
and turbulent and at 6000 rpm the ink injected in the outflow graft formed a well 
defined ―cloud-like‖ pattern that moved forward in systole with more 
exaggerated but non-significant backward displacement in early diastole (figures 
3.15 and 3.16). The ink stopped flowing in the backward direction at a certain 
point and it seemed that the stagnation point moved closer towards the HM II 
VAD. Again at no point ink travelled back into the ventricular chamber. 
Visualisation of the flow in the inflow cannula identified ink moving forward 
towards the tip of the inflow cannula in systole. In early diastole there was a 
backward displacement of ink in the inflow cannula that did not change in 
quantity as the speed decreased to 4000 rpm in either experiment.  
In both experiments, the peak flow remained almost constant whereas the 
baseline flow continued to decrease as the speed of the device decreased 
resulting in an increase in ΔQ. The rise in ΔQ was a response to both reduction 
in the speed of the HM II VAD and increased pulsatility (pulse pressure) of the 
Abiomed system. Figure 3.17 represents the changes in the ΔQ with different 
speeds of HM II at three different LV functions: poor, moderate and strong.   
167 
 
Figure 3.13: Pressure and flow traces with the ventricular pressure set at 80mmHg 
 
 
 
 
 
Fig 3.13: The pressure and flow traces recorded with the HM II VAD running at 7 different speeds with the initial ventricular pressure set at 
80mmHg. Red trace represents aortic pressure; blue trace represents ventricular pressure; and black trace represents flow in l/min. Throughout 
the seven runs the aortic valve was opening and the flow at 10000 rpm reached a peak of 9 l/min. As the speed decreased the pressure difference 
decreased and the aortic pressure decreased steadily. Also the base flow decreased in diastole as the speed was reduced whilst the peak flow 
remained at a range of 9-10 l/min. 
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Figure 3.14: Pressure and flow traces with the ventricular pressure set at 120mmHg 
 
 
 
 
 
Fig 3.14: The pressure and flow traces recorded with the HM II VAD running at 7 different speeds with the initial ventricular pressure set at 
120mmHg. Red trace represents aortic pressure; blue trace represents ventricular pressure; and black trace represents flow in l/min. 
Throughout the seven runs the aortic valve was opening and the flow at 10000 rpm reached a peak of 12 l/min. As the speed decreased, the 
pressure difference decreased, the aortic pressure decreased, the base flow decreased in diastole, and the peak flow increased to reach 15 
l/min. 
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Figure 3.15: Ink flow pattern within the outflow graft in experiment 3 
  
Fig 3.15: The ink flow pattern in experiment 3 became more turbulent and 
complex. At 10,000 rpm the pattern was very complex and more diluted 
such that the transient time of the ink was shorter as compared to 
experiment 2. Evidence of pulsatility was apparent at lower speeds of the 
HM II VAD and the pattern became cloudier. Ink never flowed back into 
the LV. Arrow represents flow direction. 
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Figure 3.16: Ink flow pattern within the outflow graft in experiment 4 
Fig 3.16: Similar to experiment 3, the ink flow pattern in experiment 4 
was more turbulent and complex. Evidence of pulsatility was apparent at 
lower speeds of the HM II VAD and the pattern became cloudier. Ink 
never flowed back into the LV. Arrow represents flow direction. 
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Figure 3.17: Changes in ΔQ at the seven different HM II speeds and three 
different ventricular contractility functions (mild, moderate, strong). 
 
 
 
 
Fig 3.17: Changes in ΔQ at the seven different speeds of HM II VAD and three 
different ventricular contractility functions. 
 
In figure 3.17, the ΔQ increased steadily with moderate and strong ventricular 
contractility as the speed of the HM II decreased from 10000 rpm to 4000 rpm. 
Interestingly when the initial setting of the ventricular pressure was set to 40 
mmHg (poor ventricle), the ΔQ decreased initially as the speed of the HM II 
decreased. This reduction only occurred whilst the aortic valve remained closed. 
When the aortic valve started opening at 7000 rpm the ΔQ started to increase. 
From the above it could be assumed that the ΔQ is an experimental 
representation of the pulse pressure.   
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3.4  Part Three – Clinical Study 
The aim of this component of the study is to clinically investigate the effects of 
different HM II LVAD speeds on the myocardial function and structure and to 
determine if 6000 rpm is an appropriate speed to examine the native myocardial 
function safely and effectively. 
3.4.1  METHODS 
3.4.1.1  Study Population 
Flow across the HM II LVAD was studied in 13 male patients out of the 23 
patients on 33 occasions. Reasons for excluding 10 patients are included in table 
3.3. Demographics and pre-implantation data for the 13 studied patients are 
presented in table 3.4. The study was performed using the low speed controller 
provided by Thoratec Inc in December 2007. This study was completed in 
March 2009. 
 
Table 3.3: Patients excluded from low speed study (n=10) 
 
Patient 
Number 
Reason for exclusion 
1, 2 , 4 Patients were explanted prior to obtaining the low speed 
controller 
 
8, 9, 15, 18, 
19, 20, 22 
Low speed device Doppler could not be acquired due to cannula 
position 
 
Table 3.3: Reasons for excluding 10 patients from this analysis. 
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Table 3.4: Demographics of the studied patients (n=13) 
Parameter Value 
Age at HM II implantation (years) 
 
BMI (kg/m
2
) 
 
HF duration (months) 
 
Average number of pre-implant inotropes per patient 
 
Pre-implantation Echo 
LVEDD (mm) 
LVESD (mm) 
FS (%) 
EF (%) 
 
Pre-implantation Haemodynamics 
Mean Pulmonary Artery Pressure (mmHg) 
Mean PCWP (mmHg) 
CO (l/min) 
CI (l/min/m
2
) 
35.46 ± 12.86 
 
23.89 ± 2.13 
 
40.35 ± 39.65 
 
2.00 ± 0.71 
 
 
76.00 ± 9.06 
70.60 ± 7. 51 
6.89 ± 2.42 
19.14 ± 7.34 
 
 
35.70 ± 5.64 
30.10 ± 4.28 
2.56 ± 0.87 
1.31 ± 0.42 
 
Table 3.4: Pre-implantation demographics of the 13 studied patients. 
 
After ensuring an INR of 2 or above, device flow pattern, LV echocardiographic 
parameters, and peripheral haemodynamics were measured on each of the 
following three speeds:  
i) the baseline speed of the HM II LVAD (range 8800-9400 rpm),  
ii) after 15 minutes of 6000 rpm, and 
iii) after 5 minutes of reducing the speed to either 5000 rpm or 4000 rpm.  
Due to time constraint in performing the echocardiographic examination, each 
patient was examined at either 5000 rpm or 4000 rpm on each occasion. Hence 
two groups were generated; Group A (18 occasions at 5000 rpm) and Group B 
(15 occasions at 4000 rpm). 
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3.4.1.2  Echocardiography 
Regular echocardiographic examinations were performed with an advanced 
cardiac ultrasound machine using harmonic imaging as standard. Examinations 
were performed on a Philips iE33 machine (Philips Electronics, Eindhoven, the 
Netherlands). Images were obtained by a senior echocardiographer (Mrs. Carole 
Webb) from standard parasternal, apical, subcostal and suprasternal views. 
Occasionally ―off-axis‖ images were obtained when the LVAD apical inflow 
cannula provided acoustic interference. LVAD flow pattern and direction were 
assessed by positioning a pulsed wave Doppler (PW) sample volume at the 
inflow cannula in the best possible window which revealed two spectra 
occurring with every heart beat; a positive spectrum occurring in systole 
representing forward flow i.e. blood flowing from the ventricle into the inflow 
cannula of the HM II LVAD (figure 3.18). The second is a negative spectrum 
occurring in diastole immediately following the positive spectrum.  Images were 
digitally acquired and read off line. 
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Figure 3.18: Doppler Examination of flow through the inflow cannula 
 
 
 
 
Fig 3.18: An illustration of how the forward flow was quantified using the 
pulsed wave Doppler. A) Peak velocity in forward direction (Vmaxf) was 
measured by measuring the distance between the baseline and the peak of the 
positive velocity spectrum. Forward velocity time integral (VTIf) is an 
integration of the area under the Doppler curve representing the distance that 
blood travelled into the inflow cannula. Z, is the negative spectrum observed 
immediately after each positive spectrum. Figures 3.14B-D are representative 
examples of the changes in the device forward flow measured spectrum in a 
patient who had the speed of the device reduced from 9000 rpm (B) to 6000 rpm 
for 15 minutes (C) then to 4000 rpm for 5 minutes (D). The Vmaxf  (thin yellow 
arrow) becomes less prominent as the LVAD speed is reduced. 
 
B) C) D) 
A) 
Z 
Z 
Z 
Z 
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3.4.1.3  Device Forward Flow 
Peak velocity in forward direction (Vmaxf) was measured by measuring the 
distance between the baseline and the peak of positive velocity spectrum on 
Doppler images. The changing velocity over the flow period in the forward 
direction was determined by tracing (integrating) the area under the Doppler 
curve from the leading edges of the positive velocity spectrum to obtain forward 
velocity time integrals (VTIf). In other words, VTIf represents the distance that 
the blood travelled into the inflow cannula with each heart beat. Since the inflow 
cannula is a rigid circular tube with a constant cross sectional area (CSA), the 
flow through the inflow cannula would have a uniform velocity. Using the 
volumetric flow equation, the blood volume that flowed into the inflow cannula 
was calculated as the product of the forward VTIf and the CSA of the inflow 
cannula: BV = CSA x VTIf, where, BV, blood volume (cm
3
); VTIf, velocity time 
integral (cms); CSA, cross-sectional area of the inflow cannula (cm
2
).
**
 
 
3.4.1.4  Ventricular Dimensions and Function 
Both LVEDD and LVESD were obtained from the parasternal long axis of the 
LV at the level of the chordal-mitral valve junction. Fractional shortening (FS) 
was calculated as the percentage of change in the LV cavity dimension with 
systole:  
FS = (LVEDD-LVESD) / LVEDD x 100%.  
Ejection fraction (EF) was calculated using the cubed function of the ventricular 
dimension formula:  
EF = (LVEDD
3
-LVESD
3
) / LVEDD
3 
x 100%. 
 
  
                                                 
**
 CSA was determined as 2.5447 cm
2
 based on an internal diameter of the inflow cannula of 1.8 
cm 
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3.4.1.5  Peripheral Haemodynamic Measurements 
Haemodynamic measurements were performed using an automatic blood 
pressure monitor, Datascope Accutorr Plus and included systolic blood pressure 
(SBP), diastolic blood pressure (DBP), and heart rate (HR). Pulse pressure (PP) 
was calculated as the difference between SBP and DBP. Mean arterial blood 
pressure (MAP) was calculated by adding one third of the PP to the DBP. 
During low speed duration patients were closely observed clinically for any 
untoward symptoms such as dizziness, sweating, palpitations, or dyspnoea. 
 
3.4.1.6  Data Collection and Statistics 
All data were collected prospectively and are represented as mean ± stdev. Data 
analysis was done using SPSS version 16.0 for windows (Lead Technologies). 
For normally distributed samples paired t-test and unpaired t-test were used. 
Wilcoxon signed-rank test and Mann-Whitney U tests were used to compare 
non-parametric variables between 2 and 3 groups, respectively. A p-value < 0.05 
was considered to be statistically significant. 
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3.4.2  RESULTS 
3.4.2.1  Safety 
No adverse incidents were noted on any of the 33 occasions when the speed was 
reduced from baseline to 6000 rpm. Further speed reduction to either 5000 rpm 
or 4000 rpm was also tolerated by all patients with no evidence of dizziness, 
palpitations, or dyspnoea. The longest period of time at less than baseline flow 
was 27 minutes. Patients were followed up for 72 hours and none reported any 
thrombotic related complications.  
 
3.4.2.2  Group Comparison 
There were no significant differences in the baseline haemodynamic, 
echocardiographic and PW Doppler measured parameters between Groups A 
and B when the HM II LVAD was at either baseline speed or at 6000 rpm (table 
3.5). Also, none of the patients had significant mitral regurgitation on 
echocardiography and the aortic valve was closed whilst the device was running 
at baseline speed. 
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Table 3.5:  Inter-group comparison.  
Parameter 
Baseline Speed Speed 6000 rpm 
Group A Group B p-value Group A Group B p-value 
SBP (mmHg) 92.71 ± 10.52 88.06 ± 8.14 0.326 86.06 ± 9.38 85.94 ± 12.11 0.683 
DBP (mmHg) 61.12 ± 10.84 58.94 ± 6.51 0.510 52.17 ± 6.14 53.56 ± 7.85 0.545 
MAP (mmHg) 71.65 ± 8.73 68.65 ± 5.63 0.402 63.46 ± 6.48 64.35 ± 8.55 0.523 
HR (bpm) 86.89 ± 14.03 88.44 ± 16.13 0.731 83.22 ± 18.68 85.63 ± 14.92 0.317 
EDD (mm) 53.16 ± 11.32 49.93 ± 14.79 0.391 56.53 ± 8.45 56.40 ± 12.26 0.537 
ESD (mm) 40.47 ± 16.17 40.47 ± 16.17 0.451 44.37 ± 9.80 44.47 ± 16.04 0.656 
FS (%) 20.90 ± 8.52 20.75 ± 10.42 0.706 22.15 ± 8.23 22.96 ± 10.89 0.864 
EF (%) 48.87 ± 16.31 47.84 ± 19.31 0.706 51.33 ± 15.17 51.71 ± 20.40 0.864 
Vmaxf (cm/sec) 69.21 ± 28.36 76.01 ± 38.54 0.682 47.33 ± 11.33 51.67 ± 21.23 0.957 
VTIf (cms) 22.49 ± 11.73 25.11 ± 12.35 0.580 12.15 ± 4.16 13.29 ± 7.04 0.817 
BV (cm
3
) 57.23 ± 29.85 63.91 ± 31.43 0.580 30.92 ± 10.58 32.24 ± 1421 0.817 
Table 3.5: Comparison of the baseline and 6000 rpm measured peripheral haemodynamics, echocardiographic and Doppler parameters between 
the two groups. 
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3.4.2.3  Device Forward Flow 
In group A, speed reduction from an average baseline speed of 9055 ± 165 rpm 
(range 8800 – 9400 rpm) to 6000 rpm resulted in a significant reduction in both 
Vmaxf and VTIf from 69.21 ± 28.36 cm/sec to 47.33 ± 11.33 cm/sec (p=0.006) 
and from 22.49 ± 11.73 cms to 12.15 ± 4.16 cms (p=0.001), respectively (figure 
3.19). Although speed reduction to 5000 rpm resulted in a significant decrease in 
both Vmaxf and VTIf as compared to the baseline speed measurements (Vmaxf: 
69.21 ± 28.36 cm/sec versus 43.54 ± 10.30 cm/sec, p=0.001; VTIf: 22.49 ± 11.73 
cms versus 10.94 ± 2.65 cms, p<0.001), both Vmaxf and VTIf measured at 5000 
rpm were not significantly lower when compared to measurements acquired at 
6000 rpm (Vmaxf, 47.33 ± 11.33 cm/sec versus 43.54 ± 10.30 cm/sec, p=0.302; 
VTIf, 12.15 ± 4.16 cms versus 10.94 ± 2.65 cms, p=0.306, respectively). 
Similar to group A, speed reduction in group B from an average baseline speed of 
9160 ± 260 rpm (range 8800 – 9800 rpm) to 6000 rpm resulted in a significant 
decrease in both Vmaxf and VTIf from 76.01 ± 38.54 cm/sec to 51.67 ± 21.23 
cm/sec (p=0.044) and from 25.11 ± 12.35 cms to 13.29 ± 7.04 cms (p=0.004), 
respectively (figure 3.20). Vmaxf and VTIf measured at speed 4000 rpm were also 
significantly lower as compared to the baseline speed measurements (Vmaxf, 
76.01 ± 38.54 cm/sec versus 38.44 ± 16.81 cm/sec, p=0.004; VTIf, 25.11 ± 12.35 
cms versus 9.93 ± 5.60 cms, p<0.001) but not significantly lower when compared 
to measurements obtained at 6000 rpm although there was a lower trend (Vmaxf, 
51.67 ± 21.23 cm/sec versus 39.43 ± 16.72 cm/sec, p=0.07; VTIf, 13.29 ± 7.04 
cms versus 9.93 ± 5.60 cms, p=0.165, respectively). 
Figure 3.21 illustrates the effects of speed reduction on blood volume flowing into 
the inflow cannula. Following the same pattern as the VTIf, the BV that travelled 
into the inflow cannula decreased as the speed decreased from baseline to 6000 
rpm by more than 40% in both groups (Group A: 57.23 ± 29.88 cm
3
 versus 30.92 
± 10.58  cm
3
, p=0.002; Group B: 63.99 ± 31.43 cm
3
 versus 32.24 ± 14.21 cm
3
, 
p=0.004). Further speed reduction in both groups resulted in a non-significant 
decrease in the forward BV travelling into the inflow cannula (Group A: 30.92 ± 
10.58 cm
3
 versus 27.84 ± 6.74 cm
3
, p=0.306; Group B: 32.24 ± 14.21 cm
3
 versus 
25.27 ± 14.24 cm
3
, p=0.165). 
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Figure 3.19: Effect of speed reduction on the HM II forward flow in Group A 
 
 
 
 
 
Fig 3.19: Changes in device forward flow measurements in group A as the speed 
was reduced from baseline to 5000 rpm. Figures 3.19 (i) and 3.19 (ii) illustrate the 
reduction in both Vmaxf and VTIf, respectively. Speed reduction to 6000 rpm 
resulted in a significant decrease in both parameters. Further speed reduction to 
5000 rpm did not cause a significant decrease in either measurement when 
compared to 6000 rpm. * p=0.006, ** p=0.001, *** p<0.001. 
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Figure 3.20: Effect of speed reduction on the HM II forward flow in Group B 
 
 
 
 
 
Fig 3.20: Changes in device forward flow measurements in group B as the speed 
was reduced from baseline to 4000 rpm. Figures 3.20 (i) and 3.20 (ii) illustrate the 
reduction in both Vmaxf and VTIf, respectively. Speed reduction to 6000 rpm 
resulted in a significant decrease in both parameters. Further speed reduction to 
4000 rpm did not cause a significant decrease in either measurement when 
compared to 6000 rpm. * p=0.04, ** p=0.004, *** p<0.001. 
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Figure 3.21: Effects of speed reduction on the blood volume being driven into 
the HM II LVAD 
 
 
 
 
 
 
 
Fig 3.21: Speed reduction resulted in a significant drop in the BV being driven 
into the HM II LVAD in both group A (figure 3.21 (A)) and group B (figure 3.21 
(B)). There was no significant difference in the BV that entered the LV inflow 
cannula between 6000 rpm and the lower speeds in either group. * p=0.002, ** 
p=0.004. 
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After combining the two groups‘ 6000 rpm measured parameters, an inter-group 
analysis of Vmaxf, VTIf and BV between 6000 rpm, 5000 rpm and 4000 rpm 
revealed that they were not significantly lower when measured at 5000 rpm and 
4000 rpm as compared to 6000 rpm (Vmaxf: 49.30 ± 16.44 cm/sec versus 43.54 ± 
10.30 cm/sec versus 38.44 ± 16.81 cm/sec, p=0.082; VTIf: 12.67 ± 5.58 cms 
versus 10.94 ± 2.65 cms versus 9.93 ± 5.60 cms, p=0.074; BV: 32.24 ± 14.21 cm
3
 
versus 27.84 ± 6.74 cm
3
 versus 25.27 ± 14.24 cm
3
, p=0.093). 
As shown in figure 3.18, there was a negative spectrum below the baseline on the 
PW Doppler assessment. This negative spectrum only occurred in diastole 
immediately after the positive spectrum. From the mock circuit, visualisation of 
the ink injected at the inflow cannula (similar position to the sample volume 
positioned whilst performing echocardiography) revealed a minute and a non-
significant retrograde flow in the inflow cannula which could not have been 
quantified. Based on this observation the negative spectrum has been not 
calculated. See discussion for further explanation for the possible reasons for the 
existence of the negative spectrum. 
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3.4.2.4  Left Ventricular Structure and Function 
The reduction in the speed of the HM II LVAD did not have a significant effect 
on either the LV dimensions or function (table 3.6).  
 
Table 3.6: Changes in LV Structure and function 
Table 3.6: Changes in the echocardiographic parameters following incremental 
speed reduction in both groups. There was no significant change in LVEDD, 
LVESD, FS or EF as the speed of the device was reduced in either group.  
  
G
ro
u
p
 A
 
Parameter 
Baseline 
Speed 
6000 rpm 5000 rpm p-value 
LVEDD (mm) 53.16 ± 11.32 56.53 ± 8.45 56.21 ± 7.11 0.581 
LVESD (mm) 42.74 ± 12.40 44.37 ± 9.80 42.47 ± 9.43 0.832 
FS (%) 20.90 ± 16.31 22.15 ± 8.23 25.18 ± 8.57 0.281 
EF (%) 48.87 ± 16.31 51.33 ± 15.17 56.54 ± 14.91 0.281 
G
ro
u
p
 B
 
Parameter 
Baseline 
Speed 
6000 rpm 4000 rpm p-value 
LVEDD (mm) 49.93 ± 14.79 56.40 ± 12.26 57.40 ± 12.59 0.295 
LVESD (mm) 40.47 ± 16.17 44.47 ± 16.04 45.07 ± 15.21 0.613 
FS (%) 20.75 ± 10.42 22.96 ±10.89 22.97 ± 9.36 0.636 
EF (%) 47.84 ± 19.31 51.71 ± 20.40 52.36 ± 17.93 0.636 
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3.4.2.5  Peripheral Haemodynamics 
Table 3.7 illustrates the changes noted in the peripheral haemodynamics 
parameters following incremental speed reduction. There was no significant 
change in SBP in either group as the speed of the device was reduced. However, 
both DBP and MAP decreased significantly as the baseline speed decreased to 
6000 rpm in both groups. Further device speed reduction did not have a 
significant effect on either DBP or MAP. The reduction in the DBP resulted in an 
increase in PP, as would be expected, but not significantly. 
 
Table 3.7: Blood pressure response to speed reduction 
Table 3.7: Changes in blood pressure parameters following incremental speed 
reduction in both groups. There was no significant change in SBP as the speed of 
the device was reduced. However, the DBP decreased significantly as the baseline 
speed decreased to 6000 RPM in both groups. Further reduction to 5000 RPM in 
Group A and 4000 RPM in Group B did not have a significant effect on the DBP. 
MAP followed the same trend as DBP. 
 
G
ro
u
p
 A
 
Parameter 
Baseline 
Speed 
6000 rpm 5000 rpm p-value 
SBP (mmHg) 92.71 ± 10.52 86.06 ± 9.38 86.33 ± 10.74 0.125 
DBP (mmHg) 61.12 ± 10.84 * 52.17 ± 6.14 * 49.22 ± 5.77 0.004 
PP (mmHg) 31.59 ± 13.25 33.89 ± 7.50 37.11 ± 9.14 0.115 
MAP (mmHg) 71.65 ± 8.73 * 63.46 ± 6.48 * 61.59 ± 6.54 0.002 
G
ro
u
p
 B
 
Parameter 
Baseline 
Speed 
6000 rpm 4000 rpm p-value 
SBP (mmHg) 88.06 ± 8.14 85.94 ± 12.11 85.75 ± 11.33 0.908 
DBP (mmHg) 58.94 ± 6.51 * 53.56 ± 7.85 * 47.94 ± 7.82 0.001 
PP (mmHg) 29.13 ± 9.15 32.38 ± 8.7 37.81 ± 8.36 0.106 
MAP (mmHg) 68.65 ± 5.63 * 64.35 ± 8.55 * 60.54 ± 8.25 0.026 
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Furthermore, both groups exhibited an initial non-significant decline in the HR 
trend as the speed decreased from baseline to 6000 rpm; Group A, 86.89 ± 14.03 
bpm  versus 83.22 ± 18.68 bpm, p=0.205; Group B, 88.44 ± 16.1 bpm versus 
85.63 ± 14.92 bpm, p=0.112. Further speed reduction in either group did not result 
in significant additional change in the HR when compared to 6000 rpm (Group A: 
83.22 ± 18.68 bpm versus 84.39 ± 18.24 bpm, p=0.731; Group B: 85.63 ± 14.92 
bpm versus 85.88 ± 15.32 bmp, p=0.734).  
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3.5  Discussion 
This chapter sets the scene on how to assess the native myocardial function in 
patients with the continuous flow HM II LVAD. Unlike pulsatile flow LVADs, 
continuous flow devices provide less pulsatility and generate negative pressure in 
the inflow cannula as a result of the suctioning effect of the rotary pump affecting 
the blood rheology (DiGiorgi PL et al., 2004). Despite this difference in the 
characteristics of the device, continuous flow devices provide an equivalent 
degree of haemodynamic support, LV unloading, end-organ perfusion, and 
exercise capacity to pulsatile LVADs (Feller ED et al., 2007;Garcia S et al., 
2008;Haft J et al., 2007;Radovancevic B et al., 2007;Yu JJ et al., 2008).  
It is well recognised that successful assessment of the underlying myocardial 
function in patients with LVAD can only occur after minimising the contribution 
from the device into the circulation and after ensuring that LV loading is a 
physiological response to the reduction of the LVAD contribution.  Practically, 
this occurs when the mechanical support is either reduced or effectively 
discontinued.  
We have previously reported that acute cessation of the pulsatile HeartMate I 
LVAD under heparin cover, is a safe and an efficient method in assessing the 
underlying function of the native myocardium (George RS et al., 2007b). It is well 
recognised that cessation of LVADs will result in blood to regurgitate from the 
ascending aorta into the outflow graft in diastole (i.e. reverse direction) towards 
the LVAD and subsequently into the LV. The regurgitant volume will be maximal 
when the device is switched off. In patients supported with pulsatile devices such 
as the HeartMate I LVAD the regurgitant volume is of insignificance due to the 
presence of a one-way valve at the inflow cannula obstructing it from reaching the 
LV and hence retrograde loading of the LV does not occur. Therefore, it can be 
concluded that LV loading when the pulsatile device is switched off is a 
physiological response to device cessation which reveals the true function of the 
underlying myocardium rather than being a consequence of retrograde filling.  
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This is not true for continuous flow devices such as the HM II LVADs due to the 
continuous rotary nature of the device and the absence of the one-way valve 
system. In part one of this tri-component study, a multi-level time model analysis 
revealed that measurements taken whilst the LVAD running at baseline speed did 
not change over a 1-year period suggesting that the contribution from the HM II 
LVAD continued to mask the native LV function preventing real assessment of 
the underlying LV function. Measurements taken at 5 and 15 minutes of low 
speed and after the 6MW, on the other hand, showed a significant alteration over 
the 1-year modelling period. Hence it could be assumed that reducing the input 
from the HM II LVAD into the circulation by decreasing the speed of the device 
would allow the LV to partially reload and hence the underlying true function is 
unmasked. However, reducing the speed of continuous flow devices will lead to 
less power being generated and less suctioning power resulting in blood flowing 
back into the outflow graft towards the HM II rotor device in diastole. It can be 
anticipated that when the device is completely switched off the regurgitant 
volume will bypass the rotor placed in the housing chamber (figure 2.3) to load 
the LV i.e. retrograde loading secondary to device cessation.  
Should the regurgitant volume reach the LV, assessment of the native myocardial 
function will be unreliable. Myers et al, have identified a direct relationship 
between the value of the regurgitant flow measured at the LV outflow tract and 
the tolerability of device cessation (Myers T et al., 2006). In their study, those 
who did not tolerate the discontinuation of Jarvik 2000 (another type of 
continuous flow LVAD) had a bigger regurgitant flow compared to those who did 
(Myers T et al., 2006). Myers‘s approach to assess the regurgitant flow through 
the LV outflow tract does not solely reflect the reverse flow through the device as 
it depends on the function of the aortic valve. Slaughter et al, have used the HM II 
flow estimator to assess the VAD flow (Slaughter MS et al., 2009a). They 
significantly correlated the readings obtained from the estimator to the 
intraoperative evaluation of VAD flows using high-fidelity probe placed in the 
outflow tract (p=0.0001), although the degree of correlation was moderate 
(r=0.56). They also concluded that data obtained from the estimator should be 
used to provide directional information for trend purposes only. Therefore, it was 
important in our patient population to identify a speed where the underlying 
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myocardial function could be safely and effectively assessed i.e. a speed where 
blood does not regurgitate back into the LV and that the forward flow generated 
by the HM II VAD does not interfere with the assessment. 
In the mock circuit, part two, a relationship between the device‘s speed, the 
ventricular pressure, the aortic pressure and the flows throughout the circuit, at 
three different ventricular strengths (poor, moderate, and strong) was identified. 
At each of the three different ventricular conditions, as the speed of the HM II 
decreased both aortic pressure and baseline flow decreased steadily whereas the 
diastolic ventricular pressure and the difference in flow between systole and 
diastole (ΔQ) increased. These changes could all be related to the reduction in the 
speed of the HM II VAD in an experimental environment such that: 
1) The reduction in the aortic pressure and the baseline flow were due to the 
reduction in the power being generated by the HM II that drives flow 
towards the Windkessel system, 
2) The rise in the diastolic ventricular pressure was due to the reduction in 
the negative pressure and the suctioning power generated by the rotary 
effect of the HM II VAD, 
3) The rise in ΔQ was a response to the increase in the pulse pressure being 
generated in the system due to increased contribution from the Abiomed 
5000 pulsatile system and was only apparent when the aortic valve was 
opening (figure 3.17). 
Unfortunately, the video captures of the ink injected in either the outflow or 
inflow grafts during ventricular contractility were qualitative and could have not 
been quantified. Nevertheless they provided a clear indication of the complex 
nature of the pattern of the flow being generated from the HM II VAD and its 
response to pre-load and after-load. In experiments 2, 3 and 4 where the 
ventricular contractility was poor, moderate and strong, respectively, the flow 
pattern at 10000 rpm was complex and turbulent. As the speed of the HM II VAD 
decreased to 6000 rpm the flow became less turbulent and formed a well defined 
―cloud-like‖ pattern that moved forward in systole with minimal but non-
significant backward movement in early diastole. The ink stopped flowing in the 
backward direction at a certain point (referred to as stagnation point i.e. end of 
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diastole – figure 3.12) and moved forward in systole. At no point the injected ink 
travelled back into the ventricular chamber of the Abiomed system even when the 
aortic pressure exceeded the ventricular pressure.  
In part three, assessment of flows within the HM II LVAD and the impact of 
speed alteration on the flow was performed by placing a Pulsed Wave Doppler 
sample volume at the tip of the inflow cannula. This approach has been previously 
described by Chumnanvej et al (Chumnanvej S et al., 2007). Using this approach 
it became clearer that flow across the HM II LVAD consists of two components; a 
positive spectrum that occurs in systole representing forward flow and a negative 
spectrum occurring in diastole. 
In this part of the study it was shown that speed reduction of the HM II LVAD to 
6000 rpm and subsequently lower to either 5000 rpm or 4000 rpm was safe in the 
clinical setting. Speed reduction was tolerated on all 33 occasions in the 13 
studied patients with no observable side effects. Participants were divided into 
two groups determined by the lowest speed of the device, either 5000 rpm (Group 
A) or 4000 rpm (Group B). There was no difference in the baseline speed between 
the two groups (9060 ± 160 rpm versus 9140 ± 240 rpm, median 9000 rpm in each 
group). The baseline speed was set to ensure no septal shift and that the aortic 
valve remained closed to ensure maximal LV unloading whilst on LVAD support. 
Others have used a HM II pulsatility index of 4 or more to provide maximal 
power output as a guide to setting the baseline speed (Garcia S et al., 2008). 
Although it would have been desirable, simultaneous assessment of device flow at 
5000 rpm and 4000 rpm in every patient was not feasible due to safety concerns 
over prolonged periods of low flow. 
The volume of blood that travelled into the inflow cannula with each cardiac cycle 
is generated from the suction effect of the HM II LVAD and from LV 
contractions. This volume could not have been measured directly and hence it had 
to be calculated as a product of the VTIf and the CSA of the inflow cannula, a 
constant value. Although the calculation assumes that the sample volume 
remained in a constant position throughout the period of the flow to obtain an 
accurate VTIf, it could be assumed that the calculated volume reflects a true 
representation of the BV that flows into the inflow cannula.  
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In both groups speed reduction from the baseline speed to 6000 rpm for 15 
minutes resulted in a significant decrease in the forward flow across the inflow 
cannula by more than 25%. The calculated BV that flowed into the inflow cannula 
also decreased significantly. This reduction unmasked the native LV function and 
resulted in the redirection of the blood flow from the LV into the LV outflow tract 
though the opening aortic valve. Speed reduction to less than 6000 rpm resulted in 
a further non-significant decrease in the forward flow velocity, the forward 
velocity time integral, and the blood volume suggesting that more blood has been 
redirected from the LV into the LV outflow tract and that speed reduction to 
levels below 6000 rpm is unnecessary to assess the myocardial function. 
From figures 3.18 B-D it could be noted that there was an identifiable negative 
spectrum below the baseline in diastole at the baseline speed and at lower speeds 
immediately after the positive spectrum (label Z). This may imply that the blood 
that had flowed into the outflow graft had bypassed the running rotor within the 
housing chamber and was driven into the LV. This may be true at lower speeds 
where the aortic valve is opening and when the power generated by the rotor is 
not high to overcome the pressure difference between the inflow and the outflow 
ends. However at baseline speeds when the aortic valve does not open and the 
power generated from the rotor is so high that it overcomes the pressure 
difference between the inflow and the outflow ends, reverse flow as far as the LV 
is unlikely. Therefore, the negative spectrum seen at the baseline speeds was 
thought to be an artefact.  
The appearance of the negative spectrum at lower speeds could be explained 
differently. From the mock circuit experiments the amount of ink that travelled in 
the backward direction in the outflow graft was under the effects of the speed of 
the device and the pressure gradient between the aorta and the ventricular 
chamber. When the speed of the HM II VAD was reduced some ink travelled in 
the backward direction until it was stopped at the point of stagnation 
††
 (figure 
3.12) before reaching the rotary pump of the HM II VAD and never reached the 
ventricular chamber. Further, visualisation of the flow of the ink injected in the 
inflow cannula confirmed that the ink moved only forward towards the tip of the 
                                                 
††
 The point of stagnation is an imaginary point and does not physically stop the flow (figure 3.12) 
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inflow cannula in systole. In early diastole there was a minute backward 
displacement of ink in the inflow cannula that did not change in quantity with 
further speed reduction. This retrograde displacement of flow in the inflow 
cannula at lower speeds could possibly explain the negative spectrum seen in the 
echocardiographic PW  Doppler assessment of the flow across the inflow cannula 
which results from the recoil feature of the elastic component of the inflow 
cannula in diastole secondary to the negative pressure being generated by the LV 
in diastole. Another explanation for the appearance of the negative spectrum is 
that it is a representation of a propagated pulse / pressure generated from the 
blood entering the outflow graft in diastole which itself never reaches the LV.  
Left ventricular dimensions and LV function (FS and EF) changed significantly as 
the speed decreased from baseline to 6000 rpm with no further significant changes 
at either 5000 rpm or 4000 rpm. This again confirms that sub-6000 rpm speeds are 
not needed to assess the underlying LV function. 
Both diastolic and mean arterial blood pressures decreased significantly in both 
groups following speed reduction to 6000 rpm. Further speed reduction caused a 
non-significant decrease in both. There was also a non-significant change in the 
SBP readings. As the speed decreased from baseline to 6000 rpm and 
subsequently to lower speed, the PP increased which could be a response to the 
drop in the DBP. The rise in PP was not significant and its inverse relationship 
with DBP confirms that the necessity to minimise the suctioning power of the HM 
II LVAD in order to assess the native LV function. Again there were no 
significant differences between 6000 rpm and lower speeds. 
Limitations 
Apart from visualising the ink pattern in the outflow cannula in the mock circuit, 
there was no other means of quantifying the volume / extent of the regurgitant 
volume that travelled in the backward direction. Another limitation of the mock 
circuit was its static characteristic. A third limitation was the position of the HM 
II VAD which was connected in parallel to the Abiomed system rather than in 
series (in LVAD patients the HM II is connected at the apex of the LV i.e. in 
series).  
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With regards to the clinical component of this study, parameters measured at 
speeds of 6000 rpm, 5000 rpm and 4000 rpm were not assessed serially in each 
patient and that the population had to be divided into two groups. A fifth 
limitation was the inability to differentiate between the blood flow that is being 
driven into the inflow cannula by the rotary action of the device and the volume 
that is being generated by LV contractility. It was also not possible to assess the 
LV outflow tract stroke volume as the inflow cannula position prevented correct 
alignment of the PW Doppler sample volume on the LV outflow tract.  
Conclusion 
The first component of this study was based on multi-level modelling analysis to 
show that speed reduction is necessary in patients with HM II LVAD to enable the 
assessment of the underlying LV function. The choice of the lowest possible 
speed to assess the native myocardium, where there will be minimum contribution 
from the device into the circulation, had never been clarified to-date. A bench 
work study revealed a direct relationship between the device‘s speed, pressure and 
flow. No significant difference in the flow pattern was noted between 6000 rpm, 
5000 rpm, and 4000 rpm and although a minute amount of blood travelled in the 
backward direction in diastole, it never reached the LV; suggesting that 
ventricular loading following speed reduction is a physiological response rather 
than retrograde filling from the blood entering through the inflow cannula. In the 
clinical setting, direct comparison of echocardiographic, haemodynamic, and 
device flow related parameters between speeds of 6000 rpm, 5000 rpm and 4000 
rpm revealed no significant difference.  This suggests that reducing the speed to 
6000 rpm is adequate to safely and effectively assess the native myocardial 
function as will be demonstrated in chapter 4. 
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CHAPTER 4 - Effects of LVAD and 
Drug Combination Therapy on Left 
Ventricular Structure, Function and 
Contractile Reserve 
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4.1  Background 
In 1996, Dr Frazier reported that the LV structure and function change with 
LVAD support (Frazier OH et al., 1996). His observation was confirmed when 
several groups studied the left ventricular‘s response to LVAD support and 
identified sufficient degree of myocardial recovery for device explantation 
(Frazier OH et al., 1996;Levin HR et al., 1996;Loebe M et al., 1997;Müller J et 
al., 1997;Mancini DM et al., 1998;Frazier OH & Myers TJ, 1999;Farrar DJ et al., 
2002;Dandel M et al., 2005). The explantation rate, however, was small and 
ranged from 5-24%. In 2006, Birks et al prospectively studied 15non-ischaemic 
DCM patients receiving pulsatile HM I LVAD and drug combination therapy, the 
Harefield Bridge-to-Recovery Protocol (Birks EJ et al., 2006). This strategy 
resulted in sufficient myocardial recovery that allowed LVAD explantation in 
73% of the patients. Detailed analyses of the changes in both LV structure and 
function were later reported by George et al (George RS et al., 2006;George RS et 
al., 2007a;George RS et al., 2007b). In these studies, it was determined that 
recovery assessment is a continuous process and that cessation of the pulsatile 
HM I LVAD is essential to assess the native myocardium.  
The Harefield Bridge-to-Recovery protocol uses peak oxygen consumption (VO2) 
assessment as one of the explantation criteria (Chapter 2, table 2.2), however, this 
test requires specific equipment, personnel, and exercise to exhaustion which does 
not reflect daily activities. The 6-minute walk (6MW) exercise test, although 
considered a submaximal test, has been shown to correspond to the demands of 
day-to-day activities and the changes in the LV function which would reflect the 
contractile reserve (CR) needed in normal day-to-day activities (Bittner V, 
1997;Bittner V, 2003). 
CR, also known as inotropic reserve, is an old concept brought together from 
observations made by many investigators who studied the performance of the LV 
in the failing and the non-failing hearts. In general, CR describes the changes in 
myocardial contractility in response to a variety of physiologic or pharmacologic 
stress agents including the sympathetic nervous system (SNS). Over the years 
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myocardial CR has been shown to provide important prognostic information in 
both ischaemic and non-ischaemic DCM patients (Pratali L et al., 2007). 
Different investigators have used different means in an attempt to provide an 
objective assessment of CR. These included haemodynamic measurements during 
cardiac catheterisation and EF assessment by echocardiography performed during 
either exercise or stress echocardiography (Borow K et al., 1985). In 1997, 
Nagaoka et al, reported that the change in LV EF following exercise is the most 
powerful indicator of CR and a strong predictor of survival in DCM patients 
(Nagaoka H et al., 1997).  
The aim of the present is to primarily determine the effects of continuous flow 
HM II LVAD and drug combination therapy on the LV size (dimensions), 
function and CR. The second aim is to correlate the changes in the LV function 
with myocardial recovery and attempt to determine echocardiographic and 
peripheral haemodynamic predictors of myocardial recovery. Thirdly, to evaluate 
and compare the differences in the LV response to two different types of LVADs; 
pulsatile HM I LVAD and continuous flow HM II LVAD. 
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4.2  Part One – Impact of HM II LVAD on 
Left Ventricular Size, Function and Contractile 
Reserve  
4.2.1  METHODS 
4.2.1.1  Patient population 
All 23 patients were included in this study. As mentioned in chapter 2 all were in 
end-stage HF and on inotropic support prior to device implantation (table 2.1). 
The Harefield Bridge to Recovery protocol was previously discussed in chapters 1 
and 2. In summary anti-failure medication was commenced immediately after 
weaning the patients from inotropic therapy with adequate end-organ recovery. 
Assessment of the native LV function was started once patients have started 
mobilisation. In those who required RVAD support, assessment of the native LV 
function was started following RVAD explantation and patient mobilisation. 
4.2.1.2  Speed reduction protocol  
After ensuring an INR of 2.0 and above assessment of the native myocardial 
function in patients with HM II LVAD was performed after reducing the speed of 
the device to 6000 rpm, a tested speed (Chapter 3 - experimental and clinical 
analysis) where forward flow contribution from the device is minimal and that LV 
loading is a physiological response to speed reduction rather than a response to 
retrograde filling i.e. off-pump testing equivalent. Assessment of the native LV 
function was implemented on an out of hour basis in the outpatient setting at 
Harefield Hospital. 
4.2.1.3  Peripheral haemodynamic measurements 
Peripheral haemodynamic parameters were measured sequentially in each patient 
using an automatic blood pressure monitor, Datascope Accutorr Plus, Datascope, 
USA. Measurements SBP, DBP, HR, and were performed at six conditions in 
each patient on every assessment:  
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i) device running at baseline speed; 
ii) immediately after speed reduction to 6000 rpm (0Min); 
iii) at 5 minutes of 6000 rpm (5Mins);  
iv) at 10 minutes of 6000 rpm (10Mins);  
v) at 15 minutes of 6000 rpm (15Mins); and 
vi) after a 6MW whilst on 6000 rpm (see section 4.2.1.5 for the protocol). 
PP was calculated as the difference between the SBP and DBP whereas the MAP 
was calculated by adding one third of the PP to the DBP.  
4.2.1.4  Echocardiographic assessment of the LV size and function 
Echocardiographic parameters were also measured sequentially in each patient 
throughout the study at four different conditions:  
i) device running at baseline speed; 
ii) at 5 minutes of 6000 rpm (5Mins);  
iii) at 15 minutes of 6000 rpm (15Mins); and  
iv) after a 6MW whilst on 6000 rpm (see section 4.2.1.5 for the protocol). 
All echocardiographic assessments were performed by one senior 
echocardiographer (Mrs Carole Webb) at Harefield using either the iE33 machine 
(Philips, The Netherlands), or the Vivid 7 (GE Healthcare, USA). All 
measurements were performed in the M-Mode using a transducer with harmonic 
imaging. To eliminate bias the radiographer was blinded to the recovery status of 
each patient. 
LVEDD and LVESD were obtained from the parasternal long axis of the LV at 
the level of chordal-mitral valve junction. The systolic diameter was measured at 
the onset of the QRS complex using the leading edge method i.e. from the leading 
edge of the LV septal endocardial tissue to the leading edge of the posterior wall 
endocardial tissue. The diastolic diameter was also measured by the leading edge 
method at either the peak of posterior wall motion or the nadir of septal motion.  
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FS was calculated as the percentage change in the LV cavity dimensions with 
systole (equation 4.1): 
FS = (LVEDD-LVESD) / LVEDD x 100%.     (4.1)  
Although it would have been desirable, but due to time constraint (each 
assessment takes at least 1 hour) and the altered internal architecture of the LV in 
patients with LVAD, Simpson‘s Biplane EF could not have been acquired on 
every assessment.  Therefore, to ensure standardisation in determining the LV 
function, EF was calculated using the cubed function formula of the ventricular 
dimensions (equation 4.2): 
EF = (LVEDD
3
-LVESD
3
) / LVEDD
3 
x 100%.   (4.2) 
4.2.1.5  Six-Minute walk exercise test to assess myocardial contractile 
reserve 
The absolute change in EF following dobutamine infusion has been commonly 
used to describe the contractile ability of the LV in response to pharmacological 
stress (dobutamine infusion). An absolute rise in the EF by 5% during dobutamine 
infusion as compared to resting was considered to be a positive indicator for the 
presence of CR with strong correlation to both prognosis and to different 
therapeutic approaches. In this study, dobutamine stress echocardiography (DSE) 
was not utilised as means for assessing CR as the presence of the LVAD in situ 
would distort the internal structure of the LV, hence rendering the pattern of LV 
wall motion and segmental viability obtained from DSE unreliable. Furthermore, 
assessment of the extent of myocardial recovery is a continuous and rigorous 
process that needed to be performed on regular basis and the use of DSE on 4-6 
weekly basis would have been unethical, unacceptable by the patient, and would 
have required a consultant cardiologist performing the examination.  
The 6MW test on the other hand had proven to be a reproducible and an 
inexpensive technique which can be performed serially in each patient in the out-
patient clinic setting and was accepted by all patients. Similar to DSE technique, 
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we have used an absolute increase in FS and EF following the 6MW by at 
least 5% as cut-off points to indicate preservation of CR. 
If the speed of 6000 rpm, although recognised that may not be optimal to assess 
the native LV function, was tolerated for 15 minutes, the patient performed a 
6MW exercise test on a flat, zero-gradient surface (75 meters long) with the speed 
of the HM II LVAD running at 6000 rpm. Upon completion of the 6MW, repeat 
echocardiographic and haemodynamic measurements were acquired to determine 
the LV‘s response to exercise. None of the patients performed the 6MW test 
during their first “low-speed” assessment such that the first low speed 
assessment test was confined to a 15 minutes of low speed testing only. This 
approach was taken for safety reasons and to make sure patients could tolerate a 
period of 15 minutes of low speed before the 6MW test and that they are more 
rehabilitated in order to complete the 6MW exercise test. CR was defined as the 
percentage difference between FS and EF obtained after the 6MW with the HM II 
LVAD running at 6000 rpm and after 15 minutes of 6000 rpm. The distance 
walked was also calculated.  
 
4.2.1.6  Data collection and statistics 
All data were collected prospectively. Data analysis was done using SPSS version 
16.0 for windows (Lead Technologies). All data was normally distributed. 
Parametric t-test was used for sequential variable analysis and unpaired t-test was 
used for inter-group analysis (recovery versus non-recovery). Receiver Operating 
Characteristic (ROC) analysis was used to determine echocardiographic and 
haemodynamic predictive factors for myocardial recovery. Linear correlation 
analysis was used to determine the correlation between CR measured indices and 
myocardial recovery. Percentage changes between subsequent measurements were 
calculated as: 
Percentage change = 
Second Measurment – First Measurement
 x 100 
 
First Measurement 
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Time model analysis was performed to determine the trends in the 
echocardiographic and haemodynamic parameters over a 1-year period and the 
differences in the trends between the recovered and the non-recovered patients. 
This model assumes that for each patient there is a linear relationship between the 
mean of each measured parameter and a 1-year period of support. The mean 
intercept of this relationship represents the value of the measured parameter at 
time 0. The mean slope of the relationship refers to the change in the measured 
parameter over a period of time such that a positive slope indicates an increase in 
the value and a negative slope indicates a reduction in the value. Refer to Model 2 
in Appendix B for model details.  
Unless stated otherwise, all measurements are presented as means ± stdev. A p-
value < 0.05 was considered to be statistically significant. 
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4.2.2  RESULTS 
4.2.2.1  Feasibility and tolerability of testing  
The first low-speed assessment was performed within 37 days (range 20-76 days) 
of device implantation. The test was repeated thereafter every 4 to 6 weeks. In 
total, the speed of the device was reduced to 6000 rpm on 170 occasions (mean of 
7.4 tests per patient, range 4-14 tests with median of 7 tests).  
Running the HM II LVAD at 6000 rpm for 15 minutes was tolerated on all 170 
assessments. None of the patients has developed any signs of overt HF. As stated 
above, none of the patients undertook the 6MW test on the first low-speed 
assessment leaving the total number of occasions where the 6MW test could have 
been performed to 147. The 6MW, however, was only tolerated on 144 out of the 
147 potential occasions (98%). On three occasions, patient number 6 has 
developed shortness of breath and the test was interrupted and the speed was re-
adjusted to his baseline speed (9000 rpm). All patients were followed up for 72 
hours and none had experienced short-term or long-term adverse events especially 
thromboembolic related complications. 
4.2.2.2  Effects of low speed on peripheral haemodynamic parameters 
Figure 4.1A illustrates the mean instantaneous effects of speed reduction on the 
SBP, DBP, PP, and MAP during the 170 low-speed assessments. Immediate speed 
reduction from the baseline speed (range 8600 rpm – 9800 rpm) to 6000 rpm has 
resulted in a significant decrease  in the SBP from 87.64 ± 6.36 mmHg to 83.56 ± 
6.88 mmHg (p=0.005), DBP from 58.06 ± 5.72 mmHg to 50.15 ± 4.04 mmHg 
(p<0.001), and MAP from 68.17 ± 5.32 mmHg to 61.41 ± 4.04 mmHg (p<0.001). 
The PP increased significantly by 12.61% immediately after speed reduction 
(29.64 ± 5.52 mmHg versus 33.38 ± 6.87 mmHg, p=0.002). At 5, 10 and 15 
minutes of 6000 rpm there were no significant changes in any of the blood 
pressure measured parameters compared to those taken immediately after speed 
reduction i.e. 0Min.  
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Figure 4.1A: Blood pressure response to speed reduction 
 
 
 
  
 
 
Fig 4.1A: There was a significant reduction in SBP, DBP and MAP 
measurements and a significant increase in PP immediately after speed reduction 
from the baseline speed to 6000 rpm. All parameters were stabilized thereafter as 
the speed of the HM II LVAD continued to run at 6000 rpm. * p=0.005, ** 
p<0.001, † p=0.002.  
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No significant change in the HR was noted as the speed of the HM II LVAD 
decreased from baseline to 6000 rpm (83.35 ± 10.40 versus 83.96 ± 11.68, 
p=0.404). There was also no significant difference in the HR at 5, 10 or 15 
minutes of low speed (figure 4.1B). 
Following the 6MW exercise test, there was a significant increase in all peripheral 
haemodynamic parameters as compared to those acquired at 15 minutes (table 
4.1).   
 
Table 4.1: Peripheral haemodynamic response to the 6MW exercise test 
 
Parameter 
15Mins of 
6000 rpm 
Post 6MW Change (%) p-value 
SBP (mmHg) 85.23 ± 9.00 92.76 ± 10.67 8.84 <0.001 
DBP (mmHg) 51.68 ± 5.34 55.04 ± 7.12 6.50 0.011 
MAP (mmHg) 63.07 ± 5.80 67.69 ± 7.58 7.32 0.001 
PP (mmHg) 33.50 ± 6.78 37.74 ± 8.87 12.66 <0.001 
HR (bpm) 82.39 ± 11.03 98.80 ± 12.64 19.91 <0.001 
 
Table 4.1: Following the 6MW all peripheral haemodynamic parameters 
increased significantly as compared to the measurements acquired at 15 minutes 
of low speed test. 
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Figure 4.1B: Speed reduction and heart rate 
 
 
 
 
 
 
Fig 4.1B: Immediate speed reduction did not have a significant effect on the HR 
which remained stable with minimal change over the 15 minutes of 6000 rpm.  
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4.2.2.3  Effects of low speed on echocardiographic parameters 
Following 5 minutes of low speed, echocardiographic assessment revealed a 
significant increase in both LVEDD and LVESD as compared to the baseline 
measurements (57.43 ± 11.45 mm versus 51.60 ± 12.26 mm, p<0.001; and 45.21 
± 13.89 mm versus 41.19 ± 14.23 mm, p<0.001, respectively). Continuous 
support at 6000 rpm for 15 minutes did not have a significant effect on either 
dimension (figure 4.2A) although they remained significantly higher as compared 
to the baseline measurements (LVEDD: 57.24 ± 12.25 mm versus 51.60 ± 13.10 
mm, p<0.001; LVESD: 45.35 ± 14.33 mm versus 41.19 ± 14.23 mm, p<0.001). 
Unlike the changes seen in the ventricular dimensions, speed reduction from 
baseline speed to 6000 rpm did not have a significant impact on either FS or EF at 
either 5 or 15 minutes (figure 4.2B). Furthermore, there was no significant 
difference between 5 and 15 minutes of low speed (FS: 22.70 ± 8.55% versus 
22.80 ± 9.04%, p=0.785; EF: 51.46 ± 16.40% versus 51.53 ± 17.30%, p=0.905). 
Following the 6MW exercise test, the LVESD decreased significantly by 4.19% 
as compared to 15 minutes low speed (43.45 ± 15.11 mm versus 45.35 ± 14.33 
mm, p=0.001) whereas the change in LVEDD was very small (0.04%) and not 
significant (57.60 ± 11.49 mm versus 57.58 ±11.62 mm, p=0.970). Also, both FS 
and EF increased significantly when compared to 15 minutes of low speed (26.29 
± 11.23% versus 22.80 ± 9.04%, p<0.001; and 56.79 ± 20.17% versus 51.53 ± 
17.30 %, p<0.001, respectively). The absolute increases in both parameters were 
equivalent to 3.49± 3.70% and 5.25 ± 5.30%, respectively. These changes 
corresponded to 15.31% and a 10.20% percentage rise after the 6MW exercise 
test, respectively (figure 4.2C). 
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Figure 4.2A: Speed reduction and ventricular dimensions 
 
 
 
 
 
 
 
Fig 4.2A: Changes in LVEDD and LVESD following speed reduction. At 5 
minutes, both LVEDD and LVESD increased significantly with no further 
changes at 15 minutes although the measurements taken at 15 minutes remained 
significantly higher than the baseline measurements. * p<0.001 
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Figure 4.2B: Speed reduction and ventricular function 
 
 
 
 
 
 
 
Fig 4.2B: Changes in FS and EF following speed reduction. There were no 
significant change at either 5 or 15 minutes.  
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Figure 4.2C: Response of LV function to 6MW 
 
  
 
 
 
 
Fig 4.2C: The percentage increase in both FS and EF following the 6MW was 
15.31% and 10.20%, respectively. * p<0.01 
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4.2.2.4  Recovered versus Non-Recovered 
As been described in chapter 2, 15 patients had recovered (Recovered (Rec) 
Group) whereas 8 did not recover (Non-Recovered (NRec) Group). A comparison 
of the pre-implantation demographics and clinical data between the two groups is 
included in table 4.2. There were no differences in the pre-implantation clinical 
parameters between the two subpopulations. 
Table 4.3 compares the haemodynamic and the echocardiographic parameters 
measured between the two groups with the HM II LVAD running at baseline 
speed and the amount of the phase I therapy at the first assessment. The average 
baseline speed was 9080 ± 250 rpm in the Rec group (median 9200 rpm, range 
8600 – 9400 rpm) as compared to 9310 ± 280 rpm in the NRec group (median 
9400 rpm, range 8800 – 9800 rpm). There was no statistical difference between 
the two average speeds (p=0.110). Furthermore, there were no significant 
differences in: (i) the time points when the first low speed assessment was 
performed, (ii) the drug regimen, and (iii) the peripheral haemodynamic 
parameters. LVESD, FS and EF were significantly better in the Rec group at the 
baseline speed on the first assessment as compared to the NRec group. The 
LVEDD was also smaller in the Rec group as compared to the NRec group but 
did not reach the level of significance. There was no correlation between the 
baseline speed of the device and the acquired haemodynamic and 
echocardiographic parameters (R
2
 = 0.29, p=0.310) suggesting that the initial 
echocardiographic and haemodynamic differences between the two groups were 
not secondary to speed differences. There was also no correlation between the 
echocardiographic parameters measured at pre-implantation and at the first 
assessment and myocardial recovery. 
The following three subsections (4.2.2.4.i – 4.2.2.4.iii) evaluate the different 
responses to speed reduction and the 6MW exercise test between the Rec and the 
NRec groups. 
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Table 4.2: Differences in the pre-implantation demographics, 
haemodynamics and echocardiographic parameters between the recovered 
and the non-recovered patients 
Variable 
Recovered 
Patients (n=15) 
Non-Recovered 
Patients (n=8) 
p-value 
HF Duration (months) 15.03 ± 24.81 61.75 ± 41.08 0.002 
Implant Age (yers) 32.30 ± 13.85 40.73 ± 14.26 0.149 
BMI (kg/m
2
) 23.17 ± 3.20 24.61 ± 2.50 0.357 
BSA (m
2
) 1.84 ± 0.21 1.88 ± 0.11 0.548 
Systolic PA pressure (mmHg) 45.13 ± 8.20 50.43 ± 13.96 0.536 
Diastole PA pressure(mmHg) 24.38 ± 6.25 30.00 ± 5.29 0.072 
Mean PA pressure (mmHg) 33.38 ± 4.14 38.71 ± 7.91 0.121 
PCWP (mmHg) 27.50 ± 4.09 33.29 ± 7.87 0.070 
Cardiac Output (l/min) 2.76 ± 1.17 2.54 ± 0.61 1.000 
Cardiac Index (l/min/m
2
) 1.54 ± 0.64 1.30 ± 0.39 0.525 
PA saturation (%) 39.43 ± 12.29 47.28 ± 9.59 0.247 
End-diastolic diameter (mm) 69.47 ± 7.38 79.50 ± 6.77 0.011 
End-systolic diameter (mm) 64.00 ± 6.49 73.67 ± 6.06 0.006 
Fractional shortening (%) 7.74 ± 4.20 7.29 ± 2.79 0.677 
Ejection Fraction (%) 21.03 ± 10.04 20.11 ± 6.71 0.680 
Urea (mmol/L) 10.08 ± 4.45 16.09 ± 7.06 0.065 
Creatinine (μmol/L) 136.60 ± 69.07 201.78 ± 89.38 0.101 
Bilirubin (μmol/L) 45.93 ± 29.56 45.56 ± 15.57 0.728 
Alkaline Phosphotase (U/L) 85.60 ± 53.01 76.33 ± 27.75 0.925 
Alanine Transaminase (U/L) 577.20 ± 671.55 90.78 ± 85.62 0.149 
Albumin(g/dL) 31.67 ± 5.65 30.56 ± 5.90 0.925 
BNP (pmol/L) 241.10 ± 259.31 459.50 ± 470.74 0.460 
Table 4.2: Direct comparison of pre-implant demographics, clinical parameters 
and biochemical profile between the recovered (n=15) and the non-recovered 
(n=8) patients.   
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Table 4.3: Differences between the Rec and the NRec groups during the first 
low speed assessment 
Table 4.3: The echocardiographic and haemodynamic parameters obtained at the 
first assessment with the HM II LVAD running at baseline speed. LVESD and LV 
function were significantly better in the Rec group as compared to the NRec 
group. There were no significant differences in the time point at which the first 
assessment was performed, the baseline speed, haemodynamic parameters, or the 
amount of phase I medication. 
Variable 
Rec Group 
(n=15) 
NRec Group 
(n=8) 
p-
value 
Time Point of first assessment 
since HMII implantation (days) 
37.53 ± 17.74 42.89 ± 20.31 0.438 
Baseline Speed (rpm) 9080 ± 250 9310 ± 280 0.110 
Haemodynamic Parameters    
SBP (mmHg) 88.00 ± 7.92 87.57 ± 12.82 0.944 
DBP (mmHg) 60.13 ± 6.53 59.71 ± 13.02 0.596 
PP (mmHg) 27.87 ± 2.89 27.86 ± 4.76 0.974 
MAP (mmHg) 69.42 ± 5.84 73.14 ± 9.81 0.217 
HR (bpm) 92.80 ± 16.50 88.43 ± 16.72 0.549 
Echo Parameters    
LVEDD (mm) 49.60 ± 13.39 61.67 ± 11.99 0.070 
LVESD (mm) 39.27 ± 12.66 * 54.11 ± 12.10 * 0.010 
FS (%) 21.50 ± 7.15 * 12.65 ± 4.64 * 0.005 
EF (%) 50.52 ± 12.60 * 32.85 ± 10.80 * 0.004 
Phase I Medication    
Lisinopril (mg) 20.00 ± 8.90 20.00 ± 16.51 0.755 
Spironolactone (mg) 25.00 ± 0.00 25.00 ± 0.00 1.000 
Digoxin (mcg) 119.32 ± 18.84 125.00 ± 0.00 0.425 
Carvedilol (mg) 15.40 ± 11.79 17.71 ± 16.50 0.932 
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4.2.2.4.i Haemodynamic responses to immediate speed reduction and the 6MW 
test 
a) Response to immediate speed reduction 
In the Rec group immediate speed reduction to 6000 RPM resulted in a drop in 
SBP, DBP, and MAP by 2.74%, 13.88%, and 9.01%, respectively, and in an 
increase in the PP by 18.92% (figure 4.3A). The reductions in both DBP and 
MAP and the increase in PP were statistically significant (DBP: 48.75 ± 3.50 
mmHg versus 56.61 ± 5.41 mmHg, p<0.001; MAP: 60.34 ± 3.70 mmHg versus 
66.32 ± 4.67 mmHg, p<0.001; PP: 34.63 ± 6.23 mmHg versus 29.12 ± 5.94 
mmHg, p<0.001) whereas the reduction in SBP was not significant (83.38 ± 6.51 
versus 85.73 ± 5.53, p=0.116). There was no further significant change in any of 
the four parameters as the HM II LVAD continued to run at 6000 rpm. 
In the NRec group (figure 4.3B) immediate speed reduction also resulted in a 
significant decrease in SBP, DBP, and MAP (SBP: 83.85 ± 7.87 mmHg versus 
90.82 ± 6.68 mmHg (-7.67%), p=0.020; DBP: 52.47 ± 3.99 mmHg versus 60.47 ± 
5.69 mmHg (-13.23%), p=0.001; and MAP: 63.19 ± 4.17 mmHg versus 71.27 ± 
5.09 mmHg (-11.34%), p=0.001) and a fractional non-significant increase in the 
PP (31.29 ± 7.74 versus 30.51 ± 4.95 mmHg (2.57%), p=0.713).  
The drop in the SBP was more significant in the NRec group as compared to the 
Rec group (7.67% versus 2.74%, p=0.04). There were no significant differences in 
the percentage reductions in either DBP or MAP between the two groups (13.88% 
versus 13.23%, p=0.186; and 9.01% versus 11.34%, p=0.186, respectively). The 
percentage change in PP at 0Min was significantly higher in the Rec group as 
compared to the NRec group (18.92% versus 2.57%, p=0.04). 
There was no significant change in the HR in either group following immediate 
speed reduction with no further changes at 5, 10 or 15 minutes (figure 4.3C). 
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Figure 4.3A: Response of blood pressure to speed reduction in the Rec group 
 
 
 
 
 
Fig 4.3A: Immediate speed reduction resulted in a significant decrease in both 
DBP and MAP and a significant increase in PP in the Rec group. The reduction in 
SBP was not significant. * p<0.001. 
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Figure 4.3B: Response of blood pressure to speed reduction in the NRec 
group 
 
 
 
 
 
 
Fig 4.3B: Immediate speed reduction resulted in a significant decrease in SBP, 
DBP and MAP. The reduction in SBP was more profound in the NRec group as 
compared to the Rec group (7.67% versus 2.74%, p=0.040). * p=0.02, ** 
p=0.001.  
0
10
20
30
40
50
60
70
80
90
100
SBP DBP PP MAP
P
re
ss
u
re
 (
m
m
H
g
)
Baseline
0Min
5Mins
10Mins
15Mins
↓ 13.23% 
↓ 11.34% 
↓ 7.67% 
** 
* 
** 
p=NS ↑ 2.57% 
217 
 
Figure 4.3C: Response of heart rate to speed reduction in both Rec and NRec 
groups 
 
  
 
 
 
Fig 4.3C: Speed reduction did not have a significant effect on the HR in either 
group. 
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b) Response to the 6MW exercise test 
In the Rec group, the 6MW exercise test  resulted in a significant increase in SBP, 
DBP, PP, MAP, and HR as compared to the measurements acquired at 15 minutes 
of low speed (SBP: 94.56 ± 10.46 mmHg versus 85.13 ± 8.75 mmHg, p<0.001; 
DBP: 53.90 ± 6.97 mmHg versus 50.45 ± 4.81 mmHg, p=0.019; PP: 40.66 ± 7.13 
mmHg versus 34.68 ± 6.58 mmHg, p<0.001; MAP: 67.55 ±7.64 mmHg versus 
62.08 ± 5.57 mmHg, p=0.001; HR: 100.48 ± 14.91 bpm versus 83.19 ± 11.43 
bpm, p<0.001, Figure 4.4A). The changes in SBP, DBP, PP, MAP, and HR 
following the 6MW exercise test represented an increase by 11.07%, 6.83%, 
17.23%, 8.82%, and 20.79%, respectively. 
In the NRec group, the 6MW did not result in a similar significant increase in any 
of the SBP, DBP, PP, and MAP parameters (SBP: 89.75 ± 10.61 mmHg versus 
85.38 ± 9.93 mmHg, p=0.117; DBP: 56.94 ± 7.37 mmHg versus 53.72 ± 5.84 
mmHg, p=0.240; PP: 32.86 ± 6.80 versus 31.52 ± 7.05, p=0.333; MAP: 67.93 
±7.92 mmHg versus 64.74 ± 6.11 mmHg, p=0.242, Figure 4.4B). The HR, 
however, increased significantly by 18.41% following the 6MW (95.99 ± 7.50 
bpm versus 81.07 ± 10.87 bpm, p<0.001). 
Figure 4.4C represents the differences in the percentage change in the peripheral 
haemodynamic parameters following the 6MW exercise test between the two 
groups such that the percentage change in SBP, DBP, MAP and HR were higher 
in the Rec group as compared to the NRec group but not significantly (11.07% 
versus 5.12%, p=0.155; 6.83% versus 5.98%, p=0.723; 8.82% versus 4.92%, 
p=0.379; and 20.79% versus 18.41%, p=0.904, respectively). The percentage 
change in the PP, however, was significantly higher in the Rec group as compared 
to the NRec group (17.23% versus 4.27%, p=0.028). 
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Figure 4.4A: Response of peripheral haemodynamics to the 6MW exercise 
test in the Rec group 
 
 
 
 
 
Fig 4.4A: There was a significant increase in SBP, DBP, PP, MAP, and HR 
following the 6MW in the Rec group. * p<0.001, ** p=0.019, † p=0.001  
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Figure 4.4B: Response of peripheral haemodynamics to the 6MW exercise 
test in the NRec group 
 
 
 
 
 
Fig 4.4B: There was no significant change in SBP, DBP, PP, or MAP following 
the 6MW. Similar to the Rec Group, the HR increased significantly after the 
6MW. * p<0.001 
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Figure 4.4C: Comparison in the percentage change in the haemodynamic 
parameters following the 6MW exercise test 
 
 
 
 
 
Fig 4.4C: Following the 6MW, the percentage change in SBP, DBP, PP, MAP 
and HR was higher in the Rec subpopulation compared to the NRec 
subpopulation. Data presented as mean percentage change. * p=0.028 
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4.2.2.4.ii  Echocardiographic responses to speed reduction and the 6MW exercise 
test 
a) Response to 5Mins of low-speed 
In the two groups, the changes seen in the LV dimensions over 15 minutes of low 
speed followed the same trend as the entire 23 studied patients (section 4.2.2.3 
and figure 4.2A). In each group, both LVEDD and LVESD were significantly 
higher at 5 minutes and 15 minutes as compared to the baseline measurements. 
Intra-group analysis revealed no difference between the 5 and 15 minutes 
measurements in either group (figure 4.5A). However, inter-group analysis 
revealed that both LVEDD and LVESD at 15 minutes were significantly lower in 
the Rec group as compared to the NRec group (LVEDD: 51.24 ± 6.67 mm versus 
68.13 ± 10.48, p<0.001; and LVESD: 36.81 ± 6.20 mm versus 59.59 ± 12.58 mm, 
p<0.001, both parameters are denoted by Ω on figure 4.5A). 
Speed reducation did not have a significant effect on the LV function in either 
group (figure 4.5B). At 15 minutes both FS and EF were significantly higher in 
the Rec group as compared to the NRec group (FS: 28.61 ± 4.13% versus 13.11 ± 
5.98%, p<0.001; and EF: 62.55 ± 6.24% versus 33.17 ± 13.63%, p<0.001).  
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Figure 4.5A: Effects of speed reduction on LV dimensions in the Rec and the 
NRec groups 
 
 
Fig 4.5A: After 5 minutes of speed reduction both LVEDD and LVESD increased 
significantly in both groups and remained significantly higher at 15 minutes of 
low speed. There were no significant differences in the LV dimensions between 5 
minutes and 15 minutes of low speed. Both LVEDD and LVESD were 
significantly lower in the Rec group versus the NRec group. * p<0.001, 
Ω  
p<0.001, ** p=0.001, *** p=0.005. 
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Figure 4.5B: Effects of speed reduction on LV function in the Rec and the 
NRec groups 
  
                                                                                                                                                                                                                                                     
Fig 4.5B: There were no significant changes in either FS or EF in either group 
after reducing the speed of the HM II LVAD for 5 minutes. There was no 
significant change in the function between 5 minutes and 15 minutes of low 
speed. At 15 minutes both FS and EF were significantly higher in the Rec group 
as compared to the NRec group. * p<0.001. 
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b) Response to the 6MW exercise test 
Following the 6MW, the LVESD in the Rec group decreased significantly as 
compared to the 15 minutes low-speed (34.42 ± 6.20 mm versus 36.81 ± 6.20 mm, 
p=0.003). There was no significant change in the LVEDD (51.83 ± 7.20 mm 
versus 51.24 ± 6.67 mm, p=0.463). Both FS and EF increased significantly by 
5.29 ± 3.39% and 7.73 ± 4.37%, respectively. The percentage increase was 
equivalent to 18.50% increase in FS following the 6MW exercise test and a 
12.35% increase in EF following the 6MW exercise test (FS: 33.91 ± 4.46% 
versus 28.61 ± 4.13%, p<0.001; and EF: 70.27 ± 5.99% versus 62.55 ± 6.24 %, 
p<0.001, figure 4.6). 
Figure 4.7 illustrates the LV response to 6MW exercise test in the NRec group. 
There was no significant change in either LVEDD or LVESD as compared to the 
15 minutes low speed (67.21 ± 11.08 mm versus 68.13 ± 10.48 mm, p=0.177, and 
58.51 ± 13.46 mm versus 59.59 ± 12.58 mm, p=0.212, respectively). Both FS and 
EF increased but not significantly by an absolute value of 0.48 ± 1.71% (13.59 ± 
6.14% versus 13.11 ± 5.98%, p=0.419) and 1.13 ± 4.20% (34.31 ± 14.05% versus 
33.17 ± 13.63%, p=0.442), respectively. These changes were equivalent to a 
percentage increase of 3.70% in FS and a percentage increase in the EF by 3.42% 
following the 6MW 
The percentage change in both FS and EF following the 6MW exercise test was 
significantly higher in the Rec group as compared to the NRec group (18.50% 
versus 3.70%, p=0.012, and 12.35% versus 3.42%, p=0.012, figure 4.8). The 
differences in these changes suggest that the CR in the recovered patients is better 
than those who did not recover reflecting the poorer LV response to exercise in 
the non-recovered patients. 
 
4.2.2.4.iii  Differences in the 6MW distance between the Rec and the NRec groups 
In total all 23 patients managed 571.96 ± 101.05 meters. The recovered group 
managed 604.07 ± 94.02 meters as compared to 518.45 ± 93.46 meters (p=0.048). 
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Figure 4.6: Response of LV structure and function to the 6MW exercise test 
in the Rec group  
 
 
 
 
Fig 4.6: There was a significant increase in FS and EF following the 6MW there 
was an absolute increase in both FS and EF by 5.30% and 7.72%, respectively, 
corresponding to a percentage change of 18.50% and 12.35%, respectively. ** 
p=0.003, * p<0.001. 
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Figure 4.7: Response of LV structure and function to the 6MW exercise test 
in the NRec group 
 
 
 
 
Fig 4.7: There was no significant change in ESD and EDD following 6MW. 
Unlike the recovered group the absolute increase in both FS and EF corresponded 
to 0.49% and 1.14%, respectively. These changes represent a percentage change 
of 3.70% and 3.42%, respectively. 
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Figure 4.8: Percentage change in the echocardiographic parameters 
following the 6MW exercise test– Rec versus NRec groups 
 
 
 
 
 
Fig 4.8: Following the 6MW, the percentage change in FS and EF were 
significantly higher in the Rec group as compared to the NRec group. Data 
presented as means of percentage change. * p=0.012 
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4.2.2.4.iv Difference in the left ventricular structural and functional trends 
between the Rec and the NRec groups over a 1-yearperiod – time modelling 
 
A multi-level time modelling was performed to determine the differences in the 
LV structural and functional trends between the Rec and the NRec groups over a 1 
year period of support (please refer to Model 2 in Appendix B for details of the 
analysis).  
The model revealed that at 15 minutes of low speed (figure 4.9A) and after the 
6MW exercise (figure 4.9B) the mean intercepts of all echocardiographic 
measured parameters are significantly better in the Rec group i.e. the mean value 
at time 0 is significantly better in the Rec group. This was also shown in table 4.3 
where the Rec group had significantly better echocardiographic parameters as 
compared to the NRec patients at the first low-speed assessment. 
Furthermore, the mean slopes were significantly better in the Rec group 
suggesting that the mean changes over the 1-year modelling period is significantly 
better in the Rec group. These results conclude that the echocardiographic 
differences seen after 15 minutes of low speed and after the 6MW exercise test 
between the Rec and the NRec groups are not just differences in average 
measurements but also differences in the trends over a period of time with better 
outcome in the recovered patients. 
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Figure 4.9A: Differences in the echocardiographic trends between the Rec 
and the NRec groups at 15 minutes of low speed 
 
 
 
 
 
 
 
Fig 4.9A: Differences in the echocardiographic trends between the Rec (     ) and 
the NRec (      ) groups at 15 minutes of low speed. The intercept was significantly 
better in the recovered group compared to the non-recovered group. The mean 
slope was also significantly better in the Rec group. 
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Figure 4.9B: Differences in the echocardiographic trends between the Rec 
and the NRec groups after the 6MW exercise test 
 
 
 
 
Fig 4.9B: Differences in the echocardiographic trends between the Rec (      ) and 
the NRec (    ) groups after 6MW. The intercept was significantly better in the 
recovered group compared to the non-recovered group. The mean slope was also 
significantly better in the Rec group. 
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4.2.2.5  Echocardiographic and haemodynamic predictors of 
myocardial recovery 
Linear correlation analysis revealed that the strongest correlation existed between 
echocardiographic parameters measured after the 6MW exercise test and 
myocardial recovery (R value ranged between 0.731 and 0.8, table 4.4). The 
correlation between the haemodynamic parameters measured throughout the 6 
different conditions and myocardial recovery were very poor with an R value 
ranging between 0.03 and 0.336 and never reached level of significance. 
Logistic regression analysis of the echocardiographic parameters measured after 
the 6MW exercise test showed that an EF of 56.3% was a strong predictor of 
myocardial recovery (ROC curve area = 1.0, 100% sensitivity, and 97.5% 
specificity, p<0.001). The percentage change in EF by 8.3%, which corresponds 
to an absolute increase by 5% after the 6MW exercise test was a strong predictor 
of myocardial recovery (ROC curve area = 0.889, sensitivity 73%, and specificity 
89% p=0.002). 
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Table 4.4: Correlation analysis between echocardiographic parameters and myocardial recovery 
 
Table 4.4: Linear correlation analysis revealed that all echocardiographic parameters were predictive of myocardial recovery, however, 
measurements acquired following the 6MW exercise test, specifically FS and EF, were the strongest with an R value of 0.8. 
Echocardiographic parameter LVEDD LVESD FS EF 
 R p-value R p-value R p-value R p-value 
HM II LVAD at baseline speed 0.600 <0.001 0.677 <0.001 0.653 <0.001 0.653 <0.001 
5 Minutes low speed 0.631 <0.001 0.698 <0.001 0.665 <0.001 0.665 <0.001 
15 minutes low speed 0.636 <0.001 0.704 <0.001 0.694 <0.001 0.694 <0.001 
Post 6MW 0.789 <0.001 0.731 <0.001 0.800 <0.001 0.800 <0.001 
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4.3  Part Two – Comparison of the LV 
Response between HM I and HM II LVAD 
In this section, the haemodynamic and the LV responses to off-pump testing and 
the 6MW exercise testing is compared between patients receiving the pulsatile 
HM I LVAD and the continuous flow HM II LVAD.
‡‡
 Differences in device 
specification and properties have been previously discussed in Chapter 1.  
In 2006 and 2007, we have reported the effects of pulsatile HM I LVAD and drug 
combination therapy on the peripheral haemodynamics, LV structure and 
function, and CR in non-ischaemic DCM patients (George RS et al., 2006;George 
RS et al., 2007a). The analysis depended on acute device cessation of the HM I 
LVAD i.e. ―off-pump‖ testing. 
4.3.1  METHODS 
4.3.1.1  HM I LVAD patient population 
Since December 1999, 39 patients with non-ischaemic DCM were implanted with 
the pulsatile HM I LVAD. Out of those four had the device implanted on 
compassionate ground and died in the interim of the peri-operative course, nine 
had early post-operative deaths, two had their device failed and one received a 
heart transplant without starting the phase II therapy. The remaining 23 patients 
remained potential candidates for myocardial recovery and received both phase I 
and phase II therapy and were assessed for recovery. A comparison in the pre-
implantation demographics and clinical characteristics between the 23 HM I 
LVAD patients and the 23 HM II LVAD patients (the main cohort of the thesis) is 
presented in table 4.5. The HM I population had a significantly higher BMI and 
BSA as compared to the HM II population justifying the use of the larger HM I 
device in the former group. Cardiac output and renal function were significantly 
worse in the HM II population. The remaining clinical parameters were also 
worse in the HM II population but did not reach level of significance. 
                                                 
‡‡
 The inclusion of the HM I LVAD group in this chapter is for comparative purposes only to 
determine the reposnes of the patients to different LVAD types. 
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Table 4.5. Pre-implantation demographics and clinical characteristics 
differences between the HM I and the HM II LVAD patients 
 
Variable HM I  (n=23) HM II (n=23) p-value 
Gender (make : female) 20 : 3 21 : 2 0.605 
Age at implant (years) 37.09 ± 12.67 35.24 ± 14.27 0.555 
BMI (kg/m
2
) 26.52 ± 7.39 23.67 ± 3.00 0.005 
BSA (m
2
) 1.93 ± 0.48 1.85 ± 0.19 0.012 
Heart failure duration (months) 42.85 ± 49.65 31.29 ± 38.03 0.751 
Symptoms duration (months) 7.30 ± 7.36 5.07 ± 4.17 0.78 
Haemodynamic Parameters 
PA Syst (mmHg) 
 
49.28 ± 15.28 
 
47.60 ± 11.17 
 
0.758 
PA Diast (mmHg) 27.56 ± 10.93 27.00 ± 6.32 0.745 
PA Mean (mmHg) 34.33 ± 8.08 35.87 ± 6.56 0.663 
PCWP (mmHg) 27.55 ± 8.44 29.88 ± 6.42 0.300 
Cardiac output (l/min) 3.55 ± 0.98 2.69 ± 1.01 0.012 
Cardiac index (l/min/m
2
) 1.74 ± 0.47 1.46 ± 0.57 0.345 
Pulmonary artery saturation (%) 51.17 ± 11.41 43.00 ± 11.36 0.254 
Echocardiographic Parameters 
End-diastolic diameter (mm) 
 
73.04 ± 12.10 
 
72.33 ± 8.43 
 
0.621 
End-systolic diameter (mm) 66.39 ± 12.16 66.76 ± 7.66 0.888 
Fractional shortening (%) 9.51 ± 5.09 7.61 ± 3.79 0.093 
Ejection fraction (%) 23.50 ± 9.01 20.73 ± 8.96 0.173 
Biochemical Profile 
Urea (mmol/L) 
 
8.77 ± 4.08 
 
12.01 ± 6.12 
 
0.041 
Creatinine (g/dl) 114.63 ± 32.56 158.61 ± 82.93 0.05 
Bilirubin (μmol/L) 39.29 ± 18.95 46.70 ± 24.98 0.435 
Alkaline phosphotase (U/L) 172.71 ± 103.52 83.48 ± 45.21 <0.001 
Alanine transaminase (IU/L) 163.33 ± 108.02 401.74 ± 590.71 0.909 
 
Table 4.5: Differences in the pre-implantation parameters between the HM I and 
the HM II LVAD patients 
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Out of the 23 HM I LVAD patients, 15 had recovered and had their HM I LVAD 
explanted whereas 8 did not recover and were transplanted. A comparison 
between the recovered and the non-recovered patients of the HM I LVAD 
population is presented in table 4.6. Unlike the HM II group (table 4.2), there was 
no significant differences in the HF duration, LVESD and LVEDD between the 
recovered and the non-recovered patients. 
Table 4.6. Differences in the pre-implantation demographics, 
haemodynamics and echocardiographic parameters between the recovered 
and the non-recovered patients in the HM I LVAD population 
Variable 
HM I Rec 
Group (n=15) 
HM I NRec 
Group (n=8) 
p-value 
Implant Age (years) 35.94 ± 12.38 39.25 ± 13.78 0.478 
BMI (kg/m
2
) 27.57 ± 4.58 24.53 ± 11.08 0.796 
BSA (m
2
) 2.02 ± 0.21 1.76 ± 0.76 0.561 
HF duration 42.08 ± 56.72 44.29 ±36.98 0.632 
Haemodynamic Parameters 
PA Syst (mmHg) 
 
46.36 ± 17.45 
 
53.86 ± 10.68 
 
0.102 
PA Diast (mmHg) 28.64 ±13.57 25.86 ± 5.15 0.785 
PA Mean (mmHg) 32.00 ± 7.47 38.00 ± 8.14 0.187 
PCWP (mmHg) 25.83 ± 7.86 30.13 ± 9.14 0.562 
CO (l/min) 3.69 ± 1.15 3.36 ± 0.71 0.364 
CI (l/min/m
2
) 1.81 ± 0.55 1.61 ± 0.29 0.421 
SvO2 (%) 42.50 ± 13.44 55.50 ± 9.04 0.355 
Echocardiographic Parameters 
LVEDD (mm) 
 
73.73 ± 14.45 
 
71.75 ± 6.27 
 
0.583 
LVESD (mm) 66.67 ± 14.23 65.88 ± 7.72 0.651 
FS (%) 10.07 ± 5.40 8.47 ± 4.61 0.872 
EF (%) 24.56 ± 7.55 21.50 ± 11.58 0.605 
 
Table 4.6: Main demographics, haemodynamics and echocardiographic 
parameters between the recovered and the non-recovered patients of the HM I 
LVAD patients.   
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4.3.1.2  Device cessation “off-pump” protocol 
Ten minutes prior to cessation of the HM I LVAD, patients were given 10,000 
units of intravenous unfractionated heparin. Pneumatic hand pumping was 
instituted at a rate of 3 hand pumps every 15 seconds as soon as the device was 
switched off in order to avoid blood stagnation within the pump. Pneumatic hand 
pumping was stopped while taking haemodynamic and echocardiographic 
measurements. These assessments were performed using similar protocol as has 
been previously described for the HM II LVAD patients (sections 4.2.1.3 and 
4.2.1.4). If patients tolerated device cessation for 15 minutes, a 6MW exercise test 
was undertaken to assess their CR and response to exercise (see section 4.2.1.5 for 
the 6MW exercise test protocol). Haemodynamic and echocardiographic 
measurements were repeated after the 6MW exercise test. Similar to the HM II 
population, HM I LVAD patients missed the 6MW exercise test during their first 
―off-pump‖ assessment. 
 
4.3.1.3  Data collection and statistics 
Tests on patients implanted prior to February 2005 were performed by Dr. Patrick 
Tansley and Dr. James Hardy (previous clinical research fellows in the VAD 
programme at Harefield). Following February 2005, all tests on the HM I LVAD 
patients were performed prospectively. Data analysis were done using SPSS 
version 16.0 for windows (Lead Technologies) and presented as means ± stdev. 
Parametric paired t-test was used for intra-group analysis and unpaired t-test was 
utilised for the HM I LVAD inter-group analysis (Recovered versus Non-
Recovered) and to compare between the HM I and the HM II LVAD patients. 
Time modelling analysis was performed to compare the differences in the trends 
in the LV response to the 6MW exercise test between HM I and HM II LVAD 
patients. A p-value < 0.05 was considered to be statistically significant.  
238 
 
4.3.2  RESULTS 
4.3.2.1  Feasibility and tolerability of testing in HM I patients  
The first off-pump assessment was performed within 53 days (range 30-82 days) 
of HM I LVAD implantation as compared to the average 37 days in the HM II 
population (p=0.007) and was repeated at 4 to 6 weeks interval.  
In total, the HM I LVAD was switched off on 226 occasions (mean of 9.8 tests 
per patient, range 2-18 tests, median 10 tests). Device cessation for 15 minutes 
was tolerated on 223 occasions. On 3 occasions 1 patient did not tolerate device 
cessation for 15 minutes and developed mild chest discomfort and the HM I had 
to be reconnected after 10 minutes. Similar to the HM II population none of the 
patients undertook the 6MW test on their first off-pump assessment leaving the 
total possible number of occasions where the 6MW exercise test that could be 
performed to 203. Out of the 203 potential tests, the 6MW was tolerated on 197 
occasions (97%). On those six occasions, 1 patient became very anxious and the 
HM I LVAD had to be reconnected abandoning the 6MW exercise test. At no 
point any of the patients has developed signs of overt heart failure during the 
assessments that necessitated hospital admission. All patients were followed up 
for 72 hours and none had experienced short term or long term adverse events. 
 
4.3.2.2  Summary of the Effects of Pump Cessation in the HM I 
Population 
A similar analysis to the HM II LVAD patients was conducted on the HM I 
studied population and presented in tables 4.7 and 4.8, respectively. 
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Table 4.7: Changes in the haemodynamic and echocardiographic parameters 
that occur immediately after cessation of the HM I LVAD (n=23) 
 
 
Table 4.7:  A summary of the immediate haemodynamic and echocardiographic 
response to acute device cessation in the HM I population.  
 
There was a significant reduction in SBP, PP, MAP, FS, and EF, and a significant 
increase in HR, LVEDD, and LVESD immediately after acute cessation of the 
HM I LVAD. Although the DBP decreased after device interruption, it did not 
reach level of significance. 
Device cessation for 15 minutes did not have further significant impact on either 
the haemodynamic or the echocardiographic measurements (table 4.8). 
 
  
             Parameter On-Pump 
Immediately 
after device 
cessation 
(%) 
Change 
p-
value 
H
a
em
o
d
y
n
a
m
ic
 
P
a
ra
m
et
er
s 
SBP (mmHg) 99.49 ± 11.57 92.22 ± 16.13 -7.31 0.006 
DBP (mmHg) 59.95 ± 10.58 58.74 ± 10.58 -2.00 0.222 
PP (mmHg) 39.55 ± 5.48 33.48 ± 7.94 -15.37 0.007 
MAP (mmHg) 73.12 ± 10.61 69.90 ±12.14 -4.41 0.020 
HR (bpm) 83.40 ± 8.91 90.66 ± 12.88 8.71 0.020 
E
ch
o
 P
a
ra
m
et
er
s 
LVEDD (mm) 48.33 ± 8.19 54.62 ± 7.64 13.02 <0.001 
LVESD (mm) 33.40 ± 7.72 40.95 ± 8.91 22.62 <0.001 
FS (%) 31.56 ± 6.81 25.68 ± 8.54 -18.64 <0.001 
EF (%) 66.26 ± 10.17 56.76 ± 15.30 -14.34 <0.001 
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Table 4.8: Sequential effects of pump cessation for 15 minutes on the HM I LVAD patients (n=23) 
 
 
 Parameter Baseline 0Mins 5Mins 10Mins 15Mins 
H
a
em
o
d
y
n
a
m
ic
 
P
a
ra
m
et
er
s 
SBP (mmHg 99.49 ± 11.57 92.22 ± 16.13 92.76 ± 16.95 92.85 ± 18.51 93.53 ± 17.02 
DBP (mmHg) 59.95 ± 10.58 58.74 ± 10.58 59.63 ± 10.69 59.34 ± 9.46 57.60 ± 11.25 
PP (mmHg) 39.55 ± 5.48 33.48 ± 7.94 33.13 ± 10.95 38.52 ± 13.96 35.94 ± 7.75 
MAP (mmHg) 73.12 ± 10.61 69.90 ±12.14 70.67 ± 12.05 72.17 ± 11.42 69.58 ± 12.95 
HR (bpm) 83.40 ± 8.91 90.66 ± 12.88 89.85 ± 13.72 89.76 ± 13.52 89.32 ± 13.15 
E
ch
o
 
P
a
ra
m
et
er
s LVEDD (mm) 48.33 ± 8.19 - 54.62 ± 7.64 - 55.32 ± 8.00 
LVESD (mm) 33.40 ± 7.72 - 40.95 ± 8.91 - 41.59 ± 9.05 
FS (%) 31.56 ± 6.81 - 25.68 ± 8.54 - 25.52 ± 7.64 
EF (%) 66.26 ± 10.17 - 56.76 ± 15.30 - 57.05 ± 13.30 
Table 4.8:  A summary of the sequential effects of device cessation in the 23 HM I LVAD population. 
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4.3.2.3  A comparison of the haemodynamic and the echocardiographic 
responses to off-pump testing and to the 6MW exercise test between the HM 
I and the HM II LVAD patients 
Figure 4.10A illustrates a direct comparison between the percentage change in the 
haemodynamic and the echocardiographic parameters between the HM I (n=23) 
and the HM II (n=23) groups. Immediately after interruption of LVAD support 
the percentage reductions in DBP and MAP were significantly higher in the HM 
II group as compared to the HM I group (-13.62% versus -2.00%, p<0.001, and         
-9.92% versus -4.41%, p=0.011, respectively). In the HM II patients there was a 
significant increase in PP in contrast to a significant decrease in the HM I group 
(12.62% versus -15.37%, p<0.001). In addition, there were no differences in the 
percentage change in either HR or SBP although the changes                                       
were more pronounced in the HM I group.  
After 5 minutes of off-pump testing, although the absolute FS and EF in the HM I 
LVAD patients had decreased, values remained higher as compared to the HM II 
group (25.68 ± 8.54% versus 22.70 ± 8.55%, p=0.338, and 56.76 ± 15.30% versus 
51.46 ± 6.40%, p=0.297, respectively). Interestingly, the HM II group 
demonstrated a percentage increase in both parameters whereas the HM I group 
demonstrated a percentage reduction in both parameters (FS: 2.66% versus -
18.64%, p<0.001; and EF:  3.43% versus -14.34%, p<0.001, figure 4.10A). The 
rise in the absolute value in the FS and EF in the HM II group at 5 minutes 
following speed reduction (22.70 ± 8.55% versus 22.11 ± 9.53%, p=0.179, and 
51.46 ± 16.40% versus 49.75 ± 18.62%, p=0.102, respectively) was unexpected 
and it could be related to either the suctioning power generated by the rotor pump 
being is reduced when the speed decreases hence allowing the LV to provide 
better contractility or the second possibility is that the LV may not be fully 
unloaded and its function is still influenced by the effect of the HM II LVAD 
unlike the HM I LVAD patients where the device is completely switched off.  
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Figure 4.10A: The percentage change in the haemodynamic and the 
echocardiographic parameters following interruption of LVAD support 
 
 
 
 
Fig 4.10A: A comparison of the haemodynamic and echocardiographic 
parameters measured after interruption of LVAD support between the HM I and 
HM II LVAD patients. Percentage decrease in DBP and MAP were significantly 
higher in the HM II LVAD patients. The HM II group also demonstrated an 
increase both FS and EF after speed reduction as compared to the HM I patients 
who showed a reduction. *p<0.001, **p=0.002, †p=0.011.  
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Left ventricular dimensions showed a trend to increase following interruption of 
support in both groups. The percentage change in both LVEDD and LVESD were 
more pronounced in the HM I LVAD patients as compared to the HM II group 
(13.02% versus 11.31%, p=0.798, and 22.62% versus 9.78%, p<0.001, 
respectively) although the absolute dimensions in the HM II group remained 
higher as compared to the absolute dimensions in the HM I LVAD patients 
(LVEDD: 57.43 ± 11.45 mm versus 54.62 ± 7.64 mm, p=0.573; LVESD: 45.21 ± 
13.89 mm versus 40.95 ± 8.91mm, p=0.489).  
There was a significant increase in the SBP, PP and HR following the 6MW 
exercise test in both groups (figure 4.10B). The percentage change in SBP, DBP, 
PP, MAP and HR were not significantly different between the two groups (8.84% 
versus 5.88%, p=0.180; 6.50% versus 1.42%, p=0.120; 12.66 % versus 13.03%, 
p=0.468; 7.32 % versus 3.42%, p=0.131; and 19.91% versus 15.50%, p=0.287, 
respectively).  
The HM I LVAD patients demonstrated a significant increase in the absolute FS 
following the 6MW exercise test as compared to the 15 minutes off-pump testing 
(26.58 ± 8.63% versus 25.52 ± 7.64%, p=0.034, an absolute increase by 1.06 ± 
2.26% corresponding to a percentage change of 4.17%) and a slight increase in 
the absolute EF (58.42 ± 15.06% versus 57.05 ± 13.30%, p=0.136, an absolute 
increase by 1.37 ± 4.24% corresponding to a percentage change of 2.40%).  
As discussed in section 4.2.2.3 and illustrated in figure 4.2C, the HM II LVAD 
patients exhibited a significant rise in both the absolute FS and the absolute EF 
following the 6MW exercise test as compared to the 15 minutes off-pump testing 
such that both FS and EF increased by an absolute value of 3.49 ± 3.70% and 5.36 
± 5.30%, respectively, which correspond to 15.31% and 10.21% percentage 
change from the 15 minutes of low-speed testing. The percentage change in both 
FS and EF were significantly higher in the HM II LVAD patients as compared to 
the HM I LVAD patients (15.31% versus 4.17%, p=0.050, and 10.20% versus 
2.40%, p=0.035, respectively) suggesting that the response to exercise was higher 
and more evident in the HM II LVAD patients.  
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Figure 4.10B: The percentage changes in the haemodynamic and the 
echocardiographic parameters after the 6MW exercise test 
 
 
 
Fig 4.10B: A comparison of the haemodynamic and echocardiographic 
parameters measured after the 6MW test between the HM I and HM II LVAD 
patients. There were no significant differences in the percentage changes in the 
haemodynamic parameters after the 6MW test as compared to the 15 minutes off-
pump. The percentage increase in both FS and EF were significantly higher in the 
HM II LVAD patients as compared to the HM I LVAD patients. *p<0.050, 
†p=0.035. 
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4.3.2.4  Differences in the haemodynamic and the echocardiographic 
responses between recovered HM I (n=15) and recovered HM II (n=15) 
LVAD patients 
Before determining the differences in the haemodynamic and the 
echocardiographic responses to off-pump testing and the 6MW exercise test 
between the two recovered groups, a comparison of the pre-implantation clinical 
parameters between the two recovered subgroups and their medication was 
performed and presented in table 4.9. 
Table 4.10 represents the differences in the haemodynamic parameters between 
the two recovered sub-groups at all measurement time points. Apart from the PP 
and the HR measurements, the HM I recovered group had significantly higher 
peripheral haemodynamic parameters as compared to the HM II recovered 
patients. 
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Table 4.9: Differences in pre-implantation clinical parameters and maximal 
medication between both recovered groups 
Variable 
HM I Group 
(n=15) 
HM II Group 
(n=15) 
p-value 
Age at implantation  35.94 ± 12.38 32.30 ± 13.85 0.461 
HF Duration (months)  42.08 ± 56.72 15.04 ± 24.81 0.440 
Pre-implantation Haemodynamic Parameters   
PA Systole (mmHg)  46.36 ± 17.45 45.13 ± 8.20 0.968 
PCWP (mmHg)  25.83 ± 7.86 27.50 ± 4.09 0.582 
CI (L/min/m
2
)  1.81 ± 0.55 1.54 ± 0.64 0.512 
Pre-implantation Echocardiographic Parameters   
LVEDD (mm) 73.73 ± 14.45 69.47 ± 7.38 0.148 
LVESD (mm) 66.67 ± 14.23 64.00 ± 6.49 0.217 
FS (%) 10.07 ± 5.40 7.74 ± 4.20 0.081 
EF (%) 24.56 ± 7.55 21.03 ± 10.04 0.098 
Maximal Medication    
Carvedilol (mg)  40 ± 20 38.45 ± 107.50 0.845 
Bisoprolol (mg) 9.50 ± 1.10 10 ± 2.10 0.923 
Lisinopril (mg)  35.00 ± 10.00 35.00 ± 8.00 0.905 
Digoxin (mcg)  125 125 1.000 
Spironolactone (mg)  25 25 1.000 
Clenbuterol (mcg)  1370.00 ± 850 1870.00 ± 470 0.632 
Clenbuterol start  
since implantation (days)  
151.00 ± 96.70 123.80 ± 43.30 0.312 
Table 4.9: Difference in pre-implantation clinical parameters and maximal 
medication between both recovered groups. There were no differences in the 
clinical parameters or the maximal medication taken by each sub-group. 
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Table 4.10: Differences in the peripheral haemodynamics between the two recovered groups 
 
Assessment time-point Baseline 0Mins 5Mins 10Mins 15Mins Post 6MW 
S
B
P
 
(m
m
H
g
) HM I 102.26 ± 10.18 99.32 ± 14.00 100.59 ± 13.91 105.93 ± 17.57 101.02 ± 15.79 108.28 ± 21.80 
HM II 85.73 ± 5.53 83.38 ± 11.33 84.89 ± 8.12 84.73 ± 8.17 85.13 ± 8.75 94.56 ± 10.46 
p-value <0.001 <0.001 <0.001 <0.001 0.002 0.033 
D
B
P
 
(m
m
H
g
) HM I 63.09 ± 9.10 62.42 ± 10.31 63.26 ± 8.60 63.61 ± 8.16 62.17 ± 10.29 63.22 ± 13.31 
HM II 56.61 ± 5.41 48.75 ± 3.50 49.87 ± 3.77 49.77 ± 4.55 50.45 ± 4.81 53.90 ± 6.97 
p-value 0.002 <0.001 <0.001 <0.001 0.001 0.026 
P
P
 
(m
m
H
g
) HM I 39.17 ± 5.89 36.91 ± 5.55 37.33 ± 6.41 42.31 ± 15.62 38.85 ± 7.02 45.06 ± 9.60 
HM II 29.12 ± 5.94 34.63 ± 6.23 35.02 ± 7.14 34.96 ± 6.82 34.68 ± 6.57 40.66 ± 7.13 
p-value <0.001 0.233 0.233 0.100 0.116 0.116 
M
A
P
 
(m
m
H
g
) HM I 76.15 ± 9.06 74.72 ± 11.38 75.71 ± 10.23 77.72 ± 9.64 75.12 ± 11.95 78.24 ± 16.00 
HM II 66.32 ± 4.67 60.34 ± 3.70 61.64 ± 4.44 61.53 ± 4.99 62.08 ± 5.57 67.55 ± 7.64 
p-value <0.001 <0.001 <0.001 <0.001 0.001 0.041 
H
R
 
(b
p
m
) 
HM I 84.53 ± 7.62 93.40 ± 13.61 92.31 ± 14.68 91.47 ± 14.69 91.78 ± 13.96 105.65 ± 14.25 
HM II 86.41 ± 11.33 85.62 ± 12.61 84.42 ± 11.78 85.01 ± 11.51 83.19 ± 11.43 100.48 ± 14.91 
p-value 1.000 0.116 0.074 0.174 0.074 0.250 
Table 4.10: There were significant differences in SBP, DBP, and MAP with the values being significantly higher in the recovered HM I LVAD 
patients as compared to the recovered HM II LVAD patients reflecting the pulsatility effects of the HM I LVAD. 
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Whilst on full support the HM I recovered group had significantly higher FS and 
EF as compared to the HM II recovered group (Table 4.11). There were no 
significant differences in the echocardiographic parameters measured at either 5 
or 15 minutes of ―low-speed / off-pump‖ testing between the two recovered 
groups. Following the 6MW exercise test there was a significant decrease in 
LVESD in both groups but more pronounced in the recovered HM II LVAD 
patients as compared to the recovered HM I LVAD patients.  
The rise in both FS and EF in each group following the 6MW exercise test was 
significantly higher as compared to the 15 minutes of ―low-speed / off-pump‖ 
testing (HM I: FS, 29.96 ± 7.13 % versus 28.20 ± 6.33%, p=0.009, EF, 64.30 ± 
11.18% versus 61.80 ± 10.79%, p=0.016; HM II , FS, 33.91 ± 4.46% versus 28.61 
± 4.13%, p<0.001, EF, 70.27 ± 5.99% versus 62.55 ± 6.24%, p<0.001). Although 
there were no differences in the absolute FS and EF values acquired following the 
6MW exercise test between the two recovered groups, the absolute increase in 
both FS and EF were higher in the recovered HM II LVAD patients as compared 
to the recovered HM I LVAD patients (FS: 5.29 ± 3.39% versus 1.76 ± 2.27%, 
and EF: 7.73 ± 4.37% versus 2.50 ± 3.55%). These values corresponded to a 
percentage rise in the FS by 18.50% in the recovered HM II LVAD group and 
6.26% in the recovered HM I LVAD group (p=0.004, figure 4.11). Also the 
absolute rise in the EF corresponded to a percentage increase in the EF by 12.35% 
in the HM II LVAD recovered patients as compared to a percentage rise of 4.04% 
in the recovered HM I LVAD patients (p=0.007, figure 4.11). These changes 
suggest that patients who recover on continuous flow LVAD may have 
enhanced CR as compared to those who recover on pulsatile LVADs despite 
the similarity in the LV function whilst the device’s input has been 
interrupted for 15 minutes. 
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Table 4.11: Differences in the echocardiographic parameters between the two 
recovered groups 
 
 
 
Assessment 
time-point 
Baseline 5Mins 15Mins Post 6MW 
p-value 
between 
15Mins and 
Post 6MW 
L
V
E
D
D
 
(m
m
) 
HM I 47.16 ± 9.67 53.85 ± 8.45 54.42 ± 8.67 54.18 ± 8.33 0.618 
HM II 44.92 ± 7.51 51.15 ± 6.37 51.24 ± 6.67 51.83 ± 7.20 0.463 
p-value 0.539 0.486 0.436 0.512  
L
V
E
S
D
 
(m
m
) 
HM I 31.56 ± 8.25 38.46 ± 8.57 39.41 ± 8.91 38.29 ± 8.69 0.046 
HM II 32.60 ± 6.89 36.93 ± 6.10 36.81 ± 6.20 34.42 ± 6.20 0.003 
p-value 0.805 0.838 0.567 0.325  
F
S
 (
%
) HM I 33.76 ± 5.30 29.29 ± 6.44 28.20 ± 6.33 29.96 ± 7.13 0.009 
HM II 28.17 ± 4.76 28.16 ± 4.06 28.61 ± 4.13 33.91 ± 4.46 <0.001 
p-value 0.004 0.595 0.806 0.116  
E
F
 (
%
 HM I 69.67 ± 7.18 63.47 ± 9.95 61.80 ± 10.79 64.30 ± 11.18 0.016 
HM II 61.36 ± 7.52 61.76 ± 6.47 62.55 ± 6.24 70.27 ± 5.99 <0.001 
p-value 0.003 0.486 0.713 0.137  
 
Table 4.11: Differences in the echocardiographic measurements between the 
recovered HM I (n=15) and the recovered HM II (n=15) LVAD patients. There 
were no intergroup differences between the two groups. Intra-group analysis, 
however, revealed that following the 6MW LVESD decreased significantly and 
both FS and EF increased significantly. 
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Figure 4.11: Differences in the percentage increase in FS and EF following 
the 6MW exercise test 
 
 
 
 
Fig 4.11: A comparison in the percentage increases in both FS and EF between 
the recovered HM I and the recovered HM II LVAD patients. The percentage rise 
in both parameters was significantly higher in the recovered HM II group as 
compared to the recovered HM I group. 
 
  
0
5
10
15
20
25
FS EF
P
er
ce
n
ta
g
e 
In
cr
ea
se
HM I
HM II
p=0.004 
p=0.007 
 251 
 
4.3.2.5  Differences in the 6MW distance between the HM I and the 
HM II LVAD patients 
The total distance walked by the HM I LVAD patients was significantly lower as 
compared to the HM II LVAD patients (491.03 ± 115.34 meters versus 571.96 ± 
101.05 meters, p=0.024). 
Similarly, the recovered HM II LVAD patients walked a longer distance walked a 
longer distance as compared to the recovered HM I LVAD patients (604.07 ± 
94.02 versus 535.52 ± 99.26) however, it did not reach the level of significance 
(p=0.081, figure 4.12). 
 
Figure 4.12: Difference in the distance walked between the recovered HMI 
and the the recovered HM II LVAD patients 
 
 
Figure 4.12: The total distance walked by the recovered HM II patients was 
higher than the recovered HM I LVAD patients.  
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4.3.2.6  Differences in the left ventricular structural and functional 
trends between the recovered HM I and the recovered HM II LVAD patients 
A multi-level time modelling was performed to determine the differences in the 
LV structural and functional trends between the recovered HM I and the 
recovered HM II LVAD patients over a 1 year period of support (see model 3 in 
Appendix B for details of the analysis).  
The model revealed that at 15 minutes of off-pump testing the intercepts of the 
LVEDD, LVESD, FS, and EF were poorer in the recovered HM II LVAD patients 
as compared to the recovered HM I LVAD patients, but not significantly (figure 
4.13A). However, over a 1-year period of support, FS and EF parameters would 
improve in both recovered groups but more so in the recovered HM II LVAD 
patients. This illustrated by better improvement in the slope values in the 
recovered HM II LVAD patients as compared to the recovered HM I LVAD 
patients over a 1-year period of support (FS: 16.34 versus 2.26, p=0.003; and EF: 
25.92 versus 4.46, p=0.005). In contrast, the trend in the LV dimensions in the 
recovered HM I LVAD patients tend to increase over a 1-year period of support as 
compared to the trend in the dimensions in the recovered HM II LVAD group 
(LVEDD: -7.06 versus 5.60, p=0.004; and LVESD: -14.19 versus 2.67, p<0.001). 
The model also revealed that following the 6MW exercise test the mean intercepts 
of both FS and EF were significantly better in the recovered HM II LVAD group 
as compared to the recovered HM I LVAD group but not statistically significant 
(figure 4.13B). Furthermore, the mean slopes were better in the recovered HM II 
LVAD patients as compared to the mean slopes of the recovered HM I LVAD 
patients but did not reach level of significance (FS: 10.74 versus 3.13, p=0.120; 
and EF: 13.25 versus 5.11, p=0.240). Therefore, this analysis concludes that the 
trends in the both FS and EF over a 1-year period of support tend to be better in 
the recovered HM II LVAD patients. Further, the analysis also suggests that the 
differences shown in the FS and EF (section 4.3.2.3) between the two recovered 
groups following the 6MW exercise test are not just differences in averaged 
measurements but differences in the trends over a period of time with better 
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outcome in the recovered HM II LVAD patients and that the CR tends to be more 
preserved in the recovered HM II LVAD patients. 
 
 
Figure 4.13A: Differences in the echocardiographic trends between the 
recovered HM I and HM II LVAD patients at 15 minutes of off-pump testing 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13A: Differences in the echocardiographic trends between the recovered 
HM I (      ) and the recovered HM II (     ) LVAD patients at 15 minutes of off-
pump testing.  
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Figure 4.13B: Differences in the echocardiographic trends between the 
recovered HM I and HM II LVAD patients following the 6MW exercise test 
 
 
 
 
 
  Figure 4.13B: Differences in the echocardiographic trends between the recovered 
HM I (      ) and the recovered HM II (        ) LVAD patients following the 6MW 
exercise test. 
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4.4  Discussion 
The main findings of the present study include the following:  
 HM II LVAD patients tolerated off-pump testing with no ill-side effects;  
 The 6MW exercise test is a safe and a useful tool that corresponds to day-
to-day activity and has a role in assessing the native LV function. The test 
was tolerated by 97-98% of the studied populations; 
 Following the 6MW exercise test, the HM II recovered patients exhibited 
a better haemodynamic and echocardiographic responses as compared to 
the non-recovered patients which could correspond to improvement in CR. 
In addition both EF and the percentage change in EF following the 6MW 
exercise test correlated strongly with myocardial recovery and may predict 
recovery; 
 The changes seen in the echocardiographic parameters are not due to data 
averaging but are trends that had occurred throughout the support period; 
 HM II LVAD patients had a better response to the 6MW exercise test than 
the HM I LVAD patients with better CR. Further, the recovered HM II 
patients have a higher response to exercise testing than the corresponding 
recovered HM I patients; 
 The walking distance was significantly higher in the recovered HM II 
LVAD patients as compared to the non-recovered HM II LVAD patients 
and also higher (but not significantly) than the recovered HM I LVAD 
patients. 
Assessment of the underlying LV function 
As has been previously described, the identification of the extent of myocardial 
recovery relies heavily on unmasking the underlying myocardial function. In 
chapter 3, the necessity for reducing the speed of the HM II LVAD was 
established as an approach to reveal the native LV function. By lowering the 
baseline speed to 6000 rpm, the contribution from the LVAD into the circulation 
was found to be minimal with no evidence of retrograde filling. Hence, LV filling 
following speed reduction was attributed to physiological loading rather than 
retrograde filling. In part one of this chapter, the clinical, peripheral 
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haemodynamic and echocardiographic responses in all 23 patients to both speed 
reduction and exercise were studied.   
Reducing the speed of the continuous flow HM II LVAD to 6000 rpm was 
performed after ensuring an INR of 2.0 and above and was tolerated by all 
patients on all 170 occasions. None of the patients had developed any signs of 
overt heart failure such as breathlessness, chest pain or discomfort. All patients 
were followed up for 72 hours Although none had reported thrombo-embolic or 
bleeding related complications the exact level of INR prior to speed reduction 
remains to be confirmed experimentally and clinically to ensure that patients are 
exposed to the least anticoagulation therapy (Amir O et al., 2005;Frazier OH et 
al., 2004a;Frazier OH et al., 2007). 
Unfortunately, the first assessment was not performed until patients were 
clinically stable (ESC, 2001), inotrope independent, started their phase I 
pharmacological therapy, and mobile. The first assessment was performed 4-6 
weeks after device implantation and hence immediate (i.e. 24-48 hours) and short-
term (i.2. 3-7 days) responses to device implantation and the effects on LV 
unloading could have not been assessed. In addition, none of the patients was 
exercised on the first assessment such that the first assessment was only confined 
to a 15 minutes of low-speed testing. This approach was taken for safety reasons 
and to ensure that patients could tolerate the 15-minutes of low-speed testing 
before the 6MW exercise test and that they are more rehabilitated in order to 
complete the 6MW exercise test. Out of the potential 147 exercise tests, the 6MW 
was tolerated on 144 occasions (98%). On 3 occasions, one patient developed 
shortness of breath within two minutes of the walk and the speed of the device had 
to be re-adjusted to his baseline speed. Previous groups have also reported 
successful toleration of speed reduction of the axial-flow Jarvik 2000 LVAD 
(Myers T et al., 2006). 
6MW exercise test to assess CR and response to exercise 
According to the American Thoracic Society guidelines, the 6MW exercise test 
evaluates the global and integrated responses of all systems involved during 
exercise, including the pulmonary and cardiovascular systems, systemic 
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circulation, blood, neuromuscular units, and muscle metabolism (ATS Statement: 
2002). In 1985, Guyatt et al were the first to report its use in patients with end-
stage HF (Guyatt GH et al., 1985) and since then it has been widely applied in 
clinical and research setting as a useful prognostic marker and a reliable test for 
the identification of effective interventions (Roul G et al., 1998;Sharma R & 
Anker SD, 2001;Bittner V et al., 1993;Rostagno C et al., 2003;Opasich C et al., 
2001;Cahalin LP et al., 1996;Schaufelberger M & Swedberg K, 1998;Olsson LG 
et al., 2005;Bittner V, 1999;Lucas C et al., 1999;Passantino A et al., 2006;Zugck 
C et al., 1998).  
Although, it is considered a submaximal test, we have used it in our LVAD 
patients as it has been shown to correspond to the demands of day-to-day 
activities, easier to accomplish by the patient, needs less operational power than 
other tests such as treadmill exercise, and not expensive (Bittner V et al., 
1993;Bittner V, 1997;Bittner V, 2003). In addition to calculating the distance 
walked this test was utilised in LVAD patients as means of assessing the cardiac 
response to exercise by repeating peripheral haemodynamic and 
echocardiographic assessments immediately after the test. The absolute changes in 
both FS and EF corresponded to the LV CR needed in normal day-to-day activity. 
Further, the percentage changes have also proven to be additional important 
indicators / predictors of myocardial recovery. 
Contractile reserve 
By definition, contractile reserve (also known as inotropic reserve) refers to the 
objective quantification of the LV contractility following either a pharmacological 
or physiological stress (Gudjonsson T & Rahko PS, 2002a). It is well established 
that CR is reduced in patients with ischaemic and non-ischaemic DCM (Nagaoka 
H et al., 1996). Mechanisms that would be responsible for this reduction include 
(Nagaoka H et al., 1996;Nagaoka H et al., 1996):  
1. Alteration in the autonomic nervous system;  
2. β-adrenergic pathway abnormalities;  
3. Defect in receptor adneylate cyclase coupling;  
4. Impaired exercise induced physiologic up-regulation of β-adrenoceptors;  
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5. Depletion of myocardial norepinephrine (NE). 
Studies have shown that CR abnormality had a strong correlation with abnormal 
cardiac sympathetic innervation (Ohshima S et al., 2005;Kobayashi M et al., 
2008) such that abnormal 
123
I-MIBG uptake (see Chapter 5 for the 
123
I-MIBG 
uptake in HM II LVAD patients study) was related to impaired myocardial CR in 
DCM patients (R=0.64, p<0.001).  
Different indices have been used to describe the contractile ability of the LV in 
response to pharmacological stress (dobutamine infusion). Examples of these 
indices include wall motion score index, ejection fraction, cardiac power output, 
end systolic pressure to volume ratio, maximal first derivative of LV pressure (LV 
dP/dtmax), and functional myocardial segments (Bax JJ et al., 2002;Chaudhry FA 
et al., 1999;Kobayashi M et al., 2008;Lim P et al., 2007;Otasevic P et al., 
2005;Szili-Torok T et al., 2005;Moonen M et al., 2008;Gudjonsson T & Rahko 
PS, 2002a). The most frequently used, however, is the absolute change in EF 
following dobutamine infusion (Bax JJ et al., 2002;Chaudhry FA et al., 
1999;Kobayashi M et al., 2008;Otasevic P et al., 2005;Ypenburg C et al., 2007) 
despite its inability to distinguish abnormalities in contractility from 
alterations in preload or afterload (Neskovic AN & Otasevic P, 2005). 
Conventionally, an absolute rise in the EF by 5% during dobutamine infusion as 
compared to resting was considered to be a positive indicator for the presence of 
CR with strong correlation to both prognosis and to different therapeutic 
approaches (Khan N et al., 2003;Nagaoka H et al., 1996;Nagaoka H et al., 
1997;Pratali L et al., 2007;Ypenburg C et al., 2007) 
In this study, dobutamine stress echocardiography (DSE) was not utilised as 
means for assessing CR as the presence of the LVAD in situ would distort the 
internal structure of the LV, hence rendering the pattern of LV wall motion and 
segmental viability obtained from DSE unreliable. Furthermore, assessment of the 
extent of myocardial recovery is a continuous and rigorous process that needs to 
be performed on regular basis and the use of DSE on 4-6 weekly basis would have 
been unethical, unacceptable by the patient, and would have required a consultant 
cardiologist performing the examination. The 6MW test on the other hand had 
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proven to be a reproducible and an inexpensive technique which can be performed 
serially in each patient in the out-patient clinic setting and was accepted by all 
patients. Similar to DSE technique, we have used an absolute increase in FS 
and EF following the 6MW by at least 5% as cut-off points to indicate 
preservation of CR. 
Effects of the HM II LVAD on peripheral haemodynamics, LV structure and 
function, and exercise tolerance (contractile reserve) 
In the entire HM II LVAD population immediate speed reduction resulted in a 
significant decrease in SBP, DBP and MAP, and a significant increase in PP. The 
rise in PP could be attributed to the profound drop noted in DBP immediately 
following speed reduction. Following the 6MW exercise test all peripheral 
haemodynamic parameters increased significantly as compared to measurements 
taken at 15 minutes of low-speed.  
Although, there was a significant increase in both LVEDD and LVESD at 5 
minutes following speed reduction, there was no difference in the ventricular FS 
and EF. Following the 6MW exercise test, there was a significant reduction in the 
LVESD as compared to the 15-minutes low speed measurements (43.45 ± 15.11 
mm versus 45.35 ± 14.33 mm, p=0.001). This drop may reflect the improved 
degree of unloading after exercise as a result of improved stroke volume. The 
reduction in the LVESD has also contributed to the absolute increase seen in both 
FS and EF (3.49 ± 3.70% and 5.25 ± 5.3%, respectively) which corresponded to a 
percentage change of 15.31 % and 10.20%, respectively (figure 4.2C). Until this 
point the rise in the EF has just fulfilled the cut-off point of CR but did not 
differentiate the degree of CR preserved between the recovered and the non-
recovered patients.  
Comparing the pre-implantation parameters between the recovered (n=15) and the 
non-recovered (n=8) patients (tables 2.3 and 4.2) revealed no significant 
differences in pre-implantation haemodynamics, LV function and biochemical 
profile. HF duration and pre-implantation LV dimensions were significantly better 
in the recovered patients as compared to the non-recovered patients. Further, a 
comparison between the two groups at the first assessment revealed no significant 
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differences in peripheral haemodynamics, the time point at which the first 
assessment was performed, the baseline speed, and the phase I therapy (table 4.3). 
Ventricular dimensions and function remained significantly better in the recovered 
group with no correlation with the speed of the device suggesting that the 
identified differences were not secondary to speed differences (in matter of fact 
the non-recovered group had a higher baseline speed as compared to the recovered 
patients: 9310 ± 280 rpm versus 9080 ± 250 rpm (p=0.110)).  
Following the 6MW exercise test, all peripheral haemodynamic measurements 
improved significantly in the recovered group, as compared to a lone rise in the 
HR in the non-recovered group. Interestingly the percentage rise in PP in the 
recovery group was significantly higher as compared to the percentage rise in the 
non-recovered group (17.23 % versus 4.27%, p=0.0028) which may reflect a 
higher stroke volume value in the recovered group. Unfortunately, stroke volume 
could have not been assessed non-invasively using Doppler as it consists of the 
volume travelling into the LVOT and the LVAD; the former could have not been 
quantified effectively. 
Both FS and EF increased in both groups following the 6MW exercise test. The 
absolute change, however, was significantly higher in the recovered as compared 
to the non-recovered group for both FS and EF (FS: 5.29 ± 3.39% versus 0.48 ± 
1.71%, p=0.001; and EF: 7.73 ± 4.37% versus 1.13 ± 4.20%, p=0.003). This 
absolute increase in EF in the recovered group was higher than the cut off point 
and corresponded to a 12.35% increase in the recovered group as compared to a 
3.42% in the non-recovered group. This could be interpreted as a significant 
improvement in cardiac sympathetic dysfunction since Ohshima et al elegantly 
correlated cardiac sympathetic dysfunction with abnormal CR in DCM patients 
(Ohshima S et al., 2005). See chapter 5 for the correlation between CR and MIBG 
uptake. 
To confirm that the changes seen in LV function following the 6MW exercise test 
were not due to averaging the data over the support period, a multi-level time 
modelling analysis was performed to determine the response over a 1-year support 
period. This revealed that the recovered group had a significantly higher slope 
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value for both FS and EF suggesting that CR preservation is a positive trend 
which is exhibited highly in the recovered patients as compared to the non-
recovered patients. Furthermore, the results also suggest that CR in the recovered 
patients predominates over the support period and hence it could have a 
prognostic value as well as being a predictor for recovery.  
No reliable morphological parameter has emerged to predict recovery whilst on 
LVAD support. In patients with the first generation pulsatile HM I LVAD, we 
have identified that only MAP of 60 mm Hg after the 6MW (p= 0.006, 
ROC=0.89, sensitivity 87.5%, specificity 83%) and EF of 53% after the 6MW 
(p=0.02, ROC=0.82, sensitivity 93%, specificity 80%) were the strongest 
predictors of recovery. In this study, linear correlation analysis revealed that all 
echocardiographic parameters exhibited a correlation with myocardial recovery; 
however, the strongest correlation was associated with the parameters examined 
following the 6MW exercise test. ROC analysis revealed that an absolute value 
for EF of 56.3% or more following the 6MW and a percentage rise in the EF by at 
least 8.3% (absolute rise by 5%) were independent strong predictors of 
myocardial recovery. Interestingly, this value corresponded to the cut-off of CR 
i.e. those who have preserved LV CR have a higher chance to recover. Finally, the 
recovered group walked a significantly longer walking distance as compared to 
the non-recovered group. 
Comparison between the effects of HM I and HM II LVAD on peripheral 
haemodynamics, LV structure and function, and the response to exercise 
In part two of the present study the differences in the LV response between the 
continuous flow HM II LVAD and the pulsatile flow HM I LVAD were assessed 
(the HM I LVAD group was independent from the main study group and was 
utilised only to compare the effects of different devices on peripheral 
haemodynamics, LV structure and function, and the response to exercise). 
Previously we have reported the effects of the pulsatile HM I LVAD and drug 
combination therapy on CR in non-ischaemic DCM patients (George RS et al., 
2006;George RS et al., 2007a;George RS et al., 2007b). The number of the 
recovered patients was similar between the two groups; 15 out of 23 (65.2%). In 
both groups off-pump testing was considered to be a safe and a reproducible 
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approach to unmask the native LV function in an outpatient clinic, such that speed 
reduction was tolerated in all 170 occasions in the HM II LVAD patients as 
compared to 98.7% of occasions in the HM I population (p=0.932). Similarly, the 
6MW exercise test was tolerated on 97% and 98% of occasions in the HM I and 
the HM II LVAD groups, respectively. 
Although the term non-pulsatile device has been considered a misnomer in 
defining continuous flow devices, in matter of fact it is an accurate term. Unlike 
the pulsatile devices, continuous flow devices do not generate pulsatile flow and 
the pulsatility that is being detected in the clinical setting is secondary to the 
underlying ventricular action which itself increases as the ventricle recovers 
(Thalmann M et al., 2005). Continuous-flow LVADs have certainly reduced 
morbidity and mortality due to easier and less traumatic surgical implantation and 
are associated with much longer durability due to their simpler design with only a 
single moving part, the internal rotor (Frazier OH et al., 2004a). However it has 
been felt their non-pulsatile pattern of flow may not be so effective for unloading 
for myocardial recovery.  
In goats, using long-term non-pulsatile left heart bypass, Nishimura et al 
investigated in detail the mechanical properties of the descending aortic wall 
relative to structural changes due to continuous flow (Nishimura T et al., 
1999b;Nishimura T et al., 1999a). The group showed that the wall was 
significantly thinner, and the volume ratio of smooth muscle cells was much 
lower, indicating morphologic, atrophic changes in the aorta. The effects on 
cerebral metabolism and cerebral blood flow was controversial with some groups 
suggesting no differences in carotid blood flow and cerebral blood flow 
autoregulation (Kashiwazaki S, 2000;Hindman B, 1994) whilst others showed 
significant detrimental effects on blood-brain flow, metabolism and autoregulation 
(Nishinaka T et al., 2000).  
Pulsatile-flow LVADs provide pulsatile blood flow patterns mimicking the 
normal physiologic blood circulation. Their use, however, has been associated 
with significant co-morbidity including the need for extensive surgery and 
frequent device related infections. Another restrictive factor is their limited long-
term durability and the increased incidence of device malfunction (Birks EJ et al., 
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2004a;Horton SC et al., 2004;Martin J et al., 2006). Despite the several design 
enhancements of the HM I TCI to the HM I XVE, durability at 2-years post-
implantation remains around 5% (Martin J et al., 2006).  
The purpose of part two was to assess whether there are any differences in the 
degree of LV unloading between pulsatile- and continuous-flow LVAD. Previous 
studies have shown that differences in LV unloading between the two types of 
devices as assessed by echocardiography were similar following six months or 
more of support (Drews T et al., 2008;Garcia S et al., 2008;Klotz S et al., 
2004;Haft J et al., 2007). Others have shown that pulsatile devices were superior 
to non-pulsatile devices in myocardial volume unloading and oxygen 
consumption / supply balance (Yu JJ et al., 2008)and in peripheral vascular 
reactivity (Amir O et al., 2006). 
The immediate peripheral haemodynamic responses to speed reduction in the HM 
I LVAD population were less significant as compared to the HM II LVAD 
population. This difference reflects the extent of support withdrawal in the HM II 
LVAD patients. The 6MW exercise test resulted in an absolute increase in both 
FS and EF in the HM I LVAD population by 1.06 ± 2.26% and 1.37 ± 4.24%, 
respectively. This rise was significantly lower as compared to the absolute rise 
seen in the HM II LVAD population. 
A direct comparison between the two recovered groups revealed that both 
absolute and percentage increase in both FS and EF were significantly higher in 
the HM II recovered LVAD patients as compared to the HM I recovered LVAD 
patients suggesting that CR was more abundant in the HM II recovered LVAD 
patients as compared to the HM I recovered LVAD patients. Also the 6MW 
exercise test distance was higher in the recovered HM II LVAD patients as 
compared to the recovered HM I LVAD patients but not significantly.  
Finally, the echocardiographic 1-year trends following device interruption and 
exercise testing were better in the HM II recovered patients. It could be argued 
that the improvement in unloading in the HM II population with time was related 
to an increase in the device speed. In all patients, however, the speed was mainly 
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adjusted within the first week of device implantation under echocardiographic 
assessment and rarely changed by much after that. 
Limitations 
The sample size of this study was relatively small. It is a non-randomised, 
observational, prospective, and single-centred study. Another major limitation of 
the present study was to calculate the EF from the cubed function formula of the 
ventricular dimensions. It was not possible to use Simpson‘s Biplane method at 
every assessment due to the architectural changes seen in the internal structure of 
the LV cavity an due to difficulties met in aligning the echo transducer at every 
assessment to acquire two appropriate planes to measure the EF. Another possible 
limitation was the use of the 6MW exercise test as a tool to assess CR. Although, 
the 6MW exercise test reflects day-to-day activity, reproducible at every clinic 
assessment, and acceptable by all patients it remains submaximal and there are no 
benchmark studies that have it to measure the CR. Further, the use of DSE would 
have been time-consuming, unethical, unacceptable by patients, and would have 
provided us with segmental viability (a non-required parameter in the assessment 
of the degree of myocardial recovery). A final limitation was the inability to 
assess the response of the myocardium to exercise sooner post-device 
implantation as this would have enabled us to correlate the response of the LV 
function to exercise with the different components of pharmacological therapy 
during the up-titration phase. 
Conclusion 
Off-pump testing is a safe approach in patients with continuous flow and pulsatile 
flow LVADs. The 6MW exercise test is also safe and a useful clinical tool that 
corresponds to day-to-day activity and has a role in assessing the underlying LV 
function and response to exercise, such that, recovered patients have exhibited 
better haemodynamic and echocardiographic responses as compared to the non-
recovered patients. The significantly enhanced EF following the 6MW could 
reflect better preservation of CR in recovered patients since it has correlated 
strongly with myocardial recovery and has proven to be a strong predictor for 
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myocardial recovery. Interestingly, patients with continuous flow LVADs had a 
better response to the 6MW exercise test as compared to those with the pulsatile 
device suggesting that the continuous flow LVADs and drug combination therapy 
result in better CR preservation and enhancement in the myocardial sympathetic 
nervous system which is significantly deranged in end-stage HF. The changes 
observed were not due to data averaging but were continuous trends that have 
occurred throughout the support period. Finally, recovered patients managed 
longer walking distances as compared to the non-recovered patients in both HM I 
and HM II LVAD populations with the recovered HM II patients managing a 
longer walking distance than the recovered HM I LVAD patients. 
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Chapter 5 - Mechanical LV unloading 
results in normalisation of the cardiac 
NET uptake mechanism 
  
 267 
 
5.1  Background 
As been described in chapter 1, patients with HF have increased activity in their 
sympathetic efferent neuronal activity leading to excessive exposure of the 
myocardium to norepinephrine (NE). Abundance of NE in the synapse leads to 
increased sympathetic drive which acts as a method of compensatory inotropic and 
chronotropic mechanisms (Eisenhofer G, 2001) explaining the initial phase of 
hypertension and tachycardia seen in the early stages of DCM. However, it has been 
clearly documented that long term exposure of the heart to NE contributes to the 
progression of CHF with the development of arrhythmias, down regulation of α- 
and β-AR, myocardial apoptosis and necrosis, tissue hypoxia, increased cardiac 
oxygen consumption and myocardial oxygen wastage, reduced coronary blood flow, 
and loss of CR (Fukuoka S et al., 1997;Gudjonsson T & Rahko PS, 2002b;Liang C, 
2003;Opie LH, 2002;Inoue H & Zipes DP, 1987;Udelson JE et al., 2002).  
In normal individuals 92% of the synaptic NE is removed from the synapse via 
norepinephrine transporter (NET) located at the presynaptic side. This percentage is 
reduced to 85% in DCM patients due to a reduction of NET uptake sites (Böhm M 
et al., 1995). Backs et al demonstrated that reduction of NET binding sites is neither 
mediated by a decreased NET gene expression nor by a loss of noradrenergic nerve 
terminals, however, a posttranscriptional downregulation of NET per neuron is 
postulated (Backs J et al., 2001).  
5.1.1  Norepinephrine Transporter 
The main role of NET is to limit the action of NE through reuptake into the 
cytoplasm (Mandela P & Ordway GA, 2006). NET is a Na
+
/Cl
-
 dependent 
transporter (Kitayama S & Dohi T, 2003) with 12-hydrophobic transmembrane 
domains ((Brüss M et al., 1995) - figure 5.1). The electrochemical gradient derived 
from the inward gradient of Na
+
 drives the intracellular accumulation of NE via 
NET. The function of NET can be selectively blocked by the Na
+
/Cl
- 
dependent 
binding of drugs such as desipramine (Liang C, 2007). 
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Figure 5.1: Topological structure of NET 
 
 
Fig 5.1: Topological structure of NET depicting 3 N-glycosylation sites on the 
second extracellular loop. From (Stober G et al., 1996). 
The gene encoding NET (SLC6A2) is located on the long arm of chromosome 16 
(locus 16q12.2) and consists of 15 exons spanning 45 kilobases (Stober G et al., 
1996;Uhl GR & Johnson PS, 1994;Bauman PA & Blakely RD, 2002).  
NET consists of 617 amino acids with both amino- and carboxy- terminals being 
located intracellularly. The first 5 trans-membrane domains  of the amino-terminal 
have been shown to be involved primarily in general uptake mechanisms and are 
well conserved in the Na
+
/Cl
-
 dependent transport family (Wang Y et al., 1999). 
The large second extracellular loop has three sites for N-linked glycosylation 
which have shown to be important for  synthesis, physical maturation, surface 
targeting and trafficking, protein stability, transport activity, and cell surface 
expression of NET (Stober G et al., 1996;Blakely RD et al., 1994;Eisenhofer G, 
2001;Kanner BI, 1994;Melikian H et al., 1994;Melikian H et al., 1996;Meyer J et 
al., 1998;Nguyen T & Amara S, 1996;Zahinser NR & Doolen S, 2001;Nelson N, 
1994;Hahn MK et al., 2005).  
Several intracellular signalling cascades regulate NET‘s activity such as PKC, 
cAMP/PKA, cGMP, and dephosphorylation (figure 5.2) (Mandela P & Ordway GA, 
2006;Torres GE et al., 2003;Apparsundaram S et al., 1998a;Apparsundaram S et al., 
1998b). 
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Figure 5.2: Trafficking mechanisms associated with NET 
 
Fig 5.2: Schematic representation of the trafficking mechanisms associated with 
NET. After being synthesised, NET is delivered to the cell surface. Activation of 
PKC induces the phosphorylation and internalisation of NET. Adapted from 
(Torres GE et al., 2003). 
5.1.3  Assessment of NET activity 
Cardiac NET activity can be assessed non-invasively using either single photon 
emission tomography (SPECT) or positron emitting tomography (PET). It is well 
recognised that PET imaging provides better spatial resolution and has superior 
quantification accuracy as compared to SPET imaging (Langer O & Halldin C, 
2002). SPECT, however, is widely available, cheaper, and has been extensively 
used over the years as a diagnostic and research tool (Mariani G et al., 
2008;Flotats A & Carrio I, 2004). 
First described in 1980 (Wieland DM et al., 1980) metaiodobenzylguanidine 
(MIBG), a SPECT tracer, is an analogue of the false neurotransmitter 
guanethidine with a molecular structure similar to NE (figure 5.3). MIBG does not 
undergo intracellular metabolism (Sisson JC et al., 1987) and when tagged with 
radiolabelled 123-Iodine, MIBG can be used to image NET in the heart with 
conventional planar techniques (Flotats A & Carrio I, 2004). 
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Figure 5.3: Chemical structure of MIBG 
 
Fig 5.3: Chemical structure of NE (left) and MIBG (right). Adapted from (Flotats 
A & Carrio I, 2004). 
Cardiac 
123
I-MIBG uptake assessment is performed on two stages: at 15 minutes 
(early) and at 4 hours (delayed) after injecting 
123
I-MIBG. A region of interest 
(ROI) is drawn on the heart and the upper mediastinum and the heart-to-
mediastinum (H/M) ratio, the ratio of the count density in the LV (specific 
activity) to that in the upper mediastinum (non-specific activity), is calculated. 
The H/M ratio represent a quantitative index of 
123
I-MIBG cardiac uptake and, 
consequently, cardiac sympathetic function (Patel A & Iskandarian A, 2002). The 
early H/M ratio (derived from 15 minutes image) reflects the integrity of 
presynaptic nerve terminals and NET function. The delayed H/M ratio (derived 
from 4 hours image) combines information on neuronal function from uptake to 
release through the storage vesicles at the nerve terminals. The washout rate 
(W/O) is an index of the degree of sympathetic drives and is calculated as the 
difference in H/M ratio between the early and delayed H/M ratios with respect to 
the early H/M ratio. An increased sympathetic activity is associated with high 
myocardial 
123
I-MIBG W/O and low myocardial 
123
I-MIBG delayed uptake 
(Agostini D et al., 2009a). Normal values for both H/M ratio and W/O rate are 2.0 
± 0.3 and more and 20 ± 10% and less, respectively (Patel A & Iskandarian A, 
2002). 
In DCM patients, 
123
I-MIBG uptake is reduced in proportion to the degree of HF 
irrespective of its aetiology (Allman KC & Lahiri A, 2002;Carrio I, 
2001;Fujimoto S et al., 2004;Imamura Y et al., 1995;Merlet P et al., 
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1999b;Somsen GA et al., 1995). Previous studies have correlated MIBG uptake 
with NYHA functional class (Glowniak JV et al., 1989;Imamura Y et al., 
1995;Schofer J et al., 1988), LV EF (Lotze U et al., 1999;Merlet P et al., 
1999a;Merlet P et al., 1999b), and maximal oxygen consumption and maximal 
exercise duration (de Milliano PA et al., 2001). Others have shown that an 
abnormal H/M ratio is an independent predictor of death in DCM patients and is 
more accurate than other predictors such as LV size, functional class, and NE 
content (Merlet P et al., 1992;Merlet P et al., 1999a). 
123
I-MIBG imaging has been shown to provide in-vivo information regarding the 
potential and actual benefits of different therapies (Nakata T et al., 2005) and 
hence can be a very useful imaging tool such that 
123
I-MIBG imaging: 
1) Predicted which patients with HF were likely to show the most 
improvement in LV function and exercise capacity following β-blocker 
treatment (Choi JY et al., 2001;Fukuoka S et al., 1997;Gerson MC et al., 
2002;Lotze U et al., 2001;Suwa M et al., 1997;Toyama T et al., 
1999;Yamazaki J et al., 2001;Agostini D et al., 2000;Cohen-Solal A et al., 
2005;de Milliano PAR et al., 2002;Fujimoto S et al., 2005;Kakuchi H et 
al., 1999;Toyama T et al., 2003). 
2) Assessed the degree of improvement of the cardiac sympathetic neuronal 
uptake function following ACE-I (Somsen GA et al., 1996c;Soeki T et al., 
1998;Kasama S et al., 2005b;Nakata T et al., 2005;Takeishi Y et al., 
1997). 
3) Illustrated the benefits of AngII receptor antagonist use in DCM patients 
(Kasama S et al., 2005a;Kasama S et al., 2003a;Kasama S et al., 
2006;Shinohara H et al., 2002).. 
4) Demonstrated that DCM patients treated with spironolactone had evidence 
of LV reverse remodelling (Kasama S et al., 2003b;Kasama S et al., 
2002;Kasama S et al., 2007b). 
5) Revealed that patients who respond to cardiac resynchronisation therapy 
(CRT) had better uptake and significantly enhanced sympathetic response 
(Burri H et al., 2008;Cha YM et al., 2008;Erol-Yilmaz A et al., 
2005;Nishioka SA et al., 2007). 
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The use of 
123
I-MIBG to determine the response of the heart‘s sympathetic 
innervation after LVAD implantation, however, had not yet been effectively 
studied to-date. 
5.1.4  Hypothesis and aims of 
123
I-MIBG Scintigraphic 
Study 
Hypothesis 
The use of LVAD and drug combination would lead to improved sympathetic 
function as assessed by cardiac 
123
I-MIBG imaging and that this improvement 
would correlate with CR as evidenced by echocardiography. 
Aims 
The main aims of the present study were therefore to investigate the effects of 
LVAD and drug combination therapy on 
123
I-MIBG uptake and to correlate 
123
I-
MIBG uptake to CR. 
Objectives 
1) Validate MIBG imaging in our hands in patients with LVAD after using a 
modified ROI over the heart that accounts for the inflow cannula positioned in 
the LV apex. 
2) Determine the intra- and inter-observer reliability.  
3) Assess early and delayed H/M ratios and W/O rate serially in patients: 
a. Immediately post LVAD implantation, 
b. Immediately pre-LVAD explanation for myocardial recovery or prior 
to listing for transplantation, 
c. Post LVAD explantation. 
4) Correlate 123I-MIBG uptake parameters to CR in LVAD patients. 
5) Investigate whether the changes seen in serial MIBG uptake in LVAD patients 
is secondary to a reduction in the LV size or solely due to alteration in the 
uptake mechanism itself. 
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5.2   Methods  
5.2.1  Study Population 
The study was approved by the ethics committee at the Royal Brompton and 
Harefield NHS Foundation Trust (Protocol Number 06/Q0404/20). All patients 
provided written informed consent. 
123
I-MIBG scintigraphy was studied serially in 14 out of the 23 patients. Here are 
the studied patients: 4, 7, 8, 10, 11, 12, 14, 16, 17, 18, 19, 21, 22, 23. Reasons for 
excluding 9 patients are included in table 5.1.  
Table 5.1: Patients excluded from the MIBG imaging study (n=10) 
Patient 
Number 
Reason for exclusion 
1 Explanted prior to commencing MIBG imaging study 
 
2 
Had already started phase II pharmacological therapy (clenbuterol) 
when MIBG imaging was commenced on LVAD patients 
‡
 
 
3, 5, 6, 13, 15 
 
Refused to take part in the study 
 
9, 20 
Diabetes Mellitus – studies have shown that diabetic patients have 
evidence of significant reduction in MIBG uptake due to autonomic 
dysfunction (Langer A et al., 1995;Uehara A et al., 1999;Kiyono Y et 
al., 2005) and sympathetic dysinnervation (Stevens MJ et al., 1998) 
despite normal contractile reserve (Scognamiglio R et al., 1998) 
 
Table 5.1: Reasons for excluding 9 patients from MIBG imaging study. 
 
‡
Although, MIBG study was approved by the RBH Ethics Committee in 
September 2006, it took nine months to validate the technique on HF and explant 
patients, the use of collimators and ensure its safety. The first MIBG scan to be 
performed on an LVAD patient was in June 2007. Patient 2 had already started the 
phase II pharmacological therapy, including clenbuterol, and therefore it was felt 
he should be excluded from the study. 
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5.2.2  Patient preparation 
123
I-MIBG imaging was performed serially in each of the 14 patient at two time 
points: 
i) early post- device implantation i.e. once patients were stabilised, 
their inotropic support been discontinued for at least 5 days, and 
their mobility has been restored (Scan 1); and  
ii) immediately prior to either device explantation for myocardial 
recovery or transplant listing for failure to recover (Scan 2). 
In 4 recovered patients who had their HM II LVAD explanted for recovery a repeat 
scan after at least 12 months following device explantation was performed. 
All patients were asked to fast and refrain from drinking caffeine products for at 
least 24 hours before the scan.  
5.2.3  Imaging Protocol 
An 18F sized cannula was inserted in the anti-cubital fossa at least 75 minutes 
before imaging. The cannula was used to collect blood for NE, epinephrine, and 
dopamine levels after at least 45 minutes of supine rest in a quiet room. See 
chapter 7 for liquid chromatography mass spectrometry analysis technique for 
these catecholamine levels.  
One hour after thyroid blockade with 400mg of potassium perchlorate, 425.92 ± 
18.80 Mega-Becquerel (MBq, range 379 - 469 MBq) of 
123
I-MIBG was 
intravenously injected through the pre-sited cannula.  
Imaging was performed with a Philips Forte dual-headed gamma camera and 
processed using a Philips Pegasys workstation. Planar anterior images were 
acquired at 15 minutes and at 4 hours post 
123
I-MIBG injection using the following 
parameters: 256 x 256 x 16 matrix and 900 seconds acquisition time. All images 
were stored in a departmental computer. 
Use of medium energy collimator: 123-I emits 159 keV photopeak photons as 
well as multiple low-abundance, high-energy 529 keV photons. The latter can 
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penetrate the collimator septa and cause scatter detected in the 159-keV energy 
window. Septal penetration affects estimation of the H/M ratio if low-energy 
collimator was used; hence, we have used medium energy collimators to provide 
better quantitative accuracy (Inoue Y et al., 2003;Verberne HJ et al., 
2005;Verberne HJ et al., 2009b). 
Use of dual energy windows: Compton window subtraction is a widely used 
method of compensation for scatter (Jaszczak RJ et al., 1984;Chen J et al., 
2006b;Chen J et al., 2006a) and is based on rectangular approximation (Matsuo S 
et al., 2009). In this study 
123
I dual energy windows were used to correct for 
scatter. The first window was 20% wide and was centred over the 159-keV 
window which represents the lower energy window whereas the second window 
was 19% wide and was centred over the 194-keV photopeak to represent the 
scatter energy window (Chen J et al., 2006b;Inoue Y et al., 2003;Kobayashi H et 
al., 2003;Nakajima K et al., 2007).  The principle of scatter correction is shown in 
figure 5.4 and an example of the effects of scatter correction is depicted in figure 
5.5. 
Figure 5.4: The use 
123
I-dual energy windows to correct for scatter 
Fig 5.4: The principle of the 
123
I dual-window method. 
E159, Energy window for 159-
keV imaging; W159, width of 
E159; C159, total counts 
within E159; Eup, upper 
energy window to estimate the 
529-keV downscatter into 
E159; Wup, width of Eup; Cup, total counts within Eup; Cscat529, estimated 
counts of the 529-keV downscatter into E159, which is calculated as k × 
W159/Wup × Cup. k is the estimated weighting value. Finally, corrected data are 
obtained by subtracting Cscat529 from C159. From (Yamashina S & Yamazaki J, 
2004). 
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Figure 5.5: Effects of dual energy window scatter correction 
 
 
 
 
 
Fig 5.5: Effect of improvement of imaging by the dual energy window method in 
our hands. MIBG planar scan of the same patient. Conventional method (left) and 
after scatter correction method (right). 
  
5.2.3.1  Heart / Mediastinum ratio calculations 
123
I- MIBG uptake is calculated as the ratio between the total number of counts 
per pixel of the ROI drawn over the heart and the total number of counts per pixel 
of a ROI drawn in the mediastinum. Definition of the heart ROI is operator 
dependent and previous studies have illustrated the importance of rigorous and 
uniform quantification to minimise inter- and intra-individual variations (Agostini 
D et al., 2009b).  
In DCM patients the ROI is drawn over the entire myocardium as illustrated in 
figure 5.6. The presence of the inflow cannula in the LV, however, poses a major 
challenge on how to define the heart‘s ROI and its accuracy.  
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Figure 5.6: An example of 
123
I-MIBG imaging in DCM patient 
 
 
 
 
Fig 5.6: A) A typical MIBG imaging with a region of interest drawn over the 
heart in a DCM patient. B) A chest X-ray of a 17-years old male with a HM II 
LVAD in-situ. The presence of the inflow cannula inside the LV creates a major 
challenge on how to define the heart contour to manually draw the ROI. 
 
In the LVAD patients, we have used a modified region of interest over the heart 
(ROIh) which excludes the inflow cannula of the device. A 1 cm
2
 rectangular ROI 
was drawn over the mediastinum (ROIm). Both regions of interest were drawn in 
both lower energy and scattered windows. To determine the exact position of the 
inflow cannula within the myocardium, a 64-slice reconstructive CT scan or a 
chest X-ray was performed within 2-3 days of the nuclear scan and the position of 
the inflow cannula was superimposed over the MIBG planar images (figure 5.7).  
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Figure 5.7: Identifying the Heart ROI in LVAD patient 
 
 
 
 
 
Fig 5.7: A) A 64-Slice reconstructed CT-scan illustrating the position of the 
inflow cannula within the LV apex. B) A schematic diagram showing the ROI on 
the anterior planar image; the ROI drawn over the heart (H) is adjusted to exclude 
the LVAD which is placed apically. M represents the ROI in the upper 
mediastinum. 
  
After drawing both ROIh and ROIm, scatter correction was performed to correct for 
the high-energy photopeaks (as discussed earlier). The corrected scatter counts for 
both ROIs were determined using the following equation: 
 Corrected Counts scatter = Counts scatter x k             (equation 5.1) 
Where, Countsscatter were obtained from the scatter-energy window, and k is a 
coefficient which is equivalent to ( 
31.8
/36.9 )and represents the difference in the 
width of the two energy windows used. 
 
H 
M B) A) 
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The final corrected counts for both heart and mediastinum were calculated as the 
counts being obtained from the lower energy window (159 keV) minus the 
calculated scattered counts (equation 5.2 and 5.3, respectively).  
 
Corrected Counts for Heart: 
 Corrected counts Heart = Counts 159KeV – Corrected Counts scatter 
            (equation 5.2) 
Corrected Counts for Mediastinum: 
Corrected counts Med = Counts 159KeV – Corrected Counts scatter 
         (equation 5.3) 
The final corrected counts were divided by the number of pixels represented within 
each ROI to provide the counts per pixel for both heart and mediastinum 
(equations 5.4 and 5.6). 
 
Counts per pixel for Heart: 
  
 H = (Corrected Counts Heart) / Number of Pixels ROIh  
         (equation 5.4) 
 
Counts per pixel for mediastinum:  
  
 M = (Corrected Counts Mediastinum) / Number of Pixels ROIm  
              (equation 5.5) 
 
Early H/M (15 minutes) and delayed H/M (4 hours) activity ratios were then 
calculated. A high H/M ratio indicates predominant localisation of 
123
I-MIBG in 
the myocardium (Patel A & Iskandarian A, 2002). In normal hearts a ratio of 2.0 ± 
0.3 and above is considered to be normal (Camacho V & Carrio I, 2007;Patel A & 
Iskandarian A, 2002). 
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5.2.3.2  Washout Rate calculations 
W/O rate was calculated after taking iodine decay into consideration using the 
following equation (Ogita H et al., 2001): 
 
Washout Rate (W/O) =    x 100 
     
           (equation 5.6) 
 
Where, H and M are the mean counts per pixel in the heart and mediastinal ROI 
acquired from equations 5.4 and 5.5, respectively. H1 and M1 refer to the counts 
per pixel at 15 minutes (i.e. early images), whereas, H2 and M2 refer to the counts 
per pixel at 4 hours (i.e. delayed images). t1 and t2 are the times from tracer 
injection to early and delayed acquisition such that t1 refers to 15 minutes and t2 
refers to 4 hours, and T is the half life of 123-Iodine (13.3 hours). 
 
 
W/O rate determines the rate of decrease in myocardial MIBG counts over time 
such that a low W/O rate reflects reduced adrenergic activity and tone (Gao DW 
et al., 2001). A W/O rate of less than 20 ± 10 % and less is considered to be 
normal (Camacho V & Carrio I, 2007;Patel A & Iskandarian A, 2002). 
 
All images were analysed by two observers for inter-observer reproducibility. 
Each observer repeated the analysis at least 6 weeks from the initial analysis to 
determine the intra-observer reproducibility. 
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5.2.4  Validation of the modified region of interest 
To validate the modified ROI, MIBG imaging was performed in 13 HF patients 
without the LVAD. The conventional ROI was drawn over the entire myocardium 
and the H/M ratios and W/O rate were calculated as described above. The 
modified ROI was then drawn on each scan missing off the apes and the H/M 
ratios and W/O rate were recalculated (figure 5.8). A comparison between the 
MIBG measured parameters derived from using the conventional and the 
modified ROI was performed. 
Figure 5.8: Validation of the modified ROI 
 
Figure 5.8: A) Conventional ROI drawn over the myocardium; B) modified ROI 
drawn over the heart missing off the apex to account for the LVAD inflow 
cannula in a heart failure without an LVAD. 
 
5.2.5  Correlation with LV function and CR 
To correlate MIBG uptake measurements to CR, all 14 had an echocardiographic 
assessment within 1 week of MIBG imaging. Echocardiographic assessment 
protocol was discussed in details in chapter 4. In summary, assessments were 
performed by one senior echocardiographer and all measurements were acquired 
in M-Mode. From the parasternal long axis of the LV at the level of chordal-mitral 
valve junction, both LVEDD and LVESD were obtained at the onset of the QRS 
complex and at either the peak of posterior wall motion or the nadir of septal 
motion, respectively. FS was calculated as the percentage change in the LV cavity 
dimensions with systole and EF was calculated using the cubed function formula 
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of the ventricular dimensions. Correlation between echocardiographic parameters 
and MIBG uptake parameters acquired at both scan 1 and scan 2 was performed. 
CR was assessed following the 6MW exercise test whilst the speed of the HM II 
LVAD was running at 6000 rpm (i.e. low speed). CR was defined as the 
percentage difference between EF obtained after the 6MW and after reducing the 
speed of the HM II LVAD to 6000 rpm for 15 minutes (see chapter 4 for more 
details). Correlation between CR and MIBG uptake parameters derived from scan 
2 was performed. 
5.2.6  The effects of LV size on MIBG uptake 
To investigate whether the serial changes in MIBG uptake in LVAD patients is 
secondary to reduction in LV size or solely due to alteration in the uptake 
mechanism itself the derived measurements at scan 2 were normalised against the 
size of the ROI. Such that the total counts from the ROIh in scan 2 were divided 
by the number of pixels in the ROI in the first scan. The counts per pixel were re-
calculated. Comparison between the H/M ratios derived from this approach and 
the H/M ratio from scan 1 was made. 
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5.2.7  Data Collection and Statistical Analysis 
All data are presented as mean ± stdev and were collected prospectively. Data 
analysis was done using SPSS, version 16.0 for Windows, created by Lead 
Technologies. To validate the use of the modified ROI, t-test statistical tool and 
Bland-Altman plots were used to assess the extent of agreement between the 
conventional ROIc drawn over the entire heart and the modified ROIh in the 13 HF 
patients (Bland JM & Altman DG, 1986;Bland JM & Altman DG, 1995). Intra-
observer and inter-observer reproducibility of data measurement were also 
assessed using Bland-Altman plots.  
As the derived H/M ratios and W/O rate in scans 1 and 2 were normally 
distributed, paired sample Student‘s t-test was used to determine the differences in 
the 
123
I-MIBG measured parameters (continuous variables) between the first and 
the second scan. Unpaired t-test was used to compare MIBG parameters between 
the recovered and the non-recovered subgroups.  
To correlate the degree of change between 
123
I-MIBG scintigraphic findings and 
CR linear regression analysis was performed using the percentage change in EF 
following the 6MW exercise test as a dependent parameter and the H/M ratios and 
the W/O rate as independent parameters. Linear regression analysis was also used 
to correlate between the changes in the echocardiographic parameters and the 
changes in the 
123
I-MIBG scintigraphic findings with the echocardiographic 
changes as the dependent factors. p < 0.05 was considered statistically significant. 
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5.3  Results 
Demographics and pre-implantation data of the 14 studied LVAD patients are 
presented in table 5.2. Out of these, 10 had recovered and were explanted. The 
remaining four patients were transplant listed. 
Table 5.2: Demographics of the studied patients (n=14) 
Parameter Value 
Age at HM II implantation (years) 
BMI (kg/m
2
) 
Duration of Heart Failure (months) 
Average number of pre-implant inotropes per patient 
Pre-implantation Echo 
LVEDD (mm) 
LVESD (mm) 
FS (%) 
EF (%) 
Pre-implantation Haemodynamics 
Mean Pulmonary Artery Pressure (mmHg) 
Mean Pulmonary Capillary Wedge Pressure (mmHg) 
Cardiac Output (l/min) 
Cardiac Index (l/min/m
2
) 
33.72 ± 14.58 
23.51 ± 3.24 
19.3 ± 24.59 
1.93 ± 0.27 
 
73.21 ± 9.78 
67.29 ± 8.96 
7.99 ± 4.51 
21.59 ± 10.89 
 
35.8 ± 4.94 
28.2 ± 3.85 
2.75 ± 0.73 
1.46 ± 0.46 
 
Table 5.2: Pre-implantation demographics of the 14 studied patients. 
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A list of medication taken at scan 1 and scan 2 are included in table 5.3. At the 
time of the first 
123
I-MIBG imaging all patients had already commenced on small 
doses of anti-failure medication. Carvedilol was administered in all 14 patients. 
Lisinopril was taken by 12 patients. Those who did not tolerate lisinopril were 
started on losartan instead. At the time of the second scan, anti-failure medication 
was maximal and the 10 recovered patients were on the β2-agonsit, clenbuterol, 
after switching carvedilol to bisoprolol. The remaining 4 were considered non-
recovered but eligible for transplantation and none were started on clenbuterol. 
Table 5.3: Medication list 
MIBG Drug 
Number of 
Patients 
Dose 
S
ca
n
 1
 
Carvedilol (mg) 14 12.1 ± 3.8 
Lisinopril (mg) 12 11.9 ± 4.1 
Losartan 2 87.5 ± 17.7 
Spironolactone (mg) 14 25 
Digoxin (mcg) 14 125 
S
ca
n
 2
 
Carvedilol (mg) 4 28.1 ± 6.25 
Bisoprolol (mg) 10 9.75 ± 2.5 
Lisinopril (mg) 13 31.35 ± 13.8 
Losartan (mg) 7 75 ± 35 
Clenbuterol (mcg) 10 1362 ± 807 
Spironolactone (mg) 14 125 
Digoxin (mcg) 14 25 
 
Table 5.3: Medications taken at the two MIBG imaging scan time points 
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5.3.1  Validation of the modified region of interest 
As described in the methods section, the use of the modified ROI was validated in 
13 heart failure patients without LVAD. The derived H/M ratios and W/O rate 
were calculated twice using a conventional ROI and the modified ROI (figure 
5.8).  
t-test analysis revealed no significant differences in the derived parameters 
between the different ROIs (figure 5.9). Early H/M ratio 2.49 ± 0.47 versus 2.58 ± 
0.50, p=0.638; Delayed H/M ratio 2.43 ± 0.75 versus 2.52 ± 0.76, p=0.777; W/O 
rate 32.00 ± 22.35% versus 31.80 ± 21.69%, p=0.981. 
Figure 5.10 represents Bland-Altman plots of H/M ratios and W/O derived from 
the conventional and the modified ROIs. There was an excellent limit of 
agreement between the two different regions. 
From both t-test analysis and the Bland-Altman plots it can be concluded that 
missing off the apex makes no difference to the overall H/M ratios and the W/O 
rate. 
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Figure 5.9: Validation of the modified ROI using t-test analysis 
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Fig 5.9: There was no significant difference in the H/M 
ratios and W/O rate between the conventional and the 
modified ROI. Early H/M ratio 2.49 ± 0.47 versus 2.58 ± 
0.50, p=0.638; Delayed H/M ratio 2.43 ± 0.75 versus 2.52 ± 
0.76, p=0.777; W/O rate 32.00 ± 22.35% versus 31.80 ± 
21.69%, p=0.981. 
Conventional ROI Modified ROI Conventional ROI Modified ROI 
Conventional ROI Modified ROI 
p=0.638 p=0.777 
p=0.981 
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Figure 5.10: Validation of the modified ROI using Bland-Altman analysis 
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Fig 5.10: Bland-Altman plots determining the validity of 
the modified region of interest. For early H/M ratio (open 
rhombus), delayed H/M ratio (open triangles), and washout 
rate (open circles), the limits of agreement were 0.23, 0.22, 
and 3.38, respectively, suggesting excellent agreement 
between the two different techniques and hence missing off 
the apex does not affect the validity of using the modified 
ROI in the LVAD patients. 
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5.3.2   Intra-observer reproducibility 
Figures 5.11 and 5.12 represent Bland-Altman plots for all MIBG parameters for 
observer 1 and observer 2, respectively. 
For observer 1, the limits of agreement for early H/M ratio, delayed H/M ratio and 
W/O rate were 0.28, 0.29 and 18.19, respectively. 26 out of the 28 (92.86%) early and 
delayed H/M ratio measurements fell within the early and delayed H/M ratio limits of 
agreement, respectively. With regards of the W/O rate reproducibility, 27 out of the 
28 of the measurements (96.43%) fell within the limits of agreement. 
Similarly for observer 2, the limits of agreement for early H/M ratio, delayed H/M 
ratio and W/O rate were 0.33, 0.29 and 19.70, respectively. 26 out of the 28 (92.86%) 
early and delayed H/M ratio measurements fell within the early and delayed H/M 
ratio limits of agreement, respectively. 27 out of the 28 W/O rate measurements 
(96.43%) fell within the limits of agreement for the W/O rate. 
In summary there was a strong intra-observer reproducibility of measurements for 
each of the observers 1 and 2.  
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Figure 5.11: Bland-Altman plots of MIBG parameters for observer 1 
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Fig 5.11: Bland-Altman plots determining the intra-observer 
reproducibility of measurements for observer 1. There was 
excellent level of agreement between the first and the 
second measurements for observer 1 with 92.86% of early 
and delayed H/M ratio measurements and 96.43% of W/O 
rate measurements falling within the limits of agreement. 
Mean + 2SD = 16.16 
Mean - 2SD = -10.44 
Mean = 2.86 
Mean + 2SD = 0.31 
Mean - 2SD = -2.5 
Mean = 0.03 
Mean + 2SD = 0.25 
Mean - 2SD = -0.33 
Mean = -0.04 
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Figure 5.12: Bland-Altman plots of MIBG parameters for observer 2 
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Fig 5.12: Bland-Altman plots determining the intra-
observer reproducibility of measurements for observer 2. 
Similar t observer 1, there was excellent level of agreement 
between the first and the second measurements for observer 
2 with 92.86% of early and delayed H/M ratio 
measurements and 96.43% of W/O rate measurements 
falling within the limits of agreement. 
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5.3.3   Inter-observer reproducibility 
Figure 5.13 represents a Bland-Altman plot for all MIBG measured parameters 
between observer 1 and observer 2. 
Inter-observer analysis revealed that the limits of agreement for early H/M ratio, 
delayed H/M ratio and W/O rate were 0.35, 0.32 and 16.47, respectively. 26 out of 
the 28 (92.86%) early H/M ratio measurements and 27 out of the 28 (96.43%) 
delayed H/M ratio measurements fell within the early and delayed H/M ratio limits of 
agreement, respectively. For the W/O rate 26 out of the 28 of the measurements 
(92.86%) fell within the limits of agreement. 
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Figure 5.13: Scatter plot of MIBG parameters between observer 1 and observer 2 
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observer reproducibility of measurements between 
observers 1 and 2. There was excellent level of agreement 
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H/M ratio, 96% of delayed H/M ratio, and 93% of W/O rate 
measurements falling within the limits of agreement. 
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5.3.4   Effects of LVAD and drug combination therapy on 
MIBG uptake 
The first MIBG imaging scan was performed early post device implantation at 35.21 
± 20.37 days. The second scan was performed at 242.57 ± 82.25 days post 
implantation resulting in time difference between the two scans of 208.43 ± 85.50 
days. 
Figures 5.14, 5.15 and 5.16 represent the effects of LVAD and drug combination 
therapy on each of both early and delayed H/M MIBG activity and the washout rate. 
There was a significant increase in the mean early H/M and the mean delayed H/M 
ratios by 0.65 ± 0.29 (1.56 ± 0.29 versus 2.21 ± 0.30, a rise by 42.1%, p<0.001) and 
by 0.80 ± 0.31 (1.46 ± 0.33 versus 2.25 ± 0.43, a rise by 54.7%, p<0.001), 
respectively. The mean washout rate decreased significantly from 46.96 ± 22.92% to 
27.04 ± 16.71% (a reduction by 42.4% reduction, p=0.003).  
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Figure 5.14: The effect of LVAD and drug combination therapy on early H/M 
ratio 
 
 
 
 
 
 
Fig 5.14: LVAD and drug combination therapy resulted in a significant increase in 
the early H/M ratio in all 14 patients. The mean early H/M ratio increased from 1.56 
± 0.29 to 2.21 ± 0.30, p<0.001. Red lines represent the changes in recovered patients 
(n=10) and the black line represent the changes in non-recovered patients (n=4). 
  
0
0.5
1
1.5
2
2.5
3
Scan 1 Scan 2
E
a
rl
y
 H
/M
 r
a
ti
o
p < 0.001 
 296 
 
Figure 5.15: The effect of LVAD and drug combination therapy on delayed H/M 
ratio 
 
 
 
 
 
 
 
Fig 5.15: LVAD and drug combination therapy resulted in a significant increase in 
the delayed H/M ratio in all 14 patients. The mean delayed H/M ratio increased from 
1.46 ± 0.33 to 2.25 ± 0.43, p<0.001. Red lines represent the changes in recovered 
patients (n=10) and the black line represent the changes in non-recovered patients 
(n=4). 
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Figure 5.16: The effect of LVAD and drug combination therapy on W/O rate 
 
 
 
 
 
Fig 5.16: LVAD and drug combination therapy resulted in a significant decrease in 
the mean washout rate from 46.96 ± 22.92% to 27.04 ± 16.71%, p=0.003. Red lines 
represent the changes in recovered patients (n=10) and the black line represent the 
changes in non-recovered patients (n=4). 
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5.3.4.1  Comparison of MIBG uptake between recovered and non-
recovered patients 
As stated above, 10 of the 14 studied patients had recovered and were explanted. 
There were no significant differences in MIBG uptake parameters between the two 
sub-groups at either the first or the second scan. The effects of LVAD and drug 
combination therapy, however, were different in each subgroup. Table 5.4 represents 
the differences in the effects of HMII and drug combination therapy on the recovered 
and the non-recovered patients. 
Table 5.4: Effects of LVAD and drug combination therapy between recovered 
and non-recovered sub-groups 
 
Group MIBG Parameter Scan 1 Scan 2 
% 
change 
p-value 
R
ec
o
v
e
re
d
 G
ro
u
p
 
(n
=
1
0
) 
Early H/M ratio 1.64 ± 0.29 2.31 ± 0.22 +40.9 <0.0001 
Delayed H/M ratio 1.53 ± 0.32 2.39 ± 0.22 +56.3 <0.0001 
Washout rate (%) 43.97 ± 15.96 23.57 ± 11.11 -46.4 0.003 
N
o
n
-R
ec
o
v
er
ed
 
G
ro
u
p
 (
n
=
4
) 
Early H/M ratio 1.35 ± 0.17 1.97 ± 0.38 +45.8 0.011 
Delayed H/M ratio 1.27 ± 0.30 1.90 ± 0.64 +50.0 0.042 
Washout rate (%) 54.41 ± 37.53 35.71 ± 26.45 -34.4 0.352 
Table 5.4: Both groups had a significant improvement in the H/M ratios, however, 
the recovered group had a more pronounced improvement also the mean ratios have 
normalised above the cut-off point of 2.0. The washout rate reduction was 
significantly better in the recovered group although the mean remained above the 
normal cut-off point of 20%. 
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5.3.4.2  Correlation between 123I-MIBG scintigraphic findings and 
contractile reserve 
As represented in chapter 4, the HM II LVAD and drug combination therapy had 
resulted in a significant change in CR such that a 6MW exercise test had resulted in 
an absolute increase in the EF by 5.25 ± 5.30% in all 23 studied patients. In the 
present group (i.e. the 14 patients who had MIBG imaging) there was an absolute 
increase in the EF following the 6MW exercise test by 5.89 ± 6.07% (11 patients (10 
recovered and 1 non-recovered) had an absolute increase and 3 non-recovered 
patients had an absolute reduction).  
Linear regression analysis revealed a moderate but significant correlation between 
CR and early H/M ratio (r=0.612, p=0.02) and between CR and the delayed H/M 
ratio (r=0.578, p=0.03 – figure 5.17 A and B). There was no correlation between CR 
and the myocardial W/O rate (r=0.414, p=0.142). 
Figure 5.17: Relationship between 
123
I-MIBG scintigraphic findings and 
contractile reserve 
 
      
Fig 5.17: A) Relationship between early H/M ratio and CR. B) Relationship between 
delayed H/M ratio and CR.  
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5.3.4.3  Relationship between LV dimensions and function and 
123
I-MIBG 
scintigraphic findings  
In the studied population, there was a significant reduction in LVESD (43.36 ± 17.81 
mm versus 47.79 ± 17.84 mm, p=0.029). The LVEDD did not change significantly 
throughout the study (56.79 ± 14.78 mm versus 58.71 ± 14.29 mm, p=0.298), 
however, there was a significant increase in both FS and EF (25.64 ± 11.64% versus 
20.83 ± 10.27%, p=0.031, and 56.07 ± 20.17% versus 48.02 ± 20.65%, p=0.024, 
respectively). 
There was no correlation between the changes in the LV dimensions and function, 
and the changes in the 
123
I-MIBG scintigraphic findings suggesting that the changes 
seen in the MIBG uptake parameters are independent of the LV dimensions and 
function (table 5.5). 
 
Table 5.5: Correlation between LV dimensions and function and 
123
I-MIBG 
scintigraphic parameters 
  Early H/M ratio Δ Delayed H/M ratio Δ W/O Rate (%) 
 R p-value R p-value R p-value 
Δ LVEDD (mm) 0.063 0.824 0.089 0.761 0.03 0.985 
Δ LVESD (mm) 0.161 0.580 0.126 0.667 0.063 0.829 
Δ FS (%) 0.114 0.694 0.226 0.438 0.032 0.896 
Δ EF (%) 0.230 0.430 0.358 0.209 0.071 0.819 
Table 5.5: There was no correlation between the changes in LV dimensions and 
function and the changes in ΔI-MIBG scintigraphic parameters throughout the study. 
Δ, delta represents the absolute change. 
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To further ensure that the improvements in 
123
I-MIBG scintigraphic findings are 
independent of the LV size, the measurements derived at scan 2 were normalised 
against the size of the ROI. The outcomes were non-significant differences between 
123
I-MIBG scintigraphic findings measured using the ROIs from the first scan and the 
findings from the second scan (early H/M ratio: 2.02 ± 0.66 versus 2.21 ± 0.30, 
p=0.208; delayed H/M ratio: 2.05 ± 0.79 versus 2.25 ± 0.43, p=0.236; W/O rate: 
30.98 ± 21.81 versus 27.32 ± 15.80, p=0.288). 
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5.3.4.4  Long term explants 
Out of the 10 explanted patients, 4 had a repeat scan (scan 3) 408 ± 165 days 
following the explant of the HM II LVAD. Following explantation there was a non-
significant rise in both early H/M and delayed H/M ratios as compared to the MIBG 
uptake assessed just prior to device explantation (early H/M ratio: 2.59 ± 0.13 versus 
2.42 ± 0.21, p=0.11; delayed H/M ratio 2.71 ± 0.36 versus 2.37 ± 0.12, p-0.090) and a 
non-significant reduction in washout rate (17.14 ± 9.65% versus 28.86 ± 5.23%, 
p=0.078) (figure 5.18 A-C). 
 
 
Figure 5.18: MIBG uptake in 4 recovered LVAD patients 
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Fig 5.18: MIBG uptake in 4 recovered LVAD patients. There were no significant 
differences in MIBG uptake parameters between the second and the third scan. 
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5.4  Discussion 
The main findings of the present study include the following: 
 The use of a modified region of interest is a valid approach to assess 123I-
MIBG uptake in LVAD patients; 
 MIBG imaging analysis is highly reproducible with strong intra-observer and 
inter-observer reproducibility; 
 LVAD and drug combination therapy result in a significant  improvement in 
H/M MIBG activity; 
 There were moderate correlations between MIBG uptake and CR in LVAD 
patients confirming that CR is linked to sympathetic function activity; 
 The changes seen in MIBG uptake are irrespective of the LV size and they 
represent an absolute improvement in sympathetic innervation; 
 There is sustained improvement in 123I-MIBG uptake following device 
explantation. 
The involvement of cardiac SNS in HF 
The role of the sympathetic nervous system in the development and progression of 
HF has become increasingly clear over the past decade (Schrier RW & Abraham WT, 
1999). Decreased cardiac output related to LV dysfunction results in a baroreceptor-
mediated increase in sympathetic tone leading to excessive exposure of the 
myocardium to NE (Davis D et al., 1988;Esler M et al., 1997;Kaye D & Esler M, 
2005;Münch G et al., 1996) which is the trigger for the activation of the 
neurohormonal pathway and myocardial remodeling. In chapter 1 the effects of NE 
on - and β- ARs, RAAS, Ca2+ handling, natriuretic peptides and endothelin have 
been discussed in detail.  
The chronic consequences of increased sympathetic tone consist of increased LV 
afterload, worsening LV function, and progression of congestive HF. Atsumi et al 
have elegantly correlated exercise intolerance in DCM patients with enhanced cardiac 
 305 
 
sympathetic nervous activity (Atsumi H et al., 1998). Other investigations have 
shown that there are elevated plasma NE levels (Cohen JT et al., 1984;Eisenhofer G 
et al., 1996;James KB et al., 1995), reduced NE concentration in cardiac tissue 
(Eisenhofer G et al., 1996), increased spillover of NE into plasma (Eisenhofer G et 
al., 1996;Hasking G et al., 1986;Rundqvist B et al., 1997) and increased muscle 
sympathetic nerve firing in patients with CHF (Narula J & Kunal S, 2003;Patel A & 
Iskandarian A, 2002). All these factors have been related to poor prognosis and have 
been reported to improve when patients had either recovered from symptoms of HF 
(James KB et al., 1995) or had heart transplant (Bengel FM & Schwaiger M, 
2004;Hunt S, 2001;Lovric SS et al., 2004;Murphy DA et al., 2000). 
 
Nuclear imaging and cardiac SNS 
The evaluation of the SNS of the heart has been limited to either post-partum 
examination or invasive procedures to determine the arteriovenous difference of 
plasma catecholamines (Schwaiger M et al., 1990). The development of several 
successful sympathetic neuronal imaging agents such as the positron emitting 
compounds 
11
C-metahydroxyphedrine, 
11
C-epinephrine, 
11
C-phenylephrine, and 
18
F-
fluorometaraminol have provided advanced information onto the role of the SNS in 
HF. Cardiac sympathetic innervation can also be assessed non-invasively using 
MIBG, a single photon emission compound with a molecular structure similar to NE. 
In vivo MIBG imaging is a sensitive and a specific non-invasive technique for 
assessing NET function and evaluation of adrenergic nerve integrity and function 
(Merlet P et al., 1995;Merlet P et al., 1996;Merlet P et al., 1999b;Sisson JC et al., 
1987;Agostini D et al., 2008). 
It is well recognised that PET imaging provides better spatial resolution and has 
superior quantification accuracy as compared to SPET imaging (Langer O & Halldin 
C, 2002). 
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In this study, however, MIBG SPECT analysis was used for the following reasons: 
i) MIBG has the highest rate of neuronal uptake, the least leakage across 
neuronal membrane after NE, and does not undergo intracellular 
metabolism making it metabolically very stable (Raffel DM & Wieland 
DM, 2001) 
ii) MIBG is widely used such that most studies (>400 studies) had utilised it 
as a sensitive tool to determine the effects of different therapeutic 
modalities in HF. In this study we used the outcome of those studies as a 
reference for the benefits of using LVAD and drug combination therapy 
on the SNS in LVAD patients (see text below and table 5.8 for further 
details), 
iii) MIBG can be obtained using a ―shake and break‖ kit and hence its 
production is much cheaper. PET tracers, however, are more expensive to 
produce and are preferred to be produced in-house where a cyclotron is 
available as they have a shorter half-life (Knuuti J & Sipola P, 2005),  
iv) Due to the lack of PET scanner availability at Harefield, it was thought 
that performing PET imaging serially on LVAD patients would be very 
costly, time consuming, and would demand extensive labour work from 
VAD specialists (every VAD patient has to be accompanied by a VAD 
specialist during transport and at the imaging sites). 
MIBG and cardiac SNS in HF 
HF animal model studies revealed that impairment of NET binding sites is neither 
mediated by a decreased NET gene expression nor by a loss of noradrenergic nerve 
terminals, however, it is due to posttranscriptional downregulation of NET per neuron 
(Backs J et al., 2001). NET-deficient mice demonstrated a significant rise in resting 
mean arterial blood pressure and heart rate as compares to controls (Keller NR et al., 
2004). 
Decreased 
123
I-MIBG uptake has been shown to be associated with cardiac and 
sudden death in ischaemic and non-ischaemic DCM patients (Imamura Y et al., 
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2001;Kasama S et al., 2008;Matsui T et al., 2002;Merlet P et al., 1999a;Nakata T et 
al., 1998;Ogita H et al., 2001;Tamaki S et al., 2009;Verberne HJ et al., 
2008a;Wakabayashi T et al., 2005;Merlet P et al., 1994)
 
and other events such as 
hospitalisation and arrhythmia (Fujimoto S et al., 2004;Fujimoto S et al., 2005;Paul 
M et al., 2006).  
Furthermore, MIBG scintigraphy has shown to be a more reliable predictor of overall 
mortality than heart rate variability measuremnts (Anastasiou-Nana M et al., 
2005;Yamada T et al., 2003;Somsen G et al., 1997), a more reliable tool in 
determining the progression of HF (Arimoto T et al., 2005;Matsuo S et al., 
2002;Agostini D et al., 2008), a strong predictor for DCM patients with increased risk 
for potentially fatal arrhythmias (Arora R et al., 2003;Jacobson AF et al., 2009), and 
an accurate and an independent predictor of cardiac transplantation or death than 
other standard clinical tests such as mVO2, radionuclide LV EF and plasma NE levels 
(Gerson MC et al., 2003). 
Technical issues with MIBG imaging 
The choice of collimator substantially influences estimation of H/M ratios in cardiac 
123
I-MIBG imaging. Previous studies have compared the use of medium energy 
collimators to low energy collimators and found that the former provides higher 
quantitative accuracy and enhances reliability in the evaluation of cardiac 
sympathetic nerve function (Inoue Y et al., 2003;Verberne HJ et al., 2005;Verberne 
HJ et al., 2009b). Scatter correction using dual energy windows has also been shown 
to provide extra reliability and accuracy of data such that it standardises the H/M 
ratios (Fletcher AA et al., 2007;Kobayashi H et al., 2003;Yang YW et al., 
2007;Matsuo S et al., 2009;Nakajima K et al., 2007;Imamura Y et al., 2001). In our 
study placing a scatter window at 194 keV has enhanced the quality of the images 
(figure 5.5). 
The first part of this study was to decide on how to draw the heart ROI. Naruse et al 
have recommended drawing the ROI over the entire myocardium (Naruse H et al., 
2000). Others have, selectively, drawn the ROI by excluding the blood pool 
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(Anastasiou-Nana M et al., 2005). In the latter approach, Anastasiou-Nana et al have 
excluded the presynaptic neurones allocated in the anterior and the posterior walls of 
the myocardium and therefore the calculated H/M ratios do not reflect the whole 
presynaptic neurones concentrated in the heart. 
We have opted to use a ROI over the entire myocardium despite the challenge 
presented by the presence of the inflow cannula. Therefore, the ROI had to be 
modified to account for the inflow cannula. Hence, a horse-shoe shaped ROI was 
used (George R et al., 2009). To validate the use of the modified ROI, the 
conventional ROI drawn over the entire myocardium was compared to the modified 
ROI in 13 HF patients. Both early and delayed H/M ratios and W/O rate were derived 
from each ROI. Bland-Altman analysis revealed excellent limits of agreements 
between the conventional ROI and the modified ROI suggesting that missing off the 
apex will not compromise the results. Hence, the use of the modified ROI throughout 
the study was considered to be valid. 
The most common ROI used as a reference to calculate the ratio is the mediastinum 
(Verberne HJ et al., 2008b). Other investigators have used different reference organs 
other than the mediastinum, such as the liver, the lungs, or the left ventricular cavity 
(Carrio I, 2001;Somsen GA et al., 1995;Somsen GA et al., 1996a;Verberne HJ et al., 
2009a;Somsen GA et al., 1996b). They have all shown that MIBG uptake is reduced 
while the washout is increased in patients with HF in proportional to their degree of 
HF irrespective of the aetiology. 
Similar to previous studies (Kasama S et al., 2003b;Ogita H et al., 2001;Yamada T et 
al., 2003) there were strong intra- and inter-observer reproducibility of all MIBG 
measured parameters (George R et al., 2009). 
The effects of LVAD on MIBG uptake 
LVAD unloading has shown to have a therapeutic effect in patients with end-stage 
HF. Unloading has a significant impact at the cellular and molecular levels in both 
humans and experimental (Bruckner BA et al., 2001;Bruggink AH et al., 2006;Dipla 
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K et al., 1998b;Khan N et al., 2003b;Xydas S et al., 2006;Zafeiridis A et al., 1998b) 
and this becomes far more significant if combines with specific drug combination 
therapy to promote a sustainable reverse remodeling followed by physiologic 
hypertrophy (Birks EJ et al., 2001;Birks EJ et al., 2005;Birks EJ et al., 2006;Latif N 
et al., 2007;Terracciano CM et al., 2007;Terracciano CMN et al., 2003;Terracciano 
CMN et al., 2004).  
The main findings of the present study are the positive effects of the HM II LVAD 
and drug combination therapy on 
123
I-MIBG uptake. We have shown that LVAD 
support alongside uptitration of the anti-failure medication has resulted in a 
significant increase in both early and delayed H/M ratios by 42.1% and 54.7%, 
respectively, and a significant reduction in the W/O rate by 42.4%. These significant 
improvements were much higher than those demonstrated by other groups. Table 5.6 
summarises the changes in H/M MIBG activity following various therapeutic 
interventions that targeted either one or a combination of the following: β-receptors, 
angiotensin converting enzymes, aldosterone, and angiotensin II receptor. Although a 
meta-analysis was not performed the percentage increase in both early and delayed 
H/M ratios ranged from 4% to 10.5% and from 2.4% to 23.1%, respectively. The 
percentage reduction in the W/O rate ranged from 2% to 27.5%. 
These findings suggest a significant improvement in sympathetic innervation 
following LVAD and drug combination therapy and the possibility for NET to be 
used as direct target for pharmacologic treatment of HF in the future (George RS et 
al., 2009). 
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Table 5.6: Effects of various therapies on MIBG uptake 
Author / Source 
Therapeutic 
option 
Number of 
patients 
Study 
duration 
(months) 
Percentage Change in MIBG parameter 
Early H/M 
ratio 
Delayed H/M 
ratio 
Washout 
Rate 
(Toyama T et al., 2003) Carvedilol 15 12 NR ↑ 20.4 ↓ 23.4 
(Toyama T et al., 2003) Metoprolol 15 12 NR ↑ 14.9 ↓ 27.5 
(Kasama S et al., 2007a) Carvedilol 30 12 ± 1 NR ↑ 13.3 ↓ 21.2 
(de Milliano PAR et al., 
2002) 
Metoprolol 59 6 NR ↑ 21.9 NR 
(Lotze U et al., 2001) β-blockers * 11 12 NR ↑ 23.1 NR 
(Gerson MC et al., 2002) Carvedilol 10 7.2 ± 2.7 ↑ 4 ↑ 3.5 NR 
(Toyama T et al., 1999) Metoprolol 12 12 NR ↑ 14.4 ↓ 23.8 
(Toyama T et al., 1999) Enalapril 12 12 NR ↑ 6.6 ↓ 6.4 
(Kasama S et al., 2006) Valsartan ‡ 25 6 NR ↑ 4.7 ↓ 10.9 
(Kasama S et al., 2006)  Enalapril ‡ 25 6 NR ↓ 0.6 ↓ 2.0 
(Kasama S et al., 2003a) Valsartan 16 6 NR ↑ 9.0 ↓ 17.0 
(Shinohara H et al., 2002) ARB ** 34 6 ↓ 0.9 ↓ 0.5 ↓ 13.5 
(Kasama S et al., 2005a) Candesartan 25 6 NR ↑ 7.0 ↓ 13.5 
(Soeki T et al., 1998) Enalapril 10 3 – 15 ↑ 10.5 ↑ 12.4 ↓ 12.7 
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Table 5.8: (continue)  
Author / Source 
Therapeutic 
option 
Number of 
patients 
Study 
duration 
(months) 
Percentage Change in MIBG parameter 
Early H/M 
ratio 
Delayed H/M 
ratio 
Washout 
Rate 
(Takeishi Y et al., 1997) Enalapril 19 9.1 ± 3.0 ↑ 8.1 ↑ 11.7 ↓ 21.1 
(Kasama S et al., 2005b) Perindopril † 20 6 NR ↑ 8.6 ↓ 16 
(Kasama S et al., 2005b) Enalapril † 20 6 NR ↑ 2.4 ↓ 6.3 
(Kasama S et al., 2002) Spironolactone 15 6 NR ↑ 13.0 ↓ 21.6 
PRESENT STUDY 
LVAD & DRUG 
COMBINATION 
THERAPY 
14 
242.57 ± 
82.25 days ↑ 42.1 ↑ 54.7 ↓ 42.4 
Table 5.6: Percentage change in MIBG measured parameters following various therapeutic interventions. All percentage changes 
highlighted in bold represent a significant change as compared to the MIBG baseline measurements taken at baseline prior to 
commencing any specific treatment. Percentage changes highlighted in red represent a non-significant change compared to the MIBG 
baseline measurements taken at baseline prior to commencing any specific treatment. 
NR, not reported.  
* refers to a cocktail of different β-blockers used in the studied population (metoprolol, n=5; bisoprolol n=1; carvedilol, n=4) 
‡ A comparison between enalapril and valsartan with valsartan having a better effect on MIBG uptake as compared to enalapril 
** Patients received either losartan or candesartan 
† Comparison between perindopril and enalapril. Perindopril had better effects on MIBG uptake as compared to enalapril. 
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MIBG, LVAD and contractile reserve 
The improvements in MIBG uptake following LVAD and drug combination 
therapy correlated moderately but significantly (r-0.612, p=0.02) with CR.
§§
 
Previously Ohshima et al have shown that abnormal myocardial 
123
I-MIBG 
accumulation in DCM patients is related to an impaired myocardial CR (Ohshima 
S et al., 2005). Three years later the same group have used dobutamine stress 
testing
***
 to correlate MIBG uptake with CR (Kobayashi M et al., 2008). They 
concluded that patients who had greatly reduced 
123
I-MIBG uptake had a reduced 
adrenergic myocardial CR. As described in chapter 4, CR has improved 
significantly in the LVAD recovered patients implying improvement in the 
cardiac SNS function. Coupled with the 
123
I-MIBG scintigraphic findings, it 
becomes the first time that MIBG uptake and CR to be positively correlated in 
LVAD patients suggesting that LVAD unloading combined with pharmacological 
therapy aiming to reverse remodelling and induce physiological hypertrophy 
results in a significant improvement in sympathetic innervation. Improved MIBG 
uptake throughout the LVAD support period reflects an improvement in NET 
functional property which itself is defected in HF (Liang C, 2007).  
Dividing the studied population into two subgroups, recovered (n=10) and non-
recovered (n=4), revealed that the uptake has improved in both groups but the 
percentage changes in the delayed H/M ratio and the W/O rate were more 
significant in the recovered patients. Also the mean values for both early and 
delayed H/M ratios were above the cut-off point in the recovered patients and not 
so for the non-recovered group (table 5.4). 
Although never highlighted in previous studies, reduction in the LV size 
following therapeutic intervention may result in concentrating the number of NET 
uptake sites in a smaller area / volume and hence the counts per pixel measured by 
drawing the ROI will be high. Therefore the improvements seen in
123
I-MIBG 
                                                 
§§
 Contractile reserve was determined as the percentage change in the EF following the 6MW 
exercise test whilst the HM II LVAD running at 6000 rpm. 
 
***
 Reasons for not using dobutamine stress echocardiography to determine CR were described in 
details in chapter 4. 
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uptake could have been a consequence of reduction in the LV size rather than a 
true improvement in the uptake mechanism itself.  
Previously, Kassama et al have identified, in most of their studies, a correlation 
between changes in the end-diastolic volume and 
123
I-MIBG scintigraphic 
findings after the treatment period with spironolactone (Kasama S et al., 
2003b;Kasama S et al., 2007b), angiotensin II antagonists (Kasama S et al., 
2003a;Kasama S et al., 2005a;Kasama S et al., 2006), and ACE inhibitors 
(Kasama S et al., 2005b) such that the significant increase seen in delayed H/M 
ratio and the significant decrease seen in the W/O rate were significantly 
correlated to significant reductions in the end-diastolic volume and significant 
increase in the LV EF (see table 5.6 for the percentage rises in delayed H/M ratio 
and percentage reduction in the washout rate for each of these studies). Other 
groups have also identified a correlation between changes in LV EF and 
improvements in MIBG uptake following the treatment with β-blockers (Choi JY 
et al., 2001;Fukuoka S et al., 1997;Yamazaki J et al., 2001). In two of their 
studied, Toyama et al have found an association but not a correlation between 
changes in echocardiographic measurements and 
123
I-MIBG scintigraphic findings 
(Toyama T et al., 1999;Toyama T et al., 2003). None of those groups, however, 
had commented on the possibility that a reduction in LV size may result in 
increased concentration of the NET uptake sites. 
In the present study similar to others (Agostini D et al., 2000;de Milliano PAR et 
al., 2002;Shinohara H et al., 2002;Soeki T et al., 1998) we did not find a 
correlation between the changes in the echocardiographic parameters throughout 
the study duration and the changes in 
123
I-MIBG scintigraphic findings (table 
5.5). Furthermore, to ensure that the changes seen in the LV size do not exhibit a 
significant effect on 
123
I-MIBG uptake, we normalised the LV size by 
superimposing the ROI drawn in the first scan over the second scan without 
changing the mediastinal ROI. Theoretically this entails that a bigger myocardial 
ROI area will have a lesser number of counts per pixels and hence early and 
delayed H/M ratios would decrease. The analysis, however, revealed a non-
significant change in the ratios. A possible explanation is that improvements seen 
in 
123
I-MIBG scintigraphic findings are genuine secondary to improvements in the 
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uptake mechanism itself irrespective and independent of the size of the LV 
following LVAD and drug combination therapy. It is worth noting that it was not 
possible to accurately measure the end-diastolic volume due to the presence of the 
LV cannula at the LV apex. 
Interestingly, the improvements seen in the H/M MIBG activity were sustainable 
after a mean of 408 ± 165 days after device explantation. The four studied patients 
were maintained on anti-failure medication. We have previously reported that 
recovery after the LVAD and drug combination therapy protocol is sustainable 
with excellent quality of life (George RS et al., 2008b;Birks EJ et al., 
2006;George RS et al., 2008a). 
The pronounced improvement in the H/M MIBG activity whilst on LVAD 
support and the sustained normalisation following LVAD explanation raise the 
possibility for NET as a therapeutic target in the treatment of HF. Although, no 
human studies have directly targeted NET in the treatment of HF as yet, some 
animal studies have shown that NET might represent a novel therapeutic 
principle. In 2005, Münch et al have shown that local overexpression of the 
uptake-1 NET using recombinant adenoviruses in rabbits with pacing induce HF 
has resulted in increased NE uptake, reversal of SERCA and β-adrenergic 
receptors downregulation, improvement in LV dimensions and function, and 
enhanced CR (Münch G et al., 2005). Others have targeted NET indirectly by 
injecting nerve growth factor reduced in HF secondary to overexpression to NE 
(Kaye DM et al., 2000b;Qin F et al., 2002) in the left stellate ganglia of rats with 
HF produced by transverse aortic constriction, resulting in enhanced uptake of 
NE, repleted cardiac NE stores, and increased FS without affecting the number of 
cardiac sympathetic nerves (Kreusser MM et al., 2006). 
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Clinical implications of MIBG imaging in LVAD patients 
Determining myocardial recovery in LVAD patients depends on rigorous and 
continuous assessment of the native LV function in the absence of LVAD support. 
As described in Chapter 2, the Harefield Bridge-to-Recovery Protocol utilises the 
following parameters as clinical guides for explanation (table 5.7). 
Table 5.7: Explantation Criteria 
 
Parameter with the speed of HM II 
reduced to 6000 rpm for 15 minutes  
Parameter value 
LV end-diastolic diameter (mm) < 60 
LV end-systolic diameter (mm) < 50 
Ejection Fraction (%) > 45 
Maximal VO2 (mls/kg/min) > 16 
LV end-diastolic pressure (mmHg) 
Cardiac Index (l/min/m
2
) 
< 12 
> 2.8 
 
Table 5.7: The explantation criteria as been previously described (Birks EJ et al., 
2006). 
Despite the above 6 criteria, the decision to explant remains a serious issue and 
the need for more explantation guidelines to assist clinicians is mandatory.  The 
main purpose of MIBG imaging was to attempt to utilise it as an additional 
explantation tool. Unfortunately, LVAD and drug combination therapy has 
resulted in a significant increase in MIBG uptake in both recovered and non-
recovered patients, although the percentage increase in the recovered patients was 
higher. The results, however, need to be interpreted cautiously due to the small 
number of the non-recovered patients. It can also be argued that MIBG imaging is 
not a useful tool to guide explantation and that this study turned out to be an 
observational study which demonstrated the direct positive effects of unloading 
and combination therapy on MIBG uptake and the indirect improvements of NET 
and the SNS.  
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Limitations 
A major limitation of this study is the small number of included patients which 
means that concrete conclusions regarding the potential benefit of 
123
I-MIBG 
imaging in LVAD patients should be drawn cautiously. Another limitation was 
the unavailability of pre-implant MIBG scan such that all patients were on 
multiple inotropic supports which interfere with the uptake mechanism (Appendix 
A for the pre-implant medication and Appendix E for the drugs that interact with 
MIBG uptake).  
However, our results are encouraging to suggest the need for a trial with a large 
number of patients to provide the opportunity to assess MIBG uptake at different 
set time points from the time of implantation such as on quarterly basis and prior 
to commencing clenbuterol. This would also allow the correlation of the changes 
seen in MIBG uptake with the uptitration of the medication in the LVAD patients. 
A fourth limitation is the lack of standardisation of imaging procedure such that 
the setting of the ROI is a major factor affecting MIBG H/M ratios. A final 
limitaiton was the inability to study regional MIBG washout rate as suggested by 
Yamazaki et al (Yamazaki J et al., 1997) due to the presence of the LVAD inflow 
cannula which exerted immense attenuation on polar images. 
Conclusion 
In summary, this study has shown that LVAD and drug combination therapy has 
directly improved H/M MIBG uptake in patients with end-stage HF. The degree 
of improvement was independent of the changes in the LV dimensions. Moreover, 
the improvement in MIBG uptake was correlated to the change in CR and hence 
improvements in CR are related to improvement in cardiac sympathetic nerves 
activity. Interestingly, the enhanced 
123
I-MIBG uptake was noted in both 
recovered and non-recovered subgroups but more significant in the former group. 
Furthermore, explanted patients had sustained normalisation of MIBG uptake. 
The use of a modified ROI to account for the inflow cannula is a validated 
technique with strong intra- and inter-observer reliability. Finally, these results 
suggest that NET could act as a potential therapeutic target for the treatment of 
patients with end-stage HF. 
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CHAPTER 6 – 
Immunohistochemistry Analysis of 
Various Nerve Markers 
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6.1   Background 
Sympathetic fibres leave the spinal cord at segments T1 to L2-3. Preganglionic 
sympathetic fibres consist of small myelinated fibres that come off the spinal roots 
as white rami communicantes and synapse in the paravertebral ganglia. 
Adrenergic fibres that innervate the heart originate in the left and right stellate 
ganglia. The left stellate innervates the right ventricle, whereas the right stellate 
innervates the anterior and lateral portions of the heart. Parasympathetic 
innervation originates from the medulla and follows through the right and left 
vagus nerves which then divide into superior and inferior cardiac nerves. Animal 
studies have previously confirmed heterogenicity in myocardial nerve distribution 
Activation of the SNS results in cardiac adrenergic stimulation with changes in 
the contractile and electrophysiologic status of the heart. In the heart 
parasympathetic innervation controls the heart rate. In HF, both systems tend to 
fail with the SNS being over-activated (Esler M et al., 1997) and the 
parasympathetic nervous system being under-activated (Olshansky B et al., 2008). 
By means of specific antigen/antibody reactions immunohistochemistry (IHC) 
combines anatomical, immunological and biochemical techniques for the 
identification of specific tissue components. IHC makes it possible to visualize the 
distribution and localization of specific cellular components within a cell or tissue. 
The principle of IHC has existed since the 1930s, but it was not until 1942 that the 
first IHC study was reported. Methods utilizing enzyme conjugated antibodies 
were developed in the 1960‘s (Nakane PK & Pierce GB Jr, 1966). After the 
antigen-antibody reaction, the enzyme label is reacted with a substrate to yield an 
intensely coloured product that can be analyzed with an ordinary light 
microscope. 
The aims of the present study were firstly to examine the localisation and 
distribution of specific nerve markers in LV cores from patients with end-stage 
HF prior to device implantation. Secondly, to quantify these nerve markers and 
attempt to correlate the findings with myocardial recovery. 
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6.2  Materials  
6.2.1  Patient population 
Out of the 23 studied patients, LV core tissues were available from 16 patients 
only. Core tissue from patients 1, 2, 3, 9, 18, 21, and 22 were not collected at 
implantation. Out of the 16 patients, 11 had recovered (Rec group) and 5 did not 
recover (NRec group). A tissue from the posterior wall of a normal heart was used 
as control. 
6.2.2  Tissue collection in LVAD patients 
During implantation a circular coring knife was used to remove the apex as been 
previously described (Slater JP et al., 1999). Core tissue was cut longitudinally 
into eight sections each measuring approximately 0.25 x 0.25 x 1.0 cm, wrapped 
into foil, stored in eppendorfs, snap frozen, and stored at – 80°C until sectioning.  
6.2.3  Sectioning, fixation and immunostaining 
Frozen tissues were supported in optimum cutting tissue (OCT) medium (R A 
Lamb Ltd, Eastbourne, UK) to allow optimum orientation. Using cryostat at -
20°C, 15µm thickness of frozen sections were collected onto poly-L-lysine coated 
glass slides (VWR Ltd., Lutterworth, Leics., UK) and allowed to dry for 30 
minutes. Sections were then fixed in freshly prepared, 4% w/v paraformaldehyde 
in PBS (0.1M phosphate; 0.9% w/v saline; pH 7.3) for a further 30 minutes.  For 
immunoperoxidase staining endogenous peroxidase was blocked by incubation in 
0.3% w/v hydrogen peroxide in methanol.  After rehydration with PBS, sections 
were incubated overnight at 4°C with primary antibodies (Table 6.1) diluted in 
PBS containing bovine serum albumin (BSA 0.05% w/v), 3% w/v normal serum 
(from donor of second antibodies) and sodium azide (0.1% w/v) preservative.  On 
the following day sections were rinsed in PBS and biotinylated secondary 
antibodies to either rabbit or mouse IgG applied for 60 min at ambient 
temperature.  After a further rinse in PBS, sections were incubated for 90 min 
with avidin-biotin peroxidase complex (ABC; Elite ABC Vector Labs, 
Peterborough, UK) prepared in advance according to manufacturer‘s instructions. 
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Sites of primary antibody attachment were revealed using nickel-enhanced, 
diaminobenzidine (DAB) and nascent hydrogen peroxide (Shu et al. 1989).
†††
  
Positive immunoreactivity was revealed as a blue/black product at primary 
antibody attachment sites.  Nuclei were counterstained with 0.1% w/v aqueous 
neutral red and sections allowed to dry before mounting with glass coverslips 
using a xylene based mountant (DPX; R A Lamb Ltd, Eastbourne, UK). Controls 
included omission of primary antibodies, or their replacement with pre-immune 
serum. 
Table 6.1: Primary antibodies 
Antibodies to Host Source (Ref#) Titre 
Nerve marker - 
Neurofilaments cocktail 
Mouse Dakocytomation (M0762) 1:500/10000 
Sodium Channel (Nav1.7) 
Rabbit GlaxoSmithKline (K241) 1:200 - 300 
 
Sodium channel (Nav1.8) Rabbit GlaxoSmithKline (K107) 1:200 - 400 
 
Sodium channel (Nav1.9) 
 
Rabbit GlaxoSmithKline (K186) 1:200 - 300 
Norepinephrine 
Transporter (NET) 
Rabbit 
Atlas Antibodies 
(HPA004057) 
1:50 - 100 
 
Substance P 
 
Rabbit Millipore (AB1566) 
1:4000 - 
8000 
VIP Rabbit Millipore (AB1581) 
1:5000 – 
10,000 
 
Acetylcholinesterase 
 
Mouse Novocastra (Clone HR2) 1:750 
Choline Acetyltransferase Mouse Novocastra (Clone 38B12) 1:250 
 
Table 6.1: Primary antibodies for different nerve markers used for 
immunostaining each sample. All antibodies were used at two different 
concentrations except for neurofilaments, acetylcholinesterase, and choline 
acetyltransferase. 
 
                                                 
†††
 ABC complex was made by diluting 5 μl of Avidin and 5 μl of Biotinilated 
peroxidase in 1 ml of PBS-A and then left to set for at least 30 minutes. 
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6.2.4  Analysis 
For image analysis, images were captured using an Olympus DP70 camera 
mounted to an Olympus BX50 microscope and analysed using analySIS 
(Olympus version 5.0) software.  Positive immunostaining in images was 
measured by setting grey-level detection limits to highlight positive nerve fibre 
immunoreactivity. Five different fields per section were randomly chosen and 
scanned at the same magnification (x20 objective). Analysis was performed by 
two independent observers and immunoreactivity for nerve fibres was quantified 
by either the percentage area or the direct counting techniques: 
Percentage area technique. This technique was used to calculate the 
amount of norepinephrine transporter in each section. After adjusting the 
threshold 
‡‡‡
, the red colour was separated to obtain black and white images. 
The amount of black immunostaining is calculated as a percentage of the 
total area. Figures 6.1 and 6.2 are examples of images pre- and post- red 
colour separation, respectively. 
Counting technique. This technique was used to count the neurofilaments 
in each section. 
 
                                                 
‡‡‡
 Threshold adjustment ensures minimal background interference 
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Figure 6.1: A captured image pre-colour separation 
 
 
Fig 6.1: Nerve fibres in a control sample prior to separation of the red colour. 
 
Figure 6.2: A captured image post-colour separation 
 
 
Fig 6.2: Nerve fibres after separation of the red colour. 
x 20 
x 20 
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6.2.5  Statistical Analysis 
All data are presented as mean ± stdev. Observer two was blinded to the recovery 
status of the patients. Intra-observer and inter-observer reliability was assessed 
using intraclass correlation coefficient (ICC) analysis. Non-parametric Mann-
Whitney U test was used for inter-group (recovered versus non-recovered) 
analysis. Linear regression analysis was performed to determine predictors of 
myocardial recovery where recovered patients were used as a dependent 
parameter and percentage abundance of norepinephrine transporter 
immunoreactive nerve fibers and counts of neurofilaments immunoreactive nerve 
fibers as independent parameters. A p-value < 0.05 was considered to be 
statistically significant. 
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6.3  Results  
Immunoreactivity was not detected for substance P, vasoactive intestinal peptide, 
acetylcholinesterase, and choline acetyltransferase.  Antibodies to norepinephrine 
transporter (NET) nerve fibers revealed abundance of NET-immunoreactive nerve 
fibers in the control (n=1) and the LV core samples (figure 6.3). Mild innervation 
in single fibres and fascicles was also detected throughout the LV core samples 
using the nerve marker neurofilaments (NF; figure 6.4). Immunoreactivity was 
much less abundant for sodium channels (Nav1.7, Nav1.8, and Nav1.9). Therefore, 
analyses focused on NET 
§§§
 and neurofilaments. 
 
 
Figure 6.3: NET immunostaining  
 
 
 
 
 
 
 
 
 
 
(continue …) 
 
 
                                                 
§§§
 Image analysis for NET-immunoreactivity was performed on section 
immunostained with 1:100 NET antibody since the higher concentration (1:50) 
demonstrated excessive background immunostaining. 
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Figure 6.3 (cont.): NET immunostaining  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.3: NET immunostaining in control and LV core samples. Magnification x20 
objective. 
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Figure 6.4: An example of neurofilament immunostaining 
 
 
 
 
Fig 6.4: An example of neurofilament immunostaining in an LV core sample. 
Magnification x10 objective. 
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6.3.1  Inter-observer reliability 
Figure 6.5 represents a scatter plot of the percentage of NET-immunoreactive 
nerve fibers per total area between observer 1 and observer 2. ICC between the 
two observers revealed a moderate but significant reliability of 45.8% with 
correlation of 0.464 (p=0.028). 
 
 
Figure 6.5: Scatter plot for NET between observer 1 and observer 2 
 
 
 
 
Fig 6.5: Scatter plot for NET percentage in total area (ICC between both 
observers was 45.8%). 
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Similarly, inter-observer reliability for the mean counts of neurofilament 
immunoreactive nerve fibers was moderate but significant; ICC was 42.7% and 
intraclass correlation was 0.424 (p=0.039; figure 6.6 for the scatter plot). 
 
 
 
 
 
Figure 6.6: Scatter plot for neurofilament between observer 1 and observer 2 
 
 
 
Fig 6.6: Scatter plot for neurofilament average counts (ICC between both 
observers was 42.7%). 
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6.3.2   Recovered versus Non-Recovered 
Of the 16 studied patients who had their LV core studied, 11 had recovered 
(patients 4, 7, 8, 10, 11, 12, 13, 15, 19, 20, and 23) and 6 did not recover (patients 
5, 6, 14, 16, and 17).  
The percentage of NET-immunoreactive nerve fibers per area in the control 
sample was 1.91%.  
A comparison between the recovered and the non-recovered subgroups revealed 
that the percentage of NET-immunoreactive nerve fibers per area was 
significantly higher in the 11 recovered patients in the LV core at the time of 
implantation (1.04 ± 0.30% versus 0.65 ± 0.43%, p=0.048, figure 6.7). 
 
Figure 6.7: NET concentration – Recovered versus Non-recovered 
 
 
Fig 6.7: NET concentration was significantly higher in the LV core samples of the 
recovered subgroup as compared to the non-recovered subgroup (p=0.048). 
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There was no difference in the neurofilament immunoreactive counts in the LV 
cores between the two sub-groups (6.95 ± 3.02 counts versus 7.83 ± 2.75 counts, 
p=0.591; figure 6.8). 
 
 
Figure 6.8: Counts of Neurofilaments – Recovered versus Non-Recovered 
 
 
Fig 6.8: There was no significant difference in the neurofilament reactive counts 
in the LV core samples between the recovered and the non-recovered subgroups 
(p=0.591). 
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6.3.3   Correlation between LV core immunostaining and myocardial 
recovery 
Figure 6.9A represents a moderate correlation between the percentage of NET-
immunoreactive nerve fibers per total area in the pre-implanted LV core and 
myocardial recovery (r=0.513, p=0.035) suggesting that the abundance of NET 
prior to device implantation could be related to myocardial recovery. No 
correlation was identified between neurofilament immunoreactive counts and the 
recovered patients (r=0.152, p=0.560) 
Figure 6.9: Correlation between nerve markers and myocardial recovery 
 
 
Fig 6.9: There was a moderately significant correlation between NET-
immunoreactive nerve fibers and myocardial recovery (A) and no correlation 
between neurofilament immunoreactive counts and myocardial recovery (B). 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
N
E
T
 (
%
 o
f 
to
ta
l 
a
re
a
)
Non-Recovered Recovered
0
2
4
6
8
10
12
14
N
eu
ro
fi
la
m
en
ts
  
(M
ea
n
 
C
o
u
n
ts
)
Non-Recovered Recovered
A) 
B) 
332 
 
6.4  Discussion  
The main findings of the present study include: 
 NET-immunoreactive nerve fibers and non-specific neurofilament 
immunoreactive nerve fibers were abundant in the LV apex (core tissue) 
as compared to other nerve markers; 
 Patients who had recovered on LVAD and drug combination therapy had 
significantly higher percentage of NET-immunoreactive nerve fibers per 
total area in the LV apical core excised at implantation as compared to 
non-recovered patients 
 The percentage of NET-immunoreactive nerve fibers correlated 
significantly with myocardial recovery. 
IHC technique and nerve markers 
In this study ABC immunoperoxidase method was important in IHC. Staining 
intensity is a function of the enzyme activity and improved sensitivity can be 
achieved by increasing the number of enzyme molecules bound at the 
immunoreactive sites. Hsu et al, has previously demonstrated that the multiple 
binding sites between the tetravalent avidin and biotinylated antibodies (bound to 
the antigen) are ideal for achieving this amplification (Hsu SM et al., 1981a;Hsu 
SM et al., 1981b). As illustrated in figure 6.1 the nerve fibres immunostained 
black and were clear to identify under light microscope. 
Nav1.7, Nav1.8, and Nav1.9 are voltage-gated sodium channels that play critical 
role in the generation and conduction of action potentials in sensory fibers. To our 
knowledge, this is the first report attempting to identify voltage-gated sodium 
channels in the LV apex. However, immunoreactive fibres for these channels were 
too few in the LV apex of DCM patients precluding image analysis.  
Immunostaining for neuropeptides such as Substance P and VIP is not optimal in 
post fixed tissues which might explain their absence in the studied samples. 
Hence, for the future, tissue would need to be immersion fixed once collected to 
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improve their preservation. In the present study, this was not practical at 
implantation time. 
AChE and ChAT were not very abundant and very difficult to analyse. Animal 
studies have confirmed regional variation in the distribution of AChE and ChAT 
in the heart (Brown OM et al., 1985;H.Criss Hartzell, 1980;Slaviková J & Tušek 
S, 1982;Vlk J et al., 1961). For example atrial areas receive richer 
parasympathetic innervation than ventricular areas, with the right portions 
receiving more than the left. The nodal areas were the most abundantly innervated 
regions examined. In our studied samples none were detected in the LV apex in 
parallel with the animal studies. 
NET-immunoreactive nerve fibers 
The heart is densely innervated with sympathetic nerves. Previous studies using 
non-invasive approaches such as 
123
I-MIBG have identified spatial variation in 
NET-immunoreactive nerve fibers distribution in the myocardium (Somsen GA et 
al., 2004;Verberne HJ et al., 2008a). Others have identified heterogenic 
distribution on regional basis in the LV wall thickness (Dae MW et al., 1997). 
However, no group has commented on the presence of sympathetic nerve fibers in 
the LV apex. The present study is the first to report that NET is localised in the 
LV apex using IHC techniques. 
Interestingly, NET-immunoreactive nerve fibers were quite abundant in the LV 
apex in all patients. Recovered patients, however, demonstrated a significantly 
greater percentage per area of fibers as compared to the non-recovered subgroup. 
Furthermore, there was a moderate but significant correlation between NET-
immunoreactive nerve fiber concentration in the LV apex and myocardial 
recovery. Unfortunately, the biopsies taken during right heart catheterisation prior 
to explant were too small to detect NET-immunoreactive nerve markers. Further, 
biopsies taken from the LVAD insertion site (i.e. around cannula) were scarred as 
been previously described (Moon JCC et al., 2003).  
In chapter 5, MIBG uptake at the apex could not be investigated as the LV 
cannula had replaced the core. In the present study a correlation between NET, as 
assessed using IHC techniques, and the first MIBG scans performed (early post 
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device implantation) was not attempted. This is due to the fact that there was an 
average of 35.21 ± 20.37 days difference between the removal of the LV core at 
implantation and the first MIBG scan to be performed. 
With these observations it has to be cautiously concluded that NET concentration 
in the LV apex may act as an early predictor of myocardial recovery. 
Limitations 
The number of LV cores is very small to conclude whether the presence of NET 
in LV apex at implantation is a strong predictor of myocardial recovery or not and 
therefore the results should be interpreted with caution. Another limitation is the 
availability of only one control sample which precluded direct comparison 
between HF cores and control cores.  
Also the lack of a paired transmural sample from the LV at the time of either 
explantation or transplantation has acted as a limiting factor to determine the 
direct effects of the LVAD and drug combination therapy on NET-
immunoreactive fibers. 
Conclusions 
This study has demonstrated that NET-immunoreactive nerve fibers and non-
specific neurofilament immunoreactive nerve fibers were abundant in the LV apex 
(core tissue) as compared to other nerve markers. At pre-implantation patients 
who had recovered on LVAD and drug combination therapy had higher 
percentage of NET-immunoreactive nerve fibers per total area in the LV apex as 
compared to non-recovered patients. This was significantly correlated to 
myocardial recovery and hence assessment of NET-immunoreactive nerve fibres 
percentage per area of samples from the LV apex acquired at implantation could 
act as predictor of recovery. 
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CHAPTER 7 – Catecholamine Levels 
 
  
336 
 
7.1  Background 
HF patients have increased sympathetic efferent neuronal activity which initially 
supports but ultimately harms the failing heart (Davis D et al., 1988;Eisenhofer G 
et al., 1996;Esler M et al., 1997). Several investigations have shown that there are 
elevated plasma NE levels (Cohen JN et al., 1984;Eisenhofer G et al., 1996;James 
KB et al., 1995), reduced NE concentration in cardiac tissue (Eisenhofer G et al., 
1996), increased spillover of NE into plasma (Eisenhofer G et al., 1996;Hasking 
G et al., 1986;Rundqvist B et al., 1997), and increased muscle sympathetic nerve 
firing in patient with HF (Narula J & Kunal S, 2003;Patel A & Iskandarian A, 
2002). All these factors have been related to poor prognosis and have been 
reported to improve when patients have either recovered from symptoms of heart 
failure or had had transplant (James KB et al., 1995). 
Catecholamines are synthesised from tyrosine as represented in figure 7.1. 
Figure 7.1: The pathway of catecholamine synthesis.  
 
Fig 7.1: Synthesis of dopamine, NE and epinephrine from tyrosine. Two major 
breakdown by-products, normetanephrine and metanephrine, reflect 
catecholamine turnover and could potentially be used as markers of catecholamine 
turnover in HF.  
337 
 
Determination of catecholamines, however, is challenging due to the low 
circulatory concentration. The best approach is to use mass spectrometry (MS) to 
analyse the circulatory amount. To achieve this liquid chromatography (LC) is 
used to generate the charged ions needed for detection by MS. LC transforms 
samples injected into sampling orifice into a beam of fine aerosol droplets. The 
droplets are charged using a fine capillary which holds 3-5 kV of electrical 
energy. Once the solvents evaporate from the droplets, the charges remain on the 
analytes for detection using MS (figure 7.2 and 7.3). 
 
Figure 7.2: Generation of ions from injected samples. 
 
Fig 7.2: Samples are injected into sample orifice and guided using two separate 
quadropoles towards the MS detector. 
Figure 7.3: The charging process of the analytes 
 
Fig 7.3: Once samples are charged, evaporation results with charged analytes 
ready for MS detection. The quadropoles shown in figure 7.2 are used to direct 
specific weighed charges (the chosen weight is predetermined by the analyser) 
towards the MS analyser. 
Sample
Column
Explosion
Evaporation Analyte Ion
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The high speed collision cell results in breaking down the large charged analytes 
to smaller substrates with different molecular weights. For example, NE has a 
molecular weight of 170 Dalton (Da) which breaks down to two compounds of 
molecular weights 152 Da and 107 Da. Epinephrine (EPI) has a molecular weight 
of 184 Da and during ionisation, it becomes very unstable and is converted to a 
molecule with 166 Da, EPI 166, which gives off two by-products with molecular 
weights of 77 Da and 107 Da. Figure 7.4 illustrates the chromatograms of seven 
different catecholamines and their breakdown products in our laboratory. 
 
Figure 7.4: The chromatogram of human catecholamines measured in serum 
 
Fig 7.4: Both epinephrine and normetanephrine have similar molecular weights 
and produce by-products with the same molecular weights. Metanephrine and 
dopamine have molecular weights of 198 Da and 154 Da, respectively, and each 
produce one ionised fragment. Norepinephrine has a molecular weight of 170 Da 
which produces two by-products with molecular weights of 107 Da and 152 Da. 
3,4-dihydroxybenzylamine is used as an internal standard.  
The aims of this study is to investigate the effects of LVAD and drug combination 
therapy on different catecholamine levels and to attempt to correlate the changes 
in their level with myocardial recovery, contractile reserve, and MIBG uptake. 
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7.2  Methods 
7.2.1  Patient population 
Blood sampling was performed serially in 14 out of the 23 patients (this is the 
same sub-population who had had the MIBG study, discussed in chapter 5) at two 
time points on the same day of MBIG nuclear imaging: 
iii) early post- device implantation i.e. once patients were stabilised, 
their inotropic support been discontinued for at least 5 days, and 
their mobility has been restored; and  
iv) immediately prior to either device explantation for myocardial 
recovery or transplant listing for failure to recover. 
Reasons for excluding 9 patients have been already discussed in chapter 5 (table 
5.1). Involved patients were asked to fast and refrain from drinking caffeine 
products for at least 24 hours before blood sampling. 
7.2.2  Sample collection and preparation 
An 18F sized cannula was inserted in the anti-cubital fossa at least 75 minutes 
before sample collection. The cannula was primed with 0.8 mls of heparin (5000 
units/ml). 36 mls of blood (24 mls serum and 12 mls plasma) were collected from 
the pre-cited cannula from each patient at each time point after at least 45 minutes 
of supine rest in a quiet room. The samples were immediately transferred to a 
fridge for storage at 4
o
C for a maximum of four hours before being centrifuged. 
Each sample was spun at 2000 rpm for 10 minutes after which the supernatant was 
removed and the cell pellet discarded. Both plasma and serum samples were then 
stored at –80oC until formal analysis could be performed as a batch process. 
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7.2.3  Assessment of catecholamines using liquid 
chromatography mass spectrometry (LCMS) 
Analysis was performed using liquid chromatography mass spectrometry 
(described above). After thawing the frozen serum samples, 0.5 ml was spiked 
with 2µl of 0.1 mM 3,4-dihydroxybenzylamine as an internal standard. Each 
sample was then added to 10 mg of activated alumina in an Eppendorff tube for 
adsorption. Sample was vortexed for 5 min. Tubes was then centrifuged at 13000 
rpm and supernatant discarded. Pellet was then washed twice with water and 0.02 
ml of 0.5 M acetic acid was used for elution (extraction).  
The eluate was then diluted three times before injecting at a flow rate of 0.2 
ml/min into a 1.8 μm diameter Agilent Eclipse Plus analytical column. Through 
the column each sample was allowed to pass a gradient from 0% to 70%.  
The total run time with re-equilibration was 12 minutes and the catecholamines 
quantified included: NE, EPI 166, Dopamine (DA), Normetanephrine (NorMET), 
and Metanephrine (MET). The peak of each chromatogram is multiplied by the 
molecular weight and the dilution factor to yield the final concentration in nmol/l. 
7.2.4   Data Collection and Statistical Analysis 
All data are presented as mean ± stdev and were collected prospectively. Data 
analysis was done using SPSS, version 16.0 for Windows, created by Lead 
Technologies. For serial analysis of catecholamine concentrations between the two 
time points, paired t-test and Wilcoxon Signed Ranks test were used for parametric 
and non-parametric measurements, respectively. Linear regression analysis was 
performed using the catecholamine measurements in the LVAD patients as 
independent parameters and myocardial recovery, CR, and MIBG uptake values as 
dependent parameters. p < 0.05 was considered statistically significant.  
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7.3  Results 
7.3.1  Effects of LVAD and drug combination therapy on 
catecholamine concentrations 
The first blood sample was taken early post device implantation at 35.21 ± 20.37 
days. The second sample was performed at 242.57 ± 82.25 days post implantation 
resulting in time difference between the two time points of 208.43 ± 85.50 days. 
Demographics and pre-implantation data for the 14 studied LVAD patients have 
been previously represented in table 5.2. Also a list of medication taken at each 
blood sampling was presented in table 5.3. 
Figure 7.5 represents the effects of LVAD and drug combination therapy on serial 
catecholamine levels. There was a significant reduction in NE by 47.6% (3.14 ± 
1.17 nmol/l versus 1.65 ± 0.46 nmol/l, p<0.001), EPI 166 by 32.0% (0.37 ± 0.15 
nmol/l versus 0.25 ± 0.11 nmol/l, p=0.028), DA by 27.6% (0.27 ± 0.12 nmol/l 
versus 0.19 ± 0.07 nmol/l, p=0.050). The reduction in both NorMET and MET 
were not significant (NorMET: 0.41 ± 0.25 nmol/l versus 0.36 ± 0.16 nmol/l, 
p=0.517; MET: 0.99 ± 0.46 nmol/l versus 0.92 ± 0.42 nmol/l, p=0.705). 
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Figure 7.5: Catecholamine levels in LVAD patients (n=14) 
   
       
 
Fig 7.5: There was a significant reduction in NE, EPI 166 and DA after a mean of 
208 days of LVAD support. 
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7.3.2  Catecholamines and myocardial recovery 
Out of the 14 HM II LVAD studied patients, 10 had recovered and were explanted 
whilst four patients were transplant listed. Comparing the effects of LVAD and 
drug combination therapy on the trend of catecholamine levels in the studied 
subgroup showed that the recovered patients had a significant reduction in NE 
(3.46 ± 1.15 nmol/l versus 1.56 ± 0.48 nmol/l, p<0.001) and EPI 166 (0.41 ± 0.16 
nmol/l versus 0.22 ± 0.11 nmol/l, p=0.007, figure 7.6) and no significant change 
in DA, NorMET and MET levels. 
 
Figure 7.6: Effects of LVAD and drug combination therapy on catecholamine 
levels in the recovered patients (n=10) 
 
      
 
Fig 7.6: Both NE and EPI 166 decreased significantly in the recovered patients. 
There were no significant differences in DA, NorMET, and MET levels. 
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The non-recovered patients showed a reduction in NE, DA, NorMET and MET 
and an increase in EPI 166 between the two time points. However, none of the 
changes reached statistical significance (figure 7.7). 
 
Figure 7.7: Effects of LVAD and drug combination therapy on catecholamine 
levels in the non-recovered patients (n=4) 
 
 
      
 
 
Fig 7.7: There was no significant difference in catecholamine levels in the non-
recovered patients. These data, however, need to be cautiously interpreted due to 
the low sample number. 
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Further, the percentage reduction in NE and EPI 166 levels were significantly 
higher in the recovered patients as compared to the non-recovered patients. NE 
decreased by 51.7% in the recovered patients as compared to 14.2% in the non-
recovered patients. EPI 166 decreased by 39.5% in the recovered patients as 
compared to a rise by 26.2% in the non-recovered patients. The percentage 
reduction in DA was higher in the non-recovered patients but did not reach 
statistical significance (figure 7.8). 
 
Figure 7.8: Percentage change in catecholamine levels 
 
      
 
Fig 7.8: There was a significant reduction in NE and EPI 166 in the recovered 
patients as compared to the non-recovered patients.  
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Linear regression analysis has revealed a strong correlation between percentage 
changes in NE and EPI 166 and myocardial recovery such that a higher 
percentage decrease in either was significantly associated with recovery (figures 
7.9 A-E). No correlation between myocardial recovery and changes in DA, 
NorMET and MET has been identified. 
 
Figure 7.9: Correlation between percentage changes in catecholamines and 
myocardial recovery 
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Fig 7.9: A-E correlation analysis between percentage change in catecholamine 
levels and myocardial recovery. There was a significant correlation between 
percentage reduction in NE and EPI 166 and myocardial recovery. 
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7.3.3  Catecholamines and CR 
As represented in chapter 4, the HM II and drug combination therapy had resulted 
in a significant change in CR such that a 6MW exercise test had induced an 
absolute increase in the EF by 5.25 ± 5.30% in all 23 studied patients. In the 14 
sub-population the absolute increase in the EF following the 6MW exercise test 
was 5.89 ± 6.07% with 11 patients (10 recovered and 1 non-recovered) had had an 
absolute increase and 3 non-recovered patients had an absolute reduction.  
Linear regression analysis revealed a significant negative correlation between CR 
and the percentage change in both NE and EPI 166 such that as the circulating 
levels of these catecholamines had decreased the CR increased. Figure 7.10 
illustrates the correlation between CR and the percentage change in NE and EPI 
166 levels between the two time points. There was no correlation between the 
other three catecholamines measured and CR.  
 
Figure 7.10: Relationship between percentage change in NE and CR      
 
  
Fig 7.10: A) Relationship between early percentage change in NE and CR. B) 
Relationship between percentage change in EPI 166 and CR. 
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7.3.4  Correlation between catecholamine levels and 
123
I-
MIBG uptake parameters 
There was a moderate positive correlation between NE and 
123
I-MIBG measured 
early H/M and delayed H/M ratios (see chapter 5) in the 14 studied patients 
(figures 7.11A and 7.11B). As the NE levels decreased, both ratios have increased 
(early H/M: r=0.522, p=0.004; delayed H/M: r=0.497, p=0.007). There was also a 
weak but a significant negative correlation between W/O rate and NE levels 
(r=0.404, p=0.033) (figure 7.11C). 
No correlation was identified between other catecholamines and MIBG uptake 
parameters. 
 
Figure 7.11: Relationship between NE concentrations and 
123
I-MIBG uptake 
parameters 
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Fig 7.11: There was a negative correlation between NE concentration and EHM 
and DHM ratios (figures A and B, respectively) and a positive correlation with 
W/O rate (figure C). 
  
0
1
2
3
4
5
6
7
0 0.5 1 1.5 2 2.5 3 3.5
N
E
 C
o
n
ce
n
tr
a
ti
o
n
 (
n
m
o
l/
l)
Delayed H/M ratio
0
1
2
3
4
5
6
7
0 20 40 60 80 100
N
E
 C
o
n
ce
n
tr
a
ti
o
n
 (
n
m
o
l/
l)
W/O rate (%)
C) 
B) 
r= 0.404 
p=0.033 
r= -0.497 
p=0.007 
351 
 
7.4  Discussion 
The main findings of the present study include: 
 LVAD and drug combination therapy resulted in a significant reduction in 
NE, EPI 166, and DA, 
 The percentage change in NE and EPI 166 concentrations were more 
significant in the recovered group as compared to the non-recovered 
patients and correlated significantly with myocardial recovery, 
 The percentage changes in NE and EPI 166 concentrations exhibited a 
significant negative correlation with contractile reserve, 
 There was a significant correlation between NE concentrations and 123I-
MIBG uptake measured parameters. 
Role of catecholamines in HF 
To overcome the deficit in cardiac output in HF the body compensates by an 
enhanced activation of the SNS (Rundqvist B et al., 1997). The adaptations in the 
neurohormonal pathway play an important role in determining the signs and 
symptoms of HF such that elevated levels of NE and epinephrine contribute to: 
i) the maintenance of perfusion of vital organs,  
ii) preservation of the systemic pressure by increasing the vascular 
resistance, and  
iii) the restoration of cardiac output by increasing myocardial contractility 
of the heart and by expansion of the extracellular volume.  
These compensatory mechanisms however, lead to a further deterioration in 
cardiac performance which includes the development of pulmonary congestion 
and peripheral oedema secondary to elevation in diastolic pressure, depression in 
cardiac function due to an increase in LV afterload which is induced by the rise in 
peripheral resistance, and coronary ischaemia which is induced by increased heart 
rate (Novo G et al., 2009). Furthermore, the rise of NE has been shown to 
correlate with the severity of cardiac dysfunction and inversely with survival 
(Cohen JN et al., 1984;Anand IS et al., 2003) and improve when patients have 
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either recovered from symptoms of HF using different therapeutic interventions 
(Anand IS et al., 2003;Liang C, 2003) or had had transplant (James KB et al., 
1995). 
Determining catecholamine concentrations – technical aspects 
The effects of LV unloading on catecholamine levels in patients who have 
recovered using LVAD without the need of transplantation, however, have not 
been investigated to date. 
Determination of catecholamines, however, is challenging due to the low 
circulatory concentration. In 1995, James et al have used radioenzyme assay 
technique to detect NE levels in plasma (James KB et al., 1995). Their approach 
and others such as ELISA have shown to be very time consuming, involve 
complicated multiple steps, and sometimes non-reproducible (Mishra A et al., 
2009). LCMS has been previously validated as a technique with high sensitivity 
and specificity in determining NE levels in either plasma or serum (Mishra A et 
al., 2009). 
Although NE was the main molecule of interest, we have also studied the effects 
of LVAD and drug combination therapy on four other catecholamines that are 
produced throughout the catecholamine synthesis pathway. To ensure that the 
collected blood samples were not contaminated from other endogenous sources of 
NE (such as from the adrenal gland), all patients were laid supine in a quiet 
environment for at least 45 minutes with a pre-cited cannula. Once samples were 
collected, they were processed rapidly to avoid biodegradation of the 
catecholamines. 
Interestingly, epinephrine was very unstable once ionised and yielded EPI 166, a 
smaller molecule with a molecular weight of 166 Da. The latter was more stable 
for analysis. In the present study we have used the Agilent Quadropole Analyser 
to measure the concentrations of NE, EPI 166, DA, NorMET, and MET levels in 
LVAD patients and hence to determine the impact of LVAD and drug 
combination therapy on these catecholamine levels. 
 
353 
 
LVAD and catecholamine levels 
All 14 studied patients exhibited a reduction in catecholamine levels following 
LVAD and drug combination therapy. Interestingly, the recovered patients 
exhibited the most significant reductions in NE and EPI 166 as compared to the 
non-recovered patients who did not show any significant change following LVAD 
support. Furthermore, the percentage decrease in both NE and EPI 166 was 
significantly higher in the recovered patients as compared to the non-recovered 
patients and correlated significantly to myocardial recovery. 
To link the relationship between CR and catecholamine / neurohormonal pathway, 
significant negative correlations between NE and EPI 166 levels and CR were 
identified suggesting that high levels of circulating neurotransmitters NE and EPI 
result into poor CR and thus poor prognosis. In conjunction with the correlation 
between 
123
I-MIBG uptake and CR (illustrated in chapter 5), this correlation 
analysis between catecholamine levels and CR is an extra supporting evidence 
that CR is an important clinical marker / parameter in determining the degree of 
myocardial recovery. 
Limitations 
A major limitation of this study is the small number of included patients which 
means that the results, especially in the non-recovered patients, should be drawn 
cautiously. Another limitation was the unavailability of pre-implant 
catecholamine concentrations such that all patients were on multiple inotropic 
supports which would interfere with the analysis (Appendix A for the pre-implant 
medication).  
The reduction in catecholamine levels using LVAD and drug combination 
therapy, however, is encouraging to suggest the need for a trial with a large 
number of patients and to obtain serial measurements at different preset time 
points from the time of implantation such as on biweekly basis and prior to 
commencing clenbuterol. This would also allow the correlation of the changes 
seen in catecholamine levels with the uptitration of the medication in the LVAD 
patients. 
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Conclusion 
In summary, this study has shown that LVAD and drug combination therapy has 
directly improved NE and EPI levels in patients with end-stage HF. The 
percentage improvement was more significant in the recovered patients and 
correlated significantly with recovery, CR and MIBG uptake parameters. 
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CHAPTER 8 – General Discussion 
and Future Directions 
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HF is a complex syndrome that is associated with enhanced neurohormonal 
activation. The pathophysiology of HF is initiated by over-stimulation of the 
cardiac SNS. The synaptic NE abundance in HF is secondary to excessive release 
from the afferent neurons and failure of NET uptake mechanism at the presynaptic 
membrane. Activation of the inflammatory axis and different pathways of the 
ECM will result into the pathological and remodeling features seen in HF. 
Clinically cardiac sympathetic dysfunction has been correlated to impaired 
myocardial contractile reserve, impaired contractility, and reduced exercise 
tolerance.  
LV unloading using LVAD has been shown to induce significant improvement in 
many pathophysiologic pathways involved in HF. Clinically these improvement 
were translated into significant advancements in haemodynamic and 
echocardiographic parameters, exercise tolerance, and QOL. The use of the 
Harefield BTR protocol in patients supported with pulsatile flow devices has 
resulted in an enhanced degree of myocardial recovery and made recovery more 
sustainable.   
For the first time, this thesis reports the effects of continuous flow LVADs 
combined with aggressive pharmacologic regimen in the induction of myocardial 
recovery. This protocol has resulted in myocardial recovery in 65% of patients 
with end-stage non-ischaemic HF, as evidenced by significant improvements in 
echocardiographic, haemodynamic, and exercise tolerance parameters. 
Despite the efficiency of the continuous flow device in providing equivalent 
degree of haemodynamic support, LV unloading, end-organ perfusion, and 
exercise capacity to pulsatile LVADs, it is believed that continuous monitoring of 
myocardial recovery, the hallmark in the recovery protocol, would be impossible 
since continuous flow device provide less pulsatility and generate negative 
pressure in the inflow cannula as a result of the suctioning effects of the rotary 
pump. Therefore, device cessation (normally performed with pulsatile devices to 
assess the native LV function) would result in severe retrograde filling of the LV 
masking the real function of the native ventricle. In chapter 3, time modelling 
analysis, bench work experiment and clinical studies have determined that speed 
reduction unmask the underlying LV function allowing ―near‖ accurate 
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assessment of the native LV. A speed of 6000 rpm was found to be safe, tolerable 
by all patients with no ill-side effects, sufficient to assess the native LV function 
and would not result in massive retrograde filling that would hinder LV 
assessment.  
To assess the effects of LVAD on direct LV unloading and tolerance to 
physiological ―day-to-day activity‖ exercise, CR following six-minute walk was 
chosen as an objective quantification to assess the effects of LVAD on LV 
contractility. The inhibition of CR associated with exercise intolerance has been 
shown to represent important clinical dilemmas in the pathophysiology of HF 
where both are induced by excessive stimulation of cardiac SNS. In our studied 
population, those who had recovered had better exercise tolerance and CR as 
illustrated by significant improvement in their echocardiographic and 
haemodynamic parameters when compared to the non-recovered patients. 
Improvements in both CR and exercise tolerance in the recovered patients were 
consistent throughout the duration of the LVAD support. Interestingly, those who 
were supported with the continuous flow HM II LVAD had a better response to 
exercise than those supported with the pulsatile HM I LVAD. 
In this thesis, 
123
I-MIBG nuclear imaging was used as a direct measure of the 
importance of NET in the pathophysiology of HF and recovery. For the first time, 
the use of 
123
I-MIBG imaging has been validated in LVAD patients. The presence 
of the inflow cannula in the LV apex posed major challenges in the technical 
aspect of imaging. This has led to the development of a specific region of interest 
that accounts for the inflow cannula without compromising the final outcome of 
the results. Furthermore, there was high intra- and inter-observer reproducibility 
in the studied population.  
LVAD and drug combination therapy has resulted in a significant improvement in 
MIBG uptake parameters independent of the LV size suggesting that 
improvements in uptake measurements are merely due to positive changes in NET 
function rather than reduction in LV size secondary to unloading.  
The main purpose of MIBG imaging, however, was to try to utilise it as an 
additional explantation tool. Alas, LVAD and drug combination therapy has 
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resulted in a significant increase in MIBG uptake in both recovered and non-
recovered patients. Although, the results need to be interpreted cautiously due to 
the small number of the non-recovered patients, it can still be argued that MIBG 
imaging is not a useful tool to guide explantation and that this component of the 
thesis turned out to be an observational study which demonstrated the direct 
positive effects of unloading and combination therapy on MIBG uptake and the 
indirect improvements of NET and the SNS. The enhancements in MIBG uptake 
parameters, however, were much higher in the recovered than the non-recovered 
patients. In addition, MIBG nuclear imaging was a useful tool to demonstrate that 
LV unloading using LVAD and drug combination therapy has resulted in much 
higher uptake levels as compared to patients who were treated with different oral 
medications. In addition the improvements in MIBG uptake parameters were 
sustained in explanted patients.  
In chapter 6 immunohistochemistry analysis was utilised as an approach to study 
the correlation between NET and myocardial recovery. Again this is the first time 
to correlate the concentration of NET-immunoreactive nerve fibers at the time of 
implantation to myocardial recovery suggesting that analysis of NET from the LV 
core could ―pre-determine‖ which patients shall recover and will have their device 
explanted. Again another novel finding of this thesis was the abundance of NET 
in the LV apex. Based on search in the English literature, this was the first time to 
demonstrate that NET-immunoreactive nerve fibers could be visualised in the LV 
apex.  
LVAD and drug combination therapy have also been shown to reduce 
catecholamine levels with the percentage reduction being more significant in the 
recovered patients. Similar to MIBG uptake, NE and epinephrine levels have 
correlated significantly with recovery.  
To illustrate the importance of CR as an important explanation tool / guide, a 
correlation analysis revealed moderate correlations between MIBG uptake and CR 
and between the percentage change in catecholamine levels and CR suggesting an 
important association between CR and SNS in HF and recovery. 
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Future Directions 
The ability to produce a rate of 65% of recovery in patients with end-stage non-
iscahemic heart failure using continuous flow LVAD and drug combination 
therapy is very encouraging to conduct a randomised multi-centre trial. It is also 
encouraging to reproduce the results using third generation devices such as 
HeartWare. Furthermore, it is of paramount importance to attempt recovering 
patients with ischaemic origin once the extent of viability has been assessed. 
It is of paramount importance to define more explanation tools / guidelines. One 
approach is to use PET imaging to determine the viability of different LV regions 
during LVAD support and to device a score to add to the current explantation 
guidelines. 
Results from the MIBG study are encouraging to suggest the need for a trial with 
a large number of patients to provide the opportunity to assess MIBG uptake at 
different set time points from the time of implantation such as on quarterly basis 
and prior to commencing clenbuterol. This would also allow the correlation of the 
changes seen in MIBG uptake with the uptitration of the medication in the LVAD 
patients. 
Although LV unloading combined with anti-failure medication was sufficient to 
induce sustained myocardial recovery, gene therapy may still have a major role. 
For example, overexpression of NET using targeted gene therapy should be 
looked at. This could improve SNS function and ameliorate the negative effects of 
dysfunctional NET. Studying the heterogeneity of NET distribution using 
immunohistochemistry, however, will be a preceding step to determine the target 
areas where NET carrying vectors could be delivered and how. 
. 
 
  
360 
 
References List 
Aaronson KD, Eppinger MJ, Dyke DB, Wright S, Pagani FD. Left ventricular 
assist device therapy improves utilization of donor hearts. J Am.Coll.Cardiol. 
2002; 39:1247-1254. 
Abraham WT. Switching between beta blockers in heart failure patients: rationale 
and practical considerations. Congest Heart Fail 2003; 9:251-254. 
Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel 
TH, Cheng ML, Wynne J. In-hospital mortality in patients with acute 
decompensated heart failure requiring intravenous vasoactive medications: an 
analysis from the Acute Decompensated Heart Failure National Registry 
(ADHERE). J Am Coll Cardiol 2005; 46:57-64. 
Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic 
DZ, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, 
Truex C, McAtee P, Messenger J. Multicenter InSync Randomized Clinical 
Evaluation: cardiac resynchronization in chronic heart failure. N Eng J Med 2002; 
346:1845-1853. 
ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE 
inhibitors in the early treatment of acute myocardial infarction: systematic 
overview of individual data from 100,000 patients in randomized trials. 
Circulation 1998; 97:2202-2212. 
Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, 
Brown JH, Dorn II GW. Enhanced G q signaling: a common pathway mediated 
cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci 1998; 
95:10140-10145. 
Adams KF, De Marco T, Berkowitz RL, Chand S. Inotrope use and negative 
outcomes in treatment of acute heart failure in patients with preserved systolic 
function: data from the ADHERE database. In: 2003. p. IV-695. 
Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham 
WT, Berkowitz RL, Galvao M, Horton DP. Characteristics and outcomes of 
patients hospitalised for heart failure in the United States: Rationale, design, and 
preliminary observations from the first 100,000 cases of Acute Decompensated 
Heart Failure National Registry (ADHERE). Am Heart J 2005; 149:209-216. 
Adams KF, Zannad F. Clinical definition and epidemiology of advanced heart 
failure. Am Heart J 1998; 135:S204-S215. 
Agostini D, Belin A, Amar MH, Darlas Y, Hamon M, Grollier G, Potier JC, 
Bouvard G. Improvement of cardiac neuronal function after carvedilol treatment 
in dilated cardiomyopathy: A
123
I-MIBG scintigraphic study. J Nucl Med 2000; 
41:845-851. 
361 
 
Agostini D, Carrio I, Verberne HJ. How to use myocardial 
123
I-MIBG 
scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging 2009a; 36:555-
559. 
Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, Unlu 
M, Estorch M, Banerjee G, Jacobson AF. I-123-mIBG myocardial imaging for 
assessment of risk for a major cardiac event in heart failure patients: insights from 
a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2009b; 
35:355-356. 
Agostini D, Verberne HJ, Hamon M, Jacobson AF, Manrique A. Cardiac 
123
I-
MIBG scintigraphy in heart failure. Q J Nucl Med Mol Imaging 2008; 52:369-
377. 
Akasaka T, Yoshida K, Hozumi T, Takagi T, Kaji S, Kawamoto T, Ueda Y, 
Okada Y, Morioka S, Yoshikawa J. Restricted coronary flow reserve in patietns 
with MR improves after mitral reconstructive surgery. J Am Coll Cardiol 1998; 
32:1923-1930. 
Akhter SA, Skaer CA, Kypson AP, McDonald PH, Peppel KC, Glower DD, 
Lefkowitz RJ, Koch WJ. Restoration of -adrenergic signaling in failing cardiac 
ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci 
1997; 94:12100-12105. 
Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, Levine 
F, Schloss M. Results of coronary artery surgery in patients with poor left 
ventricular function (CASS). Circulation 1983; 68:785-795. 
Ali Ahmed. Myocardial beta-1 adrenoceptor down-regulation in aging and heart 
failure: implications for beta-blocker use in older adults with heart failure. Eur J 
Heart Fail 2003; 5:709-715. 
Allman KC, Lahiri A. I-123 MIBG scintigraphy in idiopathic dilated 
cardiomyopathy: where next? J Nucl Cardiol 2002; 9:127-30. 
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial Viability 
Testing and Impact of Revascularization on Prognosis in Patients With Coronary 
Artery Disease and Left Ventricular Dysfunction: A Meta-Analysis. J Am Coll 
Cardiol 2002; 38:1151-1158. 
Altemose GT, Gritsus V, Jeevanandam V, Goldman B, Margulies KB. Altered 
myocardial phenotype after mechanical support in human beings with advanced 
cardiomyopathy. J.Heart Lung Transplant. 1997; 16:765-773. 
Amir O, Bracey AW, Smart FW, Delgado RM 3rd, Shah N, Kar B, Gregoric ID. 
A successful anticoagulation protocol for the first HeartMate® II implantation in 
the United States. Tex Heart Inst J. 2005; 32:399-401. 
Amir O, Radovancevic B, Delgado RM 3rd, Kar B, Radovancevic R, Henderson 
M, Cohn WE, Smart FW. Peripheral vascular reactivity in patients with pulsatile 
362 
 
vs axial flow left ventricular assist device support. J Heart Lung Transplant 2006; 
25:391-394. 
Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Studies of 
body water and sodium, renal function, hemodynamic indexes, adn plasma 
hormones in untreated congestive cardiac failure. Circulation 1989; 80:299-305. 
Anand IS, Fisher LD, Chiang YT. Changes in brain natriuretic peptide and 
norepinephrine over time and mortality and morbidity in the Valsartan Heart 
Failure Trial (Val-HeFT). Circulation 2003; 107:1278-1283. 
Anastasiou-Nana M, Terrovitis JV, Athanasoulis T, Karaloizos L, Geramoutsos 
A, Pappa L, Tsagalou E, Efentakis S, Nanas JN. Prognostic value of iodine-123-
metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic 
congestive heart failure secondary to ischemic or idiopathic dilated 
cardiomyopathy. Am J Cardiol 2005; 96:427-31. 
Andersen M, Videbæk R, Boesgaard S, Sander K, Hansen PB, Gustafsson F. 
Incidence of ventricular arrhythmias in patients on long-term support with a 
continuous-flow assist device (HeartMate II). J Heart Lung Transplant 2009; 
28:733-735. 
Anger M, Lambert F, Chemla D, Desche P, Scalbert E, Lompre AM, Lecarpentier 
Y. Sarcoplasmic reticulum Ca2+ pumps in heart and diaphragm of 
cardiomyopathic hamster: effects of perindopril. Am.J.Physiol 1995; 268:H1947-
H1953. 
Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The 
significance of the results of RECOVER, RENAISSANCE, RENEWAL and 
ATTACH. Int.J.Cardiol. 2002; 86:123-130. 
Ankersmit HJ, Tugulea S, Spanier T, Weinberg AD, Artrip JH, Burke EM, 
Flannery M, Mancini D, Rose EA, Edwards NM, Oz MC, Itescu S. Activation-
induced T-cell death and immune dysfunction after implantation of left-
ventricular assist device. Lancet 1999; 354:550-5. 
Apparsundaram S, Galli A, DeFelice LJ, Hartzell HC. Acute regulation of 
norepinephrine transport: I. protein kinase C-linked muscarinic receptors 
influence transport capacity and transporter density in SK-N-SH cells. Jr 
Pharmacol Exp Therap 1998a; 287:733-743. 
Apparsundaram S, Schroeter S, Giovanetti E, Blakely RD. Acute regulation of 
norepinephrine transport: II. PKC-modulated surface expression of human 
norepinephrine transporter proteins. J Pharm Exp Ther 1998b; 287:744-751. 
Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M. Alterations in 
sarcoplasmic reticulum gene expression in human heart failure. A possible 
mechanism for alterations in systolic and diastolic properties of the failing 
myocardium. Circ.Res. 1993; 72:463-469. 
363 
 
Arai M, Otsu K, MacLennan DH, Periasamy M. Regulation of sarcoplasmic 
reticulum gene expression during cardiac and skeletal muscle development. 
Am.J.Physiol 1992; 262:C614-C620. 
Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ, Jr., 
Olsen EG, Schoen FJ. Myocarditis. A histopathologic definition and 
classification. Am.J.Cardiovasc.Pathol. 1987; 1:3-14. 
Arimoto T, Takeishi Y, Nizeki T, Koyama Y, Okuyama H, Nozaki N, Hirono O, 
Tsunoda Y, Miyashita T, Shishido T, Okada A, Takahashi K, Kubota I. Ongoing 
myocardial damage relates to cardiac sympathetic nervous disintegrity in patients 
with heart failure. Ann Nucl Med 2005; 19:535-40. 
Aronson D, Burger AJ. Neurohormonal activation and ventricular arrhythmias in 
patients with decompensated congestive heart failure: role of endothelin. Pacing 
Clin Electrophysiol 2003a; 26:703-710. 
Aronson D, Burger AJ. Neurohormonal prediction of mortality following 
admission for decompensated heart failure. Am J Cardiol 2003b; 91:245-248. 
Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, Ng K, 
Marcano V, Heller S, Fisher JD, Travin MI. I-123 MIBG imaging and heart rate 
variability analysis to predict the need for an implantable carioverter defibrillator. 
J Nucl Cardiol 2003; 10:121-131. 
ATS Statement. Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care 
Med 2002; 166:111-117. 
Atsumi H, Takeishi Y, Fujiwara S, Tomoike H. Cardiac sympathetic nervous 
disintegrity is related to exercise intolerance in patients with chronic heart failure. 
Nucl Med Commun 1998; 19:451-456. 
Awede BL, Thissen JP, Lebacq J. Role of IGF-I and IGFBPs in the changes of 
mass and phenotype induced in rat soleus muscle by clenbuterol. Am.J Physiol 
Endocrinol.Metab 2002; 282:E31-E37. 
Bach DS, Bolling SF. Early improvement in CHF after correction of secondary 
MR in end-stage cardiomyopathy. Am Heart J 1995; 129:1165-1170. 
Bach DS, Bolling SF. Improvement following correction of secondary MR in end-
stage cardiomyopathy with mitral annuloplasty. Am J Cardiol 1996; 78:966-969. 
Backs J, Bresch E, Lutz M, Kristen A, Haass M. Endothelin-1 inhibits the 
neuronal norepinephrine transporter in hearts of male rats. Cardiovasc Res 2005; 
67:283-290. 
Backs J, Haunstetter A, Gerber SH, Metz J, Borst MM, Strasser RH, Kübler W, 
Haass M. The neuronal norepinephrine transporter in experimental heart failure: 
evidence for a posttranscriptional downregulation. J Mol Cell Cardiol 2001; 
33:461-72. 
364 
 
Badhwar V, Bolling SF. Mitral valve surgery: when is it appropriate? Congest 
Heart Fail 2002; 8:210-213. 
Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, 
Knowlton KU. Enteroviral protease 2A cleaves dystrophin: evidence of 
cytoskeletal disruption in an acquired cardiomyopathy. Nat.Med. 1999; 5:320-
326. 
Balijepallia RC, Maetzb NA, Bucka JM, Haworthe RA, Valdiviab HH, Kamp TJ. 
Depletion of T-tubules and specific subcellular changes in sarcolemmal proteins 
in tachycardia-induced heart failure. Cardiovasc Res 2003; 59:67-77. 
Ballingand JL, Ungureanu D, Kelly RA, Kobzik L, Pimental D, Michel T, Smith 
TW. Abnormal contractile function due to induction of nitric oxide synthesis in 
rat cardiac myocytes follows exposure to activates macrophage-conditioned 
medium. J Clin Invest 1993; 91:2314-2319. 
Bank AJ, Mir SH, Nguyen DQ, Bolman RM III, Shumway SJ, Miller LW, Kaiser 
DR, Ormaza SM, Park SJ. Effects of left ventricular assist devices on outcomes in 
patients undergoing heart transplantation. Ann Thorac Surg 2000; 69:1369-1375. 
Bardy GH, Lee KL, Mark DB. Amiodarone or an implantable cardioverter-
defibrillator for congestive heart failure. N Eng J Med 2005a; 352:225-237. 
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, 
Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-
Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an 
implantable cardioverter-defibrillator for congestive heart failure. N Eng J Med 
2005b; 352:225-237. 
Barnard CN. A human cardiac transplant: an interim report of a successful 
operation performed at Groote Schuur Hospital, Capetown. S Afr Med J 1967; 
41:1271. 
Barnes PJ, Karin M. Nuclear factor- B - a pivotal transcription factor in chronic 
inflammatory disease. N Eng J Med 1997; 336:1066-1071. 
Bartling B, Milting H, Schumann H, Darmer D, Arusoglu L, Koerner MM, El-
Banayosy A, Koerfer R, Holtz J, Zerkowski HR. Myocardial gene expression of 
regulators of myocyte apoptosis and myocyte calcium homeostasis during 
hemodynamic unloading by ventricular assist devices in patients with end-stage 
heart failure. Circulation 1999; 100:II216-II223. 
Batista RJ, Santos JL, Takeshita N, Bocchino L, Lima PN, Cunha MA. Partial left 
ventriculectomy to improve LV function in end-stage heart disease. J Card Surg 
1996; 11:96-97. 
Bauman PA, Blakely RD. Determinants within the C-terminus of the human 
norepinephrine transporter dictate transporter trafficking, stability, and activity. 
Arch Biochemist Biophysics 2002; 404:80-91. 
365 
 
Bax JJ, Abraham T, Barold S, Breithard OA, Fung JWH, Garrigue S, Gorcsan J, 
Hayes DL, Kass DA, Knuuti J, Leclercq C, Linde C, Mark DB, Monaghan MJ, 
Nihoyannopoulos P, Schalij MJ, Stellbrink C, Yu C. Cardiac resynchronization 
therapy. J Am Coll Cardiol 2005; 46:2153-2167. 
Bax JJ, Gorcsan J. Echocardiography and noninvasive imaging in cardiac 
resynchronization therapy: results of the PROSPECT (Predictors of Response to 
Cardiac Resynchronization Therapy) study in perspective. J Am Coll Cardiol 
2009; 53:1933-1943. 
Bax JJ, Poldermans D, Schinkel AFL, Boersma E, Elhendy A, Maat A, Valkema 
R, Krenning EP, Roelandt JRTC. Perfusion and contractile reserve in chronic 
dysfunctional myocardium: relation to functional outcome after surgical 
revascularization. Circulation 2002; 106 (Suppl I):I-14-I-18. 
Beckett AH. Clenbuterol and sport. Lancet 1992; 340:1165. 
Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function 
using PET imaging. J Nucl Cardiol 2004; 11:603-16. 
Benovic JL, Mayor F, Staniszewski C, Lefkowitz R, Caron MG. Purification and 
characterisation of the adrenergic receptor kinase. J Biol Chem 1987; 
262:9026-9032. 
Bernard Swynghedauw. Molecular mechanisms of myocardial remodeling. 
Physiological Reviews 1999; 79:216-248. 
Berry C, Clark AL. Catabolism in chronic heart failure. Eur J Heart Fail 2000; 
21:521-532. 
Bersohn MM, Scheuer J. Effects of physical training on end-diastolic volume and 
myocardial performance of isolated rat hearts. Circ.Res. 1977; 40:510-516. 
Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-
blocker bucindolol in patients with advanced chronic heart failure. N Eng J Med 
2001; 344:1659-1667. 
Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in 
isolated ventricular myocytes from patients with terminal heart failure. Circulation 
1992; 85:1046-1055. 
Bhama JK, Kormos RL, Toyada Y, Teuteberg JJ, McCurry KR, Siegenthaler MP. 
Clinical Experience Using the Levitronix CentriMag System for Temporary Right 
Ventricular Mechanical Circulatory Support. J Heart Lung Transplant 2009; 
28:971-976. 
Birks EJ, Hall JL, Barton PJ, Grindle S, Latif N, Hardy JP, Rider JE, Banner NR, 
Khaghani A, Miller LW, Yacoub MH. Gene profiling changes in cytoskeletal 
proteins during clinical recovery after left ventricular-assist device support. 
Circulation 2005; 112:57-64. 
366 
 
Birks EJ, Latif N, Owen V, Bowles C, Felkin LE, Mullen AJ, Khaghani A, Barton 
PJR, Polak JM, Pepper JR, Banner NR, Yacoub MH. Quantitative myocardial 
cytokine expression and activation of the apoptotic pathway in patients requiring 
left ventricular assist devices. Circulation 2001; 104:I-233 - I-240. 
Birks EJ, Tansley PD, Hardy JP, George RS, Bowles CT, Burke M, Banner NR, 
Khaghani A, Yacoub MH. Left ventricular assist device and drug therapy for the 
reversal of heart failure. N Engl J Med 2006; 355:1873-84. 
Birks EJ, Tansley PD, Yacoub MH, Bowles CT, Hipkin M, Hardy J, Banner NR, 
Khaghani A. Incidence and clinical management of life-threatening left 
ventricular assist device failure. J Heart Lung Transplant 2004; 23:964-969. 
Birks EJ, Yacoub MH. Role of nitric oxide and cytokines in heart failure. Coron 
Artery Dis 1997; 8:389-402. 
Birks E, Tansley PD, Bowles CT. Outcome and multiorgan function following 
transplantation of patients on left ventricular assist devices. Transplantation 2002; 
74:737. 
Birks EJ, Yacoub MH, Banner NR, Khaghani A. The role of bridge to 
transplantation: should LVAD patients be transplanted? Curr.Opin.Cardiol. 2004; 
19:148-153. 
Bishay ES, McCarthy PM, Cosgrove DM, Hoercher KJ, Smedira NG, Mukherjee 
D, White J, Blackstone EH. Mitral valve surgery in patients with severe left 
ventricular dysfunction. Eur J Cardiothorac Surg 2000; 17:213-221. 
Bishopric NH, Simpson PC, Ordahl CP. Induction of the skeletal alpha-actin gene 
in alpha 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes. J Clin 
Invest 1987; 80:1194-1199. 
Bishopric NH, Kedes L. Adrenergic regulation of the skeletal alpha-actin gene 
promoter during myocardial cell hypertrophy. Proc.Natl.Acad.Sci.U.S.A 1991; 
88:2132-2136. 
Bitran D, Merin O, Klutstein MW, Od-Allah S, Shapira N, Silberman S. Mitral 
valve repair in severe ischemic cardiomyopathy. J Card Surg 2001; 16:79-82. 
Bittner HB, Savitt MA. Off-pump coronary aretery bypass grafting decreases 
morbidity adn mortality in a selected group of high-risk patients. Ann Thorac 
Surg 2002; 74:115-118. 
Bittner V. Six-minute walk test in patients with cardiac dysfunction. Cardiologia 
1997; 42:897-902. 
Bittner V. Determining prognosis in congestive heart failure: role of the 6-minute 
walk test. Am Heart J 1999; 138:593-596. 
Bittner V. Exercise testing in heart failure. J Am Coll Cardiol 2003; 42:123-125. 
367 
 
Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, 
Kronenberg MW, Kostis JB, Kohn RM, Guilotte M, Greenberg B, Woods PA, 
Bourassa MG. Prediction of mortality and morbidity with a 6-minute walk test in 
patients with left ventricular dysfunction. JAMA 1993; 270:1702-1707. 
Blakely RD, De Felice LJ, Hartzell HC. Molecular physiology of norepinephrine 
and serotonin transporters. J Exp Biol 1994; 196:263-81. 
Bland JM, Altman DG. Statistical methods for assessing agreement between two 
methods of clinical measurement. Lancet 1986; i:307-310. 
Bland JM, Altman DG. Comparing methods of measurement: why plotting 
difference against standard method is misleading. Lancet 1995; 346:1085-1087. 
Blondheim DS, Jacobs LE, Kotler MN, Costacurta GA, Parry WR. Dilated heart 
failure with mitral regurgitation: decreased survival despite a low frequency of left 
ventricular thrombus. Am Heart J 1991; 122:763-771. 
Boateng SY, Naqvi RU, Koban MU, Yacoub MH, MacLeod KT, Boheler KR. 
Low-dose ramipril treatment improves relaxation and calcium cycling after 
established cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2009; 
280:H1029-H1038. 
Boateng SY, Seymour AM, Bhutta NS, Dunn MJ, Yacoub MH, Boheler KR. Sub-
antihypertensive doses of ramipril normalize sarcoplasmic reticulum calcium 
ATPase expression and function following cardiac hypertrophy in rats. J.Mol.Cell 
Cardiol. 1998; 30:2683-2694. 
Boehar N, Erdogan AK, Lee DC, Sabbah HN, Kern MJ, Teerlink J, Bonow RO, 
Gheorghiade M. Acute heart failure syndromes and coronary perfusion. J Am Coll 
Cardiol 2008; 52:13-16. 
Böhm M, La Rosee K, Schwinger RH, Erdmann E. Evidence for reduction of 
norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 1995; 
25:146-53. 
Bolling SF. Miral reconstruction in cardiomyopathy. J Heart Valve Dis 2002; 
11:S26-S31. 
Bolling SF, Deed GM, Brunsting LA, Bach DS. Early outcome of mitral valve 
reconstruction in patients with end-stage cardiomyopathy. J Thorac Cardiovasc 
Surg 1995; 109:676-683. 
Bolling SF, Smolens IA, Pagani FD. Surgical alternatives for ehart failure. JHLT 
2001; 20:729-733. 
Boltwood CM, Tei C, Wong M, Shah PM. Quantitative echocardiography of 
mitral complex in dilated heart failure: the mechanism of functional mitral 
regurgitation. Circulation 1983; 68:498-503. 
368 
 
Borow K, Neumann A, Arensman FW, Yacoub MH. Left ventricular contractility 
and contractile reserve in humans after cardiac transplantation. Circulation 1985; 
71:866-72. 
Bozkurt B. Medical and surgical therapy for cardiac remodeling. Current Opinion 
in Cardiology 1999; 14:196-205. 
Bozkurt B, Kribbs S, CLubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta 
Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of 
tumour necrosis factor-  promote progressive left ventricular dysfunction and 
remodeling in rats. Circulation 1998; 97:1382-1391. 
Brater DC. Diuretic therapy. N Eng J Med 1998; 339:387-395. 
Bredin E, Liska J, Franco-Cereceda A. Changes in natriuretic peptides following 
passive containment surgery in heart failure patients with dilated cardiomyopathy. 
Interact Cardiovasc Thorac Surg 2009; 8:191-194. 
Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with 
genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83:1771-
1779. 
Bristow MR. Pathophysiologic and pharmacologic rationales for clinical 
management of chronic heart failure with beta-blocking agents. Am J Cardiol 
1993; 71:12C-22C. 
Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J 
Cardiol 1997; 80:26L-40L. 
Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. 
Circulation 2000; 101:558-569. 
Bristow MR, Ginsburg R, Minobe W, Cubiciotti RS, Sageman WS, Lurie K, 
Billingham ME, Harrison DE, Stinson EB. Decreased catecholamine sensitivity 
and beta-adrenergic receptor density in failing human hearts. N Eng J Med 1982; 
307:205-211. 
Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, 
Menlove R, Shah P, Jamieson S, Stinson EB. - and 2- adrenergic-receptor 
subpopulations in non-failing and failing human ventricular myocardium: 
Coupling of both receptor subtypes to muscle contraction and selective 1-
receptor down-regulation in heart failure. Circ Res 1986; 59:297-309. 
Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson 
FL, Murray J, Mestroni L, Karwande SV, Fowler M, Ginsburg R. -adrenergic 
neuroeffector abnormalities in the failing human heart are produced by local, 
rather than systemic mechanisms. J Clin Invest 1992; 89:803-815. 
Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorm EJ. The role of third-
generation beta-blocking agents in chronic heart failure. Clin Cardiol 1998; 21:I-
3-I-13. 
369 
 
Bristow MR, Saxon LA, Boehmer J. Cardiac-resynchronization therapy with or 
without an implantable defibrillator in advanced chronic heart failure. N Eng J 
Med 2004a; 350:2140-2150. 
Bristow MR, Saxon LA, Boehmer J, Kass DA, De Marco T, Carson P, CiCarlo L, 
DeMets D, White BG, DeVries DW, Feldman AM. Cardiac resynchronization 
therapy with or without an implantable defibrillator in advanced chronic heart 
failure. N Eng J Med 2004b; 350:2140-2150. 
Brodde OE.  and 2- adrenoceptors in the human heart: Properties, function, and 
alterations in chronic heart failure. Pharmacol Rev 1991; 43:203-242. 
Brophy JM, Deslauriers G, Rouleau JL. Long term prognosis of patients 
presenting to the emergency room with decompensated congestive heart failure. 
Can J Cardiol 1994; 10:543-547. 
Brouri N, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P. 
Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce 
isoprenaline-induced cardiac fibrosis. Eur J Pharmacol 2004; 485:227-234. 
Brown OM, Salata JJ, Graziani LA. The distribution of acetylcholine adn choline 
in guinea pig heart. Life Sciences 1985; 36:383-389. 
Bruckner BA, Stetson SJ, Perez-Verdia A, Youker KA, Radovancevic B, 
Connelly JH, Koerner MM, Entman ME, Frazier OH, Noon GP, Torre-Amione G. 
Regression of fibrosis and hypertrophy in failing myocardium following 
mechanical circulatory support. J.Heart Lung Transplant. 2001; 20:457-464. 
Bruckschlegel G, Holmer SR, Jandeleit K, Grimm D, Muders F, Kromer EP, 
Riegger GA, Schunkert H. Blockade of the renin-angiotensin system in cardiac 
pressure-overload hypertrophy in rats. Hypertension 1995; 25:250-259. 
Bruggink AH, van Oosterhout MF, de Jonge N, Ivangh B, van Kuik J, Voorbij 
RH, Cleutjens JP, Gmelig-Meyling FH, de Weger RA. Reverse remodeling of the 
myocardial extracellular matrix after prolonged left ventricular assist device 
support follows a biphasic pattern. J Heart Lung Transplant 2006; 25:1091-98. 
Brüss M, Hammermann R, Brimijoin S, Bonisch H. Antipeptide antibodies 
confirm the topology of the human norepinephrine transporter. J Biol Chem 1995; 
270:9197-9201. 
Buckberg GD, Coghlan HC, Hoffman JT, Torrent-Guasp F. The Structure and 
Function of the Helical Heart and its Buttress Wrapping. VII. Critical Importance 
of Septum for Right Ventricular Function. Semin Thorac Cardiovasc Surg 2001a; 
13:402-416. 
Buckberg GD, Coghlan HC, Torrent-Guasp F. The Structure and Function of the 
Helical Heart and its Buttress Wrapping. V. Anatomic and Physiologic 
Considerations in the Healthy and Failing Heart. Semin Thorac Cardiovasc Surg 
2001b; 13:358-385. 
370 
 
Bünemann M, Bücheler MM, Philipp M, Lohse MJ, Hein L. Activation and 
deactivation kinetics of 2A- and C- adrenergic receptor-activated G protein-
activated inwardly rectifying K
+
 channel currents. J Biol Chem 2001; 276:47512-
47517. 
Burch GE, DePasquale NP. On resting the human heart. Am Heart J 1966; 
71:422. 
Burgreen GW, Loree HM 2nd, Bourque K, Dague C, Poirier VL, Farrar D, 
Hampton E, Wu ZJ, Gempp TM, Schöb R. Computational fluid dynamics analysis 
of a maglev centrifugal left ventricular assist device. Artif Organs 2004; 28:874-
80. 
Burri H, Sunthorn H, Somsen A, Fleury E, Stettler C, Shah D, Righetti A. 
Improvement in cardiac sympathetic nerve activity in responders to 
resynchronization therapy. Europace 2008; 10:374-378. 
Butler KC, Farrar DJ. Long-term reliability testing of the HeartMate II LVAD. 
ASAIO J 2005; 51:32A. 
Buttrick PM, Kaplan M, Leinwand LA, Scheuer J. Alterations in gene expression 
in the rat heart after chronic pathological and physiological loads. J Mol.Cell 
Cardiol. 1994; 26:61-67. 
Caforio AL, Keeling PJ, Zachara E, Mestroni L, Camerini F, Mann JM, Bottazzo 
GF, McKenna WJ. Evidence from family studies for autoimmunity in dilated 
cardiomyopathy. Lancet 1994; 344:773-777. 
Caforio AL, Stewart JT, Bonifacio E, Burke M, Davies MJ, McKenna WJ, 
Bottazzo GF. Inappropriate major histocompatibility complex expression on 
cardiac tissue in dilated cardiomyopathy. Relevance for autoimmunity? J 
Autoimmun. 1990; 3:187-200. 
Cahalin LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. The six-minute 
walk test predicts peak oxygen uptake and survival in patients with advanced 
heart failure. Chest 1996; 110:325-332. 
Calafiore AM, Gallina S, Di Mauro M, Gaeta F, Iacò AL, D'Alessandro S, Mazzei 
V, Di Giammarco G. Mitral valve procedure in dilated cardiomyopathy: repair or 
replacement? Ann Thorac Surg 2001; 71:1146-1152. 
Calderone A, Takahashi N, Izzo NJ, Thaik CM, Colucci WS. Pressure- and 
volume-induced left ventricular hypertrophies are associated with distinct 
myocyte phenotypes and differential induction of peptide growth factor mRNAs. 
Circulation 1995; 92:2385-2390. 
Camacho V, Carrio I. Targeting neuronal dysfunction and receptor imaging. Curr 
Opin Biotechnol 2007; 18:60-4. 
Carpentier A, Chauvaud S, Fabiani JN. Reconstructive surgery of mitral valve 
incompetence: ten-year appraisal. J Thorac Cardiovasc Surg 1980; 79:338-348. 
371 
 
Carrier L, Boheler KR, Chassagne C, de la BD, Wisnewsky C, Lakatta EG, 
Schwartz K. Expression of the sarcomeric actin isogenes in the rat heart with 
development and senescence. Circ.Res. 1992; 70:999-1005. 
Carrio I. Cardiac neurotransmission imaging. J Nucl Med 2001; 42:1062-76. 
Cascino I, Papoff G, De Maria R, Testi R, Ruberti G. Fas/Apo-1 (CD95) receptor 
lacking the intracytoplasmic signaling domain protects tumor cells from Fas-
mediated apoptosis. J Immunol 1996; 156:13-17. 
CASS Investigators. Myocardial infarction and mortality in the Coronary Artery 
Surgery Study (CASS) randomized trial. N Eng J Med 1984; 310:750-758. 
Cha YM, Oh J, Miyazaki C, Hayes DL, Rea DF, Shen WK, Asirvatham SJ, Kemp 
BJ, Hodge DO, Chen PS, Chareonthaitawee P. Cardiac resynchronization therpay 
upregulates cardiac autonomic control. J Cardiovasc Electrophysiol 2008; 
19:1045-1052. 
Chance WT, Cao L, Zhang FS, Fischer JE. Clenbuterol plus acivicin decrease 
tumor growth and increase muscle mass in rats maintained on total parenteral 
nutrition. Am.J Surg 1991; 161:51-56. 
Chaudhry FA, Tauke JT, Alessandrini RS, Vardi G, Parker MA, Bonow RO. 
Prognostic implications of myocardial contractile reserve in patients with 
coronary artery disease and left ventricular dysfunction. JACC 1999; 34:730-738. 
Chaudhry PA, Anagnostopouls PV, Mishima T, Suzuki G, Nair H, Morita H, 
Sharov VG, Alferness C, Sabbah HN. Acute ventricular reduction with the acorn 
cardiac support device. J Card Surg 2001; 16:118-126. 
Chen FY, Adams DH, Aranki SF. Mitral valve repair in heart failure. Circulation 
1998; 98:II-124-II-127. 
Chen J, Garcia EV, Galt JR, Folks RD, Carrio I. Improved quantification in 
123
I 
cardiac SPECT imaging with deconvolution of septal penetration. Nucl Med 
Commun 2006a; 27:551-558. 
Chen J, Garcia EV, Galt JR, Folks RD, Carrio I. Optimized acquisition and 
processing for protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol 2006b; 
13:251-60. 
Chen Y, Park S, Li Y, Missov E, Hou M, Han X, Hall JL, Miller LW, Bache RJ. 
Alterations of gene expression in failing myocardium following left ventricular 
assist device support. Physiol Genomics 2003; 14:251-260. 
Chien KR. Stress pathways and heart failure. Cell 1999; 98:555-558. 
Chin. Interleukin-6, tissue factor and von Willebrand factor in acute 
decompensated heart failure: relationship to treatment and prognosis. Blood 2003; 
14:515. 
372 
 
Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect 
of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 
15:327-331. 
Choi JY, Lee K, Hong KP, Kim B, Seo JD, Lee WR, Lee SH. Iodine-123 MIBG 
imaging before treatment of heart failure with carvedilol to predict improvement 
of left ventricular function and exercise capacity. J Nucl Cardiol 2001; 8:4-9. 
Choo JJ, Horan MA, Little RA, Rothwell NJ. Muscle wasting associated with 
endotoxemia in the rat: modification by the beta 2-adrenoceptor agonist 
clenbuterol. Biosci.Rep. 1989; 9:615-621. 
Chumnanvej S, Wood MJ, MacGillivray TE, Melo MF. Perioperative 
echocardiographic examination for ventrivaular asist device implantation. Anesth 
Analg 2007; 105:583-601. 
Chun TY, Pratt JH. Aldosterone increases plasminogen activator inhibitor-1 
synthesis in rat cardiomyocytes. Mol Cel Endocrinol 2005; 239:55-61. 
CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart 
failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 
90:1765-1773. 
Clark RE, Zafirelis Z. Future devices and directions. Prog.Cardiovasc.Dis. 2000; 
43:95-100. 
Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, 
Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in 
heart failure. N Eng J Med 2005; 352:1539-1549. 
Cleland JGF, Massie BM, Packer M. Sudden death in heart failure: vascular or 
electrical? Eur J Heart Fail 1999; 1:41-45. 
Cleland JGF, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD. 
Myocardial viability as a determinant of the ejection fraction response to 
carvedilol in patients with heart failure (CHRISTMAS trial): randomised 
controlled trial. Lancet 2003; 362:14-21. 
Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of 
collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 
1995; 27:1281-1292. 
Cohen JN. Structural basis for heart failure. Ventricular remodelling and its 
pharmacological inhibition. Circulation 1995; 91. 
Cohen JN. Sympathetic nervous system in heart failure. Circulation 2002; 
106:2417-18. 
Cohen JN, Levine TB, Olivari MT, Garberg V, Francis GS, Simon AB, Rector T. 
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive 
heart failure. N Eng J Med 1984; 311:819-23. 
373 
 
Cohen JT, Levine TB, Olivari MT, Garberg V, Francis GS, Simon AB, Rector T. 
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive 
heart failure. N Eng J Med 1984; 311:819-23. 
Cohen-Solal A, Rouzet F, Berdeaux A, Le Guludee D, Abergel E, Syrota A, 
Merlet P. Effects of carvedilol on myocardial sympathetic innevation in patients 
with chronic heart failure. J Nucl Med 2005; 46:1796-1803. 
Cohn JN, Arcchibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, 
Dunkman WB, Jacobs W, Francis GS, Flohr KH. Effect of vasodilator therapy on 
mortality in chronic congestive heart failure: results of a Veterans Administration 
Cooperative Study. N Eng J Med 1986; 314:1547-1552. 
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical 
implications: a consensus paper from an international forum on cardiac 
remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll 
Cardiol 2000; 35:569-582. 
Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, 
Gottleib SO, McGrew F, DeMets DL, White BG. A dose-dependent increase in 
mortality with vesnarinone among patients with severe heart failure: Vesnarinone 
Trial Investigators. N Eng J Med 1998; 339:1810-1816. 
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, 
Dunkman WB, Loeb H, Wong M. A comparison of enalapril withhydralazine-
isosorbide dinitrate in the treatment of chronic congestive heart failure. N Eng J 
Med 1991; 325:303-310. 
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker 
valsartan in chronic heart failure. N Eng J Med 2001; 345:1667-1675. 
Coletta A, Clark AL, Banarjee P, Cleland JGF. Clinical trials update: RENEWAL 
(RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002; 4:559-
561. 
Collins JF, Egan D, Yusuf S, Garg R, Williford WO, Geller N. Overview of the 
DIG trial. Control Clin Trials 2003; 24:S269-S276. 
Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J 
Cardiol 1997; 80:15L-25L. 
Colucci WS. The effects of norepinephrine on myocardial biology: implications 
for the therapy of heart failure. Clin Cardiol 1998; 21:I20-I24. 
Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, 
Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. 
Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated 
congestive heart failure: Nesiritide Study Group. N Eng J Med 2000a; 343:246-
253. 
Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB. 
Carvedilol inhibits clinical progression in patients with mild symptoms of heart 
374 
 
failure. US Carvedilol Heart Failure Study Group. Circulation 1996; 94:2800-
2806. 
Colucci WS, Sawyer DB, Singh K, Communal C. Adrenergic overload and 
apoptosis in heart failure: implications for therapy. J Card Fail 2000b; 6:1-7. 
Colyer J. Control of the calcium pump of cardiac sarcoplasmic reticulum. A 
specific role for the pentameric structure of phospholamban? Cardiovasc.Res. 
1993; 27:1766-1771. 
Communal C, Colucci WS. The control of cardiomyocyte apoptosis via the beta-
adrenergic signaling pathway. In: 2005. p. 236. 
Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates 
apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic 
pathway. Circulation 1998; 98:1329-1334. 
Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OHL. 
Myocardial fibrosis and stiffness with hypertrohy and heart failure in the 
spontaneously hypertensive rat. Circulation 1995; 91:161-170. 
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe 
congestive heart failure: results of the Cooperative North ScandinavianEnalapril 
Survival Study (CONSENSUS). N Eng J Med 1987; 316:1429-1435. 
Cooley D, Liotta D, Hallman G. Orthotopic cardiac prosthesis for two-stages 
cardiac replacement. Am J Cardiol 1969; 24:723. 
Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, McClellan D, 
Slepian MJ. Cardiac replacement with a total artificial heart as a bridge to 
transplantation. N Engl J Med 2004; 351:859-867. 
Cowie MR, Wood DA, Coats AJS, Thompson SG, Poole-Silson PA, Suresh V, 
Sutton GS. Incidence nad aetiology of heart failure: a population-based study. Eur 
Heart J 1999; 20:421-428. 
D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn II 
GW. Transgenic G q over-expression induces cardiac contractile failure in mice. 
Proc Natl Acad Sci 1997; 94:8121-8126. 
Dae MW, Lee RJ, Ursell PC, Chin MC, Stillson CA, Moise NS. Heterogeneous 
sympathetic innervation in German shepherd dogs with inherited ventricular 
arrhythmia and sudden cardiac death. Circulation 1997; 96:1337-1342. 
Dandel M, Weng Y, Siniawski H, Potapov E, Lehmkuhl H, Hetzer R, Muller JH, 
Weng Y, Meyer R, Dandel M. Long-term results in patients with idiopathic 
dilated cardiomyopathy after weaning from left ventricular assist devices. 
Circulation 2005; 112:I-37 - I-45. 
Dang NC, Topkara VK, Mercando M, Kay J, Kruger KH, Aboodi MS, Oz MC, 
Naka Y. Right heart failure afyre left ventricular assist device implantation in 
375 
 
patients with chronic congestive heart failure. J Heart Lung Transplant 2006; 
25:1-6. 
David TE, Uden DE, Strauss HD. The importance of the mitral apparatus in left 
ventricular function after correction of MR. Circulation 1983; 68:II-76-II-82. 
Davies MJ, Mann JM, Symmers WSC. Systemic pathology. 1995; 3rd ed. 
Davis D, Baily R, Zelis RJ. Abnormalities in systemic norepinephrine kinetics in 
human congestive heart failure. Am J Physiol 1988; 254:E760 - E766. 
Davis KM, Fish LC, Elahi D, Clark BA, Minaker KL. Atrial natriuretic peptide 
levels in the prediction of congestive heart failure risk in frail elderly. JAMA 
1992; 267:2625-2629. 
De Bonis M, Alfieri O. Surgery insight: surgical methods to reverse left 
ventricular remodelin. Nat Clin Prac 2006; 3:507-511. 
de Milliano PA, van Eck-Smit BL, van Zwieten PA, de Groot AC, Tijssen JGP, 
Lie KI. Relationship between cardiac metaiodobenzylguanidine uptake and 
hemodynamic, functional and neurohormonal parameters in patients with heart 
failure. Eur J Heart Failure 2001; 3:693-7. 
de Milliano PAR, de Groot AC, Tijssen JGP, van Eck-Smit BL, van Zwieten PA, 
Lie KI. Beneficial effects of metoprolol on myocardial sympathetic function: 
Evidence from a randomized, placebo-controlled study in patients with congestive 
heart failure. Am Heart J 2002; 144:e3-e11. 
DeBakey M. Left ventricular bypass for cardiac assistance. Am J Card 1971; 27:3. 
DeBakey M. The odyssey of the artificial heart. Artif Organs 2000; 24:405. 
Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 
331:1564-1575. 
Dee K, Puleo DA, Bizios R. Tissue-biomaterial interactions. In: Hoboken, editor. 
Biocompatability. John Wiley & Sons, Inc., 2002. 
Delday MI, Maltin CA. Clenbuterol increases the expression of myogenin but not 
myoD in immobilized rat muscles. Am.J Physiol 1997; 272:E941-E944. 
Delgado DH, Rao V, Ross HJ, Verma S, Smedira NG. Mechanical circulatory 
assistance: State of the art. Circualtion 2002; 106:2046-2050. 
Dembitsky WP, Tector AJ, Park S, Moskowitz AJ, Gelijns AC, Ronan NS, 
Piccione W, Holman WL, Furukawa S, Frazier OH, Weinberg AD, Heatley G, 
Poirier VL, Damme L, Long JW. Left ventricular assist device performance with 
long-term circulatory support: Lessons from the REMATCH trial. Ann Thorac 
Surg 2004; 78:2123-2130. 
Deng MC. Cardiac transplantation. Heart 2002; 87:177-184. 
376 
 
Deng MC, Edwards LB, Hertz MI, Rowe AW, Keck BM, Kormos R, Nafterl DC, 
Kirklin JK, Taylor DO. Mechanical circulatory support device database of the 
International Society for Heart and Lung Transplantation: third annual report-
2005. J Heart Lung Transplant 2005; 24:1182-1187. 
Deng MC, Naka Y. Mechanical circulatory support devices--state of the art. Heart 
Fail.Monit. 2002; 2:120-128. 
DeRobertis F, Rogers P, Amrani M, Petrou M, Pepper J, Bahrami T, Dreyfus G, 
Khaghani A, Birks EJ. Bridge to decision using the Levitronix CentriMag short-
term ventricular assist device. J Heart Lung Transplant 2008; 27:474-478. 
DeRose JJ Jr, Umana JP, Argenziano M, Catanese KA, Gardocki MT, Flannery 
M, Levin HR, Sun BC, Rose EA, Oz MC. Implantable left ventricular assist 
devices provide an excellent outpatient bridge to transplantation and recovery. J 
Am Coll Cardiol 1997; 30:1773-1777. 
Despa S, Bossuyt J, Han F, Ginsburg KS, Jia L, Kutachi H, Tucker AL, Bers DM. 
Phospholemman-phosphorylation mediates the beta-adrenergic effects on Na/K 
pump function in cardiac myocytes. Circ Res 2005; 97:252-250. 
Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. 
Cytokines and cytokine receptors in advanced heart failure: An analysis of the 
cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 
103:2055-2059. 
Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of 
hypertrophy to heart failure. J Am Coll Cardiol 1996; 28:506-514. 
Dhalla AK, Singal PK. Antioxidant changes in hypertophied and failing guinea 
pig hearts. Am J Physiol 1994; 266:H1280-H1285. 
DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A 
comparison of oral milrinone, digoxin, and their combination in thetreatment of 
patients with chronic heart failure. N Eng J Med 1987; 320:677-683. 
Didisheim P. Current concpets of thrombosis and infection in artificial organs. 
ASAIO J 1994; 40:230-7. 
DiGiorgi PL, Reel MS, Thornton B, Burton E, Naka Y, Oz MC. Heart transplant 
and left ventricular assist device costs. J Heart Lung Transplant 2005; 24:200-204. 
DiGiorgi PL, Smith DL, Naka Y, Oz MC. Retrograde and antegrade flow from 
pulsatile and non-pulsatile ventricular assist devices. J Heart Lung Transplant 
2004; 23:186-192. 
Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in 
patients with heart failure. N Eng J Med 1997; 336:525-533. 
Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte 
recovery after mechanical circulatory support in humans with end-stage heart 
failure. Circulation 1998a; 97:2316-22. 
377 
 
Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte 
recovery after mechanical circulatory support in humans with end-stage heart 
failure. Circulation 1998b; 97:2316-22. 
Doering CW, Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams C, Weber KT. 
Collagen network remodelling and diastolic stiffness of the rat left ventricle with 
pressure overload hypertrophy. Cardiovasc.Res. 1988; 22:686-695. 
Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and 
cardiovascular disease. Circ.Res. 1995; 77:863-868. 
Domanski MJ, Krause-Steinrauf MS, Massie BM, Deedwania P, Follmann D, 
Kovar D, Murray D, Oren R, Rosenberg Y, Young J, Zile M, Eichhorn E. A 
comparative analysis of the results from 4 trials of ß-blocker therapy for heart 
failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 2003; 
9:354-363. 
Dor V, Di Donato M, Sabatier M, Montiglio F, Civaia F. Left ventricular 
reconstruction by endoventricular circular patch plasty repair: a 17-year 
experience. Semin Thorac Cardiovasc Surg 2001; 2001:13-435. 
Doughty RN, Rodgers A, Sharped N, MacMahon S. Effects of beta-blocker 
therapy on mortality in patients with heart failure. A systematic overview of 
randomized controlled trials. Eur Heart J 1997; 18:560-565. 
Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular 
remodeling with carvedilol in patients with congestive heart failure due to 
ischemic heart disease. Australia-New Zealand Heart Failure Research 
Collaborative Group. J.Am.Coll.Cardiol. 1997; 29:1060-1066. 
Drakos SG, Kfoury AG, Long JW, Stringham JC, Gilbert EM, Moore SA, 
Campbell BK, Nelson KE, Home BD, Renlund DG. Effect of mechanical 
circulatory support on outcomes after heart transplantation. J Heart Lung 
Transplant 2006; 25:22-28. 
Drews T, Jurmann M, Michael D, Miralem P, Weng Y, Hetzer R. Differences in 
pulsatile and non-pulsatile mechanical circulatory support in long-term use. J 
Heart Lung Transplant 2008; 27:1096-1101. 
Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, Hasenfuss G. Expression, 
activity and functional significance of inducible nitric oxide synthase in the failing 
human heart. J.Am.Coll.Cardiol. 1998; 32:955-963. 
Edmond M, Mock MB, Fisher LD, Holmes DR Jr, Chaitman BR, Kaiser GC, 
Alderman E, Killip T. Long-term survival of medically treated patients in the 
Coronary Artery Surgery Study (CASS) registry. Circulation 1994; 90:2645-2657. 
Ehlert FA, Cannom DS, Renfroe EG, Greene HL, Ledingham R, Mitchell LB. 
Comparison of dilated cardiomyopathy and coronary artery disease in patients 
with life-threatening ventricular arrhythmias: differences in presentation and 
outcome in the AVID registry. Am Heart J 2010; 142:816-822. 
378 
 
Eichhorm EJ. The paradox of beta-adrenergic blockade for the management of 
congestive heart failure. Am J Med 1992; 92:527-538. 
Eichhorm EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, 
Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial 
function and energetics in patients with nonischemic dilated cardiomyopathy: a 
randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2009; 
24:1310-1320. 
Eisenhofer G. The role of neuronal and extraneuronal plasma membrane 
transporters in the inactivation of peripheral catecholamines. Pharm and Therap 
2001; 91:35-62. 
Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, 
Kopin IJ, Goldstein DS, Esler MD. Cardiac sympathetic nerve function in 
congestive heart failure. Circulation 1996; 93:1667-76. 
El-Banayosy A, rusoglu L, izner L, Tenderich G, Boethig D, Minami K, Körfer R. 
Predictors of survival in patients bridged to transplantation with the Thoratec 
VAD device: a single-centre retrospective study on more than 100 patients. J 
Heart Lung Transplant 2000; 19:964-968. 
Eldadah BA, Pacak K, Eisenhofer G, Holmes C, Kopin IJ, Goldstein DS. Cardiac 
uptake-1 inhibition by high circulating norepinephrine levels in patients with 
phaechromocytoma. In: 2004. p. 1227-1232. 
Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart 
failure in 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci 1999; 
96:7059-7064. 
Enriquez-Sarano M, Scaff HV, Orszulak TA, Tajik AJ, Bailey KR, Frye RL. 
Valve repair improves the outcome of surgery for mitral regurgitation. A 
multivariate analysis. Circulation 1995; 91:1022-1028. 
Entwistle JW 3rd. Long-term mechanical ventricular assistance towards 
myocardial recovery. Cardiol Clin 2003; 21:75-82. 
Epstein SE, Braunwald E. The effect of beta adrenergic blockade on patterns of 
urinary sodium excretion. Studies in normal subjects and in patients with heart 
disease. Ann Intern Med 1966; 65:20-27. 
Erol-Yilmaz A, Verberne HJ, Schrama TA, Hrudova J, De Winter RJ, van Eck-
Smit BL, De Bruin R, Bax JJ, Schalij MJ, Wilde AA, Tukkie R. Cardiac 
resynchronization induces favorable neurohumoral changes. Pacing Clin 
Electrophysiol 2005; 28:304-10. 
ESC. Recommendations for Exercise Testing in Chorinc Heart Failure Patients. 
European Heart Journal 2001; 22:37-45. 
Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in 
heart failure. Am J Cardiol 1997; 80:7L-14L. 
379 
 
Esmore D, Kaye D, Spratt P, Larbalestier R, Ruygrok P, Tsui S, Meyers D, Fiane 
AE, Woodard J. A prospective, multicenter trial of the VentrAssist left ventricular 
assist device for bridge to transplant: Safety and efficacy. J Heart Lung Transplant 
2008; 27:579-588. 
Estrada-Quintero T, Uretsky BF, Murali S, Griffith BP, Kormos RL. 
Neurohormonal activation and exercise function in patients with severe heart 
failure and patients with left ventricular assist system. Chest 1995; 107:1499-
1503. 
Farrar DJ, Compton PG, Hershon JJ, Fonger JD, Hill JD. Right heart interaction 
with the mechanically assisted left heart. 9 1985;102. 
Farrar DJ, Holman WR, McBride LR, Kormos RL, Icenogle TB, Hendry PJ, 
Moore CH, Loisance DY, El-Banayosy A, Frazier H. Long-term follow-up of 
Thoratec ventricular assist device bridge-to-recovery patients successfully 
removed from support after recovery of ventricular function. J Heart Lung 
Transplant 2002; 21:516-21. 
Farrar DJ, Lawson JH, Litwak P, Cederwall G. Thoratec VAD system as a bridge 
to heart transplantation. J Heart Lung Transplant 1990; 9:415-22. 
Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gibert EM, 
Strobeck JE, Hendrix GH, Powers ER, Bain PP. Effects of vesnarinone on 
morbidity and mortality in patients with heart failure: Vesnarinone Study Group. 
N Eng J Med 1993; 329:149-155. 
Felkin LE, Taegtmeyer AB, Barton PJR. Real-time quantitative PCR in cardiac 
transplant research. In: Hornick P, Rose ML, editors. Transplantation 
immunology: methods and protocols. Totowa: Humana Press, 2006. p. 305-29. 
Feller ED, Sorensen EN, Haddad M, Pierson RN, Johnson FL, Brown JM, Griffith 
BP. Clinical outcomes are similar in pulsatile and nonpulsatile left ventricular 
assist device recipients. Ann Thorac Surg 2007; 83:1082-1088. 
Ferrans VJ, Hibbs RG, BLACK WC, Weilbaecher DG. ISOPROTERENOL-
INDUCED MYOCARDIAL NECROSIS. A HISTOCHEMICAL AND 
ELECTRON MICROSCOPIC STUDY. Am.Heart J 1964; 68:71-90. 
Feuerstein GZ, Bril A, Ruffolo RR Jr. Pharmacology of  blockers: protective 
effects of carvedilol in the myocardium. Am J Cardiol 1997; 80:41L-45L. 
Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action 
antihypertensive agent with antioxidant activity and the potential for myocardial 
and vascular protection. Eur Heart J 1995; 16:38-42. 
Feuerstein GZ, Yue TL, Cheng HY, Ruffolo RR Jr. Myocardial protection be the 
novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant 
activity. J Hypertens 1993; 11:541-548. 
Fitzpatrick III JR, Frederick JR, Hsu VN, Kozin ED, O'Hara ML, Howell E, 
Dougherty D, McCormick RC, Laporte CA, Cohen JE, Southerland KW, Howard 
380 
 
JL, Jessup ML, Morris RJ, Acker MA, Woo YJ. Risk score derived from pre-
operative data analysis predicts the need for biventricular mechanical circulatory 
support. J Heart Lung Transplant 2008; 27:1286-1292. 
Fleischer D, Espiner EA, Yandle TG, Livesey JH, Billings J, Town I, Richards 
AM. Rapid assay of plasma brain natriuretic peptide in the assessment of acute 
dyspnoea. N.Z.Med.J. 1997; 110:71-74. 
Fleischer S, Inui M. Biochemistry and biophysics of excitation-contraction 
coupling. Annu.Rev.Biophys.Biophys.Chem. 1989; 18:333-364. 
Fletcher AA, Motherwell DW, Mccurrach G, Small AD, Martin W, Cobbe SM. 
The H/M ratio in I-123 MIBG scan cannot be accurately measured using a low-
energy collimator without scatter correction. J Nucl Cardiol 2007; 14:S56. 
Flotats A, Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 
2004; 11:587-602. 
Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, 
Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients 
with left ventricular dysfunction with and without congestive heart failure. A 
substudy of he Studies of Left Ventricular Dysfunction (SOLVD). Circulation 
1990; 82:1724-1729. 
Francis GS, Cohn JN, Johnson G. Plasma norepinephrine, plasma renin activity, 
and congestive heart failure. Relations to survival and the effects of therapy in V-
HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 
87:V140-V148. 
Francis GS, Wilson Tang WH. Pathophysiology of congestive heart failure. Rev 
Cardiovasc Med 2003; 4:S14-S20. 
Francis GS, Cohn JN. Heart failure: mechanisms of cardiac and vascular 
dysfunction and the rationale for pharmacologic intervention. FASEB J 1990; 
4:3068-3075. 
Frazier OH, Benedict CR, Radovancevic B, Bick RJ, Capek P, Springer WE, 
Macris MP, Delgado R, Buja M. Improved left ventricular function after chronic 
left ventricular unloading. Ann Thorac Surg 1996; 62:675-681. 
Frazier OH, Delgado RM 3rd, Kar B, Patel V, Gregoric ID, Myers TJ. First 
Clinical Use of the Redesigned HeartMate® II Left Ventricular Assist System in 
the United States: A Case Report. Tex Heart Inst J. 2004a; 31:157-59. 
Frazier OH, Delgado RM 3rd, Scroggins N, Odegaard P, Kar B. Mechanical 
bridging to improvement in severe acute "nonischemic, nonmyocarditis" heart 
failure. Congest Heart Fail 2004b; 10:109-13. 
Frazier OH, Gemmato C, Myers TJ, Gregoric ID, Radovancevic B, Loyalka P, 
Kar B. Initial clinical experience with the HeartMate® II axial-flow left 
ventricular assist device. Tex Heart Inst J. 2007; 34:275-281. 
381 
 
Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial 
recovery. Ann Thorac Surg 1999; 68:734-41. 
Frazier OH, Rose EA, Macmanus Q, Burton NA, Lefrak EA, Poirier VL, Dasse 
KA. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular 
assist device. Ann Thorac Surg 1992; 53:1080-1090. 
Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B, 
Poirier V, Dasse KA. Multicenter clinical evaluation of the HeartMate vented 
electric left ventricular assist system in patients awaiting heart transplantation. J 
Thorac Cardiovasc Surg 2001; 122:1186-1195. 
Frazier OH. Mechanical cardiac assistance: historical perspectives. 
Semin.Thorac.Cardiovasc.Surg. 2000; 12:207-219. 
Frazier OH. Prologue: ventricular assist devices and total artificial hearts. A 
historical perspective. Cardiol.Clin. 2003; 21:1-13. 
Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial 
recovery. Ann.Thorac.Surg. 1999; 68:734-741. 
Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B, 
Poirier VL, Dasse KA. Multicenter clinical evaluation of the HeartMate vented 
electric left ventricular assist system in patients awaiting heart transplantation. 
J.Thorac.Cardiovasc.Surg 2001; 122:1186-1195. 
Fregoneze JB, Gutkowska J, St Pierre S, Antunes-Rodrigues J. Effect of brain 
natriuretic peptide on dehydration- or angiotensin II-induced water intake in rats. 
Braz.J.Med.Biol.Res. 1989; 22:765-768. 
Frerichs O, Fansa H, Ziems P, Schneider W, Keilhoff G. Regeneration of 
peripheral nerves after clenbuterol treatment in a rat model. Muscle Nerve 2001; 
24:1687-1691. 
Fu YC, Chi CS, Yin SC, Hwang B, Chiu YT, Hsu SL. Norepinephrine induces 
apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF 
alpha-caspase signaling pathway. Cardiovasc Res 2004; 62:558-567. 
Fujimoto S, Amano H, Inoue A, Ishida S, Yamashina S, Yamashina H, Nakano H, 
Yamazaki J. Usefulness of 
123
I-metaiodobenzylguanidine myocardial scintigraphy 
in the prediction of cardiac events in patients with cardiomyopathy showing 
stabilisation of symptoms or preserved cardiac function. Ann Nucl Med 2004; 
18:591-8. 
Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, Nakano H, 
Yamazaki J. Usefulness of meta-[
123
I]iodobenzylguanidine myocardial 
scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy 
who receive long-term beta blocker treatment. Nucl Med Commun 2005; 26:97-
102. 
382 
 
Fukamachi K, McCarthy P, Smedira NG, Vargo RL, Starling RC, Young JB. 
Preoperative risk factors for right ventricular failure after implantable left 
ventricular assist device insertion. In: 1999. p. 2181-2184. 
Fukamachi K, McCarthy PM. Initial safety and feasibility clinical trial of the 
myosplint device. J Card Surg 2005; 20:S43-S47. 
Fukuoka S, Hayashida K, Hirose Y, Shimotsu Y, Ishida Y, Kakuchi H, Eto T. Use 
of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the 
effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy. Eur 
J Nucl Med 1997; 24:523-9. 
Fung MM, Nguyen C, Mehtani P, Salem RM, Perez R, Thomas B, Das M, Schork 
NJ, Mahata SK, Ziegler MG, O'Connor DT. Genetic variation within adrenergic 
pathways determines in vivo effects of presynaptic stimulation in humans. 
Circulation 2008; 117:517-525. 
Gaballa MA, Goldman S. Ventricular remodelling in heart failure. J Cardiac Fail 
2002; 8:S476-S485. 
Gaffney TE, Braunwald E. Importance of the adrenergic nervous system in the 
support of circulatory function in patients with congestive heart failure. Am J Med 
1963; 34:320-324. 
Gao DW, Talke PO, Dae MW. Effects of reduced sympathetic activity on 
myocardial metaiodobenzylguanidine (MIBG) washout. J Auton Pharmacol 2001; 
21:159-164. 
Garcia S, Kandar F, Boyle A, Colvin-Adams M, Lliao K, Joyce L, John R. Effects 
of pulsatile- and continuous-flow left ventricular assist devices on left ventricular 
unloading. J Heart Lung Transplant 2008; 27:261-267. 
Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting 
enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 
1995; 273:1450-1456. 
Garrido MJ, Oz MC. New surgical treatment for heart failure. Curr Cardiol Rep 
2002; 4:233-237. 
George R, Cheetham A, Manlapig R, Marshall A, Yacoub M, Birks EJ, Kelion A. 
Reproducibility of myocardial 123I-metaiodobenzylguanidine (123I-MIBG) 
scintigraphy in patients with Left Ventricular Assist Device (LVAD). Eur Heart J 
2009; 11:S10. 
George RS, Bowles CT, Tansley P, Hardy J, Webb C, Khaghani A, Yacoub MH, 
Birks EJ. Cessation of left ventricular assist device (LVAD) to study cardiac 
function is a safe method to monitor myocardial recovery. Circulation 2006; 114: 
II-661. 
George RS, Cheetham A, Hinton-Taylor S, Manlapig R, Ghiotto F, Marshall A, 
Kelion A, Yacoub MH, Birks EJ. Sustained normalisation of 123I-MIBG uptake 
383 
 
after explantation of left ventricular assist device (LVAD)s. J Heart Lung 
Transplant 2008a; 27:S94-S95. 
George RS, Cheetham A, Marshall A, Manlapig R, Hinton-Taylor S, Yacoub M, 
Birks EJ, Kelion A. What happens to myocardial sympathetic function in heart 
failure patients who recover on Left Ventricular Assist Device (LVAD) therapy? 
Eur Heart J 2009; 11:S67-S68. 
George RS, Tasca G, Bowles CT, Webb C, Dreyfus G, Khaghani A, Yacoub MH, 
Birks EJ. Complete discontinuation of mechanical support and assessment of 
inotropic reserve in patients with left ventricular assist devices. J Heart Lung 
Transplant 2007a; 26: S61. 
George RS, Yacoub MH, Bowles CT, Hipkin M, Rogers P, Hallas C, Banner NR, 
Dreyfus G, Khaghani A, Birks EJ. Quality of life following LVAD removal for 
myocardial recovery. J Heart Lung Transplant 2008b; 27:165-172. 
George RS, Yacoub MH, Tasca G, Webb C, Bowles CT, Tansley P, Hardy JH, 
Dreyfus G, Khaghani A, Birks EJ. Hemodynamic and echocardiographic 
responses to acute interruption of left ventricular assist device support: Relevance 
to assessment of myocardial recovery. J Heart Lung Transplant 2007b; 26:967-73. 
Gerald D.Buckberg. Basic science review: the helix and the heart. J Thorac 
Cardiovasc Surg 2002; 124:863-883. 
Gerald W Dron II. Adrenergic pathways and left ventricular remodelling. J 
Cardiac Fail 2002; 8:S370-S373. 
Gerson MC, Craft LL, McGuire N, Suresh DP, Abraham WT, Wagoner LE. 
Carvedilol improves left ventricular function in heart failure patients with 
idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous 
system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl 
Cardiol 2002; 9:608-15. 
Gerson MC, McGuire N, Wagoner LE. Sympathetic nervous system function as 
measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in 
heart failure patients with idiopathic dilated cardiomyopathy. J Card Failure 2003; 
9:384-91. 
Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO. 
Current medical therapy for advanced heart failure. Heart Lung 2000; 29:16-32. 
Gibbon JH. Application of a mechanical heart and lung apparatus in cardiac 
surgery. In: 1954. p. 171-177. 
Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P. Comparative 
hemodynamic, left ventricular functional, and antiadrenergic effects of chronic 
treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 
94:2817-2825. 
384 
 
Gilbert EM, Olsen SL, Renlund DG, Bristow MR. Beta-adrenergic receptor 
regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am 
J Cardiol 1993; 71:23C-29C. 
Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, 
Bristow MR. Comparative hemodynamic, left ventricular functional, and 
antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in 
the failing heart. Circulation 1996; 94:2817-2825. 
Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward 
WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic 
congestive cardiomyopathy and cardiac transplants. J Nucl Med 1989; 30:1182-
1190. 
Goldman ME, Mora F, Guarino T, Fuster V, Mindich BP. Mitral valvuloplasty is 
superior to valve replacement for preservation of LV function: an intraoperative 
two-dimensional echocardiographic study. J Am Coll Cardiol 1987; 10:568-575. 
Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. N 
Engl J Med 1998; 339:1522-1533. 
Goodman MN. Interleukin 6 induces skeletal muscle protein breakdown in rats. 
Proc Soc Exp Biol Med 1994; 205:182-185. 
Greenberg BH, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C. 
Effects of long-term enalapril therapy on cardiac structure and function in patients 
with left ventricular dysfunction. Results of the SOLVD echocardiography 
substudy. Circulation 1995; 91:2573-2581. 
Gregoric I, Frazier OF, Couto WJ. Surgical treatment of congestive heart failure. 
Congest Heart Fail 2002; 8:214-219. 
Grigore A, Poindexter B, Vaughn WK, Nussmeier N, Frazier OH, Cooper JR, 
Gregoric ID, Buja LM, Bick RJ. Alterations in alpha adrenoceptor density and 
localization after mechanical left ventricular unloading with the Jarvik flowmaker 
left ventricular assist device. J Heart Lung Transplant 2005; 24:609-613. 
Gross SS, Levi R. Tetrahydrobiopterin synthesis. An absolute requirement for 
cytokine-induced nitric oxide generation by vascular smooth muscle. 
J.Biol.Chem. 1992; 267:25722-25729. 
Gruver CL, DeMayo F, Goldstein MA, Means AR. Targeted developmental 
overexpression of calmodulin induces proliferative and hypertrophic growth of 
cardiomyocytes in transgenic mice. Endocrinology 1993; 133:376-388. 
Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on 
collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993; 27:2130-2134. 
Gudjonsson T, Rahko PS. Relaion of "Inotropic Reserve" to functional capacity in 
heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol 
2002a; 89:1057-1061. 
385 
 
Gulick TS, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and 
tumor necrosis factor inhibit cardiac myocyte -adrenergic responsiveness. Proc 
Natl Acad Sci 1989; 86:6753-6757. 
Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF, Jr. Remodeling of 
human myocardial collagen in idiopathic dilated cardiomyopathy. Role of 
metalloproteinases and pyridinoline cross-links. Am.J.Pathol. 1996; 148:1639-
1648. 
Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, 
Berman LB. The 6-minute walk: a new measure of exercise capacity in patients 
with chronic heart failure. Can Med Assoc J 1985; 132:919-923. 
Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, 
Morgan JP. Abnormal intracellular calcium handling in myocardium from patients 
with end-stage heart failure. Circ.Res. 1987; 61:70-76. 
H.Criss Hartzell. Distribution of muscarinic acetylcholine receptors and 
presynaptic nerve terminals in amphibian heart. J Cell Biol 1980; 86:6-20. 
Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. 
Tumour necrosis factor and inducible nitric oxide synthase in dilated 
cardiomyopathy. Lancet 1996; 347:1151-1155. 
Hadcock JR, Malbon CC. Regulation of receptor expression by agonists: 
Transcriptional and posttranscriptional controls. Trends Nerosci 1991; 14:242-
247. 
Haft J, Armstrong W, Dyke DB, Aaronson KD, Koelling TM, Farrar DJ, Pagani 
FD. Hemodynamic and exercise performance with pulsatile and continuous-flow 
left ventricular assist devices. Circulation 2007; 116:I-8-I-15. 
Hahn MK, Mazei-Robinson MS, Blakely RD. Single nucleotide polymorphisms 
in the human norepinephrine transporter gene affect expression, traficking, 
antidepressant interaction, and protein kinase C regulation. Molecular 
Pharmacology 2005; 68:457-466. 
Haj-Yahia S, Birks EJ, Dreyfus G, Khaghani A. Limited surgical approach for 
explanting the HeartMate II left ventricular assist device after myocardial 
recovery. J Thorac Cardiovasc Surg 2008; 135:453-454. 
Haj-Yahia S, George R, Waligorski S, Dreyfus G, Amrani M, Yacoub M, 
Khaghani A. Limited Surgical Approaches for LVAD Explant Following 
Myocardial Recovery Are Associated with Low Morbidity and Improved 
Outcome. J Heart Lung Transplant 2009; 28: S310. 
Hall JE, Guyton AC, Mizelle HL. Role of the renin-angiotensin system in control 
of sodium excretion and arterial pressure. Acta Physiol Scand Suppl 1990; 
591:48-62. 
Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time 
course of improvement in left ventricular function, mass and geometry in patients 
386 
 
with congestive heart failure treated with beta-adrenergic blockade. J Am Coll 
Cardiol 1995; 25:1154-1161. 
Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari 
MT, Thomas S, Le Jemtel TH. Addition of angiotensin II receptor blockade to 
maximal angiotensin-converting enzyme inhibition improves exercise capacity in 
patients with severe congestive heart failure. Circulation 1999; 99:990-992. 
Harding JP, Jessup M. New directions in the medical management of heart failure. 
Semin Thorac Cardiovasc Surg 2005; 17:334-342. 
Hasking G, Esler M, Jennings G, Burton D, Johns J, Korner P. Norepinephrine 
spillover to plasma in patients with congestive heart failure: evidence of increased 
overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73:615-
21. 
Hausdorff WP, Caron MG, Lefkowitz RJ. Turning of the signal: Desensitization 
of -adrenergic receptor function. FASEB J 1990; 4:2881-2889. 
Hayes VY, Isackson PJ, Fabrazzo M, Follesa P, Mocchetti I. Induction of nerve 
growth factor and basic fibroblast growth factor mRNA following clenbuterol: 
contrasting anatomical and cellular localization. Exp Neurol 1995; 132:33-41. 
Haywood GA, Tsao PS, der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, 
Lewis NP, Byrne CD, Rickenbacher PR, Bishopric NH, Cooke JP, McKenna WJ, 
Fowler MB. Expression of inducible nitric oxide synthase in human heart failure. 
Circulation 1996; 93:1087-1094. 
He H, Giordano FJ, Hilal-Dandan R, Choi DJ, Rockman HA, McDonough PM, 
Bluhm WF, Meyer M, Sayen MR, Swanson E, Dillmann WH. Overexpression of 
the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice 
accelerates calcium transients and cardiac relaxation. J.Clin.Invest 1997; 100:380-
389. 
Heerdt PM, Holmes JW, Cai B, Barbone A, Madigan JD, Reiken S, Lee DL, Oz 
MC, Marks AR, Burkhoff D. Chronic unloading by left ventricular assist device 
reverses contractile dysfunction and alters gene expression in end-stage heart 
failure. Circulation 2000; 102:2713-2719. 
Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. 
Increased beta-receptor density and improved hemodynamic response to 
catecholamine stimulation during long-term metoprolol therapy in heart failure 
from dilated cardiomyopathy. Circulation 1989; 79:483-490. 
Hein L, Altman JD, Kobilka BK. Two functionally distinct 2-adrenergic 
receptors regulate sympathetic neurotransmission. Nature 1999; 402:181-183. 
Henrion D, Laher I. Potentiation of norepinephrine-induces contractions by 
endothelin-1 in the rabbit aorta. Hypertension 1993; 22:78-83. 
Hetzer R, Muller JH, Weng Y, Meyer R, Dandel M. Bridging-to-recovery. Ann 
Thorac Surg 2001; 71:109-13. 
387 
 
Hetzer R, Muller J, Weng Y, Wallukat G, Spiegelsberger S, Loebe M. Cardiac 
recovery in dilated cardiomyopathy by unloading with a left ventricular assist 
device. Ann.Thorac.Surg. 1999; 68:742-749. 
Hetzer R, Muller JH, Weng YG, Loebe M, Wallukat G. Midterm follow-up of 
patients who underwent removal of a left ventricular assist device after cardiac 
recovery from end-stage dilated cardiomyopathy. J.Thorac.Cardiovasc.Surg. 
2000; 120:843-853. 
Hindman B. Cerebral physiology during cardiopulmonary bypass: pulsatile veruss 
non-pulsatile flow. Adv Pharmacol 1994; 31:607-616. 
Hirohata S, Kusachi S, Murakami M, Murakami T, Sano I, Watanabe T, 
Komatsubara I, Kondo J, Tsuji T. Time dependent alterations of serum matrix 
metalloprotainase-1 and metalloproteinase-1 tissue inhibitor after successful 
reperfusion of acute myocardial infarction. Heart 1997; 78:278-284. 
Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of hear failure: the 
Framingham Study. J Am Coll Cardiol 1993; 22:6A-13A. 
Hobai IA, O'Rourke B. Decreased sarcoplasmic reticulum calcium content is 
responsible for defective excitation-contraction coupling in canine heart failure. 
Circulation 2001; 103:1577-1584. 
Holman WL, Park SJ, Long JW, Weinberg A, Gupta L, Tierney AR, Adamson 
RM, Watson JD, Raines EP, Couper GS, Pagani FD, Burton NA, Miller LW, 
Naka Y. Infection in permanent circulatory support: Experinece from the 
REMATCH trial. J Heart Lung Transplant 2004; 23:1359-1365. 
Hon J, Steendijk P, Petrou M, Wong K, Yacoub M. Influence of clenbuterol 
treatment during six weeks of chronic right ventricular pressure overload as 
studied with pressur-volume analysis. The Jouranl of Thoracic and Cardiovascular 
Surgery 2001; 122:767-774. 
Hon JK, Steendijk P, Petrou M, Wong K, Yacoub MH. Influence of clenbuterol 
treatment during six weeks of chronic right ventricular pressure overload as 
studied with pressure-volume analysis. J Thorac.Cardiovasc.Surg 2001; 122:767-
774. 
Hon JK, Yacoub MH. Bridge to recovery with the use of left ventricular assist 
device and clenbuterol. Ann.Thorac.Surg. 2003; 75:S36-S41. 
Horiuchi M, Akishida M, Dzau VJ. Recent progress in angiotensin II type 2 
receptor research in the cardiovascular system. Hypertension 1999; 33:613-621. 
Horton SC, Khodaverdian R, Powers A, Revenaugh J, Renlund DG, Moore SA, 
Rasmussen R, Nelson KE, Long JW. Left ventricular assist device malfunction: a 
systematic approach to diagnosis. In: 2004. p. 1574-1583. 
Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The 
Registry of the International Society for Heart and Lung Transplantation: fifteenth 
official report--1998. J.Heart Lung Transplant. 1998; 17:656-668. 
388 
 
Hsu SM, Raine L, Fanger H. A comparative study of the peroxidase-
antiperoxidase method and an avidin-biotin compkex for studying polypeptide 
hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981a; 75:734-
738. 
Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-
peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 1981b; 
75:816-821. 
Hummel M, Czerlinski S, Friedel N, Liebenthal C, Hasper D, von Baehr R, 
Hetzer R, Volk HD. Interleukin-6 and interleukin-8 concentrations as predictors 
of outcome in ventricular assist device patients before heart transplantation. Crit 
Care Med 1994; 22:448-454. 
Hunt S. Reinnervation of the transplanted heart - why is it important? N Eng J 
Med 2001; 345:762-764. 
Hunt SA. Curent status of cardiac transplantation. JAMA 1998; 280:1692. 
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup 
M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, 
Stevenson LW, Yancy CW. ACC/AHA 2005 Guideline update for the diagnosis 
and management of chronic heart failure in the adult. Circulation 2005; 112:e154-
e235. 
Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N 
Eng J Med 1999; 341:1276-1283. 
Ikeda U, Maeda Y, Kawahara Y, Yokoyama M, Shimada K. Angiotensin II 
augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. 
Circulation 1995; 92:2683-2689. 
Ikeda U, Murakami Y, Kanbe T, Shimada K. Alpha-adrenergic stimulation 
enhances inducible nitric oxide synthase expression in rat cardiac myocytes. 
J.Mol.Cell Cardiol. 1996; 28:1539-1545. 
Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, Fukuyama 
T. Iodine-123 MIBG images reflect intense myocardial adrenergic nervous 
activity in congestive heart failure independent of underlying cause. J Am Coll 
Cardiol 1995; 26:1594-99. 
Imamura Y, Fukuyama T, Mochizuki T, Miyagawa S, Watanabe K. Prognostic 
value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic 
peptide levels in patients with left ventricular dysfunction resulting from 
cardiomyopathy. Jpn Circ J 2001; 65:155-160. 
Ino T, Kishiro M, Okubo M, Akimoto K, Nishimoto K, Yabuta K, Okada R. Late 
persistent expressions of ICAM-1 and VCAM-1 on myocardial tissue in children 
with lymphocytic myocarditis. Cardiovasc Res 1997; 34:323-328. 
Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: 
supersensitivity that may be arrhythmogenic. Circulation 1987; 75:887. 
389 
 
Inoue Y, Suzuki A, Shirouzu I, Machida T, Yoshizawa Y, Akita F, Ohnishi S, 
Yoshikawa K, Ohtomo K. Effect of collimator choice on quantitative assessment 
of cardiac iodine 123 MIBG uptake. J Nucl Cardiol 2003; 10:623-632. 
ISHLT Registry. ISHLT Registry. In: 2009. 
Iwase M, Bishop SP, Uechi M, Vatner DE, Shannon RP, Kudej RK, Wight DC, 
Wagner TE, Ishikawa Y, Homcy CJ, Vatner SF. Adverse effects of chronic 
endogenous sympathetic drive induced by cardiac Gs alpha-overexpression. Circ 
Res 1996; 78:517-524. 
Iwase M, Uechi M, Vatner DE, Asai K, Shannon RP, Kudej RK, Wagner TE, 
Wight DC, Patrick TA, Ishikawa Y, Homcy CJ, Vatner SF. Cardiomyopathy 
induced by cardiac Gs alpha-overepression. Am J Physiolo 1997; 272:H585-
H589. 
Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, 
Ohchima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M. 
Mineralocorticoid receptor antagonism ameliorates left ventricular dysfunction 
and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated 
cardiomyopathy: a pilot study. Circulation 2005; 112:2940-2950. 
Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and 
reprogramming of cardiac gene expression produced by pressure overload. 
Proc.Natl.Acad.Sci.U.S.A 1988; 85:339-343. 
Jacobson AF, Lomabrd J, Banerjee G, Camici PG. 
123
I-mIBG scintigraphy to 
predict risk for adverse cardiac outcomes in heart failure: Design of two 
prospective multicenter international trials. J Nucl Cardiol 2009; 16:113-121. 
James KB, McCarthy PM, Thomas JD, Vargo R, Hobbs RE, Sapp S, Bravo E. 
Effect of implantable left ventricular assist device on neuroendocrine activation in 
heart failure. Circulation 1995a; 92:II-191 - II-195. 
Jaski BE, Kim JC, Naftel DC, Jarcho J, Costanzo MR, Eisen HJ, Kirklin JK, 
Bourge RC. Cardiac transplant outcome of patients supported on left ventricular 
assist device vs. intravenous inotropic therapy. J Heart Lung Transplant. 2001; 
20:449-456. 
Jaszczak RJ, Greer KL, Floyd CE Jr, Harris CC, Coleman RE. Improved SPECT 
quantification using compensation for scattered photons. J Nucl Med 1984; 
25:893-899. 
Jay N.Cohn. Critical review of heart failure: The role of left ventricular 
remodeling in the therapeutic response. Clin Cardiol 2005; 18:IV-4-IV-12. 
John R, Lietz K, Schuster M, Naka Y, Rao V, Mancini DM, Rose EA, Smith CR, 
Oz MC, Edwards NM, Itescu S. Immunologic sensitization in recipients of left 
ventricular assist devices. J Thorac.Cardiovasc.Surg 2003; 125:578-591. 
390 
 
Johnson FK, Johnson RA, Durante W. Aldosterone promotes endothelial 
dysfunction via prostacycline independent of hypertension. Hypertension 2005; 
46:29-30. 
Jon F.Lutz. A XII century description of congestive heart failure. Am J Cardiol 
1988; 61:494-495. 
Jones RH, Valzques EJ, Michler RE, Sopki G, Oh JK, O'Connor CM, Hill JA, 
Menicanti L, Sadowski Z, DEsvigne-Nickens P, Rouleau JL, Lee KL. Coronary 
bypass surgery with or without surgical ventricular reconstruction. N Eng J Med 
2009a; 360:1705-1717. 
Jones RH, Valzquez MD, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, 
Menicanti L, Sadowski Z, DEsvigne-Nickens P, Rouleau J, Lee KL. Coronary 
bypass surgery with or without surgical ventricular reconstruction. N Eng J Med 
2009b; 360:1705-1717. 
Jones LR, Suzuki YJ, Wang W, Kobayashi YM, Ramesh V, Franzini-Armstrong 
C, Cleemann L, Morad M. Regulation of Ca2+ signaling in transgenic mouse 
cardiac myocytes overexpressing calsequestrin. J.Clin.Invest 1998; 101:1385-
1393. 
Kakuchi H, Sasaki T, Ishida S, Komamura K, Miyatake K. Clinical usefulness of 
123
I meta-iodobenzylguanidine imaging in predicting the effectiveness of  
blockers for patients with idiopathic dilated cardiomyopathy before and soon after 
treatment. Heart 1999; 81:148-152. 
Kalra DK, Zoghbi WA. Myocardial hibernation in coronary artery disease. Curr 
Atheroscler Rep 2002; 4:149-155. 
Kandolf R, Ameis D, Kirschner P, Canu A, Hofschneider PH. In situ detection of 
enteroviral genomes in myocardial cells by nucleic acid hybridization: an 
approach to the diagnosis of viral heart disease. Proc.Natl.Acad.Sci U.S.A 1987; 
84:6272-6276. 
Kandolf R, Hofschneider PH. Viral heart disease. Springer Semin.Immunopathol. 
1989; 11:1-13. 
Kanner BI. Sodium-coupled neurotransmitter transport: structure, function and 
regulation. J Exp Biol 1994; 196:237-49. 
Kapadia SR, Yakoob K, Nader S, Thomas JD, Mann DL, Griffin BP. Elevated 
circulating levels of serum tumour necrosis factor-alpha in patients with 
hemodynamically significant pressure and volume overload. J Am Coll Cardiol 
2000; 36:208-212. 
Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa 
S, Suzuki T, Kurabayashi M. Comparative effects of valsartan and enalapril on 
cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients 
with congestive heart failure. Heart 2006; 92:625-630. 
391 
 
Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa 
S, Suzuki T, Kurabayashi M. Evaluation of cardiac sympathetic nerve activity and 
left ventricular remodelling in patients with dilated cardiomyopathy on the 
treatment containing carvedilol. Eur Heart J 2007a; 28:995. 
Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, 
Kurabayashi M. Spironolactone improves cardiac sympathetic nerve activity and 
symptoms in patients with congestive heart failure. J Nucl Med 2002; 43:1279-
1285. 
Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, 
Kurabayashi M. Addition of valsartan to an angiotensin-converting enzyme 
inhibitor improves cardiac sympathetic nerve activity and left ventricular function 
in patients with congestive heart failure. J Nucl Med 2003a; 44:884-890. 
Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, 
Kurabayashi M. Effects of spironolactone on cardiac sympathetic nerve activity 
and left ventricular remodeling in patients with dilated cardiomyopathy. J Am 
Coll Cardiol 2003b; 41:574-81. 
Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, 
Kurabayashi M. Effects of candesartan on cardiac sympathetic nerve activity in 
patients with congestive heart failure and preserved left ventricular ejection 
fraction. J Am Coll Cardiol 2005a; 45:661-7. 
Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, 
Kurabayashi M. Effects of perindopril on cardiac sympathetic nerve activity in 
patients with congestive heart failure: comparison with enalapril. Eur J Nucl Med 
Mol Imaging 2005b; 32:964-971. 
Kasama S, Toyama T, Sumino H, Matsumoto N, Sato Y, Kumakura H, Takayama 
Y, Ichikawa S, Suzuki T, Kurabayashi M. Additive effects of spironolactone and 
candesartan on cardiac sympathetic nerve activity and left ventricular remodeling 
in patients with congestive heart failure. J Nucl Med 2007b; 48:1993-2000. 
Kasama S, Toyama T, Sumino H, Nakazawa M, Matsumoto N, Sato Y, 
Kumakuura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Prognostic 
value of serial 
123
I-MIBG imaging in patients with stabilized chronic heart failure 
and reduced left ventricular ejection fraction. J Nucl Med 2008; 49:907-914. 
Kashiwazaki S. Effects of artificial circulation by pulsaitle and non-pulsatile flow 
on brain tissue. Ann Thorac Cardiovasc Surg 2000; 6:389-396. 
Kass DA. Ventricular remodelling: chamber dyssynchrony and effecrs of cardiac 
resynchronization. Eur Heart J 2003; 5:I54-I63. 
Katz AM. The cardiomyoapthy of overload: an unnatural growth response in the 
hypertrophied heart. Ann Intern Med 1994; 121:363-371. 
Kavarana MN, Pessin-Minsley MS, Urtecho J, Catanese KA, Flannery M, Oz 
MC, Naka Y. Right ventricular dysfunction and organ failure in left ventricular 
392 
 
assist device recipients: a continuing problem. Ann Thorac Surg 2002; 73:745-
750. 
Kawai H, Fan TM, Dong E, Siddiqui RA, Yatani A, Stevens SY, Liang C. ACE 
inhibition improves cardiac NE uptake and attenuates sympathetic nerve terminal 
abnormalities in heart failure. Am J Physiol Heart Circ Physiol 1999; 277:H1609-
H1617. 
Kawai H, Stevens S, Liang C. Renin-angiotensin system inhibition on 
noradrenergic nerve terminal function in pacing-induced heart failure. Am J 
Physiol Heart Circ Physiol 2000; 279:H3012-H3019. 
Kaye D, Esler M. Sympathetic neuronal regulation of the heart in aging and heart 
failure. Cardiovasc Research 2005; 66:256-264. 
Kaye DM, Gruskin S, Smith I, Esler MD. Nitric oxide mediated modulation of 
norepinephrine transport: identification of a potential target for S-nitrosylation. Br 
J Pharmacol 2000a; 130:1060-1064. 
Kaye DM, Lambert GW, Lefkovits J, Morris M, Jenning G, Esler MD. 
Neurochemical evidence of cardiac sympathetic activation and increased central 
nervous system norepinephrine turnover in severe congestive heart failure. In: 
1994. p. 570-580. 
Kaye DM, Vaddadi G, Gruskin SL, Du X, Esler MD. Reduced myocardial nerve 
growth factor expression in human and experimental heart failure. Circ Res 
2000b; 86:e80-e84. 
Kaye DM, Wiviott SD, Kobzik L, Kelly RA, Smith TW. Regulation of neuronal 
(uptake-1 mediated norepinephrine transport by nitric oxide: mechanism and 
influence of autocrine and paracrine sources of nitric oxide. Am J Physiol 1997; 
272:H875-H883. 
Keller NR, Diedrich A, Appalsamy M, Tuntrakool S, Lonce S, Finney C, Caron 
MG, Robertson D. Norepinephrine transporter-deficient mice exhibit excessive 
tachycarida and elevated blood pressure with wakefulness and activity. 
Circulation 2004; 110:1191-1196. 
Kenneth B Margulies. Contractile protein abnormalities in failing hearts. J Nucl 
Cardiol 2002; 9:413-418. 
Kenneth L Franco. New devices for chronic ventricular support. J Card Surg 
2001; 16:178-192. 
Khan N, Delgado RM, Radovancevic B, Torre-Amione G, Abrams J, Miller K, 
Myers T, Okerberg K, Stetson SJ, Gregoric I, Hernandez A, Frazier OH. 
Dobutamine stress echocardiography predicts myocardial improvement in patients 
supported by left ventricular assist devices (LVADs): hemodynamic and 
histologic evidence of improvement before LVAD explantation. J Heart Lung 
Transplant 2003a; 22:137-146. 
393 
 
Khan N, Delgado RM, Radovancevic B, Torre-Amione G, Abrams J, Miller K, 
Myers T, Okerberg K, Stetson SJ, Gregoric I, Hernandez A, Frazier OH. 
Dobutamine stress echocardiography predicts myocardial improvement in patients 
supported by left ventricular assist devices (LVADs): hemodynamic and 
histologic evidence of improvement before LVAD explantation. J Heart Lung 
Transplant 2003b; 22:137-146. 
Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, Iwao H. Effects 
of combination of ACE inhibitor and angiotensin receptor blocker on cardiac 
remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 
103:148-154. 
Kirklin JK, Frazier OH. Developmental history of mechanical circulatory support. 
In: OH Frazier, JK Kirklin, editors. Mechanical Circulatory Support - ISHLT 
Monograph. Elsevier, 2006. 
Kiss E, Ball NA, Kranias EG, Walsh RA. Differential changes in cardiac 
phospholamban and sarcoplasmic reticular Ca(2+)-ATPase protein levels. Effects 
on Ca2+ transport and mechanics in compensated pressure-overload hypertrophy 
and congestive heart failure. Circ.Res. 1995; 77:759-764. 
Kitayama S, Dohi T. Norepinephrine transporter splice variants and their 
interaction with substrates and blockers. Eur J Pharmacol 2003; 479:65-70. 
Kiyono Y, Kajiyama S, Fujiwara H, Kanegawa N, Saji H. Influence of the polyol 
pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic 
nerves: implications for heterogeneous accumulation of MIBG. Eur J Nucl Med 
Mol Imaging 2005; 32:993-997. 
Klotz S, Barbone A, Reiken S, Holmes JW, Naka Y, Oz MC, Marks AR, 
Burkhoff D. Left ventricular assist device support normalizes left and right 
ventricular beta-adrenergic pathway properties. J Am Coll Cardiol 2005a; 45:668-
676. 
Klotz S, Deng MC, Stypmann J, Roetker J, Wihlem MJ, Hammel D, Scheld HH, 
Schmid C. Left ventricular pressure and volume unloading during pulsatile versus 
non-pulsatile left ventricular assist device. Ann Thorac Surg 2004; 77:143-149. 
Klotz S, Foronjy RF, Dickstein ML, Gu A, Garrelds IM, Jan Danser AH, Oz MC, 
D‘Armiento J, Burkhoff D. Mechanical Unloading During Left Ventricular Assist 
Device Support Increases Left Ventricular Collagen Cross-Linking and 
Myocardial Stiffness. Circualtion 2005b; 112:364-74. 
Knuuti J, Sipola P. Is it time for cardiac innervation imaging? Q J Nucl Med Mol 
Imaging 2005; 49:97-105. 
Kobayashi H, Momose M, Kanaya S, Kondo C, Kusakabe K, Mitsuhashi N. 
Scatter correction by two-window method standardizes cardiac I-123 MIBG 
uptake in various gamma camera systems. Ann Nucl Med 2003; 17:309-13. 
Kobayashi M, Izawa H, Cheng XW, Asano H, Hirashiki A, Unno K, Ohshima S, 
Yamada T, Murase Y, Kato TS, Obata K, Noda A, Nishizawa T, Isobe S, Nagata 
394 
 
K, Matsubara T, Murohara T, Yokota M. Dobutamine stress testing as a 
diagnostic tool for evaluation of myocardial contractile reserve in asymptomatic 
or mildly symptomatic patients with dilated cardiomyopathy. JACC: Cardiovasc 
Img 2008; 1:718-726. 
Koch WJ, Rockman HA, Samama P, Hamilton R, Bond RA, Milano CA, 
Lefkowitz RJ. Cardiac function in mice overexpressing the -adrenergic receptor 
kinase or a ARK inhibitor. Science 1995; 268:1350-1353. 
Konertz W, Dushe S, Hotz H, Braun JP, Spiess C, Endzweiler C, Stantke K, 
Sapsford E, Sabbah H, Kleber FX. Safety and feasibility of a cardiac support 
device. J Card Surg 2001; 16:113-117. 
Konertz W, Khoynerzhad A, Sidiropoulos A, Borak V, Baumann G. Early and 
intermediate results of LV reduction surgery. Eur J Cardiothorac Surg 1999; 
15:S26-S30. 
Konertz WF, Shapland JE, Hotz H, Dushe S, Braun JP, Stantke K, Kleber FX. 
Passive containment and reverse remodeling by a novel textile cardiac support 
device. Circulation 2001; 104:I-1270-I-1275. 
Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D. 
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term 
progression of left ventricular dysfunction in patients with heart failure. SOLVD 
Investigators. Circulation 1992; 86:431-438. 
Korewicki J. Cardiac transplantation is still the method of choice in the treatment 
of patients with severe heart failure. Cardiol J 2009; 16:493-499. 
Kormos RL, Gasior TA, Kawai A, Pham SM, Murali S, Hattler BG, Griffith BP. 
Transplant candidate's clinicla status rather than right ventricular function defines 
need for univentricular versus biventricular support. J Thorac Cardiovasc Surg 
1996; 111:773-783. 
Koster A, Sanger S, Hansen R, Sodian R, Mertzlufft F, Harke C, Kuppe H, Hetzer 
R, Loebe M. Prevalence and persistence of heparin/platelet factor 4 antibodies in 
patients with heparin coated and noncoated ventricular assist devices. ASAIO J 
2000; 46:319-22. 
Kostin S, Scolz D, Shimada T, Maeno Y, Mollnau H, Hein S, Schaper J. The 
internal and external protein scaffold of the T-tubular system in cardiomyocytes. 
Cell Tissue Res 1998; 294:449-460. 
Kreusser MM, Haass M, Buss SJ, Hardt SE, Gerber SH, Kinscherf R, Katus HA, 
Backs J. Injection of nerve growth factor into stellate ganglia improves 
norepinephrine reuptake into failing hearts. Hypertension 2006; 47:209-15. 
Kuhn M, Voß M, Mitko D, Stypmann J, Schmid C, Kawaguchi N, Grabellus F, 
Baba HA. Left ventricular assist device support reverses altered cardiac 
expression and function of natriuretic peptides and receptors in end-stage heart 
failure. Cardiovasc Research 2004; 64:308-314. 
395 
 
Kuznetsov V, Pak E, Robinson RB, Steinberg SF. Beta 2-adrenergic receptor 
actions in neonatal and adult rat ventricular myocytes. Circ.Res. 1995; 76:40-52. 
L'abbate A, Sambuceti G. Studying the neuronal side of the synaptic cleft. A tool 
for investigating the paradox of the sympathetic nervous system and heart failure 
in dilated cardiomyopathy. Eur Heart J 2001; 22:1521-2. 
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, 
Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, 
Sutton MS, Stewart WJ. Recommendations for chamber quantification. J Am Soc 
Echo 2005; 18:1440-1463. 
Langer A, F.M., Josse R, Armstrong P. MIBG imaging in diabetes mellitus: 
Assessment of cardiac sympathetic denervation and its relation to autonomic 
dysfunction and silent myocardial ischaemia. J Am Coll Cardiol 1995; 25:610-18. 
Langer O, Halldin C. PET and SPECT tracers for mapping the cardiac nervous 
system. Eur J Nucl Med 2002; 29:416-434. 
Latif N, Yacoub MH, George R, Barton PJR, Birks EJ. Changes in sarcomeric and 
non-sarcomeric cytoskeletal proteins and focal adhesion molecules during 
myocardial recovery after left ventricular assist device support. J Heart Lung 
Transplant 2007a; 26:230-5. 
Lazar RM, Shapiro PA, Jaski BE, Parides MK, Bourge RC, Watson JT, Damme J, 
Dembitsky W, Hosenpud JD, Gupta L, Tierney A, Kraus T, Naka Y. Neurological 
events during long-term mechanical circulatory support for heart failure. 
Circulation 2004; 109:2423-2427. 
Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Wehlen-Grandjean M, 
Pochmalicki G, Dargie H. Heart rate and cardiac rhythm relationships with 
bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 
103:1428-1433. 
Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of 
beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, 
placebo-controlled, randomized trials. Circulation 1998; 98:1184-1191. 
Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac -adrenergic 
receptors, and heart failure. Circulation 2000; 101:1634-1637. 
Lehnart SE, Wehrens XH, Marks AR. Defective ryanodine receptor interdomain 
interactions may contribute to intracellular Ca2+ leak: A novel therapeutic target 
in heart failure. Circulation 2005; 111:3342-3346. 
Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of 
chronic heart failure: a meta-analysis on individual data of two placebo-controlled 
studies, CIBIS and CIBIS II. Am Heart J 2002; 143:301-307. 
Lerman A, Hildebrand FL, Jr., Aarhus LL, Burnett JC, Jr. Endothelin has 
biological actions at pathophysiological concentrations. Circulation 1991; 
83:1808-1814. 
396 
 
Levi G, Scalvini S, Volterrani M, Marangoni S, Arosio G, Quadri A. Coxsackie 
virus heart disease: 15 years after. Eur.Heart J 1988; 9:1303-1307. 
Levin HR, Oz MC, Catanese KA, Rose EA, Burkhoff D. Transient normalisation 
of systolic and diastolic function after support with a left ventricular assist device 
in a patient with dilated cardiomyopathy. J Heart Lung Transplant 1996; 15:840-
842. 
Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkhoff D. Reversal of 
chronic ventricular dilation in patients with end-stage cardiomyopathy by 
prolonged mechanical unloading. Circualtion 1995; 91:2717-20. 
Li W, Knowlton D, Woodward W, Habecker BA. Regulation of noradrenergic 
function by inflammatory cytokines and depolarization. J Neurochem 2003; 
86:774-783. 
Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, 
Kormos RL, Feldman AM. Downregulation of Matrix Metalloproteinases and 
Reduction in Collagen Damage in the Failing Human Heart After Support With 
Left Ventricular Assist Devices. Circulation 2001; 104:1147-52. 
Li YY, Feng YQ, Kadokami T, McTieman CF, Draviam R, Watkins SC, Feldman 
AM. Myocardial extracellular matrix remodeling in transgenic mice 
overexpressing tumor necrosis factor can be modulated by anti-tumor necrosis 
factor therapy. Proc Natl Acad Sci 2000; 97:12746-12751. 
Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue 
inhibitors of metalloproteinases in the failing human heart. Circulation 1998; 
98:1728-1734. 
Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, 
Kormos RL, Feldman AM. Downregulation of matrix metalloproteinases and 
reduction in collagen damage in the failing human heart after support with left 
ventricular assist devices. Circulation 2001; 104:1147-1152. 
Liang C. Sympatholysis and cardiac sympathetic nerve function in the treatment 
of congestive heart failure. Jr Am Coll Cardiol 2003; 42:549-51. 
Liang C. Cardiac sympathetic nerve terminal function in congestive heart failure. 
Acta Pharmacol Sin 2007; 28:921-927. 
Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG, 
Naka Y, Mancini D, Miller LW. Outcomes of left ventricular assist device 
implantation as destination therapy in the post-REMATCH era: implications for 
patient. Circualtion 2007; 116:497-505. 
Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, 
Dorn GW. Early and delayed consequences of beta(2)-adrenergic receptor 
overexpression in mouse hearts: critical role for expression level. Circulation 
2000; 101:1707-1714. 
397 
 
Lim P, Bars C, Mitchell-Heggs L, Roiron C, Elbaz N, Hamdaoui B, Lellouche N, 
Dubois-Randé JL, Guéret P. Importance of contractile reserve for CRT. Europace 
2007; 9:739-743. 
Lipkin DP, Jones DA, Round JM, Poole-Wilson PA. Abnormalities of skeletal 
muscle in patients with chronic heart failure. Int.J.Cardiol. 1988; 18:187-195. 
Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. 
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 
receptor antagonists in rats with heart failure. Role of kinins and angiotensin II 
type 2 receptors. J Clin Invest 1997; 99:1926-1935. 
Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, 
Murabito JM, Vasan RS, Benjamin EJ, Levy D. Lifetime risk for developing 
congestive heart failure: the Framingham Heart Study. Circulation 2006; 
106:3068-3072. 
Loebe M, Hennig E, Muller J, Spiegelsberg S, Weng Y, Hetzer R. Long-term 
mechanical circulatory support as a bridge to transplantation, for recovery from 
cardiomyopathy, and for permenant replacement. Eur J Cardiothoracic Surg 1997; 
11(Suppl):S18-S24. 
Loebe M, Koster A, Sanger S, Potapov EV, Kuppe H, Noon GP, Hetzer R. 
Inflammatory response after implantation of a left ventricular assist device: 
comparison between the axial flow MicroMed DeBakey VAD and the pulsatile 
Novacor device. ASAIO J 2001; 47:272-4. 
Loebe M, Hennig E, Muller J, Spiegelsberger S, Weng Y, Hetzer R. Long-term 
mechanical circulatory support as a bridge to transplantation, for recovery from 
cardiomyopathy, and for permanent replacement. Eur.J.Cardiothorac.Surg. 1997a; 
11 Suppl:S18-S24. 
Loebe M, Weng Y, Muller J, Dandel M, Halfmann R, Spiegelsberger S, Hetzer R. 
Successful mechanical circulatory support for more than two years with a left 
ventricular assist device in a patient with dilated cardiomyopathy. J.Heart Lung 
Transplant. 1997b; 16:1176-1179. 
Lohse MJ, Benovic JL, Caron MG, Lefkowitz RJ. Multiple pathways of rapid 2-
adrenergic receptor desensitisation. J Biol Chem 1990a; 265:3202-3209. 
Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. -arrestin: A protein 
that regulates -adrenergic receptor function. Science 1990b; 248:1547-1550. 
Lompre AM, Anger M, Levitsky D. Sarco(endo)plasmic reticulum calcium pumps 
in the cardiovascular system: function and gene expression. J.Mol.Cell Cardiol. 
1994; 26:1109-1121. 
Lompre AM, Nadal-Ginard B, Mahdavi V. Expression of the cardiac ventricular 
alpha- and beta-myosin heavy chain genes is developmentally and hormonally 
regulated. J Biol.Chem. 1984; 259:6437-6446. 
398 
 
Long CS, Ordahl CP, Simpson PC. Alpha 1-adrenergic receptor stimulation of 
sarcomeric actin isogene transcription in hypertrophy of cultured rat heart muscle 
cells. J Clin Invest 1989; 83:1078-1082. 
Long JW. Advanced mechanical circulatory support with the HeartMate left 
ventricular assist device in the year 2000. Ann Thorac Surg 2001; 71:176-82. 
Long JW, Kfoury AG, Slaughter MS, Silver M, Milano C, Rogers J, Delgado R, 
Frazier OH. Long-term destination therapy with the HeartMate XVE left 
ventricular assist device: improved outcomes since the REMATCH study. 
Congest Heart Fail 2005; 11:133-138. 
Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging 
role of angiotensin-converting enzyme inhibitors in cardiac and vascular 
protection. Circulation 1994; 90:2056-2069. 
Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. 
Prog.Cardiovasc.Dis. 1995; 38:87-104. 
Lotze U, Kaepplinger S, Kober A, Richartz BM, Gottschild D, Figulla HR. 
Recovery of the cardiac adrenergic nervous system after long-term blocker 
therapy in idiopathic dilated cardiomyopathy: assessment by increase in 
myocardial 
123
I-Metaiodobenzylguanidine uptake. J Nucl Med 2001; 42:49-54. 
Lotze U, Kober A, Kaepplinger S, Neubauer S, Gottschild D, Figulla HR. Cardiac 
sympathetic activity as measured by myocardial 123-I-Metaiodobenzylguanidine 
uptake and heart rate variability in idiopathic dilated cardiomyopathy. Am J 
Cardiol 1999; 83:1548-51. 
Lovric SS, Avbelj V, Trobec R, Zorman D, Rakovec P, Hojker S, Gersak B, 
Milcinski M. Sympathetic reinnervation after heart transplantation, assessed by 
iodine-123 metaiodobenzylguanidine imaging, and heart rate variability. Eur J 
Cardio Surg 2004; 26:736-741. 
Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D. 
Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking 
agents. N Eng J Med 202; 346:1357-1365. 
Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, 
Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and 
mitral regurgitation in chronic heart failure. Am J Cardiol 1999; 83:1201-1205. 
Lucas C, Stevenson LW, Johnson W, Hartley H, Hamilton MA, Walden J, Lem 
V, Eagen-Bengsten E. The 6-min walk and peak oxygen consumption in advanced 
heart failure: Aerobic capacity and survival. Am Heart J 1999; 138:618-623. 
Ludwig A, Zong X, Jeglitsch M, Hofmann F, Biel M. A family of 
hyperpolarisation-activated mammalian cation channels. Nature 1998; 393:587-
591. 
Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T, 
Kranias EG. Targeted ablation of the phospholamban gene is associated with 
399 
 
markedly enhanced myocardial contractility and loss of beta-agonist stimulation. 
Circ.Res. 1994; 75:401-409. 
Lytton J, Zarain-Herzberg A, Periasamy M, MacLennan DH. Molecular cloning 
of the mammalian smooth muscle sarco(endo)plasmic reticulum Ca2+-ATPase. 
J.Biol.Chem. 1989; 264:7059-7065. 
MacLennan PA, Edwards RH. Effects of clenbuterol and propranolol on muscle 
mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce 
hypertrophy. Biochem.J 1989; 264:573-579. 
Madigan JD, Barbone A, Choudhri AF, Morales DL, Cai B, Oz MC, Burkhoff D. 
Time course of reverse remodeling of the left ventricle during support with a left 
ventricular assist device. J.Thorac.Cardiovasc.Surg. 2001; 121:902-908. 
Maeder MT, Leet A, Ross A, Esmore D, Kaye DM. Changes in right ventricular 
function during continuous-low left ventricular assist device support. In: 2009. p. 
360-366. 
Maisel A, Mehra MR. Understanding B-type natriuretic peptide and its role in 
diagnosing and monitoring congestive heart failure. Clinical Cornerstone 2005; 
7:S7-S17. 
Malcolm Johnson. Molecular mechanisms of 2-adrenergic receptor function, 
response, and regulation. J Allergy Clin Immunol 2006; 117:18-24. 
Maltin CA, Delday MI, Hay SM, Baillie AG. Denervation increases clenbuterol 
sensitivity in muscle from young rats. Muscle Nerve 1992; 15:188-192. 
Maltin CA, Delday MI, Hay SM, Smith FG, Reeds PJ. Propranolol apparently 
separates the physical and compositional characteristics of muscle growth induced 
by clenbuterol. Biosci.Rep. 1987; 7:51-57. 
Maltin CA, Delday MI, Watson JS, Heys SD, Nevison IM, Ritchie IK, Gibson 
PH. Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in 
orthopaedic patients. Clin.Sci.(Lond) 1993; 84:651-654. 
Maltin CA, Reeds PJ, Delday MI, Hay SM, Smith FG, Lobley GE. Inhibition and 
reversal of denervation-induced atrophy by the beta-agonist growth promoter, 
clenbuterol. Biosci.Rep. 1986; 6:811-818. 
Mancia G. Sympathetic activation in congestive heart failure. Eur Heart J 1990; 
11:3-11. 
Mancini DM, Beniaminovitz A, Levin H, Catanese K, Flannery M, DiTullio M, 
Savin S, Cordisco ME, Rose R, Oz M. Low incidence of myocardial recovery 
after left ventricular assist device implantation in patients with chronic heart 
failure. Circulation 1998; 98:2383-89. 
Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, 
Wilson JR. Contribution of skeletal muscle atrophy to exercise intolerance and 
altered muscle metabolism in heart failure. Circulation 1992; 85:1364-1373. 
400 
 
Mandela P, Ordway GA. The norepinephrine transporter and its regulation. J 
Neurochem 2006; 97:310-333. 
Mann DL, Bristow MR. Mechanisms and models in heart failure. Circulation 
2005; 111:2837-2849. 
Mann DL, Kent RL, Parsons B, Cooper GT. Adrenergic effects on the biology of 
the adult mammalian cardiocyte. Circulation 1992; 85:790-804. 
Mann DL, Willerson JT. Left Ventricular Assist Devices and the Failing Heart : A 
Bridge to Recovery, a Permanent Assist Device, or a Bridge Too Far? Circualtion 
1998; 98:2367-69. 
Mariani G, Bruselli L, Duatti A. Is PET always an advantage versus planar and 
SPECT imaging. Eur J Nucl Med Mol Imaging 2008; 3:1560-1565. 
Marijianowski MM, Teeling P, Mann J, Becker AE. Dilated cardiomyopathy is 
associated with an increase in the type I/type III collagen ratio: a quantitative 
assessment. J Am.Coll.Cardiol. 1995; 25:1263-1272. 
Marriott JB, Goldman JH, Keeling PJ, Baig MK, Dalgleish AG, McKenna WJ. 
Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy 
and their asymptomatic relatives. Heart 1998; 75:287-290. 
Martin J, Friesewinkel O, Benk C, Sorg S, Schultz S, Beyersdorf F. Improved 
durability of the HeartMate XVE left ventricular assist device provides safe 
mechanical support uo to 1 year but is associated with high risk of device failure 
int he second year. In: 2006. p. 384-390. 
Martino TA, Liu P, Sole MJ. Viral infection and the pathogenesis of dilated 
cardiomyopathy. Circ.Res. 1994; 74:182-188. 
Massad MG, McCarthy PM, Smedira NG, Cook DJ, Ratliff NB, Goormastic M, 
Vargo RL, Navia J, Young JB, Stewart RW. Does successful bridging with the 
implantable left ventricular assist device affect cardiac transplantation outcome? J 
Thorac.Cardiovasc.Surg 1996; 112:1275-1281. 
Matoba Y, Matsumori A, Ohtani H, Tominaga M, Fujiwara H, Toyokuni S, 
Takahashi K, Midorikawa O, Kawai C. A case of biopsy-proven myocarditis 
progressing to autopsy-proven dilated cardiomyopathy. Clin.Cardiol. 1990; 
13:732-737. 
Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of 
repeated 
123
I-Metaiodobenzylguanidine imaging in patients with dilated 
cardiomyopathy with congestive heart failure before and after optimized 
treatments - Comparison with neurohumoral factors. Circ J 2002; 66:537-43. 
Matsuo S, Nakajima K, Okuda K, Kawano M, Ishikawa T, Hosoya T, Taki J, 
Kinuya S. Standardisation of the heart-to-mediastinum ratio of 123I-labelled-
metaiodobenzylyguanidine uptake using the dual energy window method: 
feasibility of correction with different camera-collimator combinations. Eur J 
Nucl Med Mol Imaging 2009; 36:560-566. 
401 
 
Matsuo S, Nakamura Y, Tsutamoto T, Kinoshita M. Impairments of myocardial 
sympathetic activity may reflect the progression of myocardial damage or 
dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol 2002; 9:407-12. 
Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagain FD, Miller 
LW, Margulies K, McRee S, Frazier OH, Torre-Amione G. Cardiac improvement 
during mechanical circulatory support: A prospective multicenter study of the 
LVAD working group. Circualtion 2007; 115:2497-2505. 
Maybaum S, Stockwell P, Naka Y, Catanese K, Flannery M, Fisher P, Oz M, 
Mancini D. Assessment of myocardial recovery in a patient with acute 
myocarditis supported with a left ventricular assist device: a case report. J Heart 
Lung Transplant 2003; 22:202-9. 
McAlister FA, Ezekowitz J, Hooton N, Vandermeer B, Spooner C, Dryden DM, 
Page RL, Hlatky MA, Rowe BH. Cardiac resynchronization therapy for patients 
with left ventricular systolic dysfunction. JAMA 2007; 297:2502-2514. 
McCarthy JF, McCarthy PM, Starling RC, Smedira NG, Scalia GM Wong J, 
Kasirajan V, Goormastic M, Young JB. Partial left ventriculectomy and mitral 
valve repair for end-stage CHF. Eur J Cardiothorac Surg 1998; 13:337-343. 
McCarthy PM. New surgical options for the failing heart. J Heart Valve Dis 1999; 
8:472-475. 
McDonagh TA, Morrison CE, Lawrence A. Symptomatic and asymptomatic left-
ventricular systolic dysfunction in an urban population. Lancet 1997; 350:829-
833. 
McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of 
congestive heart failure: the Framingham Study. N Eng J Med 1971; 285:1441-
1446. 
McQueen MJ, Lonn E, Gerstein HC, Bosch J, Yusuf S. The HOPE (Heart 
Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab 
Invest Suppl 2005; 240:143-156. 
Melikian H, McDonald J, Gu H, Rudnick G, Moore K. Human norepinephrine 
transporter. Jr Bio Chem 1994; 269:12290-97. 
Melikian H, Ramamoorthy S, Tate C, Blakely R. Inability to N-Gylcosylate the 
human norepinephrine transporter reduced protein stability, surface trafficking, 
and transport activtiy but not ligand recognition. Molecular Pharmacology 1996; 
50:266-76. 
Menconi MJ, Pockwinse S, Owen TA, Dasse KA, Stein GS, Lian JB. Properties 
of blood-contacting surfaces of clinically implanted cardiac assist devices: gene 
expression, matrix composition, and ultrastructural characterization of cellular 
linings. J Cell Biochem 1995; 57:557-73. 
Menicanti L, Di Donato M. The Dor procedure: What has changed after fifteen 
years of clinical practice. J Thorac Cardiovasc Surg 2002; 124:886-890. 
402 
 
MERIT-HF Trial. Effect of metoprolol CR/XL in chronic heart failure. Lancet 
1999; 353:2001-2007. 
Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande J, Duval A, Loisance 
D, Castaigne A, Syrota A. Prognostic value of MIBG imaging in idiopathic 
dilated cardiomyopathy. J Nucl Med 1999a; 40:917-23. 
Merlet P, Caussin C, Poiseau E, Piot O, Maziere B, Syrota A. In vivo assessment 
of neurotransmitter system in cardiovascular diseases. Q J Nucl Med 1996; 
40:108-20. 
Merlet P, Piot O, Dubois-Rande JL, Loisance D, Castaigne A, Syrota A. Clinical 
use of metaiodobenzylguanidine imaging in cardiology. Q J Nucl Med 1995; 
39:29-39. 
Merlet P, Pouillart F, Dubois-Rande J, Delahaye N, Fumey R, Castaigne A, 
Syrota A. Sympathetic nerve alterations assessed with MIBG in the failing human 
heart. J Nucl Med 1999b; 40:224-31. 
Merlet P, Valette H, Dubois-Rande J, Mardon K, Pouillart F, Bourachot M, 
Castaigne A, Syrota A. Iodine 123-labeled metaiodobenzylguanidine imaging in 
heart disease. J Nucl Cardiol 1994; 1:S79-S85. 
Merlet P, Valette H, Dubois-Rande J, Moyse D, Duboc D, Dove P, Bourguignon 
MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A. 
Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with 
heart failure. J Nucl Med 1992; 33:471-477. 
Mestroni L, Giacca M. Molecular genetics of dilated cardiomyopathy. 
Curr.Opin.Cardiol. 1997; 12:303-309. 
Metra A, Giubbini R, Boldi E, Modena MG, Dei CL. Differential effects of beta-
blockers in patients with heart failure: A prospective, randomized, double-blind 
comparison of the long-term effects of metoprolol versus carvedilol. Circulation 
2000; 102:546-551. 
Metra A, Ponikowski P, Dickstein K, McMurray JJV, Gavazzi A, Bergh C, Fraser 
AG, Jaarsma T, Pitsis A, Mohacsi P, Böhm M, Anker S, Dargie H, Brutsaert D, 
Komajda M. A position statement from the Study Group on Advanced Heart 
Failure Association of the European Societ of Cardiology. Eur J Heart Fail 2007; 
9:684-694. 
Metra M, Nardi M, Giubbini R, Dei CL. Effects of short- and long-term carvedilol 
administration on rest and exercise hemodynamic variables, exercise capacity and 
clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll 
Cardiol 1994; 24:1678-1687. 
Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei CL. Differential 
effects of beta-blockers in patients with heart failure: A prospective, randomized, 
double-blind comparison of the long-term effects of metoprolol versus carvedilol. 
Circulation 2000; 102:546-551. 
403 
 
Meyer J, Wiedemann P, Okladnova O, Bruss M, Staab T, Stober G, Riederer P, 
Bonisch H, Lesch KP. Cloning and functional characterisation of the human 
norepinephrine transporter gene promoter. J Neural Transm 1998; 105:1341-50. 
Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF, 
Leftowitz RJ. Myocardial expression of a constitutively active alpha 1 -
adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl 
Acad Sci 1994; 91:10109-10113. 
Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, 
Johnson TD, Bond RA, Lefkowitz RJ. Enhanced myocardial function in 
transgenic mice overexpressing the beta 2-adrenergic receptor. Science 1994; 
264:582-586. 
Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, Conte JV, 
Naka Y, Mancini D, Delgado RM, MacGillivray TE, Farrar DJ, Frazier OH. Use 
of a continuous-flow device in patients awaiting heart transplantation. N Engl J 
Med 2007; 357:885-896. 
Milting H, Bartling B, Schumann H, El-Banayosy A, Wlost S, Rüter F, Darmer D, 
Holtz J, Körfer R, Zerkowski HR. Altered levels of mRNA of apoptosis-
mediating genes after mid-term mechanical ventricular support in dilative 
cardiomyopathy - first results of the Halle Assist Induced Recovery Study 
(HAIR). Thorac Cardiovasc Surg 1999; 47:48-50. 
Mishra A, Upadhyay A, Patra A, Chaudhury S, Chattopadhyay P. Simultaneous 
determination of epinephrine nad norepinephrine by high performance liquid 
chromatography. Sci Pharm 2009; 77:367-374. 
Moilanen E, Vapaatalo H. Nitric oxide in inflammation and immune response. 
Ann.Med. 1995; 27:359-367. 
Moon JCC, Sievers B, Pennell DJ, Yacoub MH, Mohiaddin RH. Myocardial 
scarring caused by left ventricular assist device (LVAD) insertion demonstrated 
by cardiovascular magnetic resonance. J Cardiovasc Mag Res 2003; 5:361-363. 
Moonen M, Senechal M, Cosyns B, Melon P, Nellessen E, Pierard L, Lancellotti 
P. Impact of contractile reserve on acute response to cardiac resynchronization 
therapy. Cardiovasc Ultrasound 2008; 6. 
Morgan JA, John R, Lee BJ, Oz MC, Naka Y. Is severe right ventricular failure in 
left ventricular assist device recipients a risk factor for unsuccessful bridging to 
transplant and post-transplant mortality. Ann Thorac Surg 2004; 77:859-863. 
Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine 
dependence. Circulation 1991; 83:13-25. 
Morgan JP, Erny RE, Allen PD, Grossman W, Gwathmey JK. Abnormal 
intracellular calcium handling, a major cause of systolic and diastolic dysfunction 
in ventricular myocardium from patients with heart failure. Circulation 1990; 
81:III21-III32. 
404 
 
Moss, Zareba W, Hall WJ. Prophylactic implantation of a defibrillator in patients 
with myocardial infarction and reduced ejection fraction. N Eng J Med 2002; 
346:877-883. 
Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small-
vessel coronary artery disease in patients with angina pectoris and patent large 
coronary arteries. Circulation 1986; 74:964-972. 
Mueller C, Laule-Kilian K, Christ A, Brunner-La Rocca HP, Perruchoud AP. 
Inflammation and long-term mortality in acute congestive heart failure. Am Heart 
J 2006; 151:845-850. 
Müller J, Wallukat G, Weng YG, Dandel M, Spiegelsberg S, Semrau S, Brandes 
K, Theodoridis V, Loebe M, Meyer R, Hetzer R. Weaning from mechanical 
cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 
1997; 96:542-549. 
Muller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen 
E, Kunze R, Hetzer R. Immunoglobulin adsorption in patients with idiopathic 
dilated cardiomyopathy. Circulation 2000; 101:385-391. 
Münch G, Rosport K, Bültmann A, Baumgartner C, Li Z, Laacke L, Ungerer M. 
Cardiac overexpression of the norepinephrine transporter uptake-1 results in 
marked improvement of heart failure. Circ Res 2005; 97:928-36. 
Münch G, Ziegler S, Nguyen N, Hartman F, Watzlowik P, Schwaiger M. 
Scintigraphic evaluation of cardiac autonomic innervation. J Nucl Cardiol 1996; 
3:265-277. 
Murphy DA, Thompson GW, Ardell JL, McCarthy R, Stevenson RS, Sangalang 
VE, Cardinal R, Craig S, Smith FM, Kingma JG, Armour JA. The heart 
reinnervates after transplantation. Ann Thorac Surg 2000; 69:1769-1781. 
Myers T, Frazier O, Mesina H, Radovancevic B, Gregoric I. Hemodynamics and 
patient safety during pump-off studies of an axial-flow left ventricular assist 
device. J Heart Lung Transplant 2006; 25:379-83. 
Nagai R, Zarain-Herzberg A, Brandl CJ, Fujii J, Tada M, MacLennan DH, Alpert 
NR, Periasamy M. Regulation of myocardial Ca2+-ATPase and phospholamban 
mRNA expression in response to pressure overload and thyroid hormone. 
Proc.Natl.Acad.Sci.U.S.A 1989; 86:2966-2970. 
Nagaoka H, Isobe N, Kubota S, Iizuka T, Imai S, Suzuki T, Nagai R. Myocardial 
contractile reserve as prognostic determinant in patients with idiopathic dilated 
cardiomyopathy without overt heart failure. Chest 1997; 111:344-350. 
Nagaoka H, Kubota S, Iizuka T, Imai S, Nagai R. Relation between depressed 
cardiac response to exercise and autonomic nervous activity in mildly 
symptomatic patients with idiopathic dilated cardiomyopathy. Chest 1996; 
109:925-932. 
405 
 
Nakajima K, Matsubara K, Ishikawa T, Motomura N, Maeda R, Akhter N, Okuda 
K, Taki J, Kinuya S. Correction of iodine-123-labeled meta-iodobenzylguanidine 
uptake with multi-window methods for standardization of the heart-to-
mediastinum ratio. J Nucl Cardiol 2007; 14:843-851. 
Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S. 
Carvedilol decreases elevated oxidative stress in human failing myocardium. 
Circulation 2002; 105:2867-2871. 
Nakamura Y, Yoshiyama M, Omura T, Yoshida K, Izumi Y, Takeuchi K, Kim S, 
Iwao H, Yoshikawa J. Beneficial effects of combination of ACE inhibitor and 
angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial 
infarction. Cardiovasc Res 2009; 57:48-54. 
Nakane PK, Pierce GB Jr. Enzyme-labeled antibodies: preparation and applicaiton 
for the localization of antigens. J Histochem Cytochem 1966; 14:929-931. 
Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, 
Tsuchihashi K, Shimamoto K. Cardiac death prediction and impaired cardiac 
sympathetic innervation assessed by MIBG in patients with failing and non-failing 
hearts. J Nucl Cardiol 1998; 5:579-90. 
Nakata T, Wakabayashi T, L'abbate A, Takahashi K, Tsuchihashi K, Shimamoto 
K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of 
angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in 
patients with heart failure. Eur J Nucl Med Mol Imaging 2005; 32:186-194. 
Narula J, Haider N, Arbustini E, Chandrashekhar Y. Mechanisms of disease: 
apoptosis in heart failure - seeing hope in death. Nat Clin Pract Cardiovasc Med 
2006; 3:681-688. 
Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, 
Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart 
failure. N Eng J Med 1996; 335:1182-1189. 
Narula J, Kunal S. A conceptual paradox of MIBG uptake in heart failure: 
Retention with incontinence! J Nucl Cardiol 2003; 10:700-4. 
Naruse H, Arii T, Kondo T, Ohnishi M, Sakaki T, Takahashi K, Masai M, 
Ohyanagi M, Iwasaki T, Fukuchi M. Relation between myocardial response to 
dobutamine stress and sympathetic nerve activation in patients with idiopathic 
dilated cardiomyopathy: A comparison of 
123
I-MIBG scintigraphic and 
echocardiographic data. Ann Nucl Med 2000; 14:427-32. 
Navia JL, McCarthy PM, Hoercher KL, Feng J, Jeevantham R, Smedira NG, 
Banbury MK, Blackstone EH. Do left ventricular assist device (LVAD) bridge-to-
transplantation outcomes predict the results of permanent LVAD implantation? 
Ann Thorac Surg 2002; 74:2051-2062. 
Nelson N. Porters and neurotransmiter transporters. J Exp Biol 1994; 196:213-
228. 
406 
 
Neskovic AN, Otasevic P. Stress-echocardiography in idiopathic dilated 
cardiomyopathy: instructtions for use. Cardiovasc Ultrasound 2005; 3. 
Nguyen T, Amara S. N-Linked oligosaccharides are required for cell surface 
expression of the norepinephrine transporter but do not influence substrate or 
inhibitor recognition. J Neurochem 1996; 67:645-55. 
Nishimura T, Tatsumi E, Nishinaka T, Taenaka Y, Nakata M, Takano H. 
Prolonged nonpulsatile left heart bypass diminishes vascular contractility. Int J 
Artif Organs 1999a; 22:492-498. 
Nishimura T, Tatsumi E, Taenaka Y, Nishinaka T, Nakata M, Nakamura M, Endo 
S, Takano H. Effects of long-term non-pulsatile left heart bypass on the 
mechanical properties of the aortic wall. ASAIO 1999b; 45:455-459. 
Nishinaka T, Tatsumi E, Nishimura T, Taenaka Y, Imada K, Takano H, Koyanagi 
H. Effects of reduced pulse pressure to the cerebral metabolism during prolonged 
nonpulsatile left heart bypass. Artif Organs 2000; 24:676-679. 
Nishioka SA, Martinelli FM, BrandãoSC, Giorgi MC, Costa R, Mathias W, 
Meneghetti JC. Cardiac sympathetic activity pre and post resynchronization 
therapy evalated by 123I-MIBG myocardial scintigraphy. J Nucl Cardiol 2007; 
14:852-859. 
Nojiri C, Fey O, Jaschke F, Medevedev A, Munjal D. Long-term circulatory 
support with the Duaheart Msglev centrifugal left ventricular assist system for 
advanced heart failure patients eligible to transplantation: European Experiences. 
J Heart Lung Transplant 2008; 27:S245. 
Norman JC, Dasco CC, Reul GJ, Massin EK, Klima T, Kahan BD, Keiser JT, 
Cooley DA. Partial artificial heart (ALVAD) use with subsequent cardiac and 
renal allografting in a patient with stone heart syndrome. Artif Organs 1978; 
2:413-420. 
Novo G, Amoroso GR, Fazio G, Sutero F, Novo S. Biomarkers in heart failure. 
Frontiers in Bioscience 2009; 14:2484-2493. 
Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, Hirata 
A, Asai M, Kusuoka H, Hori M, N H. Prognostic significance of cardiac 
123
I-
metaiodobenzylguanidine imaging for mortality and morbidity in patients with 
chronic heart failure: a prospective study. Heart 2001; 86:656-660. 
Ogletree-Hughes ML, Stull LB, Sweet WE, Smedira NG, McCarthy PM, 
Moravec C. Mechanical unloading restores -adrenergic responsiveness and 
reserves receptor downregulation in the failing human heart. Circulation 2001; 
104:881-886. 
Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama 
K, Masaki H, Tsutumi Y, Shibazaki Y, Iwasaka T, Inada M. Angiotensin type 2 
receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster 
407 
 
hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 
96:3954-3962. 
Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama 
K, Masaki H, Tsutumi Y, Shibazaki Y, Iwasaka T, Inada M. Angiotensin type 2 
receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster 
hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 
96:3954-3962. 
Ohshima S, Isobe S, Izawa H, Nanasato M, Ando A, Yamada A, Yamada K, Kato 
TS, Obata K, Noda A, Nishizawa T, Kato K, Nagata K, Okumura K, Murohara T, 
Yokota M. Cardiac sympathetic dysfunction correlates with abnormal myocardial 
contractile reserve in dilated cardiomyopathy patients. J Am Coll Cardiol 2005; 
46:2061-8. 
Olivetti G, Capasso JM, Sonnenblick EH, Anversa P. Sise-to-side slippage of 
myocytes participates in ventricular wall remodeling acutely after myocardial 
infarction in rats. Circ Res 1990; 67:23-34. 
Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous 
system and heart failure pathophysiology and potential implications for therapy. 
Circulation 2008; 118:863-871. 
Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JGF. Six minute corridor 
walk test as an outcome measure for the assessment of treatment in randomized, 
blinded intervention trials of chronic heart failure: A systematic review. Eur Heart 
J 2005; 26:778-793. 
Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-
converting enzyme: new class of orally active antihypertensive agents. Science 
1977; 196:441-444. 
Opasich C, Pinna GD, Mazza A, Febo O, Riccardi R, Riccardi PG, Capomolla S, 
Forni G, Cobelli F, Tavazzi L. Six-minute walking performance in patients with 
moderate-to-severe heart failure. Eur Heart J 2001; 22:488-496. 
Opie LH. The neuroendocrinology of congestive heart failure. Cardiovasc J South 
Afr 2002; 13:171-8. 
Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular 
remodelling. Lancet 2006; 367:356-367. 
Oral H, Dorn GW II, Mann DL. Sphingosine mediates the immediate negative 
inotropic effects of tumour necrosis factor-  in the adult mammalian cardiac 
myocyte. J Biol Chem 1997; 272:4836-4842. 
Ortiz-Lopez R, Li H, Su J, Goytia V, Towbin JA. Evidence for a Dystrophin 
Missense Mutation as a Cause of X-Linked Dilated Cardiomyopathy. Circualtion 
1997; 95:2434-2440. 
Osadchii OE, Norton GR, McKechnie R, Deftereos D, Woodiwiss AJ. Cardiac 
dilatation and pump dysfunction without intrinsic myocardial systolic failure 
408 
 
following chronic beta-adrenoreceptor activation. Am J Physiol Heart Circ 
Physiol 2007; 292:H1898-H1905. 
Otasevic P, Popovic ZB, Vasiljevic JD, Vidakovic R, Pratali L, Vlahovic A, 
Neskovic AN. Relation of myocardial histomorphometric features and left 
ventricular contractile reserve assessed by high-does dobutamine stress 
echocardiography in patients with idiopathic dilated cardiomyopathy. Eur J Heart 
Fail 2005; 7:49-56. 
Otsu K, Willard HF, Khanna VK, Zorzato F, Green NM, MacLennan DH. 
Molecular cloning of cDNA encoding the Ca2+ release channel (ryanodine 
receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J.Biol.Chem. 1990; 
265:13472-13483. 
Oz MC. Passive ventricular constraint for the treatment of congestive heart 
failure. Ann Thorac Surg 2001; 71:S185-S187. 
Oz MC, Gelijns AC, Miller L, Wang C, Nickens P, Arons R, Aaronson K, 
Richenbacher W, van Meter C, Nelson K, Weinberg A, Watson J, Rose EA, 
Moskowitz AJ. Left ventricular assist devices as permanent heart failure therapy: 
the price of progress. Ann.Surg 2003; 238:577-583. 
Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of 
disease progression in heart failure. J Am Coll Cardiol 1992; 20:248-254. 
Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. 
Comparative effects of carvedilol and metoprolol on left ventricular ejection 
fraction in heart failure: results of a meta-analysis. Am Heart J 2001a; 141:899-
907. 
Packer M, Bristow MR, Cohn JN, Fowler MB, Gibert EM, Shusterman NH. The 
effect of carvedilol on morbidity and mortality in patients with chronic heart 
failure: U.S. Carvedilol Heart Failure Study Group. N Eng J Med 1996a; 
334:1349-1355. 
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, 
Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oralmilrinone on 
mortality in severe chronic heart failure: the PROMISE Study Research Group. N 
Eng J Med 1991; 325:1468-1475. 
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, 
Tendera M, Caataigne A, Roecker EB, Schultz MK, DeMets DL. Effect of 
carvedilol on survival in severe chronic heart failure. N Eng J Med 2001b; 
344:1651-1658. 
Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, 
Freeman I. Double-blind, placebo-controlled study of the effects of carvedilol in 
patients with moderate to severe heart failure. The PRECISE Trial. Prospective 
Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 
1996b; 94:2793-2799. 
409 
 
Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith 
LK, Van Voorhees L, Gourley LA, Jolly MK. Withdrawal of digoxin from 
patients with chronic heart failure treated with angiotensin-converting-enzyme 
inhibitors: RADIANCE study. N Eng J Med 1993; 329:1-7. 
Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller 
AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of 
amlodipine on morbidity and mortality in severe chronic heart failure: Prospective 
Randomized Amlodipine Survival Evaluation Study Group. N Eng J Med 1996c; 
335:1107-1114. 
Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. 
Comparative effects of carvedilol and metoprolol on left ventricular ejection 
fraction in heart failure: results of a meta-analysis. Am.Heart J 2001; 141:899-
907. 
Pagain FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, Conte JV, 
Bogaev RC, MacGillivray TE, Nala Y, Manicini D, Massey T, Chen L, Klodell 
CT, Aranda JM, Noazami N, Ewald GA, Farrar DJ, Frazier OH. Extended 
mechanical circulatory support with a continuous-flow rotary left ventricular 
assist device. J Am Coll Cardiol 2009; 54:312-321. 
Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular 
systolic and diastolic dysfunction after infusion of tumour necrosis factor-  in 
conscious dogs. J Clin Invest 1992; 90:389-398. 
Pagani FD, Strueber M, Naka Y, Kormos RL, Long JW, Dowling RD, Massey 
HT, Farrar DJ, Frazier OH. Initial multicenter clinical results with the 
HeartMate® II axial flow left ventricular assist device. J Heart Lung Transplant 
2005; 24:S74. 
Panas D, Khadour FH, Szabo C, Schulz R. Proinflammatory cytokine depress 
cardiac efficiency by a nitic oxide-dependent mechanism. Am J Physiol Heart 
Circ Physiol 1998; 275:H1016-H1023. 
Pandalai PK, Bulcao CF, Merrill WH, Akhter SA. Restoration of myocardial -
adrenergic receptor signaling after left ventricular assist device support. J Thorac 
Cardiovasc Surg 2006; 131:975-980. 
Park SJ, Nguyen DQ, Bank AJ, Ormaza S, Bolman RM III. Left ventricular assist 
device bridge therapy for acute myocardial infarction. Ann Thorac Surg 2000; 
69:1145-1151. 
Park SJ, Tector A, Piccioni W, Raines E, Gelijns A, Moskowitz A, Rose E, 
Holman W, Furukawa S, Frazier OH, Dembitsky W. Left ventricular assist 
devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg 
2005; 129:9-17. 
Passantino A, Lagioia R, Mastropasqua F, Scrutinio D. Short term change in 
distance walked in 6 min is an indicator of outcome in patients with chronic heart 
failure in clinical practice. J Am Coll Cardiol 2006; 48:99-105. 
410 
 
Patel A, Iskandarian A. MIBG Imaging. J Neurochem 2002; 9:75-94. 
Patten M, Hartogenesis WE, Long CS. Interleukin-1 beta is a negative 
transcriptional regulator of alpha-1 adrenergic induced gene expression in cultured 
cardiac myocytes. J Biol Chem 1996; 271:21134-21141. 
Paul M, Schäfers M, Kies P, Acil T, Schäfers K, Breithardt G, Schober O, 
Wichter T. Impact of sympathetic innervation on recurrent life-threatening 
arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. 
Eur J Nucl Med Mol Imaging 2006; 33:866-870. 
Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left 
ventricular relaxation and diastolic distensibility in humans. Assessment by 
bicoronary sodium nitroprusside infusion. Circulation 1994; 89:2070-2078. 
Pavie A, Leger P. Physiology of univentricular versus biventricular support. Ann 
Thorac Surg 1996; 61:347-349. 
Perondi R, Saino A, Tio RA, Pomidossi G, Gregorini L, Alessio P, Morganti A, 
Zanchetti A, Mancia G. ACE inhibition attenuates sympathetic coronary 
vasoconstriction in patients with coronary artery disease. Circulation 1992; 
85:2004-2013. 
Petrou M, Clarke S, Morrison K, Bowles C, Dunn M, Yacoub M. Clenbuterol 
Increases Stroke Power and Contractile Speed of Skeletal Muscle for Cardiac 
Assist. Circulation 1999; 99:713-720. 
Petrou M, Wynne D, Boheler K, Yacoub M. Clenbuterol Induces Hypertrophy of 
the Latissimus Dorsi Muscle and Heart in the Rat with Molecular and Phenotypic 
Changes. Circulation 1995; 92:II-483-II-489. 
Petrou M, Wynne DG, Boheler KR, Yacoub MH. Clenbuterol induces 
hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and 
phenotypic changes. Circulation 1995; 92:II483-II489. 
Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown E, Cuddy T, Davis BR, 
Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and 
morbidity in patients with LV dysfunction after MI. Results of the survival and 
ventricular enlargement trial. The SAVE Investigators. N Eng J Med 1992; 
327:669-677. 
Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of 
captopril on progressive ventricular dilatation after anterior myocardial infarction. 
N Eng J Med 1988; 319:80-86. 
Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NT-
porBNP in routine testing and comparison to BNP. Eur J Heart Fail 2004; 6:289-
293. 
Philipp M, Brede M, Hein L. Physiological significance of 2-adrenergic receptor 
subtype diversity: one receptor is not enough. Am J Physiol Regulatory 
Integrative Comp Physiol 2002; 283:R287-R295. 
411 
 
Piña IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, 
Fletcher BJ, Fleg JL, Myers JN, Sullivan MJ. Exercise and heart failure: A 
statement from the American Heart Association Committee on exercise, 
rehabilitation, adn prevention. Circulation 2003; 107:1210-1225. 
Pinson CW, Cobanoglu A, Metwdorff MT, Grunkemeier GL, Kay PH, Starr A. 
Late surgical results for ischaemic mitral regurgitation. Role of wall motion score 
and severity of regurgitation. J Thorac Cardiovasc Surg 1984; 88:663-672. 
Pitarys CJ II, Forman MB, Panayiotou H, Hansen DE. Long-term effects of 
excision of the mitral apparatus on global andregional ventricular function in 
humans. J Am Coll Cardiol 1990; 15:557-563. 
Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam 
MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of 
losartan compared with captopril on mortality in patients with symptomatic heart 
failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. 
Lancet 2000; 355:1582-1587. 
Pitt B, Remme W, Zannad F, Neaton J, Martinez FA, Roniker B, Bittman R, 
Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in 
patients with left ventricular dysfunction after myocardial infarction. N Eng J Med 
2003; 348:1309-1321. 
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes 
J. Randomized Aldactone Evaluation Study Investigators, The effect of 
spironolactone on morbidity and mortality in patients with severe heart failure. N 
Eng J Med 1999; 341:709-717. 
Pitt M, Lewis ME, Bonser RS. Coronary aretery surery for ischemic heart failure: 
risks, benefits, and the importance of assessment of myocardial viability. Prog 
Cardiovasc Dis 2001; 43:373-386. 
Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam 
MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of 
losartan compared with captopril on mortality in patients with symptomatic heart 
failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. 
Lancet 2000; 355:1582-1587. 
Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda 
M. Comparison of carvedilol and metoprolol on clinical outcomes in patients with 
chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): 
randomised controlled trial. Lancet 2003; 362:7-13. 
Pratali L, Otasevic P, Neskovic A, Molinaro S, Picano E. Prognostic value of 
pharmacologic stress echocardiography in patients with idiopathic dilated 
cardiomyopathy: A prospective, head-to-head comparison between dipyridamole 
and dobutamine test. J Cardiac Fail 2007; 13:836-42. 
412 
 
Qin F, Vulapalli RS, Stevens SY, Liang C. Loss of cardiac sympathetic 
neurotransmitters in heart failure and NE infusion with reduced NGF. Am J 
Physiol Heart Circ Physiol 2002; 282:H363-H371. 
Radovancevic B, Vrtovec B, de Kort E, Radovancevic R, Gregoric ID, Frazier 
OH. End-organ function in patients on long-term circulatory support with 
continuous- or pulsatile-flow assist devices. J Heart Lung Transplant 2007; 
26:815-818. 
Raffel DM, Wieland DM. Assessment of cardiac sympathetic nerve integrity with 
positron emission tomography. Nucl Med Biol 2001; 28:541-559. 
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of 
serum digoxin concentration and outcomes in patients with heart failure. JAMA 
2003; 289:871-878. 
Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of 
digoxin for the treatment of heart failure. N Eng J Med 2002; 347:1403-1411. 
Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, 
Niebauer J, Hooper J, Volk HD, Coats AJS, Anker S. Plasma cytokine parameters 
and mortality in patients with chronic heart failure. Circulation 2000; 102:3060-
3067. 
Remes J, Reunanen A, Aromaa A, Pyorala K. Incidence of heart failure in Eastern 
Finland: a population-based surveillance study. Eur Heart J 2009; 1992:588-593. 
Richard S, Leclercq F, Lemaire S, Piot C, Nargeot J. Ca2+ currents in 
compensated hypertrophy and heart failure. Cardiovasc.Res. 1998; 37:300-311. 
Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen 
E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World 
Health Organization/International Society and Federation of Cardiology Task 
Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 
93:841-842. 
Richenbacher WE, Naka Y, Raines EP, Frazier OH, Couper GS, Pagani FD, 
Damme L, VanMeter CH, Magovern GJ J, Gupta L, Seemuth SC, Weinberg AD, 
Long JW. Surgical management of patients in the REMATCH trial. Ann Thorac 
Surg 2003; 75:S86-S92. 
Ridker PM, Gaboury CL, Conlin PR, Seely EW, Willaims GH, Vaughan DE. 
Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin 
II. Evidence of a potential interaction between the renin-angiotensin system and 
fibrinolytic function. Circulation 1993; 87:1969-1973. 
Rockman HA, Choi D, Akhter SA, Jaber M, Giros B, Lefkowitz RJ, Caron MG, 
Koch WJ. Control of myocardial contractile function by the level of -adrenergic 
receptorkinase 1 in gene-targeted mice. J Biol Chem 1998; 273:18180-18184. 
Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: 
Good to go in 2004. J Am Coll Cardiol 2004; 44:740-749. 
413 
 
Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, Peirson RN 
III. Chronic Mechanical Circulatory Support for Inotrope-Dependent Heart 
Failure Patients Who Are Not Transplant Candidates Results of the INTrEPID 
Trial. J Am Coll Cardiol 2007; 50:741-747. 
Rohinton J Morris. Total artificial heart - concepts and clinical use. Semin Thorac 
Cardiovasc Surg 2008; 20:247-254. 
Romano MA, Bolling SF. Update on mitral repair in dilated cardiomyopathy. J 
Card Surg 2004; 19:396-400. 
Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, 
Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan 
NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens 
P, Oz MC, Poirier VL. Long-term mechanical left ventricular assistance for end-
stage heart failure. N Engl J Med 2001; 345:1435-1443. 
Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, 
Heitjan DF, Meier P, Ascheim DD, Levitan RG, Weinberg AD, Stevenson LW, 
Shapiro PA, Lazar RM, Watson JT, Goldstein DJ, Gelijns AC. The REMATCH 
trial: rationale, design, and end points. Randomized Evaluation of Mechanical 
Assistance for the Treatment of Congestive Heart Failure. Ann.Thorac.Surg 1999; 
67:723-730. 
Rosolowsky LJ, Campbell WB. Endothelin enhances adrenocorticotropin-
stimulated aldosterone release from cultured bovine adrenal cells. Endocrinology 
1990; 126:1860-1866. 
Rossi MA, Abreu MA, Santoro LB. Images in cardiovascular medicine. 
Connective tissue skeleton of the human heart: a demonstration by cell-
maceration scanning electron microscope method. Circulation 1998; 97:934-935. 
Rostagno C, Olivo G, Comeglio M, Boddi V, Banchelli M, Galnati G, Gensini 
GF. Prognostic value of 6-minute walk corridor test in patients with mild to 
moderate heart failure: Comparison with other methods of functional evaluation. 
Eur J Heart Fail 2003; 5:247-252. 
Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis 
in patients with NYHA class II or III chronic heart failure? Am Heart J 1998; 
136:449-457. 
Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol: rationale for use in 
hypertension, coronary artery disease, and congestive heart failure. Cardiovasc 
Drugs Ther 1997; 11:247-256. 
Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin 
II activates nuclear transcription factor kappaB through AT(1) and AT(2) in 
vascular smooth muscle cells: molecular mechanisms. Circ.Res. 2000; 86:1266-
1272. 
414 
 
Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. 
Increased cardiac adrenergic drive precedes generalised sympathetic activation in 
human heart failure. Circulation 1997; 95:169-75. 
Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Kowey PR, Lamas GA, Miller 
HS, Packer M, Rouleau JL. Effects of captopril on ischemic events after 
myocardial infarction. Results of the Survival and Ventricular Enlargement trial. 
SAVE Investigators. Circulation 1994; 90:1731-1738. 
Saba MM, Ventura HO, Saleh M, Mehra MR. Ancient Egyptian medicine and the 
concept of heart failure. J Card Fail 2006; 12:416-421. 
Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced 
hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical 
role of the AT1 receptor subtype. Circ Res 1993; 73:413-423. 
Sadoshima J, Xu Y, Slater HS, Izumo S. Autocrine release of angiotensin II 
mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 
75:977-984. 
Sallach JA, Goldstein S. Use of beta-blockers in congestive heart failure. Ann 
Med 2003; 35:259-266. 
Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable 
cardioverter-defibrillators. N Eng J Med 2005; 353:1471-1480. 
Sato Y, Ferguson DG, Sako H, Dorn GW, Kadambi VJ, Yatani A, Hoit BD, 
Walsh RA, Kranias EG. Cardiac-specific overexpression of mouse cardiac 
calsequestrin is associated with depressed cardiovascular function and 
hypertrophy in transgenic mice. J.Biol.Chem. 1998; 273:28470-28477. 
Satoh N, Suter TM, Liao R, Colucci WS. Chronic -adrenergic receptor 
stimulation modulates the contractile phenotype of caridac myocytes in vitro. 
Circulation 2000; 102:2249-2254. 
Schaufelberger M, Swedberg K. Is 6-minute walk test of value in congestive heart 
failure? Am Heart J 1998; 136:371-372. 
Scheuer J, Buttrick P. The cardiac hypertrophic responses to pathologic and 
physiologic loads. Circulation 1987; 75:I63-I68. 
Scheuer J, Malhotra A, Hirsch C, Capasso J, Schaible TF. Physiologic cardiac 
hypertrophy corrects contractile protein abnormalities associated with pathologic 
hypertrophy in rats. J Clin.Invest 1982; 70:1300-1305. 
Schnitt SJ, Stillman IE, Owings DV, Kishimoto C, Dvorak HF, Abelmann WH. 
Myocardial fibrin deposition in experimental viral myocarditis that progresses to 
dilated cardiomyopathy. Circ.Res. 1993; 72:914-920. 
Schofer J, Spielmann R, Schuchert A, Weber K, Schlüter M. Iodine-123 meta-
iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate 
415 
 
myocardial adrenergic nervous system disintegrity in patients with idiopathic 
cardiomyopathy. J Am Coll Cardiol 1988; 12:1252-1258. 
Schonian U, Crombach M, Maisch B. Assessment of cytomegalovirus DNA and 
protein expression in patients with myocarditis. Clin.Immunol.Immunopathol. 
1993; 68:229-233. 
Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Eng 
J Med 1999; 341:577-585. 
Schulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD. The role 
of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour 
necrosis factor-alpha. Br.J.Pharmacol. 1995; 114:27-34. 
Schumann H, Morawietz H, Hakim K, Zerkowski HR, Eschenhagen T, Holtz J, 
Darmer D. Alternative splicing of the primary Fas transcript generating soluble 
Fas antagonists is suppressed in the failing human ventricular myocardium. 
Biochem Biophys Res Commun 1997; 239:794-798. 
Schuster M, Kocher A, Lietz K, Ankersmit J, John R, Edwards N, Oz M, Itescu S.  
Induction of CD40 ligand expression in human T cells by biomaterials derived 
from left ventricular assist device surface. Transplant Proc 2001; 33:1960-1. 
Schwaiger M, Kalff V, Rosenspire K, Haka MS, Molina E, Hutchins GD, Deeb 
M, Wolfe E Jr, Wieland DM. Noninvasive evaluation of sympathetic nervous 
system in human heart by positron emission tomography. Circulation 1990; 
82:457-464. 
Schwartz K, Boheler KR, de la BD, Lompre AM, Mercadier JJ. Switches in 
cardiac muscle gene expression as a result of pressure and volume overload. 
Am.J.Physiol 1992; 262:R364-R369. 
Scognamiglio R, Avogaro A, Casara D, Crepaldi C, Marin M, Palisi M, Mingardi 
R, Erle G, Fasoli G, Volta SD. Myocardial dysfunction and adrenergic cardiac 
innervation in patients with insulin-dependent diabetes mellius. J Am Coll Cardiol 
1998; 31:404-412. 
Selmeczy Z, Szelényi J, Vizi ES. Intact noradrenaline transporter is needed for the 
sympathetic fine-tuning of cytokine balance. Eur J Pharmacol 2003; 469:175-181. 
Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: 
the cytokine hypothesis. J Card Fail 1996; 2:243-249. 
Shah M, Ali V, Lambda S, Abraham WT. Pathophysiology and clinical spectrum 
of acute congestive heart failure. Rev Cardiovasc Med 2001; 2:S2-S6. 
Sharma R, Anker SD. The 6-minute walk test and prognosis in chronic heart 
failure - the available evidence. Eur Heart J 2001; 22:445-448. 
Sharples LD, Cafferty F, Demitis N, Freeman C, Dyer M, Banner N, Birks EJ, 
Khaghani A, Large SR, Tsui S, Caine N, Buxton M. Evaluation of the clinical 
416 
 
effectiveness of the ventricular assist device program in the United Kingdom 
(EVAD UK). J Heart Lung Transplant 2007; 26:9-15. 
Sharples LD, Dyer M, Cafferty F, Demiris N, Freeman C, Banner NR, Large SR, 
Tsui S, Caine N, Buxton M. Cost-effectiveness of ventricular assist device use in 
the United Kingdom: Results from the Evaluation of Ventricular Assist Devce 
Programme in the UK (EVAD-UK). J Heart Lung Transplant 2006; 25:1336-
1343. 
Sheppard R, Bedi M, Kubota T, Semigran MJ, Dec W, Holubkov R, Feldman 
AM, Rosenblum WD, McTiernan CF, McNamara DM. Myocardial expression of 
Fas and recovery of left ventricular function in patients with recent-onset 
cardiomyopathy. J Am Coll Cardiol 2005; 46:1036-1042. 
Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, 
Komajda M, Gheorghiade M. Review of current and investigational pharmcologic 
agents for acute heart failure syndromes. Am J Cardiol 2007; 99:4A-23A. 
Shinohara H, Fukuda N, Soeki T, Sakabe K, Onose Y, Tamura Y. Effects of 
angiotensin II receptor antagonists on [
123
I]metaiodobenzylguanidine myocardial 
findings and neurohumoral factors in chronic heart failure. Heart Vessels 2002; 
2002:-47. 
Showstack J, Katz PP, Lake JR, Brown RS, Jr., Dudley RA, Belle S, Wiesner RH, 
Zetterman RK, Everhart J. Resource utilization in liver transplantation: effects of 
patient characteristics and clinical practice. NIDDK Liver Transplantation 
Database Group. JAMA 1999; 281:1381-1386. 
Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, 
Brown JH, Chien KR. Endothelin induction of inositol phospholipid hydrolysis, 
sarcomere assembly, and cardiac gene expression in ventricular myocytes. A 
paracrine mechanism for myocardial cell hypertrophy. J.Biol.Chem. 1990; 
265:20555-20562. 
Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie 
BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure 
and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic 
Therapy in Congestive Heart Failure. N Eng J Med 1995; 333:77-82. 
Sisson JC, Wieland DM, Jaques S Jr, Sherman P, Fisher S, Mallette S, Meyers L, 
Mangner TJ. Radiolabeled meta-iodobenzylguanidine and the adrenergic neurons 
of salivary glands. Am J Physiol Imaging 1987; 2:1-9. 
Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, 
Spinale FG, Mann DL. Left ventricular remodeling in transgenic mice with 
cardiac restricted overexpression of tumor necrosis factor. Circulation 2001; 
104:826-831. 
Slater JP, Williams M, Oz MC. Implantation techniques for the TCI HeartMate 
left ventricular assist systems. Operative Techniques in Thoracic and 
Cardiovascular Surgery 1999; 4:330-344. 
417 
 
Slaughter M, Silver M, Farrar D, Tatooles A, Pappas P. A new method of 
monitoring recovery and weaning the Thoratec LVAD. Ann Thorac Surg 2001; 
71:215-18. 
Slaughter MS, Bartoli CR, Sobieski MA, Pantalos GM, Giridharan GA, Dowling 
RD, Prabhu SD, Farrar DJ, Koenig SC. Intraoperative evaluation of the 
HeartMate II Flow Estimator. J Heart Lung Transplant 2009a; 28:39-43. 
Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, 
Tatooles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, 
Frazier OH. Advanced Heart Failure Treated with Continuous-Flow Left 
Ventricular Assist Device. N Engl J Med 2009b; 361:2241-2251. 
Slaughter MS, Ward HB. Surgical management of heart failure. Clin Geriatr Med 
2000; 16:567-592. 
Slaviková J, Tušek S. Choline acetyltransferase in the heart of adult rats. Pflügers 
Archiv European J Physiol 1982; 392:225-229. 
Smolens IA, Pagani FD, Bolling SF. Mitral valve repair in heart failure. Eur J 
Heart Fail 2000; 2:365-371. 
Soeki T, Tamura Y, Bandou K TH, Takeichi N, Shinohara H, Yui Y, Fukuda N, 
Sui O. Long-term effects of the angiotensin-converting enzyme inhibitor enalapril 
on chronic heart failure. Jpn Heart J 1998; 39:743-51. 
Soloff LA. Atrophy of myocardium and its myocytes by left ventricular assist 
device. Circulation 2009; 100:1012. 
Somsen G, Szabó B, van Veldhuisen D, de Milliano P, de Groot C, Lie K. 
Comparison between iodine 123 metaiodobenzylguanidine scintigraphy and heart 
rate variability for the assessment of cardiac sympathetic activity in mild to 
moderate heart failure. Am Heart J 1997; 134:456-458. 
Somsen GA, Borm JJ, de Milliano PA, van Vlies B, Dubois EA, van Royen EA. 
Quantitation of myocardial iodine-123 MIBG uptake in SPET studies: a new 
approach using the left ventricular cavity and a blood sample as a reference. Eur J 
Nucl Med 1995; 22:1149-54. 
Somsen GA, Borm JJJ, Dubois EA, Schook MB, van der Wall EE, van Royen 
EA. Cardiac 
123
I-MIBG uptake is affected by variable uptake in reference regions: 
Implications for interpretation in clinical studies. Nucl Med Commun 1996a; 
17:872-6. 
Somsen GA, van der Wall EE, van Vlies B, Borm JJJ, van Royen EA. Neuronal 
dysfunction in heart failure assessed by 123-iodine metaiodobenzylguanidine 
scintigraphy. Int J Card Imag 1996b; 12:305-310. 
Somsen GA, van Vlies B, de Milliano PA, Borm JJJ, van Royen EA, Endert E, 
Lie KI. Increased myocardial [
123
I]-metaiodobenzylguanidine uptake after 
enalapril treatment in patients with chronic heart failure. Heart 1996c; 76:218-22. 
418 
 
Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-
subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: 
implications for clinical studies. J Nucl Cardiol 2004; 11:126-33. 
Song X, Throckmorton AL, Untaroiu A, Patel S, Allaire PE, Wood HG, Olsen 
DB. Axial flow blood pumps. ASAIO J 2003; 49:355-364. 
Soppa G, Smolenski R, Latif N, Yuen A, Malik A, Karbowska J, Kochan Z, 
Terracciano C, Yacoub M. Effects of chronic administration of clenbuterol on 
function and metabolism of adult rat cardiac muscle. Amerivan Journal of 
Physiology - Heart and Circulatory Physiology 2004; 288:H1468-H1476. 
Soppa GK, Smolenski RT, Latif N, Yuen AH, Malik AH, Karbowska J, Kochan 
Z, Terracciano CM, Yacoub MH. Effects of Chronic Administration of 
Clenbuterol on Function and Metabolism of Adult Rat Cardiac Muscle. Am.J 
Physiol Heart Circ.Physiol 2004. 
Spanier T, Oz M, Levin H, Weinberg A, Stamatis K, Stern D, Rose E, Schmidt 
AM. Activation of coagulation and fibrinolytic pathways in patients with left 
ventricular assist devices. J Thorac Cardiovasc Surg 1996; 112:1090-7. 
Spanier TB, Chen JM, Oz MC, Stern DM, Rose EA, Schmidt AM. Time-
dependent cellular population of textured-surface left ventricular assist devices 
contributes to the development of a biphasic systemic procoagulant response. J 
Thorac Cardiovasc Surg 1999; 118:404-13. 
Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen 
remodeling and changes in LV function during development and recovery from 
supraventricular tachycardia. Am.J.Physiol 1991; 261:H308-H318. 
St John SM, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas 
GA, Klein M, Sussex B, Goldman S. Quantitative two-dimensional 
echocardiographic measurements are major predictors of adverse cardiovascular 
events after acute myocardial infarction. The protective effects of captopril. 
Circulation 1994; 89:68-75. 
Stagg MA, Malik AH, MacLead KT, Terracciano CM. The effects of 
overexpression of the Na+/Ca2+ exchanger on calcium regulation in 
hypertrophied mouse cardiac myocytes. Cell Calcium 2004; 36:111-18. 
Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: 
potential for therapeutic interventions. Heart Fail.Rev. 2002; 7:115-130. 
Starling RC, Jessup M, Oh JK, Sabbah HN, Acker MA, Mann DL, Kubo SH. 
Sustained benefits of the CorCap Cardiac Support Device on left ventricular 
remodeling: three year follow-up results from the Acorn clinical trial. Ann Thorac 
Surg 2007; 84:1236-1242. 
Stein B, Bartel S, Kirchhefer U, Kokott S, Krause EG, Neumann J, Schmitz W, 
Scholz H. Relation between contractile function and regulatory cardiac proteins in 
hypertrophied hearts. Am.J Physiol 1996; 270:H2021-H2028. 
419 
 
Stevens MJ, Raffel DM, Allman KC, Dayanikli F, Ficaro E, Sandford T, Wieland 
DM, Pfeifer MA, Schwaiger M. Cardiac sympathetic dysinnervation in diabetes. 
Circulation 1998; 98:961-968. 
Stevenson LW, Fowler MB, Schroeder JS, Stevenson WG, Dracup KA, Fond V. 
Poor survival of patients with idiopathic heart failure considered too well for 
transplantation. Am J Medicine 1987; 83:871-876. 
Stevenson LW, Miller LW, Desvigne-Nickens P, Ascheim DD, Parides MK, 
Renlund DG, Oren RM, Krueger SK, Costanzo MR, Wann LS, Levitan RG, 
Mancini D. Left ventricular assist device as destination for patients undergoing 
intravenous inotropic therapy: a subset analysis from REMATCH (Randomized 
Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). 
Circulation 2004; 110:975-981. 
Stober G, Nothen M, Porzgen P, Bruss M, Bonisch H, Knapp M, Backmann H, 
Propping P. Systemic search for variation in the human norepinepherine 
transporter gene. Am Jr Med Gen 1996; 67:523-32. 
Struthers AD. Ten years of natriuretic peptide research: a new dawn for their 
diagnostic and therapeutic use? BMJ 1994; 308:1615-1619. 
Studies of Left Ventricular Dysfunction Investigators. Effect of enalapril on 
mortality and the development of heart failure in asymptomatic patients with 
reduced left ventricular ejection fractions. N Eng J Med 1992; 327:685-691. 
Studies of Left Ventricular Dysfunction Investigators (SOLVD). Effect of 
enalapril on survival in patients with reduced left ventricular ejectionfractions and 
congestive heart failure. N Eng J Med 1991; 325:293-302. 
Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in 
porcine brain. Nature 1988; 332:78-81. 
Sulakhe PV, Vo XT. Regulation of phospholamban and troponin-I 
phosphorylation in the intact rat cardiomyocytes by adrenergic adn cholinergic 
stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphotases and 
depolarisation. Moo Cell Biochem 1995; 149:103-126. 
Summers RL, Amsterdam E. Pathophysiology of acute decompensated heart 
failure. Heart Failure Clin 2009; 5:9-17. 
Sun BC, Catanese KA, Spanier TB, Flannery MR, Gardocki MT, Marcus LS, 
Levin HR, Rose EA, Oz MC. 100 long term implantable left ventricular assist 
devices: the Columbia Prebysterian interim experience. Ann Thorac Surg 1999; 
68:688-694. 
Sunners C, Raizada MK. Angiotensin II stimulates norepinephrine uptake in 
hypothalamus-brain stem neuronal cultures. Am J Physiol 1986; 250:C236-C244. 
Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: 
pathophysiology and therapy. Circulation 2000; 101:2981-2988. 
420 
 
Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, Adachi I, 
Narabayashi I. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for 
prediction of response to -blocker therapy in patients with dilated 
cardiomyopathy. Am Heart J 1997; 133:353-8. 
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating 
cardiovascular function in patients with severe congestive heart failure and their 
relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 
82:1730-1736. 
Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, 
Chaterjee K. Comparison of myocardial catecholamine balance in chronic 
congestive heart failure and in angina pectoris without heart failure. Am J Cardiol 
1984; 54:783-786. 
Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in 
patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur.Heart J 
1999; 20:136-139. 
Szili-Torok T, Bountioukos M, Muskens AJQM, Theuns DAMJ, Poldermans D, 
Roelandt JRTC, Jodaens LJ. The presence of contractile reserve has no predictive 
v alue for the evolution of left ventricular function following atrio-ventricular 
node ablation in patients with permanent atrial fibrillation. Eur J 
Echocardiography 2005; 6:344-350. 
Tada M, Katz AM. Phosphorylation of the sarcoplasmic reticulum and 
sarcolemma. Annu.Rev.Physiol 1982; 44:401-423. 
Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition 
reduces cardiac Iodine-123-MIBG release in heart failure. J Nucl Med 1997; 
38:1085-1089. 
Takeishi Y, Jalili T, Hoit BD, Kirkpatrick DL, Wagoner LE, Abraham WT, Walsh 
RA. Alterations in Ca2+ cycling proteins and G alpha q signaling after left 
ventricular assist device support in failing human hearts. Cardiovasc.Res. 2000; 
45:883-888. 
Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, Masuda 
M, Okuda K, Iwasaki Y, Yasui T, Hori M, Fukunami M. Cardiac iodine-123 
metaiodobenzylguanidine imaging predicts sudden cardiac death independently of 
left ventricular ejection fraction in patients with chronic heart failure and left 
ventricular systolic dysfunction. J Am Coll Cardiol 2009; 53:426-435. 
Tan LB, Al-Timman JK, Marshall P, Cooke GA. Heart failure: Can it be defined? 
Eur J Clin Pharmacol 1996; 29:S11-S18. 
Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis 
induced by angiotensin II. Circ Res 1991; 69:1185-1195. 
Tanganelli P, Pierli C, Bravi A, Del Sordo M, Salvi A, Bussani R, Silvestri F, 
Camerini F. Small vessel disease (SVD) in patients with unexplained ventricular 
421 
 
arrhythmia and dilated congestive cardiomyopathy. Am.J Cardiovasc.Pathol. 
1990; 3:13-19. 
Tansley P, Yacoub M. Minimally invasive explantation of implantable left 
ventricular assist devices. 2002; 124:189-91. 
Tansley P, Yacoub M, Rimoldi O, Birks E, Hardy J, Hipkin M, Bowles C, Kindler 
H, Dutka D, Camici P. Effects of Left Ventricular Assist Device Combination 
Therapy on Myocardial Blood Flow in Patients with End-Stage Dilated 
Cardiomyopathy. Journal of Heart and Lung Transplantation 2004; 23:1283-1289. 
Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Fredinand K, Taylor M, 
Adams K, Sabolinki M, Worcel M, Cohn JN. Combination of isosorbide dinitrate 
and hydralazine in blacks with heart failure. N Eng J Med 2004; 351:2049-2057. 
Taylor DO, Edwards LB, Mohacsi PJ, Boucek MM, Trulock EP, Keck BM, Hertz 
MI. The registry of the International Society for Heart and Lung Transplantation: 
twentieth official adult heart transplant report--2003. J Heart Lung Transplant. 
2003; 22:616-624. 
Tazelaar HD, Billingham ME. Myocardial lymphocytes. Fact, fancy, or 
myocarditis? Am.J Cardiovasc.Pathol. 1987; 1:47-50. 
Terracciano CM, Koban MU, Soppa GK, Siedlecka U, Lee J, Stagg MA, Yacoub 
MH. The role of the cardiac Na
+
/Ca
2+
 exchanger in reverse remodeling: relevance 
for LVAD-recovery. Ann N Y Acad Sci 2007; 1099:349-360. 
Terracciano CMN, Harding SE, Tansley PT, Birks EJ, Barton PJR, Yacoub MH. 
Changes In Sarcolemmal Ca Entry And Sarcoplasmic Reticulum Ca Content In 
Ventricular Myocytes From Patients With End-Stage Heart Failure Following 
Myocardial Recovery After Combined Pharmacological and Ventricular Assist 
Device Therapy. Eur Heart J 2003; 24:1329-39. 
Terracciano CM, Hardy J, Birks EJ, Khaghani A, Banner NR, Yacoub MH. 
Clinical recovery from end-stage heart failure using left-ventricular assist device 
and pharmacological therapy correlates with increased sarcoplasmic reticulum 
calcium content but not with regression of cellular hypertrophy. Circulation 2004; 
109:2263-2265. 
Terracio L, Rubin K, Gullberg D, Balog E, Carver W, Tyring R, Borg TK. 
Expression of collagen binding integrins during cardiac development and 
hypertrophy. Circ Res 1991; 68:734-744. 
Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH. 
Circulating levels of cytokines and their endogenous modulators in patients with 
mild to severe congestive heart failure due to coronary artery disease or 
hypertension. J Am Coll Cardiol 1996; 28:964-971. 
Tevaearai HT, Eckhart AD, Walton GB, Keys JR, Wilson K, Koch WJ. 
Myocardial gene transfer and overexpression of beta2-adrenergic receptors 
potentiates the functional recovery of unloaded failing hearts. Circulation 2002; 
106:124-129. 
422 
 
Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1  modulates the 
growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995; 
96:1093-1099. 
Thalmann M, Schima H, Wieselthaler G, Wolner E. Physiology of continuous 
blood flow in reipients of rotary cardiac assist devices. J Heart Lung Transplant 
2005; 24:237-245. 
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe 
congestive heart failure. Results of the Cooperative North Scandinavian Enalapril 
Survival Study (CONSENSUS). N Eng J Med 1987; 316:1429-1435. 
The Digitalis Investigation Group. The effect of digoxin on mortality and 
morbidity in patients with heart failure. N Eng J Med 1997; 336:525-533. 
The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 3-year 
follow-up of patients randomised in the metoprolol in dilated cardiomyopathy 
trial. Lancet 1998; 351:1180-1181. 
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced 
left ventricular ejection fractions and congestive heart failure. N Eng J Med 1991; 
32:293-302. 
Thomas KG, Redfield MM. Asymptomatic left ventricular dysfunction. Heart Fail 
Rev 1997a; 2:11-22. 
Thomas KG, Redfield MM. Asymptomatic left ventricular dysfunction. In: 1997b. 
p. 11-22. 
Tischler MD, Cooper KA, Rowen M, LeWinter MM. Mitral valve replacement 
versus mitral valve repair: a Doppler and quantitative stress echocardiographic 
study. Circulation 1994; 89:132-137. 
Todd GL, Baroldi G, Piper GM, Clayton FC, Eliot RS. Experimental 
catecholamine-induced myocardial necrosis: II. Temporal development of 
isoproterenol-induced contraction band lesions correlated with ECG, 
hemodynamic and biochemical changes. J Mol Cell Cardiol 1985;656. 
Tolis GA Jr, Korkolis DP, Kopf GS, Elefteriades JA. Revascularization alone 
(without mitral valve repair) suffices in patients with advanced ischemic 
cardiomyopathy and mild-to-moderate mitral regurgitation. Ann Thorac Surg 
2002; 74:1476-1480. 
Torda T, Nazarali AJ, Saavedra JM. Brain natriuretic peptide receptors in the rat 
peripheral sympathetic ganglia. Biochem.Biophys.Res.Commun. 1989; 159:1032-
1038. 
Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, 
Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ. Dofetilide in patients 
with congestive heart failure and left ventricular dysfunction: Danish 
Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Eng J 
Med 1999; 341:857-865. 
423 
 
Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumor 
necrosis factor  and the failing human heart. Current Opinion in Cardiology 
1999; 14:206-210. 
Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. 
Proinflammatory cytokine levels in patients with depressed left ventricular 
ejection fraction: a report from the Studies of Left Ventricular Dysfunction 
(SOLVD). J Am Coll Cardiol 1996; 27:1201-1206. 
Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine 
transporters: Structure, regulation and function. Nature Review: Neuroscience 
2003; 4:13-25. 
Towbin JA, Hejtmancik JF, Brink P, GelbB, Zhu XM, Chamberlain JS, McCabe 
ER, Swift M. X-linked dilated cardiomyopathy. Molecular genetic evidence of 
linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. 
Circualtion 1993; 87:1854-65. 
Toyama T, Aihara Y, Iwasaki T, Hasegawa A, Suzuki T, Nagai R, Endo K, 
Hoshizaki H, Oshima S, Taniguchi K. Cardiac sympathetic activity estimated by 
123
I-MIBG myocardial imaging in patients with dilated cardiomyopathy after -
blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999; 
40:217-223. 
Toyama T, Hoshizaki H, Seki R, Isobe N, Adachi H, Naito S, Oshima S, 
Taniguchi K. Efficacy of carvedilol treatment on cardiac function and cardiac 
sympathetic nerve activity in patients with dilated cardiomyopathy: comparison 
with metoprolol therapy. J Nucl Med 2003; 44:1604-1611. 
Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. 
The sympathetoc nervous system in heart failure. In: 2009. p. 1747-1762. 
Tsujinaka T, Fujita J, Ebisui C. Interlukin 6 receptor antibody inhibits muscle 
atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin 
Invest 1996; 97:244-249. 
Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB. Myocardial 
signaling defects and impaired cardiac function of a human beta 2-adrenergic 
receptor polymorphism expressed in transgenic mice. Proc.Natl.Acad.Sci.U.S.A 
1996; 93:10483-10488. 
Udelson JE, Shafer CD, Carrio I. Radionuclide imaging in heart failure: Assessing 
etiology an doutcomes and implications for management. J Nucl Cardiol 2002; 
9:S40-S52. 
Uehara A, Kurata C, Sugi T, Mikami T, Shouda S. Diabetic cardiac autonomic 
dysfunction: parasympathetic versus sympathetic. Ann Nucl Med 1999; 13:95. 
Uhl GR, Johnson PS. Neurotransmitter trasnporters: three important gene families 
for neuronal function. J Exp Biol 1994;236. 
424 
 
Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of -
adrenergic receptor kinase and -adrenergic receptors in the failing human heart. 
Circulation 1993; 87:454-463. 
Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming 
pathways in normal and failing human hearts. Circ Res 1990; 66:883-890. 
Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming 
pathways in normal and failing human hearts. Circ.Res. 1990; 66:883-890. 
Van Meter CH. Right heart failure: best treated by avoidance. Ann Thorac Surg 
2001; 71:S220-S222. 
Varo N, Iraburu MJ, Varela M, question markopez Li, Etayo JC, question markiez 
Di. Chronic AT(1) blockade stimulates extracellular collagen type I degradation 
and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 
2000; 35:1197-1202. 
Vatta M, Stetson S, Perez-Verdia A, Entman ML, Noon GP, Torre-Amione G, 
Bowles NE, Towbin JA. Molecular remodelling of dystrophin in patients with 
end-stage cardiomyopathies and reversal in patients on assistance-device therapy. 
Lancet 2002; 359:936-941. 
Ventura HO, Murgo JP, Smart FW, Stapleton DD, Price HL. Current issues in 
advanced heart failure. Med Clin North Am 1992; 76:1057-1082. 
Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of 
myocardial 
123
I-metaiodobenzylguanidine (MIBG) parameters in patients with 
heart failure: a systematic review. Eur Heart J 2008a; 29:1147-1159. 
Verberne HJ, Feenstra C, de Jong WM, Somsen GE, van Eck-Smit BLF, Sokole 
EB. Influence of collimator choice and simulated clinical conditions on 123I-
MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging 
2005; 32:1100-1107. 
Verberne HJ, Habraken JBA, van Eck-Smit BLF, Agostini D, Jacobson AF. 
Variations in 
123
I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios 
in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med 
Mol Imaging 2008b; 35:547-553. 
Verberne HJ, Somsen GA, Povinec P, van Eck-Smit BLF, Jacobson AF. Imapct 
of mediastinal, liver and lung 
123
I-metaiodobenzylguanidine (
123
I-MIBG) washout 
on calculated 
123
I-MIBG myocardial washout. Eur J Nucl Med Mol Imaging 
2009a; 36:1322-1328. 
Verberne HJ, Somsen GA, van Eck-Smit BLF. 
123
I-meta-iodobenzylguanidine in 
patients with chronic heart failure: technical aspecs, conceptual issues, and future 
prospects. Nucl Med Commun 2009b; 30:411-414. 
Vlk J, Tušek S, Habermann V. Distribution of acetylcholine and cholinesterase in 
the heart of white rats. Nature 1961; 189:924. 
425 
 
W Piccione. Bridge to transplant with HeartMate device. J Card Surg 2001; 
16:272-279. 
Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA. 
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol 
in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342:1441-
1446. 
Wagner S, Cohen K. Heart failure: A proposed definition and classification. Arch 
Intern Med 1977; 137:675-678. 
Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, 
Shimamoto K. Assessment of underlying etiology and cardiac sympathetic 
innervation to identify patients at high risk of cardiac death. J Nucl Med 2005; 
42:1757-1767. 
Wallukat G, Reinke P, Dorffel WV, Luther HP, Bestvater K, Felix SB, Baumann 
G. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. 
Int.J Cardiol. 1996; 54:191-195. 
Wallukat G, Wollenberger A. Effects of the serum gamma globulin fraction of 
patients with allergic asthma and dilated cardiomyopathy on chronotropic beta 
adrenoceptor function in cultured neonatal rat heart myocytes. 
Biomed.Biochim.Acta 1987; 46:S634-S639. 
Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-beta 1-
adrenoceptor autoantibodies with chronotropic activity from the serum of patients 
with dilated cardiomyopathy: mapping of epitopes in the first and second 
extracellular loops. J Mol.Cell Cardiol. 1995; 27:397-406. 
Wang Y, Xu F, Gainetdinov RR, Caron MG. Genetic approaches to studying 
norepinephrine function: Knockout of the mouse norepinephrine transporter gene. 
Biol Psychiatry 1999; 46:1124-1130. 
Waspe LE, Ordahl CP, Simpson PC. The cardiac beta-myosin heavy chain 
isogene is induced selectively in alpha 1-adrenergic receptor-stimulated 
hypertrophy of cultured rat heart myocytes. J Clin.Invest 1990; 85:1206-1214. 
Watson RDS, Gibbs CR, Lip GYH. ABC of heart failure: CLinical features and 
complications. BMJ 2000; 320:236-239. 
Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen. J Am 
Coll Cardiol 1989;1652. 
Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis 
and renin-angiotensin-aldosterone system. Circulation 1991; 83:1865. 
Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram K. Myocardial 
fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 1993; 
1993:Suppl 1-107. 
426 
 
Weber MA, Rurdy RE. Catecholamine-mediated constrictor effects of aldosterone 
on vascular smooth muscle. Life Sci 1982; 30:2009-2017. 
Weber KT, Pick R, Janicki JS, Gadodia G, Lakier JB. Inadequate collagen tethers 
in dilated cardiopathy. Am.Heart J. 1988; 116:1641-1646. 
Wheeldon DR, LaForge DH, Lee J, Jansen PG, Jassawalla JS, Portner PM. 
Novacor left ventricular assist system long-term performance: comparison of 
clinical experience with demonstrated in vitro reliability. ASAIO J 2002; 48:546-
51. 
Why HJ, Meany BT, Richardson PJ, Olsen EG, Bowles NE, Cunningham L, 
Freeke CA, Archard LC. Clinical and prognostic significance of detection of 
enteroviral RNA in the myocardium of patients with myocarditis or dilated 
cardiomyopathy. Circulation 1994; 89:2582-2589. 
Wickenden AD, Kaprielian R, Kassiri Z, Tsoporis JN, Tsushima R, Fishman GI, 
Backx PH. The role of action potential prolongation and altered intracellular 
calcium handling in the pathogenesis of heart failure. Cardiovasc Res 1998; 
37:312-323. 
Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwalter WH. 
Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with 
[
131
I] iodobenzylguanidine. J Nucl Med 1980; 21:349-353. 
Wieselthaler GM, Streuber M, O'Driscoll GA, Jansz P, Khaghani A. Experience 
with the novel Heartware HVAD with hydromagnetically levitated rotor in a 
multinstitutional trial. J Heart Lung Transplant 2008; 27:S245. 
Wild DM, Kukin M. Beta-blockers to prevent symptomatic heart failure in 
patients with stage A and B heart failure. Curr Heart Fail Rep 2007; 4:99-102. 
Williams RS, Caron MG, Daniel K. Skeletal muscle beta-adrenergic receptors: 
variations due to fiber type and training. Am.J Physiol 1984; 246:E160-E167. 
Wilson S.Colucci. Molecular and cellular mechanisms of myocardial failure. Am 
J Cardiol 1997; 80:15L-25L. 
Wong K, Boheler K, Bishop J, Petrou M, Yacoub M. Clenbuterol induces cardiac 
hypertrophy with normal functional, morphological and molecular features. 
Cardiovascular Research 1998; 37:115-122. 
Wong K, Boheler KR, Bishop J, Petrou M, Yacoub MH. Clenbuterol induces 
cardiac hypertrophy with normal functional, morphological and molecular 
features. Cardiovasc.Res. 1998; 37:115-122. 
Wong K, Boheler KR, Petrou M, Yacoub MH. Pharmacological modulation of 
pressure-overload cardiac hypertrophy: changes in ventricular function, 
extracellular matrix, and gene expression. Circulation 1997; 96:2239-2246. 
427 
 
Wood C, Maiorana A, Larbalestier R, Lovett M, Green G, O'Driscoll G. First 
successful bridge to myocardial recovery with a HeartWare HVAD. J Heart Lung 
Transplant 2008; 27:695-697. 
Woodcock EA, Du X, Reichelt M, Graham RM. Cardiac alpha 1-adrenergic drive 
in pathological remodeling. Cardiovasc Res 2008; 77:452-462. 
Xin X, Cai Y, Matsumoto K, Agui T. Endothelin induced interleukin 6 production 
by rat aortic endothelial cells. Endocrinology 1995; 136:1322-1327. 
Xydas S, Rosen R, Ng C, Mercando M, Cohen J, DiTullio M, Magnano A, 
Marboe CC, Mancini DM, Naka Y, Oz MC, Maybaum S. Mechanical Unloading 
Leads to Echocardiographic, Electrocardiographic, Neurohormonal, and 
Histologic Recovery. Circulation 2006a; 25:7-15. 
Yacoub MH. A novel strategy to maximise the efficacy of left ventricular assist 
devices as a bridge to recovery. Eur Heart J 2001; 22:534-540. 
Yacoub MH, Birks EJ, Tansley PT, Henein MY, Bowles CT. Bridge to recovery: 
The Harefield approach. J Cong Heart Fail Circ Support 2001a; 2:27-30. 
Yacoub MH, Tansley P, Birks EJ, Banner NR, Khaghani A, Bowles C. A novel 
combination therapy to reverse end-stage heart failure. Transplant Proc 2001b; 
33:2762-2764. 
Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, Asai M, 
Makino N, Kioka H, Kusuoka H, Hori M, Hori N. Comparison of the prognostIc 
value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate 
variability in patients with chronic heart failure. J Am Coll Cardiol 2003; 41:231-
8. 
Yamashina S, Yamazaki J. Role of MIBG myocardial scintigraphy in the 
assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol 
Imaging 2004; 31:1353-1355. 
Yamazaki J, Muto H, Ishiguro S, Okamoto K, Hosoi H, Nakano H, Morishita T. 
Quantitative scintigraphic analysis of 
123
I-MIBG by polar map in patients with 
dilated cardiomyopathy. Nucl Med Commun 1997; 18:219-229. 
Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of 
-blocker therapy in patients with dilated cardiomyopathy - Clinical meaning of 
iodine 123-metaiodobenzylguanidine myocardial single-photon emission 
computed tomography. Am Heart J 2001; 141:645-652. 
Yang YW, Chen JC, Chang CJ, Cheng CY, Wang SJ. Evaluation of collimator 
choice and scatter correction on 
123
I SPECT images. J Nucl Cardiol 2007; Article 
in press. 
Young JB. Management of chronic heart failure: What do recent clinical trials 
teach us? Rev Cardiovasc Med 2004; 5:S3-S9. 
428 
 
Ypenburg C, Sieders A, Bleeker GB, Holman ER, van der Wall EE, Schalij MJ, 
Bax JJ. Myocardial contractile reserve predicts improvement in left ventricular 
function after cardiac resynchronization therapy. Am Heart J 2007; 154:1160-
1165. 
Yu JJ, Son HS, Lim CH, Lee JJ, Park YW, Her K, Won YS, Sun K, Choi JY. 
Comparison of myocardial loading between asynchronous pulsatile and 
nonpulsatile percutaneous extracorporeal life support. ASAIO J 2008; 54:177-
180. 
Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL. Carvedilol, a 
new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free 
radical scavenger. J Pharmacol Exp Ther 1992; 263:92-98. 
Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J. Effect of enalapril 
on myocardial infarction and unstable angina in patients with low ejection 
fractions. Lancet 1992; 340:1173-1178. 
Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular 
hypertrophy after left ventricular assist device support. Circulation 1998a; 98:656-
62. 
Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular 
hypertrophy after left ventricular assist device support. Circulation 1998b; 98:656-
62. 
Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular 
hypertrophy after left ventricular assist device support. Circulation 1998; 98:656-
662. 
Zahinser NR, Doolen S. Chronic and acute regulation of Na
+
/Cl
-
 -dependent 
neurotransmitter transporters:drugs, substrates, presynaptic receptors, and 
signaling systems. Pharm and Therap 2001; 92:21-55. 
Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive 
extracellular matrix turnover may contribute to survival benefit of spironolactone 
therapy in patients with congestive heart failure: insights from the randomized 
aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 
102:2700-2706. 
Zaugg M, Xu W, Lucchinetti E, Shafiq SA, Jamali NZ, Siddiqui MA. Beta-
adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular 
myocytes. Circulation 2000; 102:344-350. 
Zeltsman D, Acker MA. Surgical management of heart failure: an overview. Ann 
Rev Med 2002; 53:383-391. 
Zeman RJ, Peng H, Etlinger JD. Clenbuterol retards loss of motor function in 
motor neuron degeneration mice. Experimental Neurology 2004; 187:460-467. 
429 
 
Zhao XL, Gutierrez LM, Chang CF, Hosey MM. The alpha 1-subunit of skeletal 
muscle L-type Ca channels is the key target for regulation by A-kinase and 
protein phosphotase-1C. Biochem Biophys Res Commun 1994; 198:166-173. 
Zierhut W, Studer R, Laurent D, Kastner S, Allegrini P, Whitebread S, Cumin F, 
Baum HP, de Gasparo M, Drexler H. Left ventricular wall stress and sarcoplasmic 
reticulum Ca(2+)-ATPase gene expression in renal hypertensive rats: dose-
dependent effects of ACE inhibition and AT1-receptor blockade. Cardiovasc.Res. 
1996; 31:758-768. 
Zugck C, Krüger C, Dürr C, Gerber SH, Haunstetter A, Horing K, Kübler W, 
Haass M. Is the 6-minute walk test a reliable substitute for peak oxygen uptake in 
patients with dilated cardiomyopathy. Eur Heart J 1998; 21:540-549. 
 
 
  
430 
 
Acknowledgments 
In the first instinct, I would like to praise God for giving the strength to complete 
this exciting endeavour. I would like to thank our patients and their families 
whose courage in desperate circumstances and ongoing fortitude has been an 
inspiration to see and has helped me grow as a human being. 
I am indebted to my principal supervisor, Professor Emma Birks (Transplant and 
Artificial Heart Consultant) for her unrelenting commitment, advice and guidance 
throughout this research and my career. Without her implacable support I would 
have not been able to acquire my specialist training number in cardiothoracic 
surgery. I am also very grateful for her helpful recommendations and suggestions 
on the text. It has also been an honour to work for Professor Sir Magdi Yacoub 
who has been an unending source of inspiration during the development of the 
thesis. Professor Yacoub has supervised my progress with the greatest interest and 
has offered valuable suggestions on numerous occasions. Without his principle 
concept about myocardial recovery using LVAD and drug combination therapy, 
this thesis would not have been possible. I would also like to thank my third 
supervisor, Dr Andrew Kelion, Consultant Nuclear Cardiologist, for making his 
support available on number of ways. Dr. Kelion has continuously helped, 
challenged and motivated the MIBG study. 
I am also thankful to Dr Christopher Bowles, senior VAD coordinator for his 
much thoughtful scientific input. Carole Webb deserves a special mention for her 
dedication to our patients and implacable commitment. I also appreciate the 
expertise, help, and goodwill of all VAD team members at Harefield throughout 
this project in particular Kate Absalom, Robert Dean, Rachel Hards, Michael 
Hedger, Mandy Hipkin, Louise Mitchinson, and Christine Saunders. 
I would also like to thank all members of the Nuclear Cardiology Department at 
Harefield, in particular Andrew Cheetham who has conducted most of the MIBG 
nuclear scans and was the second observer for the inter-observer reliability study. 
Rommel Manlapig, Fabrice Ghiotto, Suzie Hinton-Taylor, and Gabriella Bolgona 
deserve my deepest gratitude for facilitating the imaging process at Harefield 
431 
 
throughout the study. For financial support, I thank Thoratec Corporation for their 
research grant that had supported my salary and I also thank GE Healthcare for 
providing 
123
I-MIBG free of charge.  
I am most grateful to Dr Nikant Sabharwal, Consultant Cardiology at Radcliffe 
Hospital, for measuring the forward flows across the HM II LVAD 
echocardiographically. Dr Derek Robinson, statistician at Sussex University, has 
assisted in developing the time-modelling analysis. Dr Tom Smolenski (Head of 
Metabolic Research) has kindly analysed catecholamine levels using the cut-edge 
technology the Quadropole Agilent Liquid Chromatography Mass Spectrometry. 
Another appreciation goes to Professor Praveen Anand, Head of Neuropathy Unit 
at Hammersmith Hospital, for allowing me to conduct all immunohistochemistry 
staining in his laboratory. A special thanks goes to Paul Facer, his senior 
laboratory technician, for teaching me the principles of immunostaining and his 
unstinting technical assistance. I am also grateful to Professor Kim Parker who 
has given me the opportunity to perform the low speed experiments in his 
Bioengineering laboratory at Imperial College. I would like to thank Mr. Niraj 
Hirani, a MEng graduate for assisting me throughout the low flow experiments 
and teaching me how to use MatLab to analyse the flow and pressure readings. 
I am most grateful to my brother for proof reading the thesis. Most of all, I am 
most grateful to my wife, Sherine, and my two daughters for their endless comfort 
and for their support with great kindness and understanding. Finally, among the 
many people to whom I owe my deepest gratitude, respect and affection, my 
parents deserve the most special place. Their love, dedication, prayers, as well as 
their continuous support, both morale and financial, were a foundation for my 
work. I would like to dedicate this work to my family. 
  
432 
 
Personel Contribution 
As the thesis involves multiple disciplinaries and departments, I would like to 
highlight my personel contribution: 
 Involved in LVAD implantation and core tissue collection. 
 Post-operative and out-patient management of LVAD patients. 
 Set up the mock circuit in chapter 3 and performed all the benchwork 
experiments with analysis of the data points acquired and the videos 
captured. Wrote the computer script shown in Appendix D. 
 Organised patient‘s monthly follow-up and managed them during low-
speed testing (chapter 4) including testing below 6000 rpm to identify 
optimal low-speed for native LV assessment (chapter 3 – part 3). 
 Obtained ethics approval from Royal Brompton and Harefield NHS 
Foundation Trust and funding from GE Healthcare for the MIBG nuclear 
imaging on LVAD and heart failure patients. Set up the MIBG imaging 
protocol with full validation in Harefield. Acquired and anlysed all serial 
images from the 14 collaborating patients. Evolved the modified ROI to 
account for the inflow cannula in the apex. 
 Performed the immunohistochemistry experiments on the LV core tissue 
collected during implantation including slide analysis on the analySIS 
software. 
 Collected and processed blood samples for liquid chromatography mass 
spectroscopy and analysed the results. 
 Apart from the time-modelling, I have performed all the statistical 
analysis within this thesis. 
  
433 
 
 
 
 
 
 
 
Appendices  
434 
 
Publications and Presentations 
Peer-Reviewed Papers and Case Studies 
1) Emma J. Birks, Robert S. George, Mike Hedger, Toufan Bahrami, 
Christopher Bowles, Carole Webb, Mohamed Amrani, Magdi H. Yacoub, 
Giles Dreyfus, Asghar Khaghani 
 Reversal of severe heart failure using a continuous flow left ventricular 
assist device and pharmacologic therapy: A prospective study 
 Accepted by Circulation – In press 
 
2) Robert S. George, Magdi H. Yacoub, Carole Webb, Christopher T. Bowles, 
Asghar Khaghani, Emma J. Birks 
 Continuous flow LVADs provide better response to six-minute walk 
exercise as compared to pulsatile flow LVADs 
 In publication 
 
3) Robert S. George, Emma J. Birks, Andrew Cheetham, Rommel, Manlapig, 
Suzie Hinton-Taylor, Fabrice Ghiotto, Magdi H. Yacoub, Andrew Kelion 
The effect of left ventricular assist device support on myocardial 
sympathetic activity in patients with dilated cardiomyopathy 
In publication 
 
4) Emma J. Birks and Robert S. George 
Molecular changes occurring during reverse remodelling following left 
ventricular assist device support 
Journal of Cardiovascular Translational Research 2010;3(6):635-42 
 
5) Robert S. George, Nikant K. Sabharwal, Carole Webb, Magdi H. Yacoub, 
Christopher Bowles, Mike Hedger, Giles Dreyfus, Asghar Khaghani, Emma 
J. Birks  
 Echocardiographic evaluation of flow across HeartMate II axial flow 
LVADs at varying low speeds 
 Journal of Heart and Lung Transplantation 2010;29(11):1245-1252 
 
6) Djordje G Jakovljevic *, Robert S George *, David Nunan, Gay Donovan, 
Robert S Bougards, Magdi H Yacoub, Emma J Birks, David A Brodie 
*equal contribution 
The impact of acute reduction of continuous-flow left ventricular assist 
device support on cardiac and exercise performance 
Heart 2010;96(17):1390-1395 
 
7) Djordje G Jakovljevic, Robert S George, Gay Donovan, David Nunan, 
Keiran Henderson, Robert S Bougards, Magdi H Yacoub, Emma J Birks, 
David A Brodie 
Comparison of cardiac power output and exercise performance in patients 
with left ventricular assist devices, explanted (recovered) patients and those 
with moderate to severe heart failure 
American Journal of Cardiology 2010;105(12):1780-85 
435 
 
8) Robert S. George, Claire Khaghani, Christopher T. Bowles, Asghar 
Khaghani, Emma J. Birks 
 Sustained Myocardial Recovery Five Years following in-situ Disconnection 
of a Jarvik 2000 Device 
 Journal of Heart and Lung Transplantation 2010;29(5):587-588 
 
9) Leanne E. Felkin, Enrique Lara-Pezzi, Robert George, Magdi H. Yacoub, 
Emma J. Birks, Paul J. R. Barton 
 Expression of extracellular matrix genes during myocardial recovery from 
heart failure following left ventricular assist Device (LVAD) Support 
 Journal of Heart and Lung Transplantation 2009;28(2):117-122 
 
10) R. S. George, M. Yacoub, C. Bowles, M. Hipkin, P. Rogers, C. Hallas, N. 
Banner, G. Dreyfus, A. Khaghani, E. J. Birks 
 Quality of Life Following LVAD Removal for Myocardial Recovery 
 Journal of Heart and Lung Transplantation 2008;27(2):165-72 
 
11) George R. S., Yacoub M. H., Tasca G., Webb C., Bowles C. T., Tansley P., 
Hardy J.P., Dreyfus G., Khaghani A., Birks E. J. 
 Haemodynamic and Echocardiographic Responses to Acute Interruption of 
Left Ventricular Assist Device Support: Relevance to Assessment of 
Myocardial Recovery. 
 Journal of Heart and Lung Transplantation 2007;26(10):967-73 
12) E. Birks, P. Tansley, J. Hardy, R. S. George, C. Bowles, M. Burke, N. 
Banner, A. Khaghani, M. Yacoub. 
 Left Ventricular Assist Device and Drug Therapy for the Reversal of Heart 
Failure. 
 New England Journal of Medicine 2006;18(355):1873-1884 
 
Book Chapter 
 
Title: Advances in Tissue Engineering 
Robert S George and Emma J Birks 
Book Chapter: Myocardial Recovery Following LVAD Support 
Editor: Julia Polak 
 
 
Abstracts 
 
1) R. S. George, M. H. Yacoub, A. Cheetham, A. Kelion, E. J. Birks 
LVAD Support Results in a Significant Improvement in the Myocardial 
Sympathetic Nervous System, as Assessed by 
123
I-Metaiodobenzylguanidine 
(
123
I-MIBG), Independent of Ventricular Function 
Journal of Heart and Lung Transplantation 2010;29(2 Suppl 1): S180 
 
2) R. S. George, M. H. Yacoub, H. Lister, C. Webb, A. Khaghani, E. J. Birks 
The Effects of Clenbuterol on the Left Ventricular Wall Thickness and 
Function in Patients Recovered on Left Ventricular Assist Device (LVAD) 
Journal of Heart and Lung Transplantation 2010;29(2 Suppl 1): S182 
436 
 
 
3) E. J. Birks, R. S. George, M. Hedger, A. Firouzi, T. Bahrami, M. Amrani, 
M. H. Yacoub, G. Dreyfus, A. Khaghani 
Myocardial Recovery from Advanced Heart Failure Using the HeartMate II 
LVAD with Drug Combination Therapy: Results from a Prospective Study 
Journal of Heart and Lung Transplantation 2010;29(2 Suppl 1): S66 
 
4) E. J. Birks, R. S. George, M. Noor, T. Bahrami, M. Amrani, J. Pepper, G. 
Dreyfus, M. Petrou, M. H. Yacoub, A. Khaghani 
Long Term Outcome of Bridge to Recovery versus Bridge to 
Transplantation 
Journal of Heart and Lung Transplantation 2010;29(2 Suppl 1): S176-7 
5) J. Beale, R. S. George, J. Smith, A. Khaghani, M. H. Yacoub, E. J. Birks, P. 
Barton 
Myocardial Recovery is Assocaiated with Low Levels of circulating MMP8 
at LVAD Implantation 
Journal of Heart and Lung Transplantation 2010;29(2 Suppl 1): S65-6 
 
6) Robert S George, Magdi H Yacoub, Carole Webb, Christopher Bowles, 
Asghar Khaghani, Emma J Birks 
 The Extent of Myocardial Recovery as Assessed by the Response of 
Echocardiographic Parameters to Exercise in Patients With Heartmate I and 
Heartmate II Left Ventricular Assist Devices (LVADs) 
 Circulation, Nov 2009; 120: S798 
 
7) Robert S George, Magdi H Yacoub, Carole Webb, Asghar Khaghani, 
Emma J Birks 
 Contractile Reserve Assessment in DCM Patients Supported With 
Continuous Flow Left Ventricular Assist Device (LVAD) 
 Circulation, Nov 2009; 120: S726 
 
8) R.S. George, M.H. Yacoub, A. Cheetham, R. Manlapig, A. Khaghani, A. 
Kelion, E.J. Birks 
 The Effects of Left Ventricular Assist Device (LVAD) Unloading on 
Cardiac Sympathetic Innervation 
 Journal of Heart and Lung Transplantation 2009;28(2 Supplement 
1):S129 
 
9) R.S. George, N.K. Sabharwal, C. Webb, M. Hedger, M.H. Yacoub, G. 
Dreyfus, A. Khaghani, E.J. Birks  
 Echocardiographic Evaluation of Flow across HeartMate II Axial Flow 
LVADs at Varying Low Speeds 
 Journal of Heart and Lung Transplantation 2009;28(2 Supplement 
1):S244 
 
10) E.J. Birks, R.S. George, M. Hedger, T. Bahrami, M. Amrani, M.H. Yacoub, 
G. Dreyfus, A. Khaghani   
Myocardial Recovery from Advanced Heart Failure Using the Heartmate II 
LVAD Combined with Drug Therapy: Early Results from a Prospective 
Study 
437 
 
 Journal of Heart and Lung Transplantation 2009;28(2 Supplement 
1):S304 
 
11) Robert S. George, Magdi H. Yacoub, Carole Webb, Christopher Bowles, 
Robert Dean, Mike Hedger, Giles Dreyfus, Asghar Khaghani, Emma J. 
Birks 
Serial Assessment of Pulsatile and Non-Pulsatile Left Ventricular Assist 
Devices on Left Ventricular Unloading 
 Circulation, Oct 2008; 118: S_1016 
 
12) R. S. George, A. Cheetham, S. Hinton-Taylor, R. Manlapig, F. Ghiotto, A. 
Marshall, A. Kelion, M. H. Yacoub, E. J. Birks 
 Sustained Normalisation of 
123
I-MIBG Uptake after Explantation of Left 
Ventricular Assist Device (LVAD)s 
 Journal of Heart and Lung Transplantation 2008;27(2 Supplement 
1):S94-95 
 
13) R.S. George, G. Tasca, C.T. Bowles, C. Webb, G. Dreyfus, A. Khaghani, 
M.H. Yacoub, E.J. Birks 
 Complete discontinuation of mechanical support and assessment of 
inotropic reserve in patients with left ventricular assist devices 
 Journal of Heart and Lung Transplantation 2007;26(2 Supplement 
1):S61 
 
14) R.S. George, P. Rogers, C. Hallas, M.Petrou, N.R. Banner, G. Dreyfus, A. 
Khaghani, M.H. Yacoub, E.J. Birks 
 Quality of life two or more years following LVAD removal 
 Journal of Heart and Lung Transplantation 2007;26(2 Supplement 
1):S161 
 
15) Robert George, Christopher Bowles, Patrick Tansley, James Hardy, Carole 
Webb, Asghar Khaghani, Mgdi Yacoub, Emma Birks 
 Cessation of Left Ventricular Assist Device (LVAD) to study cardiac 
function is a safe method to monitor myocardial recovery 
 Circulation, Nov 2006;114:II_661 
 
 
 
438 
 
Presentations and Scientific Meetings 
 
1. “Assessment of Myocardial Recovery in Patients with Left Ventricular 
Assist Device” 
Invited Speaker 
 
Meeting: The Gordon Research Conference on Mechanical Circulatory 
Support, New Hampshire, USA, June 2011 
 
2. “Higher Implant Norepinephrine Transporter Levels in the Myocardium 
are Associated with Myocardial Recovery during Left Ventricular Assist 
Device Support” – Poster 
 
Robert S. George, Paul Facer, Magdi H. Yacoub, Anand Praveen, Emma J. 
Birks 
Meeting: The American Heart Association, Chicago, USA (November 2010) 
 
3. “The Effects of Clenbuterol on the Left Ventricular Wall Thickness and 
Function in Patients Recovered on Left Ventricular Assist Device (LVAD)” 
- Poster 
 
Robert S. George, M.H. Yacoub, H. Lister, C. Webb, A. Khaghani, E.J. Birks  
Meeting: The International Society for Heart and Lung Transplantation Paris, 
France (Chicago 2010) 
 
4. “LVAD Support Results in a Significant Improvement in the Myocardial 
Sympathetic Nervous System, as Assessed by 123I-Metaiodobenzylguanidine 
(123I-MIBG), Independent of Ventricular Function” - Poster 
 
Robert S. George, M.H. Yacoub, A. . Cheetham, A. Kelion, E.J. Birks  
Meeting: The International Society for Heart and Lung Transplantation Paris, 
France (Chicago 2010) 
 
5. “Myocardial Recovery from Advanced Heart Failure Using the Heartmate 
II LVAD Combined with Drug Therapy: Results from a Prospective Study” 
 
E.J. Birks, R.S. George, M. Hedger, A. Firouzi, T. Bahrami, M. Amrani, 
M.H. Yacoub, G. Dreyfus, A. Khaghani 
Meeting: The International Society for Heart and Lung Transplantation Paris, 
France (Chicago 2010) 
 
6. “Long Term Outcome of Bridge to Recovery Versus Bridge to 
Transplantation” 
 
E.J. Birks, R.S. George, M. Noor, T. Bahrami, M. Amrani, J. Pepper, G. 
Dreyfus, M. Petrou, M.H. Yacoub, A. Khaghani  
Meeting: The International Society for Heart and Lung Transplantation Paris, 
France (Chicago 2010) 
 
439 
 
7. “Myocardial Recovery Is Associated with Low Levels of Circulating MMP8 
at LVAD Implantation” 
 
J. Beale, R.S. George, J. Smith, A. Khaghani, M.H. Yacoub, E.J. Birks, P. 
Barton 
Meeting: The International Society for Heart and Lung Transplantation Paris, 
France (Chicago 2010) 
 
8. “A Safe and a Cost-Effective Approach for Managing Patients with 
Levitronix CentriMag® Short Term Devices” - Poster 
 
A. Firouzi, R.S. George, K. Absalom, S.M. Panther, H. Doyle, A. Bashford, 
C. Bindoff, A. Khaghani, E.J. Birks 
Meeting: The International Society for Heart and Lung Transplantation Paris, France 
(Chicago 2010) 
  
9. “The Extent of Myocardial Recovery as Assessed by the Response of 
Echocardiographic Parameters to Exercise in Patients with HeartMate I 
and HeartMate II  left ventricular assist devices (LVADs).”   
 
Robert S. George, Magdi H. Yacoub, Carole Webb, Christopher Bowles, 
Asghar Khaghani, Emma J. Birks 
Meeting: The American Heart Association, Orlando, USA (November 2009) 
 
10. “Contractile reserve assessment in DCM patients supported with continous 
flow Left Ventricular Assist Device (LVAD)” 
 
Robert S. George, Magdi H. Yacoub, CArole Webb, Asghar Khaghani, 
Emma J.Birks 
Meeting: The American Heart Association, Orlando, USA (November 2009) 
 
11. “Clinical Aspects of Myocardial Recovery Following LVAD Treatment” 
 
Invited Speaker 
Meeting: The Mechanoreceptor and Heart Symposium. Imperial College, 
Harefield (October 2009) 
 
12. “What happens to myocardial sympathetic function in heart failure patients 
who recover on Left Ventricular Assist Device (LVAD) therapy? 
 
Robert S. George, Andrew Cheetham, Aandrew Marshall, Rommel 
Manlapig, Suzie Hinton-Taylor, Magdi H.. Yacoub, Emma J. Birks, Andrew 
Kelion 
Meeting: 9
th
 Biannual International Conference in Nuclear Cardiology, 
Barcelona, Spain (May 2009) 
 
13. “Reproducibility of Myocardial 123I-Metaiodobenzylguanidine (123I-
MIBG) Scintigraphy in Patients with Left Ventricular Assist Device 
(LVAD).” 
 
440 
 
Robert S. George, Andrew Cheetham, Rommel. Manlapig, Andrew Marshall, 
Magdi H Yacoub, Emma J. Birks, Andrew Kelion 
Meeting: 9
th
 Biannual International Conference in Nuclear Cardiology), 
Barcelona, Spain (May 2009) 
 
14. “Echocardiographic Evaluation of Flow across HeartMate II Axial Flow 
LVADs at Varying Low Speeds.” 
 
Robert S George, Nikant K Sabharwal, Carole Webb, Mike Hedger, Magdi 
H. Yacoub, Gilles Dreyfus, Asghar Khaghani, Emma J. Birks 
Meeting: The International Society for Heart and Lung Transplantation Paris, 
France (April 2009) 
 
15. “Effects of Left Ventricular Assist Device (LVAD) Unloading on Cardiac 
Sympathetic Innervation.” 
 
Robert S George, Magdi H. Yacoub, Andrew Cheetham, Rommel Manlapig, 
Asghar Khaghani, Andrew Kelion, Emma J. Birks 
Meeting: The International Society for Heart and Lung Transplantation, Paris, 
France (April 2009) 
 
16. “Myocardial Recovery from Advanced Heart Failure Using the Heartmate 
II LVAD Combined with Drug Therapy: Early Results from a Prospective 
Study” 
 
Emma J. Birks, Robert S. George, Mike Hedger, Toufan Bahrami, Mohamed 
Amrani, Magdi H. Yacoub, Gilles Dreyfus, Asghar Khaghani  
Meeting: The International Society for Heart and Lung Transplantation, Paris, 
France (April 2009) 
 
17. “Limited surgical approaches for LVAD explant following myocardial 
recovery are associated with low morbidity and improved outcome.” 
 
Saleem Haj-Yahia, Robert S. George, Szymon Waligorski, Gilles Dreyfus, 
Magdi H. Yacoub, Emma J. Birks, Asghar Khaghani 
Meeting: The International Society for Heart and Lung Transplantation, Paris, 
France (April 2009) 
 
18. “Analysis of Implantable Left Ventricular Assist Device (LVAD) Acoustic 
Waveform by Fourier Transform and Empirical Mode Decomposition: 
Dependence on Rotation Speed, Device Design and Left Ventricular 
Interaction.” – Poster 
 
Christopher Bowles, Mohamed Borhani, Ann van der Horst, Robert S. 
George, Kim H. Parker, Emma J. Birks  
Meeting: The International Society for Heart and Lung Transplantation, Paris, 
France (April 2009) 
 
 
441 
 
19. “What happens to myocardial sympathetic function in heart failure patients 
who recover on left ventricular assist device (LVAD) therapy?”  
Robert S. George, Andrew Cheetham, Romel Manlapig, Fabrice Ghiotto, 
Suzie Hinton-Taylor, Andrew Marshall, Magdi H. Yacoub, Emma J. Birks, 
Andrew Kelion 
Meeting: British Nuclear Cardiology Society, NHLI, London (December 
2008) 
 
20. “Serial Assessment of Pulsatile and Non-Pulsatile Left Ventricular Assist 
Devices on Left Ventricular Unloading.”  
 
Robert S George, Magdi H. Yacoub, Carole Webb, Christopher Bowles, 
Robert Dean, Mike Hedger, Giles Dreyfus, Asghar Khaghani, and Emma J. 
Birks  
Meeting: The American Heart Association, New Orleans, USA (November 
2008) 
 
21. “Sustained Normalisation of 123I-MIBG Uptake after Explantation of Left 
Ventricular Assist Devices (LVAD)” 
 
Robert S. George 
Meeting:  Postgraduate Student Presentation Day, NHLI, Imperial College 
(June 2008) 
 
22. “Role of MIBG imaging in Heart Failure, Left Ventricular Assist Device 
and Recovery Patients” 
 
Robert S. George, A Cheetham, S Hinton-Taylor, R Manlapig, F Ghiotto A 
Kelion, MH Yacoub, EJ Birks 
Meeting: The International Society for Heart and Lung Transplantation, 
Boston, USA (April 2008)  
 
23. “Normalisation of Autonomic Dysfunction in Patients following Left 
Ventricular Assist Device Combination Therapy.” 
 
David Nunan, Robert S. George, Gavin R. Sandercock, Robert S. Bougard, 
James Hardy, Asghar Khaghani, Magdi H. Yacoub, David A. Brodie, Emma J. 
Birks 
Meeting: The International Society for Heart and Lung Transplantation, 
Boston, USA (April 2008) 
 
24. “Bridge to Recovery Using Combination Therapy. The Harefield Protocol” 
 
Invited Speaker 
Meeting: 4
th
 Lugano Cardiosurgical Postgraduate Course. The Failing Heart: 
a Paradigm of Multidisciplinary Approach. Lugano, Switzerland (October 
2007) 
 
442 
 
25. “Investigation of the Neuronal Uptake System in Patients with Heart 
Failure and Patients Recovered using Left Ventricular Assist Device” - 
Poster 
 
Robert S. George, Asghar Khaghani, Enrique Lara-Pezzi, Nadia Rosenthal, 
Andrew Kelion, Magdi H Yacoub, Emma J Birks 
Meeting:  Postgraduate Student Presentation Day, NHLI, Imperial College 
(June 2007) 
 
26. “Complete Discontinuation of Mechanical Support and Assessment of 
Inotropic Reserve in Patients with Left Ventricular Assist Devices.”  
 
Robert S. George, Giordano Tasca, Christopher Bowles, Carole Webb, Gilles 
Dreyfus, Aasghar Khaghani, Magdi H. Yacoub, Emma J. Birks 
Meeting: The International Society for Heart and Lung Transplantation, San 
Francisco, USA (April 2007) 
 
27. “Quality of Life Two or More Years Following LVAD Removal.” - Poster 
 
Robert S. George, Paula Rogers, Claire Hallas, Mario Petrou, Nicholas 
Banner, Gilles Dreyfus, Asghar Khaghani, Magdi H. Yacoub, Emma J. Birks 
Meeting: The International Society for Heart and Lung Transplantation, San 
Francisco, USA (April 2007) 
 
28. “Patient Outcome Following LVAD Bridge to Recovery Compared to Bridge 
to Transplantation.”  
 
Emma J.  Birks, Robert S. George, Paula Rogers, John R. Pepper, Gilles 
Dreyfus, Magdi H. Yacoub, Asghar Khaghani 
Meeting: The International Society for Heart and Lung Transplantation, San 
Francisco, USA (April 2007) 
 
29. “Cessation of Left Ventricular Assist Device (LVAD) to study cardiac 
function is a safe method to monitor myocardial recovery.”  
 
Robert S. George, Christopher Bowles, Patrick Tansley, James Hardy, Carole 
Webb, Asghar Khaghani, Magdi H. Yacoub, Emma J. Birks 
Meeting: The American Heart Association, Chicago, USA (November 2006) 
  
443 
 
Appendix A 
Box 1: INTERMACS level of Limitation at Time of Implant 
INTERMACS profile description 
Time frame for 
intervention 
Profile 1: Crtical cardiogenic shock 
Patients with life-threatening hypotension despite rapidly 
escalating inotropic support, critical organ hypoperfusion, 
often confirmed by worsening acidosis and/or lactate levels. 
―Crash and burn‖ 
 
Definitive 
intervention needed 
within hours. 
Profile 2: Progressive decline 
Patient with declining function despite intravenous inotropic 
support. May be manifest by worsening renal function, 
nutritional depletion, inability to restore volume balance 
―Sliding on inotropes.‖ 
 
Definitive 
intervention needed 
within few days. 
 
Profile 3: Stable but inotrope dependent 
Patient with stable blood pressure, organ function, nutrition, 
and symptoms on continuous intravenous inotropic support 
(or a temporary circulatory support device or both), but 
demonstrating repeated failure to wean from support 
―Dependent stability.‖ 
 
Definitive 
intervention 
elective over a 
period of weeks to 
few months. 
Profile 4: Resting symptoms 
Patient can be stabilized close to normal volume status but 
experiences daily symptoms of congestion at rest. Doses of 
diuretics generally fluctuate at very high levels. More 
intensive management and surveillance strategies should be 
considered. Some patients may shuttle between 4 and 5.  
 
Definitive 
intervention 
elective over period 
of weeks to few 
months. 
Profile 5: Exertion intolerant 
Comfortable at rest but unable to engage in any other activity, 
living predominantly within the house. May have underlying 
refractory elevated volume status, often with renal 
dysfunction.  
 
Variable urgency. 
Profile 6: Exertion limited 
Patient without evidence of fluid overload is comfortable at 
rest, and with activities of daily living and minor activities 
outside the home but fatigues after the first few minutes of 
any meaningful activity. ―Walking wounded.‖ 
 
Variable urgency. 
 
Profile 7: Advanced NYHA III 
A placeholder for more precise specification in future, this 
level includes patients who are without current or recent 
episodes of unstable fluid balance, living comfortably with 
meaningful activity limited to mild physical exertion. 
 
Transplantation or 
circulatory support 
maynot currently 
be indicated. 
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Box 2: Definition of advanced HF (Swedberg K et al., 1990) 
1. Symptoms of NYHA class III or IV; 
2. Episodes of fluid retention or reduced cardiac output at rest; 
3. Objective evidence of severe cardiac dysfunction, shown by at least one of 
the following: 
a. Low left ventricular ejection fraction (<30%), 
b. Severe abnormality of cardiac function on Doppler 
echocardiography with pseudonormal or restrictive mitral inflow 
pattern, 
c. High left ventricular filling pressure (mean pulmonary capillary 
wedge pressure > 16 mmHg, or mean atrial pressure > 12 mmHg 
by pulmonary artery catheterisation), 
d. High brain natriuretic peptide or N-terminal pre-brain natriuretic 
peptide plasma levels, in the absence of non-cardiac causes, 
4. Severe impairment of functional capacity shown by one of the following: 
a. Inability to exercise, 
b. 6-minute walk test distance < 300 m or less in women or patients 
aged  75 years, 
c. Peak oxygen consumption < 12 to 14 ml/min/kg, 
5. History of at least one heart failure hospitalisation in the past 6 months; 
6. Presence of all previous features despite ―attempts to optimise‖ therapy, 
including diuretics, inhibitors of renin-angiotensin-aldosterone system, and 
β-blockers, unless these are poorly tolerated or contraindicated, and 
cardiac resynchronisation therapy, when indicated. 
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Table A1 represent the pre-implantation demographics, clinical parameters and 
reasons for exclusion of the 13 excluded patients. 
Tables A2 and A3 represent the pre-implantation demographics and clinical 
parameters of each individual patient. All patients were inotrope dependent, 5 
patients required IABP, 2 were intubated and 2 were haemofiltered. 
Study end date refers to the time point up to which patient‘s echocardiographic 
and haemodynamic parameters are included in the thesis. For the non-recovered 
patient it was assigned as the date when they were transplant listed. For the 
recovered patients the study end date refers to the date when the device was either 
explanted or the decision to explant was made. 
As stated in chapter 2, 15 patients recovered of whom 14 were explanted and 8 
did not show signs of myocardial recovery and were either transplanted or 
transplant listed. 
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Table A1: Excluded patients (n=13) 
Patient 
Number 
Diagnosis Gender 
Implant 
Date 
Implant 
Age (yrs) 
Support 
Duration (d) 
Global 
EF (%) 
Reason for exclusion 
E1 IHD M 20/07/2006 60.48 62 42 Ischaemic Origin 
E2 HOCM M 28/08/2006 41.07 Ongoing 12 HOCM 
E3 PPM DCM F 16/10/2006 35.09 312 28 
Developed chest pain every time the speed of the HM II 
was reduced to assess the underlying myocardial function 
E4 IHD F 12/02/2007 45.43 166 30 Ischaemic Origin 
E5 DCM M 26/02/2007 57.46 311 10 Apical VSDs 
E6 DCM M 03/03/2007 27.51 23 10 Died 23 days after device implantation 
E7 DCM M 26/06/2007 47.20 9 - Died 9 days after device implantation 
E8 Becker’s MD M 10/07/2007 18.67 674 - Becker’s muscular dystrophy 
E9 DCM M 11/07/2007 21.87 Ongoing 24 Severe MR 
E10 IHD M 13/10/2007 56.04 276 25 Ischaemic Origin 
E11 DCM F 29/12/2007 28.85 246 15 
Severe MR and prolonged ITU stay prevented from 
recovery assessment 
E12 PPM DCM F 30/09/2008 41.94 240 20 Poor clinic attendance and compliance with medication 
E13 IHD F 09/02/2009 32.08 Ongoing - Ischaemic Origin 
Table A1: Basic demographics of the 13 excluded patients with reasons for exclusion. 
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Table A2: Pre-implantation demographics and clinical parameters of each individual patient. 
 
Patient 
Number 
Diagnosis Gender 
Disease 
Duration 
(mths) 
Symptoms 
Duration 
(mths) 
Implant 
Date 
Implant 
Age 
(yrs) 
Support 
Duration 
(d) 
Outcome 
Outcome as of 1
st
 
Oct 2009 
Study end 
date 
Study 
Duration 
(d) 
1 *
, ††
 DCM M 2 2 27/02/2006 16.88 219 Recovered Explanted; Alive 04/10/2006 219 
2 *
, †, §
 DCM M 2 2 06/02/2007 18.89 204 Recovered Explanted; Alive 29/08/2007 204 
3 DCM M 48 6 15/02/2007 41.41 Ongoing Non-Recovered Awaiting Tx 12/08/2008 544 
4 DCM F 4 4 11/05/2007 58.26 215 Recovered Explanted 12/12/2007 215 
5 
†, ††
 DCM M 132 2 07/06/2007 42.86 776 Non-Recovered Tx; Dead 03/02/2009 607 
6 
††, §
 DCM M 50 9 19/06/2007 27.14 Ongoing Non-Recovered Awaiting Tx 29/05/2008 345 
7 DCM M 2 2 22/06/2007 29.71 474 Recovered Explanted; Dead 08/10/2008 474 
8 
††
 
Familial 
DCM 
M 
48 4 27/06/2007 21.04 260 Recovered Explanted; Dead 13/03/2008 260 
9 DCM M 108 12 20/08/2007 55.89 363 Non-Recovered Tx; Dead 17/08/2008 363 
10 DCM M 48 4 13/11/2007 39.67 276 Recovered Alive 15/08/2008 276 
11 DCM M 1.5 1.5 15/12/2007 35.23 387 Recovered Alive 05/01/2009 387 
12 DCM M 1.5 1.5 20/01/2008 21.55 213 Recovered Explanted; Alive 20/08/2008 213 
 
 
  
448 
 
Table A2 (cont.): 
Patient 
Number 
Diagnosis Gender 
Disease 
Duration 
(mths) 
Symptoms 
Duration 
(mths) 
Implant 
Date 
Implant 
Age 
(yrs) 
Support 
Duration 
(d) 
Outcome 
Outcome as of 1
st
 
Oct 2009 
Study end 
date ** 
Study 
Duration 
(d) 
13 
§
 DCM M 84 6 01/03/2008 48.10 439 Recovered Explanted; Alive 14/05/2009 439 
14 DCM M 12 12 01/04/2008 23.90 Ongoing Non-Recovered Awaiting Tx 14/08/2009 500 
15 DCM F 9 9 19/05/2008 33.92 317 Recovered Explanted; Alive 01/04/2009 317 
16 DCM M 78 12 06/10/2008 51.66 Ongoing Non-Recovered Awaiting Tx 27/08/2009 325 
17 DCM M 30 1 23/11/2008 24.18 Ongoing Non-Recovered Awaiting Tx 15/08/2009 265 
18 
§
 DCM M 1.5 1.5 27/12/2008 16.58 138 Recovered Explanted; Alive 14/05/2009 138 
19 
††
 DCM M 5 5 02/01/2009 42.37 235 Recovered Explanted; Alive 25/08/2009 235 
20 DCM M 14 14 06/01/2009 53.23 Ongoing Recovered Awaiting Explant 31/10/2009 298 
21 DCM M 36 3 12/01/2009 58.82 Ongoing Non-Recovered Awaiting Tx 15/08/2009 215 
22 DCM M 1.5 1.5 07/03/2009 32.39 205 Recovered Explanted; Alive 28/09/2009 205 
23 DCM M 1.5 1.5 19/03/2009 16.72 202 Recovered Explanted; Alive 01/10/2009 196 
* Patient 1 and 2 were intubated prior to device implantation 
† Patients 2 and 5 were haemofiltered prior to device implantation 
†† Patients 1,5,6,8 and 19 had IABP prior to device implantation 
§ Patients 2,6,13, and 18 had pre-implant short term support (patients 2,6, and 13 had BiVAD Levitornics
®
 and patient 18 had ECMO) 
** Study end date refers to the time point up to which patient’s echocardiographic and haemodynamic parameters are included in the 
thesis. For the non-recovered patient it was assigned as the date when they were transplant listed and for the recovered patients as the 
either explant date or the decision to explant 
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Table A3: Pre-implantation demographics and clinical parameters of each individual patient 
Patient 
Number 
BMI 
(kg/m
2
) 
BSA 
(m
2
) 
PMH 
Number of 
Inotropes 
Pre-Implant Haemodynamics 
Sys PA 
(mmHg) 
Dia PA 
(mmHg) 
Mean PA 
(mmHg) 
PCWP 
(mmHg) 
CO 
(l/min) 
CI 
(l/min/m
2
) 
PA sats 
(%) 
1 20.68 1.83 Nil 4  - - - 31 5.4 2.9 43 
2 25.62 2.04 Nil 4 - - - - - - - 
3 23.77 1.96 ICD 1 31 20 27 22 1.7 0.9 38.4 
4 19.01 1.38 Nil 2 43 17 32 23 2.1 1.53 61.6 
5 22.86 1.84 Nil 2 42 32 38 - - - - 
6 25.57 1.95 ICD 4  - - - - - - - 
7 22.52 2.10 Nil 1 - - - - - - - 
8 19.14 1.76 Nil 2 37 35 33 28 2.9 1.65 - 
9 28.85 1.74 ICD, Type II DM, AF 1 72 37 52 48 2.9 1.7 58 
10 25.94 1.85 Asthma 2 58 25 42 26 2.21 1.2 35 
11 26.85 2.09 Multiple PE‘s 2 38 23 28 27 4.23 2.03 36 
12 21.30 1.73 Mild asthma 2 43 31 36 29 2.7 1.56 - 
13 24.98 1.77 DVT 2 46 19 32 34 1.55 0.88 25 
14 26.84 2.07 Nil 2 40 27 33 33 2.1 1.1 36 
15 19.83 1.57 Nil 1 - - - 32 2.1 1.33 - 
16 24.09 1.78 ICD, Hypercholesterolaemia 2 62 31 44 33  - - - 
17 20.63 1.79 ICD 2 53 32 39 29 2.9 1.6 51 
18 26.73 1.96 Nil 2 - - - - - - - 
19 21.50 1.74 Nil 2 57 19 33 22 3.4 1.9 - 
20 23.05 1.81 
CRT-D, restless leg syndrome, Type II 
DM 
2 39 26 31 23 2 1.6 - 
21 24.21 1.91 ICD, Aortic regurgitation 2 53 31 38 32 3.12 1.63 53 
22 29.32 2.18 Mild asthma 2 - - - - - - - 
23 21.05 1.74 Nil 2 - - - - - - - 
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Table A3 (cont.): 
 
Patient 
Number 
Pre-Implant Echocardiography Pre-Implant Serum Biochemistry 
LVEDD 
(mm) 
LVESD 
(mm) 
FS (%) EF (%) 
Urea 
(2.3-6.7 mmol/L) 
Creatinine 
(60-130 μmol/L) 
Bilirubin 
(0-20 μmol/L) 
ALP 
(30-130 U/L) 
ALT 
(5-65 U/L) 
BNP 
1 73 70 4.11 11.83 17.7 159 58 83 1026 - 
2 63 59 6.35 17.86 17.9 318 18 36 970 - 
3 70 65 7.14 19.93 10.6 122 66 62 30 71 
4 67 63 5.97 16.86 5 71 34 41 28 99 
5 - - - 20.00 18.3 341 47 75 38 592 
6 - - - - 21.8 315 55 101 13 16 
7 69 67 2.90 8.45 4.6 100 21 80 294 - 
8 66 61 7.58 21.05 6.4 100 14 82 42 248 
9 78 72 7.69 21.35 11.7 170 30 133 47 271 
10 85 78 8.23 22.73 9.9 132 78 102 629 220 
11 63 61 3.18 9.23 10.4 96 38 70 33 146 
12 63 59 6.35 17.86 11.8 127 76 86 2180 - 
13 74 67 9.46 25.78 5.3 173 22 57 36 50 
14 78 73 6.41 18.02 10.2 131 65 44 62 95 
15 69 65 5.80 16.40 13.7 104 99 265 531 373 
16 79 71 10.13 27.41 30.3 277 54 80 220 360 
17 91 82 9.89 26.83 8.6 105 29 57 140 >1352 
18 62 58 6.45 18.13 13 248 60 57 1484 >919 
19 76 61 19.74 48.29 7.3 53 85 83 1258 214 
20 67 62 7.46 20.76 13.5 139 8 64 29 31 
21 81 79 2.47 7.23 13.6 138 39 84 32 >919 
22 62 54 12.90 33.93 9.2 145 60 87 101 - 
23 83 75 9.64 26.22 5.5 84 18 91 17 112 
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Appendix B 
Multi-Level Time Model Analysis 
To ensure that the echocardiographic and haemodynamic parameters are not due to 
data averaging, a multi-level time model analysis was performed to determine the 
trends in the echocardiographic and haemodynamic parameters over a 1-year period.  
The model assumes that for each patient there is a linear relationship between the 
response and time since device implantation. In the thesis the response has been 
defined as one of the following: 
1) The change in absolute value in the echocardiographic measured parameters 
(LVEDD, LVESD, FS, and EF) at: 
a. 15 minutes of off-pump 
b. Post 6-minute walk exercise test 
2) The percentage change in echocardiographic parameters from 15 minutes of 
off-pump testing to post 6-minute walk exercise test. 
 
Model 1 
Model 1 is a basic model which allows for a linear change in the response with time 
since operation. In this model recovered and non-recovered patients were 
considered separately.  
The intercept and the slope of the linear relationship are assumed to vary randomly. 
In detail, if yij is the response for Patient j at Occasion i, and tij is the time (years 
after operation) of Occasion i for Patient j, then 
   yij = β0j + β1jtij + eij 
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Where: 
 eij = Σ(0,σe
2
),  
β0j = Σ(β0,σu0
2
),  
β1j = Σ(β1,σu1
2
),  
cov(β0j , β1j) = σu01.  
So, β0 is the overall mean intercept (i.e. mean response at time 0) and β1 is the 
overall mean slope (i.e. mean increase in response per year). eij and σe
2 
relate to 
within-patient variability, while σu0
2
, σu1
2
, and σu01 relate to between-patient 
variability.  
It is the mean increase in the measured parameters after the response has occurred 
per year which is the main quantity of interest. The mean slope of the relationship 
refers to the change in the measured parameter over a period of time such that 
a positive slope indicates an increase in the value and a negative slope indicates 
a reduction in the value.  
 
Model 2 
When comparing the trends of a response, for example the absolute change in EF 
following the 6-minute walk exercise test, between two subgroups of a certain 
population such as recovered versus non-recovered patients with HM II LVAD, the 
same equation is used: 
   yij = β0j + β1jtij + eij 
Where: 
eij = N(0,σe
2
),  
β0j = β00 + β01xj + u0j, { xj is the value of the “recovered” for patient j} 
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β1j = β10 + β11xj + u1j, σu0
2
),  
u0j = N(0, σu0
2
) 
So, β00 is the overall mean intercept (i.e. notional mean response at time 0) for non-
recovered patients and β01 is the increase in mean intercept for recovered patients 
(i.e. the intercept for recovered patients is β00 + β01). β10 is the coefficient of t (i.e. 
the slope) for non-recovered patients, while β11 is the increase in the coefficient of t 
for recovered patients (i.e. the coefficient of t for recovered patients is β10 +  β11).   
When comparing two sub-groups, the key quantities are therefore β11 and β10; such 
that if β11 = 0, then the slope is the same for the two groups; if β01 = 0, then the 
notional mean response at time 0 is the same for the two groups; if both β11 = 0 and 
β01 = 0, then the relationship between the response and time since operation is the 
same for the two sub-groups. 
 
Model 3 
Similar to model 2, this model compares two groups but two different populations 
such as HM I LVAD versus HM II LVAD. In this model, the coefficients are 
allowed to differ between the HM I and HM II patients. The group is indicated by 
the variable ―HM2‖, which takes the value 1 for HM II patients and 0 for HM I 
patients.  
The same relationship is considered: 
yij = β0j + β1jtij + eij 
Where: 
eij = N(0,σe
2
),  
β0j = β00 + β01xj + u0j, { xj is the value of the “HM II” for patient j} 
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β1j = β10 + β11xj + u1j,  
u0j = N(0, σu0
2
) 
u1j = N(0, σu1
2
) 
So, β00 is the overall mean intercept (i.e. notional mean response at time 0) for HM I 
patients and β01 is the increase in mean intercept for the HM II patients (i.e. the 
intercept for HM II patients is β00 + β01). β10 is the coefficient of t (i.e. the slope) for 
the HM I patients, while β11 is the increase in the coefficient of t for HM II patients 
(i.e. the coefficient of t for HM II patients is β10 + β11).   
When comparing two sub-groups from two different populations, the key quantities 
are therefore β11 and β10; if β11 = 0, then the slope is the same for the two groups; if 
β01 = 0, then the notional mean response at time 0 is the same for the two groups; if 
both β11 =0 and β01 = 0, then the relationship between the response and time since 
operation is the same for the two sub-groups of the two populations. 
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Appendix C 
Viscosity calculations 
A Cannon-Fenske Routine Viscometer for transparent liquids size 50 (Poulten Selfe 
& Lee Ltd, United Kingdom) was used. 
 
Steps to calculate viscosity: 
1. The viscometer was cleaned using suitable solvents, and by passing 
clean, dry, filtered air through the instrument to remove the final traces of solvents. 
2. The instrument was inverted and suction was to tube L after 
immersing tube N in the glycerol-water mixture. Liquid was then drawn to mark F.  
3. After cleaning arm N, the instrument was turned to its normal 
vertical position and was place into a holder. Since the experiments were to run at 
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room temperature, the viscometer was kept in the straight position at room 
temperature and not immersed in a temperature regulated bath. 
4. The liquid sample was then allowed to flow freely down past mark F, 
measuring the efflux time for the meniscus to pass from mark E to mark F.  
5. Steps 1-4 were repeated three times on each experimental day and at 
the end of the experiment to ensure no alteration had occurred in the viscosity 
throughout the experiment.  
6. The kinematic viscosity in mm2/s(cSt) of the sample was calculated 
by multiplying the efflux time in seconds by the viscometer constant. Such that: 
 
Viscosity = Ct  
Where: 
 C is the calibrating factor which is 0.003962 (mm
2
/s
2
). The value is based 
upon a value for the kinematic viscosity of distilled water at 20°C of 1.0038 mm
2
/s; 
t is the efflux time taken in seconds. 
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Appendix D 
Computer Script for Matlab® 
Below is the computer script that was run in the 
computer programme MatLab® R2007b to produce ventricular 
and aortic pressure traces and flow trace. The generated 
graphs were then transported as JPEG images. 
% INSTRUCTIONS: 
% Open File and get the file: 
 % 0 mmHg 
 % 40 mmHg 
 % 80 mmHg 
 % 120 mmHg 
% 0 mmHg “off” 
% subplot to plot 7 by 2: ventricular pressure 
% subplot to plot more than 1 plot 
% matrix used is two rows by 7 columns 
% 7 different speeds from 10,000 rpom to 4,000 rpm 
% Column "1" = time (sec) - 10001Hz:16000Hz (3 sec) 
subplot(2,7,1);plot(((rpm10000off(10001:16000,1)/10
00)-5), 
% Average trace = all trace period 
% Filter = sgolay filter: 11=ventricular pressure; 
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% Column "2" = ventricular pressure (mmHg) 
% b=blue; 
sgolayfilt((averagetrace(rpm10000off,2)),2,11),'b')
; 
% X AXIS and Y AXIS 
AXIS([0 3 -40 60]) 
      grid on 
      YLABEL('Pressure(mmHg)') 
      TITLE('10000 rpm') 
      hold on 
% subplot to plot 7 by 2: aortic pressure 
% subplot to plot more than 1 plot 
% matrix used is two rows by 7 columns 
% 7 different speeds from 10,000 rpom to 4,000 rpm 
% Column "1" = time (sec) - 10001Hz:16000Hz (3 sec) 
plot(((rpm10000off(10001:16000,1)/1000)-5) 
% Average trace = all trace period 
% Filter = sgolay filter: 351=aortic pressure; 
% Column "3" = aortic pressure (mmHg) 
% b=blue 
% linewidth = 1.5 pts 
sgolayfilt((averagetrace(rpm10000off,3)),2,351),'r'
,'linewidth',1.5); 
% repeat the runs for each speed at the different 
ventricular pressure 40 mmHg, 80 mmHg, and 120 mmHg 
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subplot(2,7,2);plot(((rpm9000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm9000off,2)),2,11
),'b'); 
    AXIS([0 3 -40 60]) 
    grid on 
    TITLE('9000 rpm') 
    hold on 
    plot(((rpm9000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm9000off,3)),2,35
1),'r','linewidth',1.5); 
subplot(2,7,3);plot(((rpm8000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm8000off,2)),2,11
),'b'); 
    AXIS([0 3 -40 60]) 
    grid on 
    TITLE('8000 rpm') 
    hold on 
plot(((rpm8000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm8000off,3)),2,35
1),'r','linewidth',1.5); 
subplot(2,7,4);plot(((rpm7000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm7000off,2)),2,11
),'b'); 
    AXIS([0 3 -40 60]) 
    grid on 
    TITLE('7000 rpm') 
    hold on 
plot(((rpm7000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm7000off,3)),2,35
1),'r','linewidth',1.5); 
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subplot(2,7,5);plot(((rpm6000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm6000off,2)),2,11
),'b'); 
    AXIS([0 3 -40 60]) 
    grid on 
    TITLE('6000 rpm') 
    hold on 
    plot(((rpm6000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm6000off,3)),2,35
1),'r','linewidth',1.5); 
subplot(2,7,6);plot(((rpm5000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm5000off,2)),2,11
),'b'); 
    AXIS([0 3 -40 60]) 
    grid on 
    TITLE('5000 rpm') 
    hold on 
    plot(((rpm5000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm5000off,3)),2,35
1),'r','linewidth',1.5); 
subplot(2,7,7);plot(((rpm4000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm4000off,2)),2,11
),'b'); 
   AXIS([0 3 -40 60]) 
    grid on 
    TITLE('4000 rpm') 
    hold on 
    plot(((rpm4000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm4000off,3)),2,35
1),'r','linewidth',1.5);   
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% Average trace = all trace period 
% Filter = sgolay filter: 351=flow; 
% Column "4" = flow (l/min) 
% k=black; 
subplot(2,7,8);plot(((rpm10000off(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm10000off,4)),2,3
51),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
    YLABEL('Flow(l/min)') 
    XLABEL('Time(sec)')   
subplot(2,7,9);plot(((rpm9000off(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm9000off,4)),2,35
1),'k'); 
AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,10);plot(((rpm8000off(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm8000off,4)),2,35
1),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,11);plot(((rpm7000off(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm7000off,4)),2,35
1),'k'); 
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    AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,12);plot(((rpm6000off(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm6000off,4)),2,35
1),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,13);plot(((rpm5000off(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm5000off,4)),2,35
1),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,14);plot(((rpm4000off(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm4000off,4)),2,35
1),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
 
% 40 mmHg 
subplot(2,7,1);plot(((rpm1000040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm1000040,2)),2,11
),'b'); 
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    AXIS([0 3 -40 60]) 
    grid on 
    YLABEL('Pressure(mmHg)') 
    TITLE('10000 rpm') 
    hold on 
    plot(((rpm1000040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm1000040,3)),2,35
1),'r','linewidth',1.5); 
subplot(2,7,2);plot(((rpm900040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm900040,2)),2,11)
,'b'); 
    AXIS([0 3 -40 60]) 
    grid on 
    TITLE('9000 rpm') 
    hold on 
    plot(((rpm900040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm900040,3)),2,351
),'r','linewidth',1.5); 
subplot(2,7,3);plot(((rpm800040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm800040,2)),2,11)
,'b'); 
    AXIS([0 3 -40 60]) 
    grid on 
    TITLE('8000 rpm') 
    hold on 
    plot(((rpm800040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm800040,3)),2,351
),'r','linewidth',1.5); 
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subplot(2,7,4);plot(((rpm700040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm700040,2)),2,11)
,'b'); 
    AXIS([0 3 -40 60]) 
    grid on 
    TITLE('7000 rpm') 
    hold on 
    plot(((rpm700040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm700040,3)),2,351
),'r','linewidth',1.5); 
subplot(2,7,5);plot(((rpm600040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm600040,2)),2,11)
,'b'); 
    AXIS([0 3 -40 60]) 
    grid on 
    TITLE('6000 rpm') 
    hold on 
    plot(((rpm600040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm600040,3)),2,351
),'r','linewidth',1.5); 
subplot(2,7,6);plot(((rpm500040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm500040,2)),2,11)
,'b'); 
    AXIS([0 3 -40 60]) 
    grid on 
    TITLE('5000 rpm') 
    hold on 
    plot(((rpm500040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm500040,3)),2,351
),'r','linewidth',1.5); 
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subplot(2,7,7);plot(((rpm400040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm400040,2)),2,11)
,'b'); 
   AXIS([0 3 -40 60]) 
    grid on 
    TITLE('4000 rpm') 
    hold on 
    plot(((rpm400040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm400040,3)),2,351
),'r','linewidth',1.5);   
 
subplot(2,7,8);plot(((rpm1000040(10001:16000,1)
/1000)-
5),sgolayfilt((averagetrace(rpm1000040,4)),2,35
1),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
    YLABEL('Flow(l/min)') 
    XLABEL('Time(sec)')   
subplot(2,7,9);plot(((rpm900040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm900040,4)),2,351
),'k'); 
   AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,10);plot(((rpm800040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm800040,4)),2,351
),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
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    XLABEL('Time(sec)') 
subplot(2,7,11);plot(((rpm700040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm700040,4)),2,351
),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,12);plot(((rpm600040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm600040,4)),2,351
),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,13);plot(((rpm500040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm500040,4)),2,351
),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,14);plot(((rpm400040(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm400040,4)),2,351
),'k'); 
    AXIS([0 3 0 8]) 
    grid on 
    XLABEL('Time(sec)') 
% 80 mmHg 
figure; 
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subplot(2,7,1);plot(((rpm1000080(10001:16000,1)
/1000)-
5),sgolayfilt((averagetrace(rpm1000080,2)),2,35
1),'b'); 
    AXIS([0 3 -40 100]) 
    grid on 
    YLABEL('Pressure(mmHg)') 
    TITLE('10000 rpm') 
    hold on 
    plot(((rpm1000080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm1000080,3)),2,35
1),'r','linewidth',1.5); 
subplot(2,7,2);plot(((rpm900080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm900080,2)),2,351
),'b'); 
    AXIS([0 3 -40 100]) 
    grid on 
    TITLE('9000 rpm') 
    hold on 
    plot(((rpm900080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm900080,3)),2,351
),'r','linewidth',1.5); 
subplot(2,7,3);plot(((rpm800080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm800080,2)),2,351
),'b'); 
    AXIS([0 3 -40 100]) 
    grid on 
    TITLE('8000 rpm') 
    hold on 
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    plot(((rpm800080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm800080,3)),2,351
),'r','linewidth',1.5); 
subplot(2,7,4);plot(((rpm700080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm700080,2)),2,351
),'b'); 
    AXIS([0 3 -40 100]) 
    grid on 
    TITLE('7000 rpm') 
    hold on 
    plot(((rpm700080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm700080,3)),2,351
),'r','linewidth',1.5); 
subplot(2,7,5);plot(((rpm600080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm600080,2)),2,351
),'b'); 
    AXIS([0 3 -40 100]) 
    grid on 
    TITLE('6000 rpm') 
    hold on 
    plot(((rpm600080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm600080,3)),2,351
),'r','linewidth',1.5); 
subplot(2,7,6);plot(((rpm500080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm500080,2)),2,351
),'b'); 
    AXIS([0 3 -40 100]) 
    grid on 
    TITLE('5000 rpm') 
    hold on 
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    plot(((rpm500080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm500080,3)),2,351
),'r','linewidth',1.5); 
 
subplot(2,7,7);plot(((rpm400080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm400080,2)),2,351
),'b'); 
   AXIS([0 3 -40 100]) 
    grid on 
    TITLE('4000 rpm') 
    hold on 
    plot(((rpm400080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm400080,3)),2,351
),'r','linewidth',1.5);     
 
subplot(2,7,8);plot(((rpm1000080(10001:16000,1)
/1000)-
5),sgolayfilt((averagetrace(rpm1000080,4)),2,35
1),'k'); 
    AXIS([0 3 -5 15]) 
    grid on 
    YLABEL('Flow(l/min)') 
    XLABEL('Time(sec)')   
subplot(2,7,9);plot(((rpm900080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm900080,4)),2,351
),'k'); 
    AXIS([0 3 -5 15]) 
    grid on 
    XLABEL('Time(sec)') 
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subplot(2,7,10);plot(((rpm800080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm800080,4)),2,351
),'k'); 
    AXIS([0 3 -5 15]) 
    grid on 
    XLABEL('Time(sec)') 
 
subplot(2,7,11);plot(((rpm700080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm700080,4)),2,351
),'k'); 
    AXIS([0 3 -5 15]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,12);plot(((rpm600080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm600080,4)),2,351
),'k'); 
   AXIS([0 3 -5 15]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,13);plot(((rpm500080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm500080,4)),2,351
),'k'); 
   AXIS([0 3 -5 15]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,14);plot(((rpm400080(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm400080,4)),2,351
),'k'); 
    AXIS([0 3 -5 15]) 
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    grid on 
    XLABEL('Time(sec)') 
% 120 mmHg 
figure; 
subplot(2,7,1);plot(((rpm10000120(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm10000120,2)),2,3
51),'b'); 
    AXIS([0 3 -60 120]) 
    grid on 
    YLABEL('Pressure(mmHg)') 
    TITLE('10000 rpm') 
    hold on 
    plot(((rpm10000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm10000120,3)),2,3
51),'r','linewidth',1.5); 
subplot(2,7,2);plot(((rpm9000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm9000120,2)),2,35
1),'b'); 
    AXIS([0 3 -60 120]) 
    grid on 
    TITLE('9000 rpm') 
    hold on 
    plot(((rpm9000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm9000120,3)),2,35
1),'r','linewidth',1.5); 
subplot(2,7,3);plot(((rpm8000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm8000120,2)),2,35
1),'b'); 
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    AXIS([0 3 -60 120]) 
    grid on 
    TITLE('8000 rpm') 
    hold on 
    plot(((rpm8000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm8000120,3)),2,35
1),'r','linewidth',1.5); 
subplot(2,7,4);plot(((rpm7000120(10001:16000,
1)/1000)-
5),sgolayfilt((averagetrace(rpm7000120,2)),2,35
1),'b'); 
    AXIS([0 3 -60 120]) 
    grid on 
    TITLE('7000 rpm') 
    hold on 
    plot(((rpm7000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm7000120,3)),2,35
1),'r','linewidth',1.5); 
subplot(2,7,5);plot(((rpm6000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm6000120,2)),2,35
1),'b'); 
    AXIS([0 3 -60 120]) 
    grid on 
    TITLE('6000 rpm') 
    hold on 
    plot(((rpm6000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm6000120,3)),2,35
1),'r','linewidth',1.5); 
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subplot(2,7,6);plot(((rpm5000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm5000120,2)),2,35
1),'b'); 
    AXIS([0 3 -60 120]) 
    grid on 
    TITLE('5000 rpm') 
    hold on 
    plot(((rpm5000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm5000120,3)),2,35
1),'r','linewidth',1.5); 
subplot(2,7,7);plot(((rpm4000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm4000120,2)),2,35
1),'b'); 
    AXIS([0 3 -60 120]) 
    grid on 
    TITLE('4000 rpm') 
    hold on 
    plot(((rpm4000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm4000120,3)),2,35
1),'r','linewidth',1.5);     
 
subplot(2,7,8);plot(((rpm10000120(10001:16000,1
)/1000)-
5),sgolayfilt((averagetrace(rpm10000120,4)),2,3
51),'k'); 
    AXIS([0 3 -5 25]) 
    grid on 
    YLABEL('Flow(l/min)') 
    XLABEL('Time(sec)')   
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subplot(2,7,9);plot(((rpm9000120(10001:16000,1)/1000)-
5),sgolayfilt((averagetrace(rpm9000120,4)),2,35
1),'k'); 
    AXIS([0 3 -5 25]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,10);plot(((rpm8000120(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm8000120,4)),2,35
1),'k'); 
    AXIS([0 3 -5 25]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,11);plot(((rpm7000120(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm7000120,4)),2,35
1),'k'); 
    AXIS([0 3 -5 25]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,12);plot(((rpm6000120(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm6000120,4)),2,35
1),'k'); 
    AXIS([0 3 -5 25]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,13);plot(((rpm5000120(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm5000120,4)),2,35
1),'k'); 
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    AXIS([0 3 -5 25]) 
    grid on 
    XLABEL('Time(sec)') 
subplot(2,7,14);plot(((rpm4000120(10001:16000,1)/1000)
-
5),sgolayfilt((averagetrace(rpm4000120,4)),2,35
1),'k'); 
    AXIS([0 3 -5 25]) 
    grid on 
    XLABEL('Time(sec)') 
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Appendix E 
Medicines known to interact with MIBG uptake 
Amitriptyline 
Amoxapine 
Benperidol 
Bethanidine 
Bretylium 
Butriptyline 
Chlorpromazine 
Clomipramine 
Cocaine 
Debrisoquine 
Dexamphetamine 
Desipramine 
Diethylpropion 
Diltiazem 
Dopamine 
Doxepin 
Dothiepin 
Dobutamine 
Droperidol 
Ephedrine 
Fenfluramine 
Fenoterol 
Fluphenazine 
Flupenthixol 
Guanethidine 
Haloperidol 
Imipramine 
Iprindole 
Isradipine 
Isoetharine 
Isoprenaline 
Labetalol 
Lidoflazine 
Lofepramine 
Loxapine 
Maprotiline 
Mazindol 
Metaraminol 
Methoserpidine 
Methotrimeprazine 
Methoxamine 
Methylephedrine 
Mianserin 
Nicardipine 
Nifedipine 
Nimodipine 
Nora-epinephrine 
Nortriptyline 
Orciprenaline 
Oxymetazoline 
Oxypertine 
Pericyazine 
Perphanazine 
Phentermine 
Phenylephedrine 
Phenylpropanolamine 
Pimozide 
Pipothiazine 
Pirbuterol 
Prochlorperazine 
Promazine 
Promethazine 
Protriptyline 
Pseudoephedrine 
Reproterol 
Reserpine 
Rimiterol 
Salbutamol 
Terbutaline 
Thiethylperazine 
Thioridazine 
Tramazoline 
Trazodone 
Trifluoperazine 
Trifluperidol 
Trimiparmine 
Verapamil 
Viloxazine 
Xamoteroi 
Xylometazoline 
Zuclopenthix
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